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Abstract 
 
 
The introduction of highly active antiretroviral therapy (HAART) has led to significant 
improvements in survival and morbidity for HIV-positive patients. Though HIV can 
now be well managed with treatment, interlinked barriers to successful treatment are 
still prevalent. In particular, low adherence to therapy, resistance to drugs and drug 
toxicity can have a considerable impact on the success of HAART.   
 
The potential of HAART is limited from the outset if patients are infected with a drug-
resistant virus. Evidence suggests that a small minority of patients are starting 
HAART with drugs that the virus is resistant to, and consequently, are less likely to 
achieve virological suppression.  A large proportion of resistance tests performed 
after patients‟ start HAART are not followed by a switch within 4 months of the result 
being received. This raises questions as to why the test was performed and whether 
limited future drug options are of concern.  
 
A single abnormal laboratory value may be the result of random fluctuations and 
may not necessarily be a reason for concern over drug toxicity. I derive a more 
stringent definition of an ALT flare and compare this definition with that commonly 
found in the literature. Treatment interruptions, perhaps due to drug toxicity, should 
not take place when the viral load is detectable. Patients who have achieved viral 
suppression after interrupting treatment and who have failed a higher number of 
HAART regimens are at a greater risk of viral rebound, though this risk is reduced 
substantially as duration of suppression increases.  
 
A score to characterise laboratory abnormalities is derived and used to predict 
mortality. Several methods were used; I felt the most appropriate was that based on 
the estimates from a regression model in which the current laboratory 
measurements were fitted; only three routinely measured laboratory measures were 
needed to calculate the score. 
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Chapter 1: Introduction 
1.  
  
1.1. The HIV epidemic 
The number of people living with human immunodeficiency virus (HIV) in 2007 
worldwide was estimated to be around 33 million, with the number of new infections 
in that year standing at 2.7 million (1).  Since the first described case of what was 
later recognised to be HIV in 1981, 25 million people have died of Acquired 
Immunodeficiency Syndrome (AIDS) (1). Although the issues surrounding the 
management of HIV have changed over the last 25 years, with better understanding 
of the mechanisms behind the virus, together with advances in therapy, the 
challenges faced by clinicians now reflect the difficulties of dealing with a viral 
infection for which a cure is still not available. Toxicities associated with therapy, the 
accumulation of resistance to antiretroviral (ART) drugs and the financial cost of a 
lifetime of therapy are just some of these issues. 
 
1.2. History of HIV 
Although blood samples taken from a man who died in Africa in 1959 have shown 
that he died from HIV-complications (2), HIV-associated illnesses are generally 
dated back to 1981. The emergence of Kaposi‟s Sarcoma (KS) and Pneumocystis 
carinii Pneumonia (PCP) amongst gay men in New York and California were the first 
signs of the epidemic (3). In 1982, the United States Centers for Disease Control 
(CDC) defined a case of AIDS as „a disease, at least moderately predictive of a 
defect in cell-mediated immunity, occurring in a person with no known cause for 
diminished resistance to that disease. Such diseases include KS, PCP, and serious 
other opportunistic infections (OOI)‟ (4). Research by both French and American 
scientists (5;6) isolated the virus which was believed to cause AIDS, later named as 
HIV by an international committee of scientists (7). 
 
1.3. Mechanisms of HIV 
HIV belongs to a class of viruses called retroviruses, which have genes composed 
of ribonucleic acid (RNA) molecules. HIV attacks the immune system, the body‟s 
mechanism for protecting itself against bacteria and viruses that try to invade it. The 
virus infects particular types of white blood cells called CD4 lymphocytes (also 
known as T-cells or T-lymphocytes) which are needed to fight against infection.  By 
copying its own genetic code into the DNA of the CD4 cells, the virus is able to 
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create new copies of HIV which are then released from the CD4 cell into the blood 
to infect and destroy other CD4 cells (and some other cells). This leads to a 
reduction in the number of CD4 cells, leaving the immune system with a decreased 
ability to fight certain infections and cancers (8-11). A healthy uninfected person 
usually has 800-1,200 CD4 cells per cubic millimetre (mm3) of blood. During 
untreated HIV infection, this count falls towards zero – once the CD4 count cell has 
fallen below 200/mm3, the body is particularly vulnerable to opportunistic infections 
(OIs). The CDC‟s most current definition of AIDS (12) includes all HIV-positive 
persons who have a CD4 cell count of less than 200 cells/mm3, a CD4 cell 
percentage of total lymphocytes of less than 14, or one of 26 clinical indicator 
conditions. The European definition of AIDS differs somewhat from the CDC‟s 
definition, in that it does not include the CD4 lymphocyte count criteria.  
 
1.4. Strains, subtypes and transmission of HIV 
There are two types of HIV: HIV-1 and HIV-2.  The predominant virus worldwide is 
HIV-1 and is the virus which was initially discovered by researchers at the Pasteur 
Institute in France (5). HIV-2 is largely confined to West Africa and is thought to be 
less easily transmitted than HIV-1 (13-15). HIV-1 is classified into three groups: M 
(major group), O (outlier group) and N (new group). The vast majority of infections 
worldwide fall into group M (16) and the rest of this thesis relates to this group only.  
Within Group M, there are known to be at least 9 different subtypes (clades) of HIV-
1: A, B, C, D, F, G, H, J and K. Due to evolution of the virus over time (particularly in 
those exposed to greater than one strain), some cases are of a circulating 
recombinant form (CRF). CRF A/C, for example, is a combination of subtypes A and 
C. It is possible that further subtypes will be found in the future and hence this is not 
a complete list. Subtype B is the most common subtype in Europe, America, Japan 
and Australia, although other subtypes are becoming more frequent and now 
account for at least 25% of new infections in Europe (16). 
 
There are 3 main transmission routes for HIV; unprotected penetrative sex with 
someone who is infected, sharing unsterilized injection equipment that has been 
used by someone who is infected and from mother to child during pregnancy, at 
birth and through breastfeeding. Other less common routes include transfusion of 
contaminated blood/blood products and oral sex (17;18). Historically, in Western 
countries, the virus has been spread mainly by anal intercourse between men and 
sharing of injection equipment, whilst in African countries heterosexual intercourse 
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has been the main mode of infection (19). Trends over time show that although the 
number of infections acquired through heterosexual contact in the UK have been 
increasing since 2000, the vast majority of these infections were amongst those who 
were infected abroad (20). Further, the number of newly identified heterosexual 
infections in more recent years appears to be relatively stable, whilst infections 
acquired through homosexual contact have been increasing (21). 
 
1.5. Stages of infection and markers of disease progression 
After an individual is infected with HIV, it takes around 7-10 days for RNA from the 
virus to be detectable in plasma (this period is known as primary HIV infection); 
thereafter antibodies to the virus can be detected in serum using several different 
tests within a few weeks. The first of these to be introduced into clinical use was the 
ELISA test, which was licensed in 1985 (22). The development of antibodies (such 
that an individual goes from being HIV-negative to HIV-positive) may take up to 6 
months and is known as „seroconversion‟ (23;24). An HIV-specific cellular immune 
response is also generated (25). During this period, people may have symptoms 
such as a mild glandular fever, headache, skin rash and enlarged lymph nodes, 
lasting for around 2 weeks (26;27). The CD4 count declines rapidly and there is a 
high rate of viral replication, leading to a rise in HIV viral load (the number of viral 
particles found in each millilitre of plasma) (28-30) (Figure 1.5.1). This period is 
followed by an asymptomatic or „silent‟ phase, during which time the person infected 
is likely to remain clinically healthy. The body continues to produce antibodies and 
though the virus is active in the lymph nodes (31), the antibody and cellular immune 
response reduces the rate of viral replication, i.e. the viral load falls to low levels 
amongst the majority of infected individuals. The fall in viral load is typically 
accompanied by a rise in CD4 cell count to sub-optimal levels (30;32). This 
asymptomatic stage lasts for an average of 10 years and other than swollen glands 
and some CDC „B‟ events (12), the individual is generally free from major symptoms 
(33-36). As the disease progresses, the viral load increases and the number of CD4 
cells declines (the rate of the CD4 cell count decline varies from individual to 
individual). This allows opportunistic infections, normally controlled by CD4 cell-
mediated immunity, to occur. If the immune system is severely weakened, it is 
vulnerable to serious opportunistic infections and cancers and it is at this stage that 
a person who has acquired HIV is said to have AIDS (12). 
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Although there are several markers of HIV disease progression (37-43), the CD4 
cell count and plasma viral load have long been established as the two most 
predictive markers (44-51) and hence are widely used in clinical care. The risk of 
AIDS is significantly increased with lower CD4 counts and higher viral loads 
(48;50;51), throughout the course of infection. Whilst the CD4 count captures the 
number of CD4 cells in the blood to give an indication of the state of the individual‟s 
immune system, the viral load provides a direct measure of the amount of virus in 
the blood (and is usually given in RNA copies per millilitre of blood plasma). These 
tests are continuously being improved; the first viral load test had a lower limit of 
quantification of 10,000 copies/mL whilst some current tests now have a lower limit 
of quantification of 10 copies/mL or lower, although most tests in routine practice 
have a lower limit of 40-50 copies/mL.  
 
Figure 1.5.1: The natural history of the CD4 cell count during HIV infection (29) 
 
 
Other co-factors which impact on the rate of disease progression include older age 
(52-54), co-infection with cytomegalovirus (52), low concentrations of albumin 
(38;41), low concentrations of haemoglobin (38;55-57), female gender (58-60) and 
black ethnicity (58;61).  
 
1.6. Treatment of HIV 
There is currently no vaccine to prevent HIV infection. ART drugs are used to treat 
HIV infection by inhibiting the replication of HIV. Table 1.6.1 shows the ART drugs 
currently licensed in the UK and the date of approval from the Food and Drug 
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Administration (FDA). Historically, there have been 3 classes of ART drugs, though 
drugs from new classes are now part of clinical practice. The first drugs approved by 
the FDA to fight HIV infection were from the nucleoside reverse transcriptase 
inhibitor (NRTI) class and worked by preventing the HIV RNA from converting into 
double-stranded DNA, thus preventing the virus from reproducing. NRTIs had been 
used previously to treat malignancies and herpes virus and were first introduced to 
treat HIV infection in 1987. 
 
In 1995, the first protease inhibitor (PI) to treat HIV was approved by the FDA. 
Protease is one of HIV‟s enzymes. As the infected cell starts to produce viral 
proteins in order to produce new virions, it makes long chains of proteins and 
enzymes that will form new copies of HIV. However, in order to do this, the long 
chains have to be cut into smaller pieces by the HIV protease enzyme. PIs prevent 
this from happening. Although new copies of the virus are still made, these are not 
completely formed and so cannot infect other cells, slowing down the course of 
infection (62). 
 
Shortly after, a third class, the non-nucleoside reverse transcriptase inhibitors 
(NNRTI), was approved by the FDA in 1996. Like NRTIs, NNRTIs prevent the virus 
from being able to reproduce by targeting the structure of reverse transcriptase to 
inhibit enzyme activity. Enzymes are prevented from converting RNA to DNA, 
stopping the virus from making DNA to be inserted in the cell‟s genetic material, and 
hence preventing it from producing new virus. 
More recently, other classes of ARTs have been licensed by the FDA to treat HIV. 
Nucleotide reverse transcriptase inhibitors (NtRTIs) are similar to NRTIs but 
possess a phosphate molecule which NRTIs do not. This enables the NtRTI to skip 
the initial phosphorylation step needed by NRTIs for activation.  
 
Fusion or entry inhibitors work at an earlier stage in the HIV cycle, by preventing the 
virus from entering CD4 cells. By attaching themselves to the protein on the surface 
of the CD4 cells (or on the surface of HIV), entry inhibitors stop HIV from binding to 
the CD4 cells. The first integrase inhibitor was licensed in 2007. If HIV RNA is able 
to convert to DNA (i.e. the NRTIs/NtRTIs are unable to block this process), in order 
for HIV to reproduce, the HIV DNA must be incorporated into the CD4 cells DNA. 
Integrase inhibitors work by blocking this integration. Figure 1.6.1 illustrates the 
targets of the various HIV drug classes. 
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Table 1.6.1: Antiretrovirals licensed in the United Kingdom 
Antiretroviral agent Brand name Abbreviation Date UK 
license 
Common side effects 
Nucleoside reverse transcriptase inhibitors (NRTIs) 
Zidovudine  Retrovir© AZT or ZDV 1986 Headache, insomnia, nausea, stomach discomfort 
Didanosine Videx EC© ddI 1991 Numbeness, tingling, diarrhoea, vomiting, rash 
Zalcitabine Hivid© ddC 1992 Burning in hands/feet, numbeness, pain, tingling 
Stavudine Zerit© d4T 1994 Numbeness, tingling, diarrhoea, vomiting, rash 
Lamivudine Epivir© 3TC 1995 Insomnia, nausea, vomiting, abdominal pain, rash, fever 
Abacavir ZiagenTM ABC 1998 Insomnia, nausea, vomiting, abdominal pain, rash, fever 
Emtricitabine Emtriva FTC 2003 Dizziness, insomnia, nausea, diarrhoea, hyperglycaemia 
Protease Inhibitors (PIs)     
Saquinavir hard gel Invirase© SQV (HGC) 1995 Poor absorption, so rarely used 
Indinavir Crixivan© IDV 1996 Kidney stones in 6-8%, occasional nausea, GI upset 
Ritonavir Norvir© RTV 1996 Nausea, diarrhoea, numb lips, occasional hepatitis, 
hyperlipidaemia 
Saquinavir soft gel Fortovase© SQV (SGC) 1997  
Nelfinavir Viracept© NFV 1997 Diarrhoea, nausea 
Amprenavir AgeneraseTM APV 1999 Rash, diarrhoea, nausea 
Lopinavir+ritonavir Kaletra© LPV 2000 GI side effects common but mild, hyperlipidaemia 
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Tipranavir Aptivus TM TPV 2005 Raised lipids, liver disease 
Atazanavir Reyatz ® ATV 2003 High levels of bilirubin,  
Fos-amprenavir Telzir/LexivaTM  FPV 2003 Raised triglycerides,  
Darunavir Prezista DRV 2007 Diarrhoea, nausea, headache, skin rashes 
Non-nucleoside reverse transcriptase inhibitors (NNRTIs) 
Nevirapine Viramune© NVP 1996 Transient rash, hepatitis 
Efavirenz SustivaTM EFV 1998 Initial dizziness, insomnia, transient rash 
Delavirdine (Not licensed in UK)                                                               1997                        
Nucleotide reverse transcriptase inhibitors (NtRTIs) 
Tenofovir disoproxil fumarate VireadTM TDF 2001 Generally well tolerated 
Fusion (Entry)/CCR5 inhibitors 
Enfuvirtide Fuzeon ® T-20 2003 Skin reactions at injection site 
Maraviroc                                                                      Selzentry MRV 2007 Fever, upper respiratory infections, rash, diarrhoea 
Integrase inhibitors     
Raltegravir Isentress RTG 2007 Diarrhea, nausea, headache, and fever, rash, depression 
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Figure 1.6.1: HIV life cycle and anti-HIV drug targets  
Entry inhibitors work by 
stopping HIV getting into the CD4 
cell  
 
Reverse transcriptase 
inhibitors (NRTIs/NNRTIs) stop 
HIV changing from a single strand 
of RNA into a double strand of 
DNA  
 
Integrase inhibitors block HIV 
from being 'integrated' into the 
cell's DNA 
 
Protease inhibitors block new 
HIV from being cut into the right 
size proteins and this prevents 
new virus from being infectious 
 
Copyright (2002) American Medical Association. All rights reserved (63)
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1.6.1. History of ART and treatment strategies 
Although the first cases of AIDS were documented in 1981, it wasn‟t until 1987 that 
the first drug to treat HIV was approved by the FDA. Zidovudine (AZT), an NRTI, 
was initially administered as monotherapy. A randomised controlled trial comparing 
145 patients receiving AZT with 137 receiving placebo was terminated early due to 
the significantly higher number of deaths in the placebo arm (64). However, further 
research showed that this effect wasn‟t sustained beyond around 6 months. The 
Concorde trial compared immediate with deferred AZT monotherapy in 
asymptomatic HIV-positive patients and found no difference in clinical outcome 
between the two groups (65), showing only a limited beneficial effect on overall 
survival amongst patients with HIV. 
 
In the following years, three more NRTIs were approved by the FDA: didanosine 
(ddI) in 1991, zalcitabine (ddC) in 1992 and stavudine (d4T) in 1994.  Although each 
of these drugs used alone were somewhat effective in slowing down the progression 
of HIV, when used in combination with AZT, outcomes were further improved 
(64;66-69). However, it soon became clear that these improvements were also short 
lived. Strategies that involved either sequencing (i.e. discontinuing one NRTI and 
replacing it with another) or concomitant use of two NRTIs were not potent enough 
to suppress viral replication for long, allowing the virus to develop drug resistance 
mutations (Section 1.8.3)  
 
In 1995, the first PI, saquinavir invirase (hard gel capsules, SQV-HGC) was 
approved by the FDA. This essentially marked the beginning of the highly active 
antiretroviral (HAART) era. Used in conjunction with NRTIs (usually 2), SQV-HGC  
was associated with significantly better immunological and virological outcomes than 
dual NRTI therapy alone (70;71). Further, a statistically significant prolongation of 
time to first AIDS defining illness or death was observed in those receiving triple 
therapy compared with those receiving dual NRTIs. However, later studies showed 
that SQV-H was less potent than other PIs that subsequently became available, as it 
only had approximately 4% bioavailability (72), prompting the licensing of a soft-gel 
version of the drug in 1997 (saquinavir fortovase, SQV-SGC) (73). 
 
Two other PIs, indinavir (IDV) and ritonavir (RTV) were approved by the FDA shortly 
after SQV-HGC and were associated with a dramatic improvement in HIV disease 
outcomes in both early and late disease (74-76).  Different combinations of PIs and 
NRTIs were examined and evidence in favour of triple therapy again emerged. Due 
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to the high toxicity associated with full dose ritonavir (77-80), and the high 
interaction levels with other drugs (81;82), full dose ritonavir was not recommended. 
However, low doses of ritonavir were used to pharmacologically „boost‟ the levels of 
other PIs when taken together, because it inhibits the breakdown of the drug in the 
liver. Regimens consisting of boosted PIs (in conjunction with 2 NRTIs) had fewer 
adverse events than when using full dose ritonavir and better clinical outcomes than 
single PIs (83-85). 
 
In 1996 a third class of ART was introduced. Nevirapine was the first NNRTI 
approved by the FDA. Regimens containing nevirapine and two NRTIs not only 
showed superior efficacy than dual NRTI therapy alone (86;87) but also compared 
well against PI-containing regimens.  The COMBINE Study compared 70 patients 
receiving two NRTIs and nelfinavir (a PI approved by the FDA in 1997) with 72 
patients receiving two NRTIs and nevirapine; the study investigators concluded that 
the regimen containing the NNRTI was at least as effective as that containing the PI 
(88;89). Other studies have also reached similar conclusions (89;90).  
 
However, as with earlier drugs, nevirapine also had disadvantages. Although the 
most common adverse event was mild or moderate rash, particularly amongst 
women (91;92), it soon became evident that the emergence of resistance was a 
major concern. Amongst patients who did not achieve viral suppression, resistance 
developed rapidly – the virus mutated and was able to multiply, reducing the ability 
of particular drugs to block HIV replication (Chapter 2.1) (86;93;94). The FDA 
approved two other NNRTIs in the following two years; delavirdine in 1997 and 
efavirenz in 1998. Although triple therapy including delavirdine (in combination with 
2 NRTIs) was shown to be have somewhat better clinical efficacy than dual NRTI 
therapy (95), this difference was only modest (96). Further, delavirdine did not 
appear to provide any significant improvements over nevirapine (97), although its 
use amongst patients who had failed previous regimens, especially those containing 
PIs, was recommended (98;99).  Consequently, delaviradine has not been licensed 
in Europe. 
 
Efavirenz, on the other hand, compared well against nevirapine. Results from 
several cohort studies showed efavirenz to be either superior or equivalent to 
nevirapine, both in terms of CD4 increase and virological suppression (100-103). 
Further, adverse events (i.e. hepatotoxicity and rash amongst patients taking both 
drugs) were generally comparable (104-106), though in a large randomised trial, the 
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2NN study published in 2004, patients receiving NVP were at a greater risk of 
hepatotoxicity. Although it is well documented that patients using efavirenz are likely 
to experience short-term side effects associated with the central nervous system 
(107-109), data showing similar effects amongst patients using nevirapine also exist 
(110). The 2NN study found no significant differences in week-48 virological 
outcomes amongst those starting HAART with two NRTIs and either efavirenz or 
nevirapine (104). These results verified the clinical similarities between the two 
NNRTIs reported by authors of a smaller trial a few years earlier (111). 
 
1.6.2. PI vs. NNRTI containing HAART 
Given the relative success of both boosted PI- and NNRTI-containing HAART 
regimens, together with the number of NRTI drugs available (Lamivudine (3TC) was 
licensed in 1995 and Abacavir (ABC) in 1998) at the time when efavirenz was 
approved by the FDA, there was a choice of not only which drugs to start treatment 
with but also which class of drugs. Patients starting HAART with PI-containing 
regimens were likely to experience severe long-term toxicities, including an 
increased risk of lipodystrophy (this has since mainly been ascribed to the NRTIs in 
the regimen) and hyperlipidemia (112;113). However, these regimens had been 
associated with improved clinical outcomes and had the added advantage of 
requiring several mutations to confer resistance. Resistance to NNRTIs, on the other 
hand, is likely to develop quickly if viral suppression is not achieved or maintained. 
Only one resistance mutation is needed to confer resistance to either of the two 
original NNRTIs and there is the added complication of patients often being resistant 
to all drugs from the NNRTI class if they develop resistance to any NNRTI drug 
(114-116). However, NNRTIs have the advantages of fewer diet restrictions, less 
frequent dosing and greater tolerability, outweighing the risk of resistance for many 
clinicians and/or patients.  
 
Many studies have compared the efficacy of PIs (boosted or single) with NNRTIs. A 
meta-analysis published in 2006 by Chou et al (117) found 12 trials of at least 24 
weeks duration which directly compared NNRTI-based versus PI-based therapy in 
patients with limited or no previous exposure to ART. Virological results favoured 
NNRTI-based regimens, though the difference was reduced when a subset of higher 
quality trials was considered. No difference was found in death rates, disease 
progression or adverse events between the two groups. A previous meta-analysis 
published in 2004 had also shown NNRTI- to be superior to PI-based regimens 
(118). Other meta-analyses have found PI-regimens to be superior, but these are 
    36 
 
 
often indirect comparisons of smaller and older trials, so newer drugs such as 
efavirenz were not included (119). The choice in the use of PI or NNRTI regimens 
as first-line therapy is also dependent on clinical site. Data from the UK 
Collaborative HIV Cohort (CHIC) Study published in 2008 showed that although the 
use of PIs in first-line regimens declined from 1997 to 2000 in most centres, the rate 
of decline varied between centres. An increase in the proportion of patients being 
prescribed NNRTIs was also observed over the same time period, and though this 
increase appeared to stabilise from 2000 to 2005 at around 80% for most centres, 
only 40% of patients were being prescribed NNRTI-regimens at one particular 
centre in 2005. Results from multivariable regression showed clinical site and 
calendar year to be independent predictors in the choice of first-line therapy (120). 
On the whole, in recent years, NNRTI-therapy is the preferred choice as a first-line-
regimen, leaving PI-based regimens as options for those who do not achieve viral 
suppression.  
 
1.6.3. Drugs approved in the last 10 years 
Since 1998, several more ART drugs have been approved to fight HIV infection. 
Newer drugs from existing classes tend to have fewer side effects and require less 
frequent dosing. They offer options to patients who have virologically failed existing 
drugs and have resistance to those failed drugs and others with a similar resistance 
profile. Further, these new drugs are also used as part of first-line regimens. In the 
NRTI/NtRTI classes, emtricitabine (FTC) was approved in 2003 and tenofovir (TDF) 
in 2001. Six PIs have been licensed since 1998; amprenavir (APV) in 1999, Kaletra 
(consisting of lopinavir co-formulated with low dose-ritonavir, LPV) in 2000, 
atazanavir (ATV) in 2003, fos-amprenavir (FPV) in 2003, tipranavir (TPV) in 2005 
and darunavir (DRV) in 2006. These PIs are now rarely used without low-dose 
ritonavir. Etravirine (ETR) is the newest NNRTI to be licensed (2008) and unlike 
efavirenz/nevirapine, resistance to other NNRTIs does not seem to always confer 
high level resistance to etravirine (121), though this is likely to depend on which 
mutations are present.   
 
The first, and thus far only, fusion inhibitor to be licensed was enfuvirtide (T-20) in 
2003. It was thought that this drug may open treatment options for patients who had 
advanced HIV infection and were unable to achieve viral suppression using existing 
drugs. However, T-20 has to be injected twice daily, can cause local painful skin 
reactions and some patients using T-20 may develop bacterial pneumonia. Further, 
T-20 is the most expensive ART drug used to treat HIV. These issues have led to T-
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20 being rarely used for any patients, other than those with documented resistance 
to the three main drug classes. Maraviroc is an entry inhibitor which was approved 
for treatment experienced patients in 2007. Also known as a CCR5 antagonist, 
clinical trials showed that patients taking maraviroc (with other ART drugs) were 
more likely to achieve viral suppression than those taking placebo (with the same 
other drugs) and reported no clinically relevant differences in safety between the two 
groups (122). Raltegravir is the only integrase inhibitor to be currently approved. 
Licensed in late 2007, raltegravir is recommended for use amongst patients who are 
resistant to other HIV drugs/classes. Patients taking raltegravir in clinical trials 
achieved viral suppression sooner than those taking NNRTIs and PIs. Research on 
how raltegravir alters HIV viral dynamics and decay is ongoing (123).  
 
1.6.4. Treatment guidelines – what to start therapy with 
The British HIV Association (BHIVA) was founded in 1995 and is a well established 
organisation that produces guidelines for the management of HIV infection for the 
UK. The International AIDS Society (IAS) is a worldwide organization of 
professionals and was established in 1985. The IAS also produces a wide range of 
guidelines for both patients and clinicians for managing HIV infection. Other advisory 
boards include the European AIDS Clinical Society (EACS) and the United States 
Department of Health and Human Services (DHHS).  
First-line regimens recommended by these groups have changed to reflect the 
steady emergence of new drugs since 1985. Table 1.6.4.1 shows both BHIVA and 
IAS simplified guidelines for the first-line treatment of HIV infection in adults since 
1996. Factors such as initial CD4 count, pregnancy and transmitted drug resistance 
may influence treatment choice.  
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Table 1.6.4.1: Simplified IAS and BHIVA guidelines for first-line treatment of 
HIV infection 
 IAS-USA BHIVA 
Year of 
publication 
Nucleoside 
backbone 
‘third’ drug Nucleoside 
backbone 
‘third’ 
drug 
2008 (124;125) TDF+FTC or 
ABC+3TC 
EFV or PI/r1 TDF+FTC or 
ABC+3TC 
EFV 
2006 (126;127) TDF+FTC or 
AZT+3TC or 
ABC+3TC 
EFV or PI/r2 TDF+FTC or 
AZT+3TC or 
ABC+3TC 
EFV or 
LPV/r or 
FVP/r 
2005 (128) - - TDF+FTC or 
AZT+3TC or 
ABC+3TC 
EFV or 
LPV/r 
2004 (129) AZT+3TC/FTC or 
TDF+3TC/FTC 
EFV or PI/r3 - - 
2003 (130) - - 2 NRTIs NNRTI or 
LPV/r or 
SQV/r 
20024 (131) 2 NRTIs NNRTI or PI/r or 
ABC 
- - 
2001 (132) - - 2 NRTIs NNRTI 
2000 (133;134) 2 NRTIs NNRTI or PI/r 2 NRTIs PI or PI/r 
or NNRTI 
1998 (135;136) 2 NRTIs PI (unboosted) 2 NRTIs PI or PI/r 
or NNRTI 
1997 (137;138) 2 NRTIs PI (unboosted) 2 NRTIs Na 
1996 (139) 2 NRTIs - - Na 
1
LPV, AZV, FPV, DRV or SQV 
2
LPV, AZV, FPV or SQV 
3
LPV, AZV, SQV or IDV 
4
Specific 
drugs not specified before and including 2002 
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1.7. Treatment of HIV in children and pregnant women 
Up to 30% of babies born to HIV-positive women are likely to become infected with 
HIV if the mother does not receive antiretroviral treatment during pregnancy (140). It 
has been reported that up to a further 20% are likely to be infected through breast-
feeding. However, the risk of HIV infection in babies can be reduced to less than 2% 
if the mother is receiving antiretroviral treatment during pregnancy and if the baby is 
bottle-fed. Elective caesarean section and prophylactic treatment for the newborn 
baby also contribute to reducing this risk (141;142). Although the rate of disease 
progression varies greatly in children, children are likely to progress to AIDS more 
quickly than adults (143;144). The antiretroviral drugs used to treat HIV-positive 
children are the same as those licensed to treat adults, though doses are dependent 
on age. Although children have been shown to achieve virological suppression and 
CD4 increases whilst taking HAART, the degree of response is somewhat less than 
that seen in adults (145).  
 
1.8. Limitations of ART 
HIV replication occurs at an extremely high rate in untreated individuals. The 
number of new virions created each day is estimated to be in the region of 1 to 10 
billion copies (146;147). ART drugs are unable to completely stop all HIV replication 
(new replication may be stopped but if ART is discontinued, infected cells are 
activated and start producing virus) and so the aim of therapy is to suppress viral 
replication for as long as possible. However, there are several interlinked barriers to 
successful treatment. Adherence to therapy, toxicities associated with ART drugs 
and resistance to ART drugs/classes are major issues which may prevent the 
optimal treatment of HIV.  
 
1.8.1. Adherence 
Maintaining a high level of adherence to an ART regimen is vital for sustaining viral 
suppression (148-151). It has been reported that in order for HIV medications to 
effectively reduce viral load, adherence rates must be around 95% (152) if receiving 
unboosted PIs, though this percentage is lower amongst patients receiving NNRTI-
based regimens (153). However, toxicities associated with ART may make this a 
difficult target to achieve. Busy lifestyle choices and the need to take certain drugs 
with particular foods may reduce adherence rates further. Studies have shown 
certain groups of patients are less likely to be adherent to medication than others. In 
particular, patients who contracted HIV via intravenous drug use, those of younger 
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age, females and patients of black African ethnicity (154-159) are likely to have 
lower adherence, leading to poorer virological response.  
 
1.8.2. Drug toxicity 
Drug toxicity is a major barrier to successful HIV treatment. Regimens containing 
drugs with high toxicities are likely to result in lower levels of adherence (160) and 
thus patients are less likely to achieve virological suppression. HIV drug toxicity was 
first described with the introduction of AZT and has since been associated in some 
form with almost all HIV antiretroviral drugs. Toxicities may be acute or long-term 
and either class specific or drug-specific.  
 
One of the most serious side effects of NRTIs/NtRTIs is mitochondrial toxicity. 
Associated in particular with the „d-drugs‟, d4T, ddI and ddC, mitochondrial toxicity 
can lead to pancreatitis and peripheral neuropathy (161;162). The newer NRTI, 
ABC, has been shown to cause hypersensitivity reactions in around 8% of patients 
(163;164) and ABC has also been associated with a raised risk of myocardial 
infarction (165). Dyslipidemia, (e.g. high total and LDL cholesterols, elevated 
triglycerides and reduced HDL-C) and gastrointestinal side effects are generally 
associated with PIs (166). As mentioned earlier, efavirenz has been associated with 
a risk of dysphoria (107). Short-term milder toxicities, such as nausea, vomiting, 
diarrhoea, anaemia and headaches have been associated with most available drugs 
(Table 1.6.4.1).  Hepatotoxicity (can also be acute), renal disease and ALT 
elevations are examples of longer-term toxicities. Definitions of such toxicities vary 
considerably and are discussed in detail in Chapter 2.2.1.  
 
1.8.3. Resistance 
At the time of HIV infection, usually a single virus replicates (i.e. individuals are 
infected with a single strain), producing new virions as mentioned above. As the 
RNA genome is transcribed to viral DNA, replication of the virus is highly error-
prone. There is a high frequency of alterations to the genetic code, resulting in 
genetic mutations in the replicated copies of the virus (167). Mutations cause 
different strains of the virus to be produced.  Some of these mutations are harmful to 
the virus – they cause changes in the viral proteins that are needed for viral 
replication.  
 
There are some mutations, however, which are advantageous to the virus. In the 
presence of therapy, genetic mutations may exist that allow the virus to replicate, 
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despite the presence of antiretrovirals. This strain, with mutations conferring 
resistance to antiretroviral drugs is more likely to survive than one which is drug-
sensitive (i.e. wild type) and hence is known to have a higher level of fitness in the 
presence of therapy. 
 
Resistance mutations are often drug specific but can also be class specific. If a 
mutation occurs in the reverse transcriptase or protease region of the virus, 
antiretroviral drugs designed to inhibit viral replication in these areas may have a 
reduced effect or no effect at all. Such mutations are often referred to as primary 
resistance mutations. In the presence of ART, strains with resistance mutations will 
tend to out-compete other strains because they are able to replicate in the presence 
of ART. If therapy is subsequently stopped, the wild type virus is likely to have 
higher fitness than the resistant strain and hence will become the dominant strain 
again (168). For example, if a patient receiving 3TC has developed a strain of virus 
resistant to 3TC and subsequently stops therapy, the HIV variants with the mutation 
associated with 3TC (M184V) rapidly disappear (169). The resistant virus however 
does remain a minority sub-species, and so if the patient was reintroduced to 3TC 
monotherapy, the resistant virus is likely to again become the dominant virus, 
making virological suppression unlikely.  
 
In the absence of ART, the strain of virus which is able to replicate the most quickly 
is known as the „wild type‟ virus. Since some or most resistance mutations tend to 
result in some reduced replicative capacity of the virus, when the associated drug is 
no longer used they tend to get outcompeted and replaced by virus without such 
mutations. 
 
A strain of HIV which is resistant to antiretroviral drugs is more likely to dominate 
amongst patients in whom viral suppression is not achieved. For example, patients 
who were exposed to sub-optimal therapy such as AZT monotherapy were unlikely 
to achieve low viral loads – the ongoing replication of virus results in a higher 
number of mutations and therefore a higher chance of these mutations being 
resistance mutations. When such resistance mutations arise, they will be selected 
for as they have the advantage of the presence of a particular drug (if this particular 
drug was not present, the resistance mutations would not be selected). Patients with 
low levels of adherence to therapy are also at increased risk of developing 
resistance since their viral loads are unlikely to be suppressed.  
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Drug resistance may also be present amongst patients who receive optimal HAART 
therapy as their first-line of treatment. These patients are likely to have been 
infected with a strain of virus which was already resistant to specific drugs/classes. 
This, together with the impact of resistance amongst patients who start second-line 
HAART, is discussed in detail in Chapter 2.2.1. 
 
These limitations of ART are all interlinked - for example, a patient may be infected 
with a drug resistant virus which will limit his/her treatment options from the outset. 
After starting treatment, toxicity to drugs may result in poor adherence and even 
discontinuation of treatment altogether. This is then likely to result in accumulation of 
resistance, prompting a switch in regimen and potential for further toxicities.  
  
1.9. Focus of thesis 
My thesis will be focused on the barriers to successful treatment which are of key 
importance in the developed world. A more detailed literature review forms Chapter 
2 of the thesis and the methodology of the thesis is discussed in Chapter 3 – this 
includes a description of the processes involved when establishing and linking the 
datasets, as well as a summary of trends over time in key markers of clinical 
success within the UK CHIC Study. Chapter 4 describes the frequency of 
transmitted resistance and the impact of such resistance on the selection of first-line 
therapy. In Chapter 5, I investigate how well the selection of second-line therapy 
relates to identified resistance mutations of first-line therapy. I discuss a particular 
toxicity to treatment in Chapter 6 (ALT flares). In this Chapter, I also justify the need 
for a new definition of an ALT flare and derive such a definition. The impact of 
treatment interruptions on long-term virological outcomes is discussed in Chapter 7. 
In Chapter 8, I develop a combined score for a range of toxicities to predict mortality.  
Finally, an overall summary and discussion of the above chapters is provided in 
Chapter 9.   
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Chapter 2: Literature review 
2.  
  
2.1. HIV drug resistance 
 
2.1.1. HIV drug resistance testing 
Resistance testing is now recommended in all newly diagnosed patients and those 
who are looking to change treatment because of virological failure (124). Currently 
there are two types of resistance tests: genotypic and phenotypic.  
 
2.1.1.1. Genotypic resistance testing 
Genotypic resistance testing generates a list of mutations which are known to confer 
resistance to antiretrovirals; such tests are generally recommended for those who 
have recently been infected or have used only a limited number of HIV 
antiretrovirals. There are two main types of genotypic tests: sequencing assays and 
point-mutation assays. Sequencing assays are used to detect mutations in genes 
that are involved in the replication of HIV, i.e. the reverse transcriptase and protease 
genes. The assays give a complete nucleotide sequence by means of cycle 
sequencing (dideoxy chain termination) or gene chip sequencing. Point mutation 
assays detect mutations in the specific genes that are known to cause antiretroviral 
drug resistance and are cheaper and easier to perform and interpret. As a result, 
these are performed more often than sequencing assays. 
 
A blood plasma sample is used to examine whether the virus in the blood contains 
any mutations. This is done by comparing the genetic code in the virus in the 
plasma sample to that of wild type virus. This code is a chain of molecules called 
nucleotides; each group of three nucleotides (defined as a „codon‟) defines a 
specific amino acid which forms part of any new virus produced. Mutations are 
described using a combination of letters and numbers. The K103N mutation for 
example, correlates with high-level resistance to efavirenz and confers cross 
resistance to nevirapine and delavirdine (114;116). The first letter „K‟ is the code for 
the amino acid in the wild type virus. The position of the codon is identified by the 
number „103‟, and the last letter „N‟ is the code for the altered amino acid in the 
mutated virus. Interpretation of mutations is not straight-forward.  A single mutation 
could result in resistance to one drug but make the virus more sensitive to a different 
drug. Further, in some cases, several mutations are required to exist in order for the 
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virus to be resistant to a single antiretroviral drug, whilst in other cases, only one 
particular mutation may be required for HIV to be resistant to an entire class of 
antiretrovirals. 
 
Several genotypic resistance interpretation systems have been developed, most of 
which are rule based (http://hivdb.stanford.edu/, http://www.hivfrenchresistance.org/, 
http://www.kuleuven.ac.be/rega/cev/links/rega_algorithm/index.htm). Each algorithm 
outputs a genotypic sensitivity score (GSS), which predicts how resistant the virus is 
to each drug. However, substantial differences in the interpretation of genotypic 
results using these different systems have been reported (170-172).  Genotypic 
tests do not provide a direct measure of resistance and tests may not be useful if a 
patient‟s viral load is below 1000 copies/mL as it may not be possible to amplify the 
virus. Further, patients may have many different strains of virus and genotypic tests 
are unable to detect minority mutations, which may occur in less than 20% of the 
virus population (173). Genotypic tests are, however, relatively cheap, have a quick 
turn-around time and are now commonly used in clinical practice to test for 
resistance in HIV-positive patients. 
 
2.1.1.2. Phenotypic resistance testing 
Phenotypic tests measure the ability of HIV to reproduce in the presence of 
antiretrovirals. Blood plasma samples are divided into many test tubes and mixed 
with different antiretroviral drugs. The concentration of each drug is gradually 
increased until it is high enough to stop viral replication. The results are compared to 
a wild type virus that is known to be 100% susceptible to all antiretrovirals and a 
resistance „profile‟ is created (174). Clinical cut-offs are used to determine whether 
the virus is resistant to each drug and, if resistance does exist, the level of 
resistance (high, intermediate, low) is defined; results are, however, somewhat open 
to interpretation (175;176). A lower cut-off is used to determine the value at which a 
particular drug has partial susceptibility and an upper cut off defines the point at 
which no clinical response is expected. 
  
Since phenotypic tests measure the combined effect of all mutations, they may be 
more useful in patients who are likely to have multiple mutations. Phenotypic tests 
also provide a quantitative measure of resistance, which is particularly useful for 
patients who have limited treatment options. A disadvantage of phenotypic testing is 
that it is unable to measure how combinations of drugs work together (although this 
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is a challenge also when using genotypic testing). Phenotypic testing is also 
considerably more expensive and time-consuming than genotypic testing.  
 
2.1.1.3. Virtual resistance testing 
This method uses genotypic tests to predict phenotypic results. A database 
containing matched genotypic and phenotypic data of over 10,000 patients is used 
to match the results of a genotypic assay to that of other patients in the database. 
The corresponding phenotypes are extracted and a predicted result, i.e. the virtual 
phenotype, is synthesized (177).  
 
2.1.2. Primary and secondary drug mutations 
Resistance mutations are generally defined as either primary or secondary 
mutations. Each antiretroviral drug is known to be associated with at least one 
primary mutation and it is these mutations that are associated with some level of 
resistance. However, the identification of a primary mutation does not guarantee 
high-level resistance as further mutations may reverse the effect. Secondary 
mutations cannot cause drug resistance unless a primary mutation is present. 
Combinations of secondary mutations are complex to interpret and confer varying 
levels of resistance.  
 
2.1.3. Transmitted drug resistance (TDR) 
There has been evidence of the transmission of drug-resistant virus strains since the 
AZT monotherapy era (178-180). Newly infected patients were found to be resistant 
to AZT despite never having taken the antiretroviral before. Since then, the number 
of antiretroviral drugs used to treat HIV infection has increased considerably and 
hence the number of patients infected with a virus resistant to specific antiretrovirals 
also initially increased (though is now decreasing), limiting future treatment options 
for patients infected with resistance virus from the outset.   
 
2.1.3.1. Prevalence of TDR   
The prevalence of TDR globally has been reported to range from 1 to 25% (181). 
This difference is likely to be explained by the variation in study patients/design, the 
access and availability of antiretroviral drugs, the sensitivity of the resistance assays 
and the differences in interpretation of the results from the resistance tests. The IAS-
USA drug resistance mutation list maintains a current list of mutations associated 
with resistance (182). This list has been edited by Shafer et al, who have compiled a 
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list of drug-resistance mutations for epidemiologic estimates of transmitted 
resistance (183) (most recently updated in 2009 by Bennett et al (184)). Recently 
published studies found little difference between the two lists and other 
interpretation algorithms when estimating overall rates of resistance in a cohort 
study (185;186).  
 
Transmitted resistance mutations can exist for several years since there is no 
archived dominant wild type virus present in the infected individual (187-189). A 
recent study, based on expected infection duration, has suggested that transmitted 
resistance mutations may exist for up to 8 years (190). TDR, though reported 
worldwide, is most prevalent in the United States of America (US) and Europe. A 
study published by Shet et al on a New York City cohort of newly infected HIV 
individuals found that the prevalence of TDR had increased from 13% in 1995-8 to 
24% in 2003-4 (191). This is the current highest reported prevalence of TDR 
worldwide. Of note, rates of TDR are often conservative. Even amongst patients 
who have been infected with a virus resistant to ART, the majority virus is likely to 
revert back to wild type in the absence of therapy. In this case, the person has 
clinically significant resistance (which is likely to re-emerge if the relevant drug is 
taken), but this is not detectable using standard resistance testing. Hence the longer 
the duration between infection and resistance testing, the less accurate the test 
result. 
 
Since the vast majority of patients currently living with HIV in developed countries 
have access to HAART, the literature review on TDR will focus on those papers 
published from 1996 onwards in Europe, North America, South America and 
Australia. A summary of these papers is presented in Table 2.1.3.1.1. 
 
  
 
    
4
7 
Table 2.1.3.1.1: Studies investigating the prevalence of TDR 
Author, region 
and year of 
publication 
Year 
diagnosed 
N Main 
risk 
Age  Interpretation 
algorithm 
Prevalence (%) of TDR Risk factors for 
TDR/other main 
results 
      Overall MDR NRTI NNRTI PI  
Hattori, Japan 
2010
(192)
 
2003-2008 2573 MSM 35 Stanford 7.7 na na na na Subtype B 
Stanczak, Poland 
2010
(193)
 
2008 95 MSM 32 Stanford 5.3 0.0 na 1.1 4.2 na 
Murillo, Hondruas 
2010
(194)
 
2004-2007 200 Het 31 ANRS 7.0 2.5 3.0 5.0 0.5 na 
Wheeler, US 
2010
(195)
 
2006 1997 MSM na Stanford 14.6 2.6 5.6 7.6 4.5 na 
Haidara, Mali 
2010
(196)
 
2007-2008 101 na 35 Virco 9.9 1.0 5.0 6.0 0.0 na 
Liao, China 
2010
(197)
 
2004-2005 676 Blood doners 38 Stanford 3.8 na 1.6 2.1 0.4 na 
Riva, Italy 2010
(198)
 1992-2003 112 
CAS
1
 
271 
SPR 
MSM 
Het 
31 
35 
IAS-USA 15.1 
12.2 
0.0 
2.6 
8.0 
7.7 
0.9 
5.5 
0.0 
2.9 
na 
Vercauteren 
(SPREAD),  Europe 
2009
(199)
 
2002-2005 2793 MSM 37 SDRM-list 8.4 1.0 4.7 2.3 2.9 Subtype B 
Bracciale, Italy 
2009(200) 
1996-2007 1690 Het 36 SDRM-list 15.1 3.7 11.0 6.0 4.0 Low VL, high CD4, 
subtype B 
Green, UK 2008
(185)
 
 
1997-2008 
 
8272 
sample 
na na 1)IAS-USA 
2)SDRM-list 
3)Stanford 
1) 10.0 
2)  9.2 
3) 10.4 
na na na na na 
Madsen, Greenland 
2008
(201)
 
1999-2007 
 
60 Het na Stanford 25.0 10.0 na na na na 
Payne, UK 2008
(202)
 
 
2005-2007 
 
406 70.6% Het 35 IAS-USA & 
Stanford 
3.3 0.0 0.5 1.8 1.0 None 
Bannister, UK 2008 1996-2004 525 na na SDRM-list & 11.4 1.7 9.3 1.0 3.0 HCV+, region. 
  
 
    
4
8 
(203)
  Stanford  TDR did not impact on 
CD4/VL response 
Huang, US 
2008
(204)
 
2005-2006 
 
228 55.7% 
MSM 
37 Stanford 12.1 2.2 4.5 9.8 1.8 na 
Vercauteren, 
Belgium 2008
(205)
 
2003-2006 
 
285 55.0% MSM 36 SDRM-list & 
REGA 
9.5 na 7.0 3.5 1.8 Subtype B, Belgian 
nationality 
SPREAD Program, 
Europe 2008
(206)
 
2002-2003 
 
1050 44.0% 
MSM/Bi 
37 IAS-USA & 
REGA 
9.1 0.1 5.4 2.6 3.0 na 
Brenner, Canada 
2008
(207)
 
1997-Jul 
07 
848 MSM/IDU na SDRM-list 14.9 2.1 6.8 7.6 5.0 na 
Cachay, US 
2007
(208)
 
2004-2006 115 89% MSM 32 Genseq
Tm
 & 
IAS-USA 
23.0 1.7 10 11 2.6 Methamphetamine use 
Booth, UK 2007
(209)
 2004-2006 
 
239 52.7% MSM 35 IAS-USA & 
Stanford 
7.1 0.4 4.2 1.7 1.7 Born in the UK, high 
baseline CD4 
Yerly, Switzerland 
2007
(210)
 
1996-2005 
 
822 42% MSM na 1)Stanford  
2)ANRS 
1) 7.9 
2) 7.7 
na 1) 6.0 
2) 5.5 
1) 2.0 
2) 1.9 
1) 2.5 
2) 2.7 
Subtype B 
Poggensee, 
German 2007
(211)
 
1988-2004 
(majority 
>2001) 
504 88.0% MSM 32 IAS-USA & 
Stanford 
16.0 2.0 9.1 2.0 2.8 TDR did not impact on 
VL response 
Parker, US 
2007(212) 
2000-2004 
 
151 53.0% Het 39 IAS-USA & 
Stanford 
11.3  6.6 5.3 0.7 na 
Peuchant, France 
2007
(213)
 
2004-2005 
 
55 76.4% MSM 35 IAS-USA & 
ANRS 
20.0 
res to 
T-20 
na na na na na 
UK Collab/UK CHIC 
/UK Seroconv 
2007
(214)
 
1996-2004 
 
4454 
sample 
na na IAS-USA 9.2 in 
2004 
na 4.6 4.4 2.1 na 
Ross, US  
2007
(215)
 
2007 317 74% MSM na 1)Phenosense 
2)IAS-USA 
1) 8.0 
2) 0.0 
na 1) 1.0 
2) 0.0 
1) 7.0 
2) 0.0 
1) <1 
2) 0.0 
White ethnicity 
Fox,UK 2007
(216)
 
 
2005-2006 140 61% MSM 34 IAS-USA 9.4 na 2.7 4.0 0.7 na 
Sagir, Germany 
2007
(217)
 
2001-2005 
 
831 51.0% MSM na IAS-USA & 
geno2pheno 
9 1.3 na na na Non-white ethnicity, 
non-B subtype, non-
MSM 
Rodrigues, Brazil 
2006
(218)
 
2004 108 ~80% Het 31 Stanford 3.0 na na na na na 
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9 
Petroni, Argentina 
2006
(219)
 
2004-2005 
 
52 52.0% Het 36 IAS-USA 7.7 RT 
0.0 PI 
na na na na na 
Oette, Germany 
2006
(220)
 
2001-2003 
 
269 48.3 %MSM 39 IAS-USA 11.2 1.5 8.6 3.7 1.5 TDR did not impact on 
CD4/VL response 
Fox, UK 2006
(189)
 2000-2004 
 
140 ~90% MSM 32 Stanford 6.0 1.4 na na na TDR did not impact on 
VL response 
Truong, US 
2006
(221)
 
2004 
 
129 78% MSM 41% 
>35 
IAS-USA & 
Stanford 
13.2 3.1 na 8.5 na na 
Jayaraman, 
Canada 2006
(222)
 
2000-2001 
 
715 na na IAS-USA 8.1 1.0 4.1 1.4 1.5 na 
Shet, US 
2006
(191)
 
2003-2004 116 97.0% MSM 35 IAS-USA 24.1 9.8 16.1 13.4 7.1 TDR did not impact on 
CD4/VL response 
Bezemer 2006  
UK
(223)
 
1984-2005 440 na na IAS-USA & 
Stanford 
14.8 na na na na na 
Babic 2006 
Slovenia
(224)
 
2000-2004 
 
77 62.3% MSM 36 IAS-USA & 
Stanford 
3.9 na 3.9 0.0 0.0 na 
Cane, UK 2005
(225)
 1996-2003 2357 76.4% MSM na Stanford 14.2 2.0 9.9 4.5 4.6 na 
Masquelier, UK 
2005
(226)
 
1987-2003 
 
438 74.9% MSM 32 IAS-USA & 
Stanford4 
10.3 0.5 5.7 >1 
NRTI 
3.4 3.0 No sig factors 
associated with TDR 
Paraskevis, Greece 
2005
(227)
 
2002-2003 
 
101 55.0% MSM 37 IAS-USA 9.0 0.0 5.0 4.0 0.0 na 
De Mendoza, Spain 
2004
(228)
 
1997-2003 
 
89 75.3% MSM na IAS-USA 16.8 4.5 14.6 3.4 3.4 na 
Weinstock, US 
2004
(229)
 
1997-2001 1082 45.3% Het 
44.5% MSM 
na Automated 
sequencing 
8.3 1.3 6.4 1.7 1.9 na 
Ammaranond, 
Australia 2003
(230)
 
1992-2000 
 
130 na na na na na 30.8 na 0.8 na 
Little, US 
2002
(231)
 
1995-2000 
 
301 77.0% 
MSM 
35 IAS-USA 12.0 na na na na TDR associated with 
longer time to VS 
Simon, US 
2002
(232)
 
1995-2001 
 
154 >90% MSM na IAS-USA 13.2 -
19.7 
2.6 – 
4.0 
13.2 - 
18.4 
na 1.3 - 
5.3 
na 
Violin, Italy 2002
(233)
  1995-1998 68 na  na na 1.5 14.7 0.0 5.9 na 
Grant, US 
2002
(234)
 
 
1996-2001 
 
225 86.2% MSM 35 IAS-USA 23.1 13.2 in 
00/01 
20.9 in 
00/01 
13.2 in 
00/01 
7.7 in 
00/01 
Higher CD4 counts 
/TDR associated with 
longer time to VS 
Goudsmit, Holland 1990-1998 43 na na IAS-USA 7.0 na na na na na 
  
 
    
5
0 
2001
(235)
  
Briones, Madrid 
2001
(236)
 
1997-1999 
 
30 70.0% MSM 31 IAS-USA 26.7 6.7 23.3 3.3 6.7 na 
Duwe, Germany 
2001
(237)
 
1996-1999 
 
64 89.1% MSM na US Los Alamos 
database 
Pheno:
13% 
na 9.4 4.7 na 
Garcia, US 
2001
(238)
 
1997-1999 
 
603 na na Phenotypic 3.3 
ZDV 
na na na na na 
UK Collaborative 
Group, 2001
(239)
 
1994-2000 
 
69 84.1% MSM na IAS-USA 14.0 2.9 na na na Later calendar year 
Descamps, France 
2001
(240)
 
1998 
 
404 48.5% MSM 35 IAS-USA & 
ANRS 
3.4 na 3.3 0.8 1.9 Low baseline viral load 
Weinstock, US 
2000
(241)
 
1993-1998 
 
99 57.0% Het 29 IAS-USA 7.0 1.0 4.0 1.0 na 
Balotta, Italy 
2000
(242)
 
1994-1997 
 
38 44.7% MSM na Phenotypic 21% 
ZDV 
na na na na TDR did not impact on 
CD4/VL response 
Tamalet, France 
2000
(243)
 
1995-1998 
 
48 na na IAS-USA na na 17.0 2.0 TDR did not impact on 
CD4/VL response 
Salomon, Canada 
2000
(244)
 
1997-1999 
 
81 64.3% MSM na Phenotypic na na 18.5 12 na 
Boden, US 
1999
(245)
 
1995-1999 
 
80 93.8% MSM na US Los Alamos 
database 
na 3.8 12.5 7.5 2.5 na 
Yerly, Switzerland 
1999
(246)
 
1996-1998 
 
82 40% MSM, 
40% Het 
34 Schinazi 1997 na 1.2 10 4.9 na 
Age is summarised as „median‟ age. 
MDR: Multi-drug resistance (resistance to >1 class of ART drugs), MSM: Men having sex with men, Het: Heterosexual, Bi: Bisexual, na: Not applicable 
1: CAS:CASCADE, SPR:SPREAD Study
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2.1.3.2. Early reports of TDR (pre-2000) 
Though reported rates of transmitted resistance (also referred to as „primary 
resistance‟) to antiretroviral therapy vary considerably from study to study, few 
studies have published rates of less than 10% in the years following the introduction 
of HAART.  A large number of patients infected prior to the year 2000 were likely to 
have been exposed to some degree of AZT monotherapy/nucleoside dual therapy 
and thus were unable to maintain viral suppression. These patients were more likely 
to transmit a virus resistant to specific nucleosides and hence primary resistance to 
nucleosides peaked before the introduction of HAART in 1996.  A study by Balotta 
et al published in 2000 reported that 21% of patients newly infected in Italy in 1994-
1997 were resistant to AZT (242). Of those infected in 1994, 1995, 1996 and 1997, 
12.5%, 28.6%, 22.2% and 14.3% had mutations conferring resistance to AZT, 
illustrating the peak in resistance rates prior to the widespread use of HAART. Other 
European and American studies have reported similar rates. Tamalet et al found 
17% of patients newly infected in France in 1995-1998 had a mutation in the reverse 
transcriptase gene and 2% had a resistance mutation associated with PIs (243). In 
Switzerland, Yerly et al reported a TDR prevalence rate of 10% amongst those 
infected in 1996-1998 (246). A German cohort study published in 2001 found that 
13% of newly infected HIV-positive patients carried at least one primary resistance 
mutation (237). The proportion of patients with primary resistance mutations in 1995 
had increased to 16% from 7% in 1994 but a decrease was seen thereafter, with 
11% of patients reported to have TDR in 1998. Rates of TDR in Italy and Madrid 
amongst those infected before 1999 were 14.7% and 26.7% respectively (233;236). 
A study published in 2001 by the UK Collaborative Group on Monitoring the 
transmission of HIV Drug Resistance found that 14% of individuals infected in 1994-
2000 had at least one primary mutation (239).  However, rather than a decreasing 
trend after the introduction of HAART, authors reported a significant increase over 
time, with 27% of those infected in the year 2000 having resistance mutations.  
 
US studies have reported a wide range of prevalence rates, differing with area, 
sample size and interpretation algorithms used as described above. A study of 80 
predominately men having sex with men (MSM) in New York and Los Angeles found 
that 16% were likely to have been infected with a resistant virus before the year 
2000 (245). A considerably larger study was conducted by Little et al in North 
America (231).  Of 301 patients seen across 10 clinics in 1995-2000, 12% were 
found to have at least one resistant mutation.  Like the UK based study published in 
2001 (239), Little et al also found that an increasing proportion of patients had TDR 
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after the introduction of HAART, with prevalence figures increasing from 8% in 
1995-1998 to 22.7% in 1999-2000. Simon et al reported similar figures in their study 
of 154 individuals in New York City. TDR rates increased from 13.2% in 1995-1998 
to 19.7% in 1999-2001 (232). An even higher rate was reported by Grant et al (234). 
Amongst 225 patients first seen for care in 1996-2001, 23.1% were found to have at 
least one primary resistance mutation. 
 
However, other studies have reported considerably lower rates of TDR.  In a large 
nationwide study in France, 404 patients were tested for primary resistance 
mutations in 1998 and only 3.4% were identified as having a resistant virus (240). 
Garcia et al reported a similar rate of AZT TDR amongst 603 patients seen across 
10 American cities in 1997-1999 (3.3%) (238). Although seen for care a little earlier, 
Weinstock et al published a study in 2001 which assessed the prevalence of 
mutations in 6 United States cities (241). Of the 99 patients first attending for care in 
1993-1998, only 5% were found to have a primary resistance mutation. A smaller 
study in Holland analysed 43 antiretroviral naive patients, first seen for care in 1990-
1998, and reported a TDR prevalence rate of 7% (235).  
 
2.1.3.3. TDR trends after 2000 
There has also been considerable variability in the rates of TDR reported since the 
year 2000. Whilst some studies have reported relatively high rates, both across 
Europe and America (191;220;221;223;225-228), other studies have reported rates 
of less than 10% (189;218;219;222;224). The SPREAD study is the largest study 
analysing rates of primary drug resistance across Europe. By analysing genotypic 
data of 1245 newly infected patients in 2002-2003 from 17 countries, organisers 
reported a TDR prevalence rate of 9.1% (206). Several studies were able to assess 
trends over time. Shet et al reported an increasing trend of TDR from 1995 to 2004; 
rates of TDR in 1995-1998, 1999-2000, 2001-2002, 2003-2004 were 13.2%, 19.7%, 
16.7% and 24.1% respectively. This study was completed in New York City and 
consisted of predominately MSM (191). A UK study by Cane et al investigated the 
prevalence rates of TDR by using different interpretation systems and also 
concluded that TDR had increased markedly from 1996 to 2003 (225). De Mendoza 
et al in Spain reported rates of TDR dropping considerably between 1997-1999 and 
2000-2001 from 27.6% to 4.1% but rising again in 2002-2003 to 16.0% (228). 
However, a UK Study by Fox et al reported stable incidence rates of TDR between 
2000 and 2004 of 6% (189). Rates of TDR in Switzerland were also stable at around 
7% between 1996 and 2005 (210). 
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More recent studies generally have reported a TDR prevalence rate of around 10%. 
Green et al used the IAS mutation list, the list of mutations suggested by Shafer et al 
and the Stanford algorithm to calculate rates of resistance amongst newly infected 
patients in 1997-2008 and found all 3 lists provided similar estimates of 10.0%, 9.2% 
and 10.4% respectively (185). A study using data from the EuroSIDA cohort 
reported a TDR rate of 11.4% amongst 525 patients seen across Europe in 1996-
2004 (203). Similar rates have been reported in Germany (211;217), Belgium (205) 
and Canada (207). Rates of recent TDR in the US are not as varied as those in 
earlier calendar years and are also generally around 10% (204;212;215). A lower 
prevalence of TDR has been reported in Switzerland and in parts of the UK 
(202;209;210). There are also reports of considerably higher prevalence rates than 
the 10% reported above. Madsen et al used the Stanford algorithm to identify 
resistance mutations amongst newly infected patients in 1999-2007 (201). Of the 60 
predominately heterosexual patients tested in Greenland, over a quarter were found 
to carry at least one primary mutation.  Trends over time in recent studies also vary. 
Bannister et al used data from 1994 to 2004 to describe trends of TDR across 
Europe (203); a decrease in the prevalence of primary resistance was seen between 
1994 and 2001 (from 20.3% to 6.5%) but this was followed by an upward trend in 
2002-2004. The rate of TDR in the latter period was reported to be 9.1%, suggesting 
that the proportion of patients with primary resistance is increasing. Brenner et al 
also reported an increase of TDR in Canada (207), from 15.7% in 1997-2001 to 
21.2% in 2004-2005. The UK Collaborative Group on HIV Resistance analysed data 
on over 4000 samples from treatment naive patients (214) and reported prevalence 
rates from 1996-1998 to 2004. Rates were generally around 10% though after an 
initial increase, appeared to be declining towards the end of the period: rates in 
1996-1998, 1999, 2000, 2001, 2002, 2003 and 2004 were 8.4%, 10.0, 11.2%, 
14.2%, 13.0%, 15.6%, 12.5% and 9.2% respectively .  
 
In the recently published SPREAD study, TDR prevalence rates across Europe 
stood at 8.4% between 2002 and 2005. Though no statistical significant decrease 
was seen in overall prevalence rates, authors did find that the proportion of patients 
with PI and NNRTI resistance were decreasing and concluded that the overall rates 
of TDR were stabilising (199).  
 
2.1.3.4. Resistance patterns  
Most reported resistance mutations occur in the reverse transcriptase (RT) gene, 
though actual frequencies vary considerably from study to study. A relatively low 
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prevalence of mutations conferring resistance to NRTIs (3.3%) was reported by 
Descamps et al in 2001, in a nationwide study in France (240). Other studies 
published before 2002 have reported similar rates (241;245). However, a study in 
Madrid of 30 newly infected patients reported 23.3% had NRTI mutations (236). This 
estimate is markedly higher than other estimates published both earlier and later. 
Earlier trends in time of the prevalence of RT resistance also vary. Duwe et al 
reported an overall decline in TDR in Germany from 1996 to 1999 but saw an 
increase in the proportion of patients with RT resistance (237). In France, however, 
a decline in RT resistance was reported between 1995 and 1998 (243). Simon et al 
also reported that the proportion of patients conferring mutations resistant to NRTIs 
had declined between 1995 and 2001, though in the same period the proportion of 
patients with mutations conferring resistance to NNRTIs had increased from 5% to 
8.1% (232). In a larger study in the US, the proportion of NRTI resistance mutations 
decreased from 25% to 7% between 1996/7 and 1998/9 but then increased to 
20.9% in 2000/1. Authors also reported the proportion of NNRTI resistance 
mutations steadily increasing from 0.0% in 1996/7 to 13% in 2000/1 (234). 
 
In recent years, the proportion of patients with mutations conferring resistance to 
NRTIs has been reported to be fewer than 10%. In the EuroSIDA study, 9.3% of 
patients were resistant to NRTIs and 1.8% were resistant to NNRTIs (203). Other 
large studies have reported lower rates of NRTI resistance but higher rates of 
NNRTI resistance. For example, the SPREAD study reported an NRTI mutation 
prevalence rate of 5.4% and an NNRTI mutation prevalence rate of 2.6% (206). A 
study in Switzerland reported similar rates of 5.5% and 1.9% respectively (210). A 
large study in the UK reported similar rates of mutations conferring resistance to 
NRTIs and NNRTIs of 4.6% and 4.4% respectively (214), whilst data published in 
America and Canada suggest that the proportion of patients with NNRTI resistance 
mutations is now higher than that with NRTI resistance mutations (204;207).  
 
Mutations conferring resistance to the protease gene (PR) have generally been 
reported to occur in fewer than 5% of newly infected patients (202-205). Although an 
Australian study found no difference in the proportion of patients with either primary 
or secondary PR mutations before and after the widespread use of PIs (230), other 
studies have reported an increasing trend in the proportion of patients with primary 
muations. Simon et al reported PR mutation prevalence rates of 1.7% in 1995-1998 
increasing to 5.4% in 1999-2001 (232). Another US study reported PR mutation 
rates increasing from 2.5% to 7.7% between 1996 and 2001 (234). A third US study 
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conducted by Shet et al reported a markedly higher rate of PR mutations. Of those 
newly infected in 2003-2004, 13% harboured a mutation conferring resistance to a 
PI (191) 
 
2.1.3.5. Multi-drug resistance (MDR) 
Patients who are infected with a virus which is resistant to more than one class of 
antiretrovirals are defined as having MDR. The management of these patients is 
difficult since many drugs which are used as part of first-line treatment are 
ineffective amongst patients who have MDR. Further, there is a risk that patients 
with MDR will transmit their resistant virus to others, resulting in a potential increase 
of prevalence of MDR.  
 
As early as 1999, Boden et al identified 3 (3.8%) patients who were resistant to two 
or more classes of antiretrovirals (245). A significantly higher rate of MDR was 
reported in a Spanish study conducted by Briones et al (236). Albeit with a relatively 
small sample size of 30, Briones et al reported that 6.7% of patients who were seen 
in 1997-1999 had MDR. Estimates of MDR from the CASCADE study over a similar 
time period were lower; between 1987 and 2003, Masquelier et al reported a MDR 
prevalence rate of 0.5% (226). A UK study conducted by Cane et al reported 2% of 
newly infected patients had MDR (225). Canadian studies also reported similar 
estimates (207;222). The rate of MDR in more recent studies appears to be stable 
or even declining (231). A stochastic model (a method of modelling in which one or 
more variables within the model are randomly distributed, e.g. mode of infection) 
developed by Phillips also predicted a decline in the proportion of cases with MDR, 
from 4.7% in 2006 to 1.5% in 2010 (247). A suggested reason for this decline is that 
most infectious people are actually not receiving antiretroviral therapy and those that 
are have successfully suppressed their viral load.  
 
2.1.3.6. Predictors and outcomes of TDR  
There is conflicting evidence on the predictors of TDR. A study by Sagir et al 
published in 2007 found patients of „other‟ ethnicity (compared to white), those who 
were infected with non-B subtypes of HIV and those who weren‟t MSM were more 
likely to have a resistant strain of HIV (217). However, a US study published in the 
same year found that patients of white ethnicity were actually more likely to have 
TDR (215) and a Belgium study of newly infected patients in 2003-2006 reported 
that patients infected with subtype-B HIV were more prone to having primary 
resistance (205). 
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Another study conducted in the US in 2004-2006 focused on recreational substance 
use amongst HIV-positive patients (208). The prevalence of alcohol, marijuana and 
methamphetamine use were 98%, 71% and 64% respectively. Authors reported a 
TDR prevalence rate of 23% and found methamphetamine use to be significantly 
associated with TDR. Positive hepatitis status was associated with TDR in the 
EuroSIDA study (163) and low viral load was reported to be significantly linked to 
primary resistance mutations in the study by Poggensee in Germany (211). 
Amongst 239 predominately MSM patients in the UK, Booth et al identified an 
association between high CD4 counts, being born in the UK and TDR (209). 
 
Though being infected with a resistant virus limits treatment options, it does not 
necessarily result in worse long-term immunological and virological outcomes than 
those infected with wild type virus. In the period where monotherapy/dual therapy 
was the most common form of treatment for HIV, Balotta et al concluded that that 
there was no difference in 6 month outcomes between patients infected with an AZT 
resistant virus and those infected with wild type virus (242). Tamalet et al analyzed 
outcomes between those with TDR and those without over a similar calendar period 
and also concluded that there was no significant difference in outcomes between the 
two groups (243). Although in these particular studies, sub-optimal therapy is likely 
to explain the similarities between the two groups, later studies have reached similar 
conclusions. Oetta et al analyzed outcomes of 269 patients infected with TDR in 
2001-2003 in Germany and also found no difference between this group and those 
not infected with TDR (220). Shet et al also reached similar conclusions in their 
cohort of US patients seen for care in 2003-2004 (191). 
 
2.1.3.7. Summary of TDR 
The introduction of routine resistance testing amongst newly infected HIV-positive 
patients has contributed immensely to patients with TDR being able to achieve 
similar immunological and virological outcomes as those without TDR. Though these 
patients often do not have the option of using recommended first-line HAART, 
clinicians are able to select effective antiretroviral drugs individually suited to patient 
needs.   
 
Estimates of TDR are conservative yet still show that the prevalence of primary 
resistance in developed countries stands at around 10%. There is conflicting 
evidence on trends of TDR, though with effective HAART and higher rates of viral 
suppression, it is anticipated that the prevalence of TDR is likely to decrease. 
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Though patients infected with a MDR virus have significantly fewer treatment 
options than those infected with a single drug resistant virus, the prevalence rate of 
MDR is relatively low at below 5%. Mutations conferring resistance to NRTIs are 
most frequently detected, though those conferring resistance to NNRTIs appear to 
be on the rise. The proportion of newly infected patients conferring resistance to PIs 
is relatively low. With baseline resistance testing now recommended in all newly 
infected patients, virological and immunological responses amongst patients with 
TDR are comparable to those without primary resistance.  
 
2.1.4. Resistance testing post-ART  
 
2.1.4.1. BHIVA guidelines 
Current BHIVA guidelines recommend that all patients who experience virological 
failure, i.e. a detectable viral load (>50 copies/mL) on their current treatment 
regimen after 24-36 weeks, should consider changing therapy (124). This decision 
should be guided by the availability of a treatment option that is likely to suppress 
viral loads to undetectable levels. Resistance testing whilst the patient is still on the 
failing regimen is recommended as resistant viruses may cease to dominate when 
therapy is stopped, and hence may not be as detectable using current resistance 
tests which are unable to detect all mutations in a non-dominant virus. Patients who 
remain on failing regimens for prolonged periods of time are likely to continue 
developing resistance mutations, particularly to NRTIs (248), and hence resistance 
testing needs to be performed rapidly and results need to be analysed quickly to 
avoid the potential of cross resistance when choosing a new regimen. 
 
2.1.4.2. Prevalence of resistance mutations in pre-treated patients 
A recent study published in 2007 assessed the prevalence of resistance mutations 
amongst patients in Italy who had at least 6 months of antiretroviral experience and 
were experiencing virological failure (2 consecutive viral loads >1000 copies/mL) 
(249). Most patients (over 50% in years 1999-2004) had started treatment with 
suboptimal NRTI mono/dual therapy and had failed a median of 5 ART regimens. Of 
the total number of patients experiencing virological failure in 1999-2005, 36.1% had 
had a genotypic resistance test in the same calendar year. Authors reported that the 
prevalence (based on the results of the last genotypic test result available) of any 
drug resistance had declined from 95% in 1999 to 53% in 2005. The proportions of 
patients with resistance mutations to NRTIs, NNRTIs and PIs had changed from 
89.3%, 33.6% and 63.9% in 1999 to 47.4%, 10.3% and 23.1% in 2005, respectively. 
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Independent predictors of the detection of resistance mutations were earlier 
calendar year, male sex, higher CD4 counts and suboptimal NRTI therapy.  
 
The UK Collaborative Group on HIV Drug Resistance also published a study that 
reported the prevalence of drug mutations amongst treated patients, though did not 
restrict analyses to those experiencing virological failure (250) after a defined period 
of time. A total of 4218 patients were identified as having a resistance test whilst 
receiving therapy in 1998-2002. When using only the last resistance test result 
available, between 75% and 82% of patients with resistant tests were found to have 
resistant mutations to at least one class during follow-up. Mutations conferring 
resistance to PIs decreased over time, whilst mutations conferring resistance to 
NNRTIs increased. However, if the results of all prior resistance tests were also 
taken into account, together with the number of patients receiving treatment used as 
the denominator (rather than the number of patients with resistance tests), these 
proportions were considerably lower. An increase in the proportion of treated 
patients with a resistance mutation, however was still evident (4.5% by the end of 
1998 to 15.3% by the end of 2000), though this did stabilise by the end of 2002 
(17.0%). As noted by the authors, these proportions are likely to be underestimates 
since only around 30% of patients experiencing virological failure had a resistance 
test performed.  
 
Other studies have used various numerators/denominators to calculate the 
proportion of treated patients with detectable resistance mutations. Tamalet et al 
reported the prevalence of resistance mutations in a French cohort, using the total 
number of patients with resistance tests as a denominator (251). The proportion of 
patients with mutations indicating resistance to at least one NRTI was reported to be 
stable at around 80% during 1999-2002, whilst a marked increase was noted in the 
proportion of patients carrying resistance mutations to at least one NNRTI (40.4% in 
2002). For PIs, the proportion of patients with resistant viruses reached a high of 
50.9% in 1999 but a downward trend was observed in the following years (41.9% in 
2002). The proportion of patients with resistance to 3 classes increased from 3.4% 
in 1998 to 25.9% in 2000, after which time it remained stable. Authors of an earlier 
US study had used the number of patients with viral loads >500 copies/mL as the 
denominator and reported that 76.3% of patients tested had at least one drug 
resistance mutation during the study follow-up period (1996 to 1998) (252). The 
proportion of patients who were resistant to at least one NRTI, NNRTI and PI was 
reported to be 71.4%, 40.5% and 25.2% respectively. MDR was detected in 47.7% 
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of the viremic population, with 13.1% of patients having mutations conferring 
resistance to all 3 classes. A higher prevalence of resistance was detected amongst 
patients with lower current viral load and lowest self-reported CD4 count. Scott et al 
published similar estimates in 2004 (253) relating to 91, 92 and 92 patients on 
treatment who were under follow-up with viral loads >2000 copies/mL in 1998,1999 
and 2000 respectively. The proportion of patients with any resistance mutations to at 
least one drug increased from 69% to 88% between 1998 and 1999, and then 
dropped to 55% in 2000. As in other studies, a significant rise was seen in the 
proportion of patients with NNRTI resistance and MDR.  
 
Hertogs et al focussed specifically on patients with mutations conferring resistance 
to PIs (254). Of those with a resistance test performed whilst having a detectable 
viral load of >1000 copies/mL, 17% to 25% of patients were found to harbour a 
mutation conferring resistance to a PI. The prevalence of drug resistance amongst 
patients experiencing viral rebound was analysed in the Frankfurt HIV clinic cohort 
(255). In total, 45.1% and 88.9% of patients were identified as having mutations 
conferring resistance to the PI or NNRTI in their initial HAART regimen. These 
proportions appear to be markedly higher than others – one possible reason for this 
is that phenotypic resistance testing was performed (rather than genotypic as in 
most studies). A cross sectional study performed in 2000 in Spain identified that 
79% of pre-treated patients carried resistance mutations (256); 77% carried NRTI 
mutations, 53% carried PI mutations and 42% carried NNRTI mutations. These 
results are similar to those published earlier in Spain, despite varying denominators 
and definitions of resistance (257;258).  
 
2.1.4.3. Summary of the prevalence of resistance mutations in pre-treated 
 patients 
The proportion of pre-treated patients with a resistant virus peaked in around 1999-
2000. Although comparability between estimates is difficult due to differing 
denominators/definitions of resistance, around 70% of patients in the above 
mentioned studies appeared to harbour mutations resistant to at least one drug. The 
proportion of patients with mutations conferring resistance to NRTIs was high, at 
above 75% in most studies, whilst the proportion of patients conferring resistance to 
PIs was somewhat lower at below 50%. Mutations conferring resistance to NNRTIs 
appeared to be on the increase in most studies. One possible explanation for this is 
that prescribing patterns have changed over the last 10 years, moving towards an 
increase in NNRTI prescribing. Further, the genetic barrier to resistance differs 
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considerably between the two classes. NNRTI resistance is significantly more likely 
to occur than PI resistance in patients taking HAART, explaining the lower rates of 
PI resistance seen across studies (259;260). Another explanation for these 
differences is that denominators between studies often vary; in some studies only 
those currently receiving drugs from the class of interest are included, whilst in other 
studies, this restriction is not enforced.  
 
Improved management of patients infected with HIV, together with improvements in 
therapy has led to the prevalence of resistance amongst treated patients declining in 
recent years. Around 50% of those who have had resistance tests performed after 
2000 were identified as carrying resistant mutations (214;261). This downward trend 
was noted particularly in the proportion of patients with NRTI resistance and PI 
resistance, again likely to be explained by changing prescribing patterns.  
 
An important issue that has not been well addressed is the impact of number of prior 
regimens on treatment failure and hence prevalence of resistant mutations. Patients 
on their first line of HAART are less likely to experience virological failure than those 
on subsequent regimens, and thus this should be taken into account when 
calculating resistant mutation prevalence rates. 
 
2.1.4.4. Genetic barriers of drugs 
Together with drug susceptibility, viral fitness, drug concentration and drug 
interactions, the number of mutations required to confer resistance defines the 
genetic barriers of drugs to the emergence of resistance. The genetic barrier is 
intermediate for most NRTIs and low for 3TC, FTC, EFV and raltegravir. 
For example, for 3TC, only one mutation is needed to produce a resistant virus 
which can replicate better than the current virus. However, if 3TC is used in 
conjunction with AZT, the genetic barrier to resistance is higher. 
 
Ritonavir boosted PIs have the highest genetic barrier and hence are least likely to 
result in development of a resistance virus. At least two mutations are needed for 
resistance to PIs; a single mutation is a step towards resistance but that 
intermediate virus can‟t replicate as well as the current virus, so the second mutation 
is needed before the barrier is overcome. The virus with just the one mutation is 
likely to be outcompeted and die out before the second mutation has a chance to 
appear. The current list of mutations associated with resistance to each antiretroviral 
is provided by Johnson et al (182). 
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2.2. HIV drug toxicities 
Although the introduction of HAART in 1996 saw a rapid decline in the number of 
new AIDS illnesses and deaths (262), the association between HAART and 
toxicities was soon well recognised. Toxicities associated with antiretrovirals can be 
mild to severe in intensity, either short-term or long-term and either drug-specific or 
class-specific. Short-term toxicities were discussed in Chapter 1.6 (Table 1.6.1).  
Occurring usually in the first few weeks/months of starting treatment, early adverse 
effects tend to be mild/moderate and can include headaches, nausea, diarrhoea and 
vomiting (128). As patients remain on treatment for longer periods of time, the 
emergence of more severe and life-threatening drug related toxicities has become 
apparent.  These include lactic acidosis, fat redistribution, hepatotoxicity, renal 
disease and peripheral neuropathy (263-267). 
 
Drug-related toxicity is a major factor leading to the interruption of treatment, which 
in turn is likely to lead to virological failure (152;268). In this Section, toxicities 
associated with HAART, i.e. hepatotoxicity (in particular rises in alanine 
transaminase [ALT]) will be described. Further, renal-related toxicities (both due to 
HIV itself and anti-HIV drugs) and the relationship between HIV, HAART and 
dyslipidaemia (demonstrated by abnormal total cholesterol, triglycerides, low density 
lipoprotein (LDL)- and high density lipoprotein (HDL)-cholesterol levels) will be 
discussed. Finally, I will briefly summarise other abnormal measures associated with 
HAART, including abnormalities in haemoglobin, neutrophil, urate, and creatinine 
levels.  
 
2.2.1. Hepatotoxicity 
Hepatotoxicity has been reported to develop in patients taking all of the original 
three antiretroviral classes. An increase in liver enzymes in the blood, in particular 
ALT, aspartate aminotransferase (AST) and gamma–glutamyltransferase (GGT) are 
early signs of liver disease. Numerous studies have investigated the association 
between HAART and liver disease, often concluding that HAART may cause a rise 
in ALT levels (269-278). These studies are summarised in Table 2.2.1.1. However, 
the prevalence of hepatotoxicity and the magnitude of the association between 
hepatotoxicity and HAART vary considerably from study to study. For example, Livry 
et al reported the incidence of ALT elevations to be 20.9% (269), whilst a study by 
Saves et al found only 2.2% of patients in their cohort experienced ALT elevations 
(279). Other studies have reported incidence figures in the region of 10% 
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(270;277;280;281), whilst a study by Butt et al in 2007 concluded that up to 58% of 
patients had signs of ALT elevation (282).   
 
These differences are largely due to the choice of definition used to assess ALT 
elevations. Some studies include new ALT elevations which persist, while others 
refer only to transient elevations which return to baseline, or to within the normal 
range. Many studies use the AIDS Clinical Trials Group (ACTG) classification of 
hepatotoxicity (283), with severe hepatotoxicity being classed as either grade 3 or 
grade 4, referring to ALT levels >5-times and >10-times the upper limit of normal 
(ULN), respectively. However, even the ULN is subject to variability, ranging from 31 
to 40 (284;285) IU in different laboratories. Furthermore, not all studies use the 
ACTG classification (282) whilst others use an amended version (277). 
 
Chronic infection with hepatitis C virus (HCV) or hepatitis B virus (HBV) is an 
independent risk factor for liver damage in HIV-positive patients (269;279;286-288). 
The prevalence rates of both HCV and HBV vary greatly between studies, partially 
explained by differing definitions of HCV and HBV.  Authors may use a positive HCV 
antibody result or alternatively use the detection of HCV RNA to define HCV-positive 
status. Positive HBV status may be defined by a single positive surface antigen 
result or either 2 consecutive results measured a defined period of time apart 
(272;285). Further, hepatitis status is associated with means of HIV transmission 
and so reported prevalence rates will vary greatly according to the population being 
studied. Intravenous drug users (IDUs) and those infected through blood products 
are highly likely to be co-infected with HCV and, in some cases, HBV, whilst those 
with other risk contacts, i.e. heterosexual and homosexual, are likely to have a 
significantly lower rate of co-infection (289). Hence, even amongst studies with 
similar definitions of HCV, the prevalence of HCV may vary considerably, impacting 
directly on the prevalence of hepatotoxicity. For example, studies by Palmon and 
Sulkowski used similar definitions of HCV but reported prevalences of HCV of 10% 
and 52% respectively (277;290). This difference is most likely to be attributable to 
the proportion of IDUs in each study (4% in Palmon‟s study and 42% in Sulkowski‟s 
study).  
 
Specific antiretrovirals have also been associated with ALT rises and so the 
prevalence of ALT elevations in a study may also be dependent on the frequency of 
prescribing these drugs. Several studies have found NVP and RTV, in particular, to 
be associated with hepatotoxicity. Wit et al found that patients who were currently 
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taking NVP or RTV were 9.6 times and 4.9 times, respectively, more likely to 
experience grade 4 liver enzyme elevations, independent from hepatitis status 
(272). In a case control study published by Requena et al, higher NVP levels in 
blood plasma were found to be independently associated with ALT rises. Further, 
amongst patients with HCV, NVP concentrations above 6 microg/ml were 
associated with a 92% risk of liver toxicity (276). Other studies have reported similar 
findings. Amongst patients starting HAART with a NVP based regimen, Martinez et 
al found that hepatotoxicity developed in 12.5% of patients. Each additional year of 
NVP use was associated with a 10% higher risk of hepatotoxicity (275). RTV use 
was found to be associated with an 8.6 times higher risk of severe hepatotoxicity by 
Sulkowski et al (277) and similarly, Bonfanti et al reported that patients taking RTV 
were twice as likely to experience liver toxicity than those who had not been 
exposed to RTV (271). It should be noted that the majority of studies which have 
found an association between RTV and liver toxicity tended to include patients on 
high dose RTV (i.e. 1000mg, or single RTV). Since RTV is now only prescribed as a 
booster for other PIs, this association has weakened considerably, though has not 
disappeared completely (274). Several studies have shown that mitochondrial 
toxicity is associated with the use of certain NRTIs and may lead to liver 
enlargement/fatty liver (291;292). In particular, the “d” drugs, ddI, ddC and d4T, are 
more likely to have an effect on mitochondria than the other NRTIs (293). These 
drugs have been shown to increase the risk of hepatic steatosis, especially amongst 
those infected with HCV (294;295).   
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Table 2.2.1.1: Summary of studies examining risk factors for hepatotoxicity 
Author, region 
and year 
published  
Study type N IDU 
% 
HCV % HBV % ART inclusion 
criteria 
Definition of 
hepatotoxicity 
Incidence/ 
prevalence rate 
of hepatotoxicity 
Independent risk factors 
Aaron, America 
2010
(296)
 
Retrospective 
cohort 
612 12.4 15 na Initiating new 
ART regimen 
ALT/AST >2.6 
times baseline 
6% HCV+ 
Piazza, America 
2010
(297)
 
Cross-
sectional 
432 na 0 0 None Liver fibrosis 8% Diabetes, high VL 
Kovari, 
Switzerland 
2010
(298)
 
Prospective 
cohort 
2365 1 0 0 None ALT>ULN on 2 
occasions 
16%: 3.9/100 p-
yrs 
White ethnicity, high CD4, 
VL >100,000 
Chaudhry, 
America 
2009
(299)
 
Prospective 
cohort 
1358 45 49 8 None Liver fibrosis 
(APRI) 
11.6% with 
APRI>1.5 
Male gender, HBV+, 
HCV+, IDU, hazardous 
alcohol consumption 
Yunihastuti, 
Indonesia 
2009
(300)
 
Retrospective 
cohort 
284 78 100 0 ART naive ALT >5 times 
ULN 
21% High baseline ALT 
Vergara, Spain 
2007
(301)
 
Retrospective 
cohort 
116 94 100 na 12 months on 
HAART 
Liver fibrosis 36% ALT >5 times ULN, >3.5 
times baseline if abnormal 
at baseline 
Chihrin, Canada 
2007
(274)
 
Retrospective 
cohort 
102 45 100 9 Receiving 
HAART 
ALT >5 times 
ULN 
22% None 
Butt, America 
2007
(282)
 
Prospective 
cohort 
HCV mono 
HIV/HCV co-
infected 
390 
 
315 
75 
 
 
60 
68 
 
 
100 
100 
na None ALT>50  
 
58% 
41% 
HCV+, prior treatment for 
HCV and HCV mono-
infection 
Maggiolo, Italy 
2007
(302)
 
Prospective 
cohort 
582 56 55 na Receiving NVP 
HAART 
Grade 3 toxicity  5.3/100 p-yrs Not tested 
Maida, Spain 
2006
(303)
 
 
Cross 
Sectional 
3200 na na na None Persistently 
elevated LFTs 
in absence of 
other causes 
0.5% ddI 
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Cooper, Canada 
2006
(304)
 
Retrospective 
cohort 
186 75 100 5 Receiving first 
HAART regimen 
ALT >5 times 
ULN 
7% Not tested 
Uberti Foppa, 
Italy 2006
(305)
 
Prospective 
cohort 
326 87 100 0 None Liver fibrosis 66% Older age, CD4<500 
cells/mm3 and ALT>55 for 
men, >50 for women 
Manfredi, Italy 
2006
(306)
 
Retrospective 
cohort 
742 na 14 3 Receiving NVP/ 
EFV ≥12 mths 
>2 fold increase 
in AST/ALT  
NVP: (27%) 
EFV: (14%) 
NVP 
Torti, Italy 
2005
(273)
 
Prospective 
cohort of Naïve 
(N) & 
Experienced 
(E) 
1038 
N:155 
E:833 
N:68 
E:77 
N:100 
E:100 
N:10 
E:6 
Receiving 
HAART 
AST/ALT >5 
times ULN 
 
N:18/100 p-yrs 
E: 8/100 p-yrs 
N: univariable only, higher 
baseline ALT 
E:previous hepatotoxicity, 
higher baseline ALT,  and 
NNRTI regimen 
Olalla, Spain 
2005
(307)
 
 
Retrospective 
cohort 
145 82 73 na None AST/ALT >5 
times ULN, >3.5 
times baseline if 
abnormal at 
baseline 
28% HCV+ and higher baseline 
ALT and 
Servin-Abad, 
America 
2005
(308)
 
 
Retrospective 
case control 
85 60 100 77 Receiving 
HAART 
ALT >5 times 
ULN, plus an 
increase of 
>100 IU/L 
11% Univariable only: high 
baseline AST, low abumin 
levels and high INR 
Bonfanti, Italy 
2005
(309)
 
Prospective 
cohort 
551 40 40 7 Either naive or 
experienced 
starting LPV/r 
ALT >5 times 
ULN, >3.5 times 
baseline if 
abnormal at 
baseline 
0.59/100 p-yrs Not tested 
Mocroft, Europe 
2005
(310)
 
Prospective 
cohort 
10937 24 17 5 (1) None 
(2) Those who 
had received 
HAART 
Death from liver 
related disease 
(1) Overall: 
3.5/1000 p-yrs 
(2) 12% increase 
in risk per year 
longer 
(1) IDU, HBV+, HCV+, 
lower current CD4 count, 
3TC and later calendar 
year 
(2) Taking HAART < 2 yrs 
Sanne, South 
Africa 2005
(311)
 
RCT 468 na na NVP: 4 Naïve receiving 
NVP or EFV 
and randomized 
to d4T/3TC or 
d4T/FTC 
>5 times ULN NVP: 66 (17%) 
EFV: 0 (0%) 
NVP arm only: female sex, 
low BMI, low VL, low 
albumin, low AST, low 
LDH, low MCV, at baseline 
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Macias, Spain 
2004
(312)
 
Cross sectional 
study 
152 95 100 na 41% naive, 59% 
received 
HAART (of 
whom 87% had 
received a PI) 
Fibrosis stage 
≥F3* 
ALT 2.5* 
baseline 
39% 
 
 
Older age, no prior PI, prior 
NVP, lower CD4 count 
Not tested 
Sulkowski, 
America 2004 
(313)
 
Prospective 
cohort 
1161 43 45 10 PI-naïve, 
starting PIs 
AST/ALT>5 
times ULN, >3.5 
times baseline if 
abnormal at 
baseline. 
9.9/100 p-yrs HCV+, low CD4 count, 
high VL, IDR, IDV/r, SQV/r 
Meraviglia, Italy 
2004
(314)
 
Prospective 
cohort 
782 42 39 47 Treatment 
experienced 
starting LPV/r 
>100 IU/L 
higher than 
baseline if 
abnormal at 
baseline 
9.1% Higher baseline ALT,GGT, 
younger age, EFV 
Livry, France 
2003
(269)
 
 
Retrospective 
cohort 
239  14 5 None ALT 2.5 times 
baseline 
9.9/100 p-yrs HBV+, HCV+, ART, CDC 
Stage 3, high alkaline 
phosphatise 
Puoti, Italy 
2003
(315)
 
 
Prospective 
cohort 
755 65 70 7 Previously ART-
naïve 
AST/ALT >5 
times ULN, >2.5 
times baseline if 
abnormal at 
baseline 
17/100 p-yrs Univariable only: male, 
IDU, younger age, HBV+, 
HCV+, HDV+, higher 
baseline ALT, higher 
bilirubin, <75% 
prothrombin time, prior 
alcohol abuse 
Aceti, Italy 
2002
(316)
 
 
Retrospective 
cohort 
1325 50 47 4 Receiving at 
least 1 PI for 6 
months 
ALT>5 times 
ULN, or if high 
baseline then 
relative to 
baseline value 
3.2% Univariabe only: HBV+, 
HCV+ 
Wit, Netherlands 
2002
(272)
 
Retrospective 
cohort 
560 7 9 11 Previously naïve 
starting HAART 
AST/ALT >5 
times ULN, 
>100 U/L 
compared to 
baseline value 
17% HBV+, HCV+, recent 
discontinuation of 3TC, use 
of NVP, use of RTV 
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Sulkowski, 
America 
2002
(317)
 
Prospective 
cohort 
568 42 43 8 Starting NNRTIs 
(NVP (N) or 
EFV (E)) 
AST/ALT>5 
times ULN, >3.5 
times baseline if 
abnormal at 
baseline 
N: 16% 
E: 8% 
NVP, HCV+, HBV+, 
concurrent PI use 
Palmon, 
America 
2002
(290)
  
Retrospective 
cohort 
272 4 12 9 Receiving 
NNRTIs 
>5 times ULN, 
>3.5 times 
baseline if 
abnormal at 
baseline. 
1.1% None 
Martin-
Carbonero, 
Spain 2002
(318)
 
Retrospective 
cohort 
42 88 100 0 Previously naive 
starting HAART 
>5 times ULN, 
>3.5 times 
baseline if 
abnormal at 
baseline 
14% HCV+ 
Bonfanti, Italy 
2002
(271)
 
Prospective 
cohort 
1477 48 47 7 Starting PI 
containing ART 
AST/ALT>5 
times ULN, 
changes from 
baseline if 
abnormal 
baseline 
2.7/100 p-yrs 
 
IDUs, hepatitis, RTV, 
HBV+, HCV+ 
Nunez, Spain 
2002
(111)
 
Retrospective 
cohort 
222 48 38 5 Naïve starting 
HAART. 
AST/ALT>5 
times ULN or 
>3.5 times 
baseline if 
abnormal at 
baseline 
9% Alcohol abuse, HCV+ and 
older age 
D‟Arminio 
Monforte, Italy 
2001
(278)
 
Prospective 
cohort 
1255 38 47 7 Starting 
HAART, 214 
ART-
experienced 
ALT>200 U/L or 
5 times ULN or 
stopping 
regimen due to 
hepatotoxicity 
4.5% Pre-treated, higher 
baseline ALT, HBV+, d4T 
containing regimens 
Bica, America 
2001
(319)
 
Retrospective 
cohort 
84 70 na na None Death (causes 
of) 
na End-stage liver disease 
leading cause of death 
Martinez, Spain 
2001
(275)
 
Prospective 
cohort 
610 35 46 9 Starting NVP-
containing 
regimen 
AST/ALT >3 
times increase 
from baseline 
12.5% Longer duration of ART, 
HCV+, higher baseline 
ALT 
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Sulkowski, 
America 
2000
(277)
 
Prospective 
cohort 
298 54 52 3 Starting ART AST/ALT>5 
times ULN or 
>3.5 times 
baseline if 
abnormal at 
baseline 
10.4% RTV, CD4 increase >50 
Den Brinker, 
Netherlands 
2000
(285)
 
Retrospective 
cohort 
394 9 14 7 PI-naïve starting 
PIs 
AST/ALT>5 
times ULN, at 
least >100 from 
baseline 
18% HBV+, HCV+, abnormal 
baseline ALT levels 
Saves, France 
2000
(279)
 
Prospective 
cohort 
1047 17 26 4 All starting PIs ALT>5 times 
ULN 
5/100 p-yrs HBV+, HCV+ 
Melvin, America 
2000
(281)
 
Prospective 
case-control 
95 na Case:100 
Ctrl: 0 
na Receiving ART ALT>5 times 
ULN 
Case:17.0% 
Ctrl: 6.8% 
HCV+ 
Gisolf, Belgium 
& Netherlands 
2000
(270)
 
RCT 208 5% 8% 
HCVAb 
12% 
HBsAg 
Previously naive 
starting 
RTV/SQV or 
RTV/SQV/d4T 
ALT/AST>5 
times ULN plus 
>100 U/L 
compared to 
baseline value 
9% 
 
HBV, d4T 
Saves, France 
1999
(280)
 
Prospective 
cohort 
1) 1253 
2) 748 
1) 27 
2) 21 
1) 27 
2) 35 
1)9 
2)13 
1) 2 NRTI 
2) PI-containing 
HAART 
ALT>200 U/L or 
5 times the ULN 
1) 5.7/100 p-yrs 
2) 7.3/100 p-yrs 
1 ) history of cytolysis, 
HBV+, HCV+ 
2) history of cytolysis, 
higher baseline ALT, 
HBV+, HCV+ 
Rodriguiz, Spain 
1998
(286)
 
Prospective 
cohort 
187 48 na na Starting HAART ALT >2 times 
baseline 
na HCV+ 
IDU: Injecting drug users Na: not applicable 
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2.2.2. Renal failure 
Several factors can confer an increased risk of renal disease amongst HIV-positive 
patients; HIV-associated nephropathy (HIVAN) has been reported to be one of the 
leading diagnoses, followed by noncollapsing focal segmental glomeruosclerosis 
and acute interstitial nephritis (320-323). Patients who experience HIVAN are likely 
to have high levels of protein present in urine, high levels of waste products in the 
blood and scarring of blood vessels in the kidneys. Kidney disease is tested for with 
urinalysis, a creatinine test and/or a blood urea nitrogen test (BUN). Healthy 
individuals usually have 0.8-1.4mg/dl and 7-20mg/dl of creatinine and BUN, 
respectively. Elevated levels of either laboratory marker may indicate kidney 
disease. Creatinine measurements are used to estimate an individual‟s glomerular 
filtration rate (eGFR). The most common formula to calculate the eGFR takes into 
account age, weight, gender and ethnicity. The eGFR is used to determine how well 
kidneys are able to filter blood over a period of time; measurements below 60 units 
normally indicate kidney disease. 
 
Although HIV itself can infect the cells inside the kidneys causing HIVAN, 
antiretrovirals used to treat HIV have also been linked to kidney damage. In 
particular, NRTIs such as TDF and the PI IDV have been shown to cause kidney 
damage amongst HIV-positive patients (324;325); it is recommended that patients 
taking these drugs undergo annual blood and urine tests to evaluate kidney function. 
If diagnosed early, HAART can be used to either treat HIVAN (i.e. if the cause of 
HIVAN is HIV infection itself) or can be modified so drugs which are causing HIVAN 
are switched. 
  
Kidney complications amongst HIV-positive patients were first noted in 1984, a few 
years after cases of HIV/AIDS were initially identified. A variety of renal lesions were 
found amongst a small group of patients diagnosed with AIDS (326) and mortality 
rates amongst these patients were found to be significantly worse than those in 
AIDS patients without renal problems. Before the HAART era, the prevalence of 
HIVAN was reported to be between 1-10% (322) with mortality rates approaching 
50% at one year after diagnosis and 70% at three years after diagnosis (327). 
Patients with acute renal failure had poorer outcomes than those not infected with 
HIV (328) and in many cases were only diagnosed with HIVAN at the time of AIDS 
diagnosis (329;330). HIVAN was found to be closely associated with ethnicity – over 
90% of HIVAN cases were seen in black HIV-positive patients (322;331-333). Hence 
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prevalence rates of HIVAN appear to be closely associated with geographical area - 
this is likely to be explained by the ethnicity distribution in certain areas.    
 
After the introduction of HAART, initial reports suggested a rise in the incidence of 
acute renal failure amongst hospitalised HIV-positive patients in New York. 
Compared to the 2.9% with HIVAN in 1995, 6.0% of hospitalised patients had 
HIVAN in 2003 (334). However, there were reports of a beneficial effect of ART 
even before the year 2000 (335) so the rise in acute renal failure may be explained 
by other factors. For example, in the same time period there was also a rise in HIV 
negative patients diagnosed with acute renal failure and hence renal failure may 
have been more recognised in the population as a whole.   
 
Chronic kidney disease (CKD) is of increasing importance in the HAART era. As 
HIV-positive patients are living longer, the prevalence of CKD is increasing, though 
not necessarily due to HIV-infection itself. Major risk factors of CKD are older age, 
hypertension and diabetes (336-338). Amongst patients with HIV infection, HCV, 
lower nadir CD4 count and AIDS diagnoses have also been shown to be associated 
with CKD (339). Although early HIVAN is not associated with impaired renal function 
in patients on HAART (340), patients with HIVAN do progress more rapidly to end 
stage renal failure (ESRF) (320;321).  As with HIVAN, prevalence rates of CKD vary 
greatly depending on geographical area and the proportion of black ethnicity 
patients in the study population. There have been several recent studies 
investigating the prevalence of CKD (stages 3-5, GFR<60mL/min/1.732), in Europe, 
Asia and America. A study using the EuroSIDA dataset published in 2007 found only 
3.5% of patients experienced CKD (339). Patients included in this analysis were of 
predominately white ethnicity (85.1%) and risk factors for CKD were much the same 
as those found in the general population, i.e. older age, diabetes and hypertension. 
Lower nadir CD4 count and AIDS diagnosis were also found to be independently 
associated with CKD. Data from Spanish HIV-positive patients showed a slightly 
higher prevalence of CKD of 7.6% (341). Again, this study consisted of 
predominately non-black patients and older age was found to be a risk factor for 
CKD. Female gender was also found to be associated with CKD, though this has not 
been reported by other studies. Similar prevalence rates were reported by Cheung 
et al in a Chinese cohort study and Wyatt et al in an urban American study 
(342;343). Interestingly, when a less restrictive definition of CKD was used by Wyatt 
et al (all stages of CKD, without the restriction of GFR <60mL/min/1.732), the 
prevalence increased to 15.5%. CKD was most prevalent in patients of black and 
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Hispanic ethnicities, those with HCV and lower CD4 cell counts. Another American 
study reported a CKD prevalence rate of 9.7%, observed in patients seen in 2004. 
This was notably higher than the prevalence of CKD in the general American 
population and amongst other factors, black African Americans were found to be at 
a significantly higher risk of CKD than whites (344).  
 
2.2.2.1. HAART and renal disease 
Before the introduction of HAART, the number of new cases of HIVAN rose 
significantly (345). ZDV, the only antiretroviral available at the time was reported to 
slow down the progression of HIVAN considerably (335;346;347). Since 1996, the 
incidence of ESRF has declined (345) but the impact of HAART on overall renal 
function is unclear. A beneficial effect of antiretroviral therapy has been reported in 
some small studies (348;349). For example, Wali et al reported the beneficial effect 
of NFV-based HAART on renal function in 1998 and Szczech et al reported similar 
findings for PIs in 2002. Whether these benefits are related directly to the use of 
specific antiretrovirals or the effect of the antiretrovirals on viral suppression is not 
well understood. However, of concern, many other studies have reported a 
detrimental effect of HIV drugs, in particular IDV and TDF, on renal function (350-
355). In the EuroSIDA study, Mocroft et al also found that patients who were taking 
either TDF or IDV were at an increased risk of experiencing chronic renal failure 
(339). Though the benefits of HAART are undoubtedly immense, it is important to 
recognise that the management of HIV should take into account not only the specific 
patient risk factors, i.e. ethnicity, that are related to toxicities, but also the HIV drugs 
which are most prone to contribute to these toxicities.  
 
2.2.3. Relationship between HIV, HAART and other laboratory markers 
HIV and HAART have been linked to an adverse change in a number of laboratory 
markers. Although CD4 count and HIV RNA are the two most recognised markers of 
disease progression, other laboratory markers may provide useful information on 
outcome that cannot fully be captured using CD4 count and HIV RNA alone. The 
association between HAART and adverse changes in routinely collected laboratory 
markers has been investigated in several studies, though it is difficult to attribute 
these changes to a single drug used in a HAART regimen. The known effects of 
HIV, HAART and adverse changes in routinely collected laboratory markers are 
briefly discussed below.  
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2.2.3.1. Haemoglobin 
Haemoglobin is a protein in red blood cells. Normal values are generally defined as 
>13.5 g/dL for men and >11.5 g/dL for women. Individuals with haemoglobin values 
below these points are defined as being anaemic. HIV positive patients frequently 
experience anaemia, both due to HIV infection itself and the drugs used to treat HIV. 
A relationship between anaemia and shorter survival has been frequently reported. 
As early as 1988, a study consisting of almost 5000 patients showed that only 56% 
of AIDS patients with baseline haemoglobin values of <100 g/L survived to the end 
of the follow-up period, compared to 83% of patients with baseline haemoglobin 
values of >120 g/L (356). A much smaller study published a year later also found a 
highly significant relationship between low haemoglobin levels and death (357). The 
results of these two studies were confirmed by several other subsequent studies 
(57;358-362). 
 
The association between ZDV and anaemia has been well documented (363-365). 
Even when used as part of combination therapy, ZDV use has been shown to be a 
risk factor for anaemia. A study published in 2007 reported that patients who 
received ZDV-containing HAART had a 3-fold higher incidence of anaemia in the 
first 6 months of receiving therapy compared to those who received non-ZDV-
containing regimens (366). ddI and d4T have also been associated with anaemia, 
though not as frequently or as strongly as ZDV (367;368). Combination therapy 
consisting of 3TC and ZDV has further been linked to anaemia, as has 3TC alone 
(369-371), although larger studies have not found this association (67;69).  
The introduction of HAART has been associated with a decrease in the incidence of 
anaemia. Semba et al investigated the impact of HAART in 361 HIV-positive women 
and found that 26% of women who were receiving HAART developed anaemia, 
compared to 37% of those receiving non-HAART regimens and 45% of those 
receiving no antiretrovirals. Further, after 1 year of treatment, HAART was 
associated with a 32% reduction in anaemia (372). In a predominately male 
population, Moore et al reported a significantly higher proportion of patients with 
haemoglobin levels >140g/L receiving HAART than those who did not receive 
HAART, irrespective of ZDV use (373). Receipt of ZDV-containing HAART was 
found to be an independent predictor of not being anaemic during 1 year of follow-
up. Similar findings were reported amongst IDUs in a sub-study of the ALIVE study 
(372). 
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2.2.3.2. Neutrophil count 
Neutrophils are white blood cells that fight bacterial infections. The normal range of 
neutrophils is between 45% and 70% of total white blood cells (or >500 absolute 
neutrophil count). A low neutrophil count is associated with an increased risk of 
bacterial infections and occurs mostly in HIV-positive patients who are severely 
immnosuppressed. Low neutrophil count has been reported to be an independent 
risk factor for bacterial infection in patients with advanced HIV disease (374) and 
occurs frequently amongst patients infected with HIV (375;376). Episodes of low 
neutrophil count usually last around 2 weeks and are more common amongst 
patients with late stage disease and amongst those receiving ZDV (377). 
 
2.2.3.3. Platelet count 
Platelets are cells found in the blood that help it to clot. The normal range for 
platelets is 150,000 – 400,000/ml3. Very low platelet counts (thrombocytopenia) 
increase the risk of bleeding and can be life-threatening. The prevalence of 
thrombocytopenia in HIV-positive patients has been reported to range from 10% to 
50% and occurs in around 10% of newly infected patients  (378;379). HIV-infection 
itself can cause thrombocytopenia, though malignancies and medication may also 
play a part (380;381). A case-control study by Migues-Burbano et al showed that 
patients with low platelet counts were more likely to experience CD4 counts <200 
cells/mm3, independent of anaemia and neutropenia (382). Thrombocytopenia is an 
„uncommon‟ side effect of AZT (as stated on the drug label provided with AZT) but 
the drug has, in fact, been shown to increase platelet counts. Jackson et al reported 
an increase within several weeks of initiating treatment with AZT, which was not 
sustained after treatment cessation (383). HAART has also been shown to improve 
platelet count. A study by Servais et al reported a mean platelet count increase of 
70,000 after 6 months of treatment in patients receiving HAART (384) and a 
significant increase after 3 months of receiving HAART has been reported by 
Carbonara et al (385). However, Miguez et al have reported conflicting results (386). 
After 2 years of follow-up, 70% of patients with persistent thrombocytopenia, most of 
whom were on HAART, still had a low platelet count. Over 50% of patients in this 
cohort were IDUs and hence the authors argue that thrombocytopenia may be 
associated with more rapid HIV disease progression in IDUs, despite antiretroviral 
therapy.  
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2.2.3.4. Urate  
The normal reference range for uric acid is between 3.6mg/dL and 8.3mg/dL. Uric 
acid above this range (hyperuricemia) can lead to a type of arthritis known as gout 
and has been associated with cardiovascular disease and diabetes. Hypouricemia 
refers to uric acid below the normal range. Though not a medical condition in itself, 
hypouricemia has been associated with renal failure. Both hyperuricemia and 
hypouricemia are frequent amongst HIV-positive patients (387-389). Together with 
HIV infection itself, antiretroviral drugs have also been reported to be associated 
with adverse changes in uric acid. In particular, ddI has been associated with an 
increased risk of hyperuricemia (390;391). Patients receiving 3TC and PIs have also 
been reported to be at an increased risk of hyperuricemia, whilst patients receiving 
TDF may be at an increased risk of hypouricemia (392;393). 
 
2.2.3.5. Bilirubin 
Bilirubin is produced through the normal breakdown of haemoglobin and is usually in 
the range of 0.3 to 1.9 mg/dL. Increased levels of bilirubin are linked to jaundice 
associated with hepatitis, cirrhosis and anaemia.  High bilirubin may be caused by 
liver disease, blood disease and drug toxicity. AZV and IDV, in particular, have been 
associated with increased bilirubin levels. Some patients may be genetically prone 
to bilirubin elevations when taking AZV. In a large study of treatment-naive 
individuals comparing EFV with AZV, one third of patients receiving AZV had 
elevated bilirubin levels and clinical jaundice was reported in 7% of patients (394). 
However, discontinuation of AZV due to these adverse events was rare and this was 
confirmed in a later study by the same authors (395). Of note, raised bilirubin levels 
amongst patients receiving AZV are unlikely to directly cause liver disease and are 
generally associated with direct inhibition of glucorinidation. IDV is associated with 
up to a 25% incidence of elevated bilirubin levels and has prompted drug 
discontinuation amongst patients (75;396-399). 
  
2.2.3.6. Amylase 
Amylase is an enzyme that breaks starch down into sugar and is mainly produced 
by the pancreas. A normal serum amylase level is 50-160 IU/L and a level above 
this range is often a sign of pancreatitis. Although pancreatitis is a relatively rare 
condition amongst HIV-positive patients, the cells that produce insulin may be 
damaged in patients with this condition, effectively causing diabetes and adverse 
changes in glucose levels in the blood. The most common cause of pancreatitis is 
alcohol, though other infections that affect the gall bladder, high levels of 
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triglycerides and certain HIV drugs have also been associated with raised amylase 
levels. HIV-positive patients with certain genetic markers may also be more prone to 
pancreatitis (400). The most common HIV drug reported to cause raised amylase 
levels is ddI. Although ddI causes only mild elevations of amylase in most patients, 
there have been reports of deaths caused directly by ddI-related pancreatitis. 
Patients exposed to a higher dose of ddI appear to be at a greater risk of 
pancreatitis and this is further increased amongst patients with low CD4 counts 
(401). Drugs such as TDF increase the concentration of ddI in the blood and so also 
may increase the risk of pancreatitis (402;403). A large study consisting of over 
2500 patients reported the incidence rate of pancreatitis amongst patients receiving 
ddI with Hydroxyurea as 6.25/100 person years, significantly higher than those 
receiving NRTIs other than ddI (404) 
 
2.2.3.7. Lactate 
Lactic acid is produced by cells during chemical processes in the body that do not 
require oxygen. It is normally removed from the blood by the liver but when this 
process is not fully functional, lactate acid may accumulate causing   
hyperlactatemia which can lead to lactic acidosis. Lactate levels above 5mmol/dL 
are regarded as abnormal and can be life threatening. Mortality associated with 
lactic acidosis has been linked to NRTIs (161;405-407). d4T, in particular, has been 
reported to be associated with high levels of lactic acid (408-410). A study published 
by Lo et al reported that duration of treatment with NRTIs was also an independent 
risk factor for elevated lactate levels (411).  
 
2.2.4. Summary of toxicities associated with HAART 
Abnormalities in laboratory markers can result in mortality and hence it is important 
to identify the underlying cause of such elevations. Given the large number of 
mechanisms involved in HIV and in HAART, it is difficult to attribute laboratory 
abnormalities to single specific causes. Further, one abnormality often results in 
another and hence it may also be difficult to attribute cause of death to a single 
laboratory marker.  
 
2.3. Viral rebound 
The ultimate goal of HAART is to fully suppress HIV replication as this minimizes the 
risk of resistance evolution and results in the greatest potential for immune recovery. 
However patients who do manage to suppress their viral load to below detectable 
levels may experience viral rebound. This is often associated with the emergence of 
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resistance, though can also be caused by other factors such as an inability to 
maintain long term adherence and a lack of treatment options.  Rates of viral 
rebound have been reported to be as high as 40% amongst patients who have 
achieved viral suppression (412-416). Several factors have been shown to be 
associated with viral rebound and the most frequently reported factors are discussed 
below.  
 
2.3.1. Sub-optimal therapy before HAART 
Many studies have shown that the use of NRTI single or dual therapy before HAART 
is associated with a raised risk of viral rebound. In the Swiss HIV Cohort Study of 
2232 patients who achieved an undetectable viral load after the initiation of HAART, 
those who had been treated with prior mono/dual therapy were reported to have a 
viral rebound rate of 35-40% after 2 years of achieving an undetectable viral load, 
compared to 20.1% of treatment-naïve patients (417).  Similar results were reported 
in the EuroSIDA cohort. Amongst 925 patients who had achieved an undetectable 
viral load, 35% of those who were pre-treated experienced viral rebound by 6 
months, compared to 18% of those who were naïve at HAART initiation (418). Sub-
optimal therapy before HAART was found to be an independent risk factor for viral 
rebound. Another large study in France showed patients starting HAART with a PI-
containing regimen had a 72% increased risk of viral rebound if they had been pre-
treated with NRTI mono/dual therapy (412). An even greater risk was reported by 
Phillips et al; patients with prior nucleoside experience were 2.86 times more likely 
to experience viral rebound than naïve patients (413). A later study by the EuroSIDA 
group confirmed earlier published findings. Taking into account the improved 
efficacy of HAART by 2003, Mocroft et al concluded that the rate of viral rebound 
among treatment-naïve patients remained approximately half that of treatment-
experienced patients (414). Although the efficacy of HAART has continued to 
improve since 2003, recent findings still show that treatment experienced patients 
have a raised risk of viral rebound compared to those starting HAART from naïve 
(415;416).  
 
Patients who received NRTI mono/dual therapy before initiating HAART are likely to 
experience higher rates of viral rebound as these patients are more likely to harbour 
resistance mutations (419). Several studies have demonstrated a significant 
correlation between drug resistance and virological response to new treatment 
regimens amongst patients who have failed previous regimens (116;420).  
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2.3.2. Age 
Several studies have found that patients of older age are less likely to experience 
viral rebound. Mocroft et al reported that patients in the EuroSIDA study were 14% 
less likely to experience viral rebound for every 10 year increase in age (414). A 
greater reduction in risk was found by authors of an American study published in 
2008 (421).  In this study, older age at seroconversion was associated with a 32% 
reduction (per 5 year increase) in the risk of viral rebound. Older age was also found 
to be significantly associated with a lower risk of viral rebound by Le Moing et al in 
France (412). Results from the UK CHIC Study showed a similar reduction in risk of 
viral rebound in older patients amongst both those who were treatment-naive and 
experienced (422). Estimates from other studies have also shown that older patients 
are at a lower risk of experiencing viral rebound, albeit not always reaching 
statistical significance (416;423). 
 
The largest study to date looking at the response to ART in different age groups is 
the COHERE study (145). Authors of this study evaluated virological and 
immunological responses to HAART in 49,921 patients. Though the authors did not 
analyse factors associated with viral rebound, they did find that patients of older age 
were more likely to experience a virological response after HAART initiation than 
those of younger age.  
 
One possible reason for the association seen between older age and a lower risk of 
viral rebound may be that patients of older age have better adherence to HIV 
medications and therefore better virological outcomes. Although many studies have 
found a positive correlation between older age and adherence (155;424;425), other 
studies have been able to control for adherence and have still found age to be an 
independent predictor of virological response (412). Hence other factors such as 
pharmacokinetics of ART drugs in older patients may also explain the association 
seen between age and viral rebound, though there is little evidence in the literature 
to support this argument.  
 
2.3.3. Viral load at baseline 
Studies have suggested that patients with higher baseline viral loads at start of ART 
are at an increased risk of experiencing viral rebound or long term virological failure.  
A 39% increase per 1 log copies/mL higher in the risk of viral rebound was observed 
by Le Moing et al (412), whilst results from the EuroSIDA study found that patients 
with viral loads >400 copies/mL at the start of HAART were at an increased risk of 
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viral rebound (414;418). Similar results were reported by Staszewski et al and 
Grabar et al when analysing virological response to PI therapy (426;427). A 9% 
increase per 1 log copy/ml higher was reported in a recent study by Smith et al 
(416), although this association was not seen amongst a subset of highly treatment 
experienced patients.  It has been well established that high levels of plasma RNA 
are correlated with HIV disease progression (51;428) and there is general 
consensus on the explanation for the association seen between baseline viral load 
and viral rebound.  
 
2.3.4. Ethnicity and duration of suppression 
Patients of black ethnicity have also been found to be at an increased risk of viral 
rebound. Results from the UK CHIC study showed that patients of black ethnicity 
had a 75% higher risk of viral rebound if they started HAART from naive and over a 
2-fold increase of viral rebound if they had received prior mono/dual therapy (422). A 
study directly comparing virological outcomes between African patients and 
British/European patients also found evidence of a significantly higher increase in 
viral load after initial suppression amongst African patients compared to non-African 
patients (158). This may in part be related to socio-economic factors. Patients with 
increasing duration of virological suppression have also been shown to be less likely 
to experience viral rebound (413;414;429). This association has been reported for 
both treatment naive and experienced patients. The finding of an association 
between duration of suppression and viral rebound may be explained by a selection 
effect. Patients who manage to suppress their viral loads for long periods of time are 
likely to be those who are most adherent and have the fewest pre-existing drug 
mutations. Hence patients who are likely to experience virological failure will have 
been selected out as the time from initial response increased.  
 
2.3.5. Specific drugs 
The role of specific HIV antiretrovirals on viral rebound has been investigated in 
many studies. In a EuroSIDA study of 2120 patients, regimens were classified 
according to nucleoside pairs and the „third‟ drug. Of the nucleoside pairs, only 
ZDV/ddI (compared to ZDV/3TC) was significantly associated with an increased risk 
of viral rebound. However, with regards to the „third‟ drug in the regimen, compared 
to EFV, NVP, NFV and, in particular, ABC was associated with an increased risk of 
viral rebound (430). Other observational studies have also shown patients receiving 
NFV are at an increased risk of viral rebound (412;422) and randomised controlled 
trials comparing EFV to NFV have shown similar results (431;432). Analyses from 
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the Swiss HIV Cohort Study have suggested that treatment experienced patients 
receiving ABC are at an increased risk of viral rebound (433), whilst results from the 
UK CHIC Study also reached similar conclusions (422). Interestingly, ABC was not 
associated with an increased risk of viral rebound amongst patients who started 
HAART from naive in any of the above studies. In line with findings from the 
EuroSIDA study, naive patients in the UK starting HAART with either ZDV/ddI or 
d4T/ddI compared to ZDV/3TC have been shown to be at a higher risk of 
experiencing viral rebound (422). This study also found that naive patients receiving 
IDV/r compared to EFV were at an increased risk of viral rebound, whilst in 
treatment experienced patients, the reverse was true. Countless studies have 
directly compared antiretroviral drugs in relation to virological response – these 
studies have been briefly discussed in Chapter 1.6.  
 
It is important for patients to maintain virological suppression as viral rebound is 
often associated with the emergence of resistance mutations. Even amongst 
patients who have experienced viral rebound, the aim of HAART is to reduce viral 
replication to undetectable levels. As the occurrence of viral rebound increases, viral 
suppression becomes less likely and hence the number of regimens patients have 
previously failed is an important factor to consider when analysing the risk of viral 
rebound.  
 
2.3.6. Treatment interruption 
Eradication of HIV appears to be unlikely with current antiretroviral regimens. 
Although HIV infection is manageable with lifelong therapy, the side effects, 
toxicities, high costs and inconvenience of taking HIV drugs are reasons why 
patients may consider short term treatment breaks. Further, in order for medication 
to work effectively, adherence is of key importance. Many patients find this lifelong 
commitment to HIV treatment an extremely difficult task and hence much research 
has been conducted into structured treatment interruptions (STI) for HIV-positive 
patients. It has also been suggested that STI may provide other benefits. For 
example, viral rebound after full suppression of viral replication may enhance the 
body‟s natural immune responses, known as „auto-immunization‟. Secondly, 
amongst treatment experienced patients with resistant virus, STI may allow the virus 
to revert back to wild-type which, it has been argued, will improve subsequent 
virological response to treatment. Early studies investigating the impact of STIs were 
small, often with sample sizes of fewer than 20 patients and hence conclusions were 
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difficult to reach. Table 2.3.6.1 summarises studies of larger sample size, published 
from 2000 onwards.  
 
Until the publication of the Strategies in Management of Antiretroviral Therapies 
(SMART) trial in 2006, there was little consensus on the impact of treatment 
interruptions amongst those with low viral loads on ART. Whilst some studies had 
shown that those who interrupted treatment had significantly worse virological, 
immunological and/or disease progression outcomes than those on continuous 
therapy (434-440), other studies had shown little difference between the two groups 
or no additional risk for those who interrupted therapy (441-448). Of the cohort 
studies, those of larger size generally found treatment interruptions associated with 
negative outcomes. Results published from the Swiss HIV Cohort Study in 2002 
showed that of the 4720 patients under follow-up, 1299 interrupted treatment at 
least once and these patients were less likely to experience a CD4 cell increase. In 
this study, however, no difference between those with prior treatment interruptions 
and those without was detected in terms of morbidity, mortality or disease 
progression (434). Authors of a nested cohort study of 687 patients in the US 
reported those who interrupted treatment had over a 2-fold risk of experiencing a 1 
log increase in viral load (437) and results from the ICONA study in Italy showed 
that amongst the 3142 patients under follow-up, those who had interrupted 
treatment for over 2 weeks were almost 3 times as likely to experience clinical 
progression compared to those who had never interrupted treatment (438). Two 
relatively large randomised trials published before the SMART trial reached different 
conclusions. The Trivican Study in Africa consisted of 326 patients with CD4 cells 
counts of 150-300 cells/mm3, randomised to either continued therapy or deferred 
therapy until CD4 counts dropped to below 250 cells/mm3 (440). Although no 
difference was found between the two groups with regards to mortality, patients in 
the deferred group were found to be at a 2-fold increased risk of morbidity and the 
authors concluded that treatment interruption should not be recommended. The 
Staccato Study consisted of 430 patients in Thailand, Australia and Switzerland with 
CD4 counts >350 cells/mm3 and VL <50 copies/mL, randomised to either continued 
therapy or deferred therapy until CD4 counts fell below 350 cells/mm3. Low CD4 
counts were more frequent in the deferred arm but no difference was found with 
regards to the primary outcome, VL <50 copies/mL (448). Authors of this study 
concluded that the cost of drugs were reduced substantially in the deferred arm and 
boosted PI regimens could be interrupted without the fear of resistance emerging.  
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The largest study to date investigating the impact of treatment interruptions on 
clinical endpoints is the SMART study, consisting of 5472 patients (449). Patients 
with CD4 counts of >350 cells/mm3, irrespective of whether or not they had received 
or were currently receiving ART were assigned to either continued therapy (viral 
suppression group)  or deferred therapy (drug conservation group) until CD4 counts 
fell below 250 cells/mm3. Patients in the viral suppression group received 
uninterrupted treatment, whilst those in the drug conservation group received ART 
only when their CD4 counts fell below 250 cells/mm3 or if symptoms of HIV disease 
infection were present. For these patients, ART was discontinued if/when their CD4 
counts reached 350 cells/mm3.  
 
The primary outcome of the study was opportunistic disease or death from any 
cause. Patients were followed for an average of 16 months before the study protocol 
was modified for those in the deferred arm. Of the 167 patients who experienced the 
primary end point, 120 (72%) had been randomised to the drug conservation arm. 
The unadjusted hazard ratio for this group compared to those who were randomised 
to the viral suppression arm was 2.6 (95% CI: 1.9, 3.7) and though adjusting for 
latest CD4 count and viral load reduced the hazard ratio to 1.5 (1.0, 2.1), this was 
still statistically significant. This effect was partly explained by patients spending 
longer periods of time with reduced CD4 counts and authors concluded that 
treatment strategies incorporating episodic treatment interruptions were „deleterious‟ 
and were not to be recommended. 
 
Since the publication of the SMART Study, several other studies looking at the effect 
of treatment interruptions have been published. Results of two cohort studies in 
Europe showed little difference in outcomes between those who interrupted 
treatment and those who did not (450;451), whilst results from the DART trial in 
Africa (n=813) showed that patients who were randomised to the STI arm of the 
study were significantly more likely to experience AIDS/death (452). Results from 
the recent LOTTI Study consisting of 329 patients (both treatment naïve and 
experienced) with very high CD4 counts (>700 cells/mm3) and low VLs, randomised 
to either continued treatment or deferred treatment until CD4 counts fell below 350 
cells/mm3, found no difference in the proportion of patients experiencing AIDS/death 
in each group (453). Although the differences between this trial and the SMART trial 
are likely to be explained by the inclusion criteria, (i.e. the former trial included only 
those with CD4 counts >700 cells/mm3), patients in the STI arm of the LOTTI trial 
were less likely to experience cardiovascular events, in contrast to results from the 
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SMART Study (453). These results suggest that despite the large number of 
patients included in the SMART Study, the question of whether interrupting 
treatment is safe remains unanswered. Although newer drugs are less toxic and 
easier to administer, other reasons for interrupting therapy as described above 
remain and hence the long term risks of interrupting treatment need further 
investigation. 
             
 
 
    
8
3 
Table 2.3.6.1: Studies investigating the impact of treatment interruptions amongst HIV-positive patients 
Author, region and 
year of publication 
N % 
Male  
Inclusion criteria Interruption 
strategy 
Endpoint Main results Other results/conclusions 
Randomised controlled trials      
Maggiolo, Italy 2009 
(LOTTI)
(453)
 
329 73 CD4>700, VL <50 Continuous (C) vs. 
STI until CD4<350 
AIDS/death 12% C vs. 12% STI, 
p=0.85 
Clinical events influencing the 
cardiovascular risk of patients 
were significantly (p < 0.0001) 
more frequent among controls. 
DART, Uganda/ 
Zimbabwe 2008
(452)
 
813 27 CD4>300 at week 
48 or 72 after ART 
initiation 
Continuous (C) vs. 
STI 12 weeks on, 
12 weeks off 
AIDS/death C: 2.4/100 person-yrs 
STI:6.4/100 p-yrs, HR 
(STI vs. C)=2.73, 
p=0.007 
ART change due to toxicity 
occurred more frequently in 
continuous arm 
Walmsley, Canada 
2007
(454)
 
147 87 CD4>50,VL >1000 
>3 months 
Immediate (IS) vs. 
12 week deferred 
switch (STI) 
VL <50 >3 
months 
51% STI vs. 64% IS No difference in CD4 count / VL at 
week 60 
Ruiz, Spain & Italy 
2007
(455)
 
201 73 On continuous 
HAART >1 year, 
CD4>500,VL <400 
Continuous (C) vs. 
STI until CD4<350 
% of adverse 
events 
HR (STI vs, C)=2.71, 
p<0.0001 
Week 96 CD4 counts significantly 
lower in patients with TI. TI is not 
as safe as continuing therapy 
SMART Study Group, 
Europe & Australia 
2006
(449)
 
5472 73 CD4>350  Continued (C) vs. 
deferred (D) until 
CD4<250  
Opportunistic 
disease or death 
HR (D vs. C)=2.6, 
p<0.0001 
Continuous use superior to 
episodic use of ART 
Staccato Study Group, 
Thailand, Switzerland, 
Australia 2006
(448)
 
430 46 CD4>350, VL <50, 
no evidence of 
resistance 
Continued vs. 
Deferred until 
CD4<350 
VL <50 at trial 
end 
Difference in patients 
with VL <50: 1.3%, 
p=0.90 
Low CD4 counts more frequent in 
STI arm, 62% saving on cost 
Trivacan Study Group, 
Africa 2006
(440)
 
326 21 150<CD4<350 Continued (C) vs. 
Deferred until 
CD4<250 (STI) 
Mortality and 
morbidity at trial 
end 
Mortality RR (C vs STI) 
=0.48, p=0.57. Morbidity 
RR=0.38,p<0.001 
CD4-guided structured treatment 
interruption strategy should not be 
recommended 
Beatty, America 
2006
(456)
 
30 na On ART, VL >500, 
3 class resistance 
Immediate (I) vs. 
deferred (D) 
enfuvirtide 
VL <75 48 weeks 
after initiating 
enfuvirtide 
53% I vs. 35% D, p=NS Baseline phenotypic susceptibility 
score predicted virological 
response in multivariable analyses 
Benson, America 
2006(457) 
41 na VL >10,000, 
CD4>150, MDR 
Immediate (I) vs. 
deferred (D) ART 
VL <400 48 
weeks after  
19% I vs. 33% D, 
p=0.44 
 
Ananworanich,  74 na CD4>350, VL <50 Continuous (C) vs CD4>350, VL CD4>350: 96% C vs.  1 week on, 1 week off stopped 
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Thailand 2005
(447)
 > 6 months CD4 guided STI 
vs, 1 week on, 1 
week off 
<400 at week 
108 
100% STI 
VL:96% vs. 91% 
early due to high rates of failure. 
STI well tolerated and cost-saving 
Cardiello, Thailand 
2005
(446)
 
74 49 CD4>350, VL <50 
for 6 months 
Continuous (C) vs. 
CD4 guided (STI) 
vs. 1 week on, 1 
week off (W) 
AIDS/death and 
CD4>350 at 
week 48 
No deaths, 1 AIDS 
event in W 
arm.CD4>350:100% (C) 
vs. 87% (STI) vs. 96% 
(W), p=0.03 
Virological/ immunological failure 
in W and C arms: 31% vs. 0% 
respectively. 
STI is clinically comparable to C 
Katlama, France 
2004
(458)
 
68 97 VL >50,000, 
CD4<200, on ART 
Continuous (C) vs. 
8-week deferred 
(STI) 
1 log decrease in 
VL at 12 weeks 
26% C vs. 62% STI, 
p=0.01.  
STI led to an increase in the 
number of sensitive drugs 
(P=0.004) 
Maggiolo, Italy 
2004
(444)
 
69 25 CD4>800, VL <50 
on HAART 
Continuous (C) vs. 
STI until VL <400 
CD4>400 at 
every 8 weeks 
No statistical difference 
at any time point 
Nadir CD4 predicted CD4 decline 
(p<0.001).  
Papasavvas, America 
2004
(443)
 
42 90 CD4>400, VL 
<500 > 6 months 
Continuous (C) vs. 
2, 4 and 6 week 
repeated 
interruptions (STI) 
Time to viral 
rebound (VL 
>5000) 
C : 4 (1, 8) weeks, STI: 
5 (4, 8) weeks, p=0.36 
No difference between groups in 
terms of safety, immune 
reconstitution, and clinical therapy 
failure 
Lawrence, America 
2003
(436)
 
270 91 VL >500, MDR Continuous vs. 4 
month STI 
Disease 
progression or 
death 
HR for STI group: 2.7, 
p=0.004 
STI did not confer immunologic or 
virologic benefits or improve the 
overall quality of life. 
Ananworanich, 
Thailand,Switzerland, 
Australia 2003
(435)
 
36 na CD4>350, VL <50, 
no evidence of 
resistance 
1 week on, 1 week 
off 
VL >500 53%.  Unacceptably high failure rate and 
hence terminated. 
Ruiz, Spain 2003
(441)
 46 na Heavily 
experienced, VL 
>1000 
Immediate (I) vs. 
12 week deferred 
(D) 5-drug regimen 
VL <50 at 48 
weeks 
45% I vs. 46% D, 
p=0.62 
No difference in CD4 counts at 
week 48. Only no. of NRTI 
mutations were significantly 
associated with VL <50 
Cohort studies        
Sanchez, Spain 
2007
(451)
 
20 75 TI >4 weeks, prior 
VL <50 for 6 
months 
Interrupted due to 
toxicity, choice or 
surgery 
VL >50 after 
week 24 after 
restarting 
0 patients experienced 
failure 
45% developed resistance 
mutations. Interruption safe for 
those with viral suppression 
Boschi, Italy 2006
(450)
 112 72 CD4>500, 
undetectable VL, 
HAART>1 year 
Deferred until 
CD4<200/patient 
choice  
Duration of TI, 
AIDS,virological 
failure 
Median duration: 1 year. 
1 case of AIDS, 1 case 
of failure. 
 The strategy of TI is safe if the 
criteria for
 
restarting therapy are 
applied correctly 
Mata, Spain 2005
(459)
 141 76 VL <50 for >6 
months, baseline 
Interrupted with 
clinicians approval 
>300 cell decline 
in CD4 count 
Risk factors: lower CD4 nadir, greater CD4 increase after 
starting HAART, higher CD4 count pre interruption, higher 
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CD4>500 until CD4<350 viral load rebound. 
Wolf, Germany 
2005
(439)
  
399 na   CD4 increase, 2 
years AIDS free 
survival 
Patient with TI had fewer cells increase than those on 
continuous ART, p<0.001. No difference in survival. TI did not 
lead to increased disease progression. 
d'Arminio Monforte, 
Italy 2005
(438)
 
3142 72 Initiating HAART Interruption of all 
drugs for >2 weeks 
Clinical 
progression 
HR for those with prior 
interruption: 2.75 
(p=0.03) 
23% had interrupted treatment at a 
median of 41 months 
Li, America 2005
(437)
 687 na Initiating HAART (i)TI for >2 days 
within 6 months (ii) 
ART 
discontinuation 
>1 log VL 
increase 
OR=2.62 and 43.32 
(p<0.005) for TI and 
discontinuation 
compared to 
continuous HAART 
Long interruptions have negative 
virological and immunological 
consequences  
Boschi, Italy 2004
(445)
 71 51 CD4>500, low VL, 
stable ART 
Interrupt until 
CD4<200/patient 
choice 
AIDS/ VL >50 at 
6 months after 
restarting ART 
No AIDS. 1 patient 
had VL >50 after 
restarting ART 
Treatment interruptions in patients 
with high CD4 counts do not reduce 
the efficacy of therapy when re-
started 
Fagard, Switzerland 
2003
(442)
 
133 69 VL <50 6 months, 
baseline CD4>300 
4* 2 weeks off, 8 
weeks on ART  
VL <5000  17%. Risk factors: low 
pre HAART VL, lack 
of rebound 
STI did not provoke clinical 
complications. Results do not favour 
autovaccination 
Yerly, Switzerland 
2003
(460)
 
133 69 VL <50 6 months, 
baseline CD4>300 
4* 2 weeks off, 8 
weeks on ART  
VL >50 after 
retreatment 
29% The M184V/I mutation is frequently 
selected during repeated treatment 
interruptions 
Metzner, Switzerland 
2003
(461)
 
28 29 1
st
 line HAART >6 
months, without 
failure 
4* 2 weeks off, 8 
weeks on ART 
Detection of drug 
resistance 
M184V and L90M 
detected in 56% and 
12% respectively 
Multiple STIs can result in the 
emergence of drug‐resistance  
Tarwater, America 
2003
(462)
 
105 na Interrupted ART 
with intention to 
resume 
na Resuming 
therapy 
43% at a median of 
114 weeks.  
Lower CD4 count at interruption 
significantly associated with 
resuming therapy 
Taffe, Switzerland 
2002
(434)
 
4720 71 Receiving HAART TI for at least 1 
month 
Mortality, CDC 
stage C, >50 cell 
CD4 increase 
TI not associated with 
mortality/morbidity 
TI significantly decreased the 
likelihood of CD4 increase. TI 
neither worsen nor improve disease 
outcome 
Miller 2000 
Germany
(463)
  
48 92 ART experienced  >2 month 
interruption at 
detectable VL 
Drug 
susceptibility 
28/45 patients 
reverted to wild type 
Shift to wild type was significantly 
associated with response to re-
initiation 
Na: Not applicable, STI: structured treatment interruption, TI: treatment interruption, VL: viral load, MDR: multi-drug resistance 
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Chapter 3: Data collection and methods 
3.  
  
3.1. Introduction 
All analyses presented in this thesis have been undertaken using data from the UK 
Collaborative HIV Cohort (CHIC) Study.  Data from the UK HIV Drug Resistance 
Database have been linked to the UK CHIC dataset for analyses involving HIV drug 
resistance. This chapter describes the data collection methods for these datasets, 
the approach taken to link the datasets and a summary of the key clinical findings in 
the UK CHIC dataset used for analyses in this thesis.   
 
3.2. The UK CHIC Study 
The UK CHIC Study was initiated in 2001 with the aim of collating routinely collected 
data on HIV-positive individuals attending some of the largest clinical centres in the 
UK since 1st January 1996. Initial objectives of the UK CHIC Study included 
describing changes over time in the frequency of AIDS-defining illnesses, describing 
the uptake of and response to HAART and identifying factors associated with 
virological and immunological responses to HAART. The collaboration originally 
included data on 13,833 patients from 7 centres: Chelsea and Westminster NHS 
Trust; King‟s College Hospital; Mortimer Market Centre; St. Mary‟s Hospital; St. 
Thomas‟ Hospital; The Royal Free Hospital; and Brighton and Sussex University 
Hospital. Annual data downloads from the original centres and from new centres are 
provided to ensure that the database is up-to-date. The current dataset includes 
data from an additional 4 centres (Homerton University Hospital, Bristol NHS Trust, 
North Middlesex NHS Trust and Edinburgh Western General), and the 11 
participating centres provide data on a total of 32,607 individuals (Figure 3.2.1).  
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Figure 3.2.1: Number of patients from each centre providing data to UK CHIC 
in 2008 (N=32,607) 
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3.2.1. Data collection 
All HIV-positive patients aged 16 years or above, attending one of the centres for 
care at any time after 1st January 1996 are eligible for inclusion in the study. 
Electronically formatted data are provided by each centre in specified datasets. 
Information collected includes demographics (date of birth, gender, risk-group, 
ethnicity), AIDS diagnoses, CD4 and CD8 counts, viral loads and HAART history 
(start and stop date of each drug taken).  Table 3.2.1.1 lists all variables currently 
included in the main CHIC dataset. In addition, data are also provided on hepatitis 
status (Table 3.2.1.2) and laboratory markers of HAART-related toxicities. All data 
provided are pseudo-anonymised in accordance with data protection policy. 
Patients‟ names are replaced with initials and soundex codes and all clinic numbers 
are replaced by a unique study identifier before the dataset is distributed for 
analysis. 
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Table 3.2.1.1: Data collected in The UK CHIC Study 
Demographics Gender 
 Ethnicity 
 Date of birth 
 Primary risk factor for HIV transmission 
Clinical data Date of first recorded HIV positive test 
 Date of last recorded HIV negative test 
 Date of first clinic visit 
 Date of last clinic visit 
 Date of death 
 Cause of death 
 Date and description of each AIDS-defining event 
Laboratory  Date and result of CD4 cell count for all available measurements 
Markers Date and result of CD8 cell count for all available measurements 
 Date and result of CD4 percentage for all available measurements 
 Date and result of CD8 percentage for all available measurements 
 Date and result of HIV RNA viral load for all available measurements 
Antiretroviral  Date of starting all antiretrovirals 
Treatment Date and up to 3 reasons for stopping all antiretrovirals 
PCP  Date of starting PCP prophylaxis 
Prophylaxis Date of stopping PCP prophylaxis 
 PCP prophylaxis taken 
Hepatitis1   Date of hepatitis test 
 Hepatitis test  
 Hepatitis test result (negative/positive/unknown) 
1 
See Table 3.2.1.2 
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Table 3.2.1.2: Hepatitis data collected 
Hepatitis Test 
Hep A antibody (total) 
Hep B surface antigen (HbsAg) 
Hep B surface antibody (anti-HBs) 
Hep B core antibody (anti-HBc) 
Hep B e antigen 
Hep B e antibody 
Hep C antibody 
Hep C virus PCR/bDNA 
Hep B core antibody (IgM) 
Hep A antibody (IgM) 
Hep B DNA (Type unknown) 
Hep D antibody (total) 
Hep B surface antigen (titre) 
Hep D antibody (IgM) 
Other  
Not known 
 
3.2.2. Data checks 
Data from each centre are checked for accuracy and completeness by the study 
manager (Teresa Hill). A range of data queries is used to highlight errors in the 
datasets provided, for example HIV positive test results that predate HIV negative 
test results and dates of any laboratory tests that occur after the patient was last 
seen. All highlighted errors are reported back to individual centres. This gives 
centres the opportunity to improve their existing databases and reduces the number 
of errors identified in future downloads. If errors are resolved (by examining patient 
records for example) and more accurate information is established, the UK CHIC 
database is updated accordingly.  
 
The datasets containing HAART history are checked extensively for completeness. 
Most centres provide start and stop dates for all individual drugs a patient has 
received in text format.  I import these data into SAS and as an initial check, ensure 
that all stop dates occur after the start dates for each drug. If stop dates do occur 
before start dates, it is assumed that the dates were inputted under the wrong 
headings and hence are switched with each other. This assumption is based on a 
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sample of records which were sent back to the centres with inconsistent stop/start 
dates and confirmed by the clinician to have been inputted incorrectly.  
 
I then highlight any instances in which one record is completely nested within a 
second record of the same drug. For example, a patient may appear to have started 
taking AZT on 01/01/2004 and stopped on 01/12/2004 but may also have a second 
record of starting AZT on 01/03/2004 and stopping on 01/06/2004. In situations 
involving such cases, the second record is removed from the dataset. Overlapping 
dates are edited in a similar manner. Gaps in treatment history of less than 2 weeks 
are also removed from the dataset. For example, if a patient appears to have started 
and stopped receiving AZT on 01/01/2004 and 01/06/2004 respectively, but has a 
second record of receiving AZT on 14/06/2004 and stopping on 01/12/2004, the stop 
date of the first record and the start date of the second record are removed, so the 
AZT history would then read from 01/01/2004 to 01/12/2004.  HAART data from 
Kings College Hospital is provided in the form of prescription data and hence 
contains only start dates for drugs received. After importing the text file into SAS, I 
impute stop dates at 3 months after each start date for treatment data received from 
this centre. I then apply the above algorithm to remove any inconsistent records and 
to close any gaps which may have resulted from the imputation of stop dates. Data 
in the form of regimens is provided by Chelsea and Westminster NHS Trust.  This 
text file is imported into SAS and regimens in the form of text characters are 
changed into individual records. Records may contain regimens which are 
theoretically identical but appear differently, e.g. „AZT+3TC+NVP‟ and 
„ZDV+TTC+NVP‟. Each drug name is individually extracted and recoded to a 
standard CHIC code, i.e. „3TC‟ to „5‟ before the above algorithms are applied.  Since 
not all drug names contain three letters (e.g. SQVH), this process involves a certain 
degree of manual editing in the text file before it can be imported in to SAS. After the 
treatment data have been cleaned, they are exported back to text files and passed 
to the data manager to link back to the other datasets provided by the centres.   
 
3.2.3. Linkage to death registries and Health Protection Agency (HPA) 
In addition to the data provided by the centres, the Office for National Statistics 
(ONS) and General Registrar Office for Scotland (GRO) death registers are used to 
ascertain whether patients lost to follow-up had subsequently died. UK CHIC 
records which matched a record in the ONS or GRO database based on first name 
initial, soundex, date of birth and soundex were identified and any missing date of 
deaths in UK CHIC were replaced by the ONS/GRO date of death for those patients 
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identified as having died.  For those patients who were not recorded as having died 
in UK CHIC, matches were reported back to the appropriate centres for verification 
before being updated on the CHIC database.  
The number of deaths in UK CHIC at each centre, stratified by year of death is also 
compared to those reported to the HPA through national surveillance schemes.  
Discrepancies are reported back to individual centres and information on date of 
death is then updated on both databases accordingly.  
 
3.2.4. Duplicate records 
Since the current UK CHIC Study dataset contains information from 11 centres, it is 
possible that the same individual has attended two or more of these centres, 
resulting in two or more separate records for a single individual. Such potential 
matches are initially identified using date of birth, initials and soundex codes. A 
computerised algorithm which utilises information on several demographic and 
clinical factors is then used to determine whether each potential match is a definite 
match, a definite non-match or remains indeterminate.  The indeterminate matches 
are manually checked by two independent investigators who decide whether the 
records are likely to be matches or non-matches. A third investigator manually 
checks any records where consensus is not reached – if he/she is unable to make a 
decision on the two records, they are left as distinct individuals in the final dataset. 
All records which were determined to be related to the same individual are merged 
using a computer program which updates any missing information from one record 
using the matched record. The example below shows two separate records (in 
simplified form) which have been matched to give the merged record (Table 
3.2.4.1). In this case, record B is identical to record A in all aspects, other than the 
HIV positive date (missing in record B). These records will have been identified as 
being from the same individual and the merged record will contain all information 
from records A and B.   
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Table 3.2.4.1: Example of a manual record check 
Record A Record B Merged record 
Male Male Male 
MSM MSM MSM 
White ethnicity White ethnicity White ethnicity 
HIV POS: 01/05/2002 HIV POS: No date HIV POS: 01/05/2002 
DOB: 21/12/1976 DOB: 21/12/1976 DOB: 21/12/1976 
ART HISTORY: ART HISTORY: ART HISTORY: 
01/05/02 – 23/12/2004 
AZT/3TC/NVP 
01/05/02 – 23/12/2004  
AZT/3TC/NVP 
01/05/02 – 23/12/2004 
AZT/3TC/NVP 
Death: No date Death: No date Death: No date 
 
 
3.2.5. Final dataset 
After the datasets have been cleaned and duplicate records have been merged, a 
final version of the combined dataset is generated, with all patient identifiers 
removed and study numbers assigned. Using this final dataset, I run several 
queries, for example, removing duplicate laboratory data and ensuring last seen 
dates occur before date of deaths. Treatment history is also re-checked to highlight 
any inconsistencies which may have resulted from the de-duplication process. 
Finally, all datasets are merged together using the unique study identifier and a final 
SAS dataset is made available for distribution for analysis. A copy of this dataset is 
archived should it be required in the future.  
 
3.2.6. Toxicity data and Hepatitis B/C status 
Information on HAART-related toxicities is also provided by the majority of the 
centres. A full list of the variables collected is shown in Table 3.2.6.1. These data 
are provided in the form of text files and are checked for inconsistencies using SAS. 
Any duplicate records are removed and checks are carried out to ensure that the 
unit of measurement is consistent both within and between centres. All toxicity 
measurements are merged using the unique study identifier and are stored in a SAS 
dataset which can be linked to the main dataset using the CHIC study identifier.  
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Table 3.2.6.1: HAART-related toxicity data collected  
Laboratory marker Normal range and units 
Total cholesterol <5.2 mmol/l 
HDL-cholesterol >1 mmol/l 
LDL-cholesterol <4 mmol/l 
Triglycerides <2.3 mmol/l 
Lactate 0.5-2.0 mmol/l 
Glucose Fasting <5 days: 0.7-4.2 mmol/l 
Fasting >5 days: 2.9-5.3 mmol/l 
AST 5-40 IU/l 
ALT 5-40 IU/l 
Albumin 35-50 g/l 
Bilirubin 5-17 Umol/l 
Alkaline phosphate 42-128 IU/l 
Gamma GT Male: 9-54 IU/l 
Female: 8-35 IU/l 
Urea 3.0-6.5 mmol/l 
Creatinine 60-97 μmol/l 
White blood count 3.7-9.5 x 109 cells/l 
Haemoglobin Male: 13.5-17.5 g/dl 
Female: 11.5-15.5 g/dl 
Platelets 140-400 x 109 cells/l 
 
 
3.3. Overview of trends over time in UK CHIC 
Since the original UK CHIC dataset was made available for analysis in 2002, 
information on almost 20,000 new patients has been provided, with the latest 
dataset consisting of 32,607 records. This number represents around 40% of all 
HIV-positive patients in the UK. The London-based HIV-positive population is well 
represented in UK CHIC (8 out of 11 centres are London-based), as are HIV-
positive individuals located in Brighton and Bristol. Currently, one centre from 
Scotland provides data and it is extremely likely that centres from the Midlands will 
also soon provide data to UK CHIC. I will be using the current dataset (n=32, 607) 
for all analyses in this thesis. Table 3.3.1 summarises the demographics of the 
cohort.    
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Table 3.3.1: Demographics of current (2008) UK CHIC dataset  
  N % 
Total number of patients 32607 100.0 
Sex Female 7856 24.1 
Risk group MSM 16960 52.0 
 IDU 1372 4.2 
 Heterosexual 10353 31.8 
 Other/not known 3922 12.0 
Ethnicity White 18989 58.2 
  Black African 7728 23.7 
  Not known 1618 5.0 
  Other 4272 13.1 
Median (IQR1) age at first entry into cohort (years) 30 24-36 
1
 IQR: Interquartile range 
 
3.3.1. Demographic changes over time (2000-2007) 
In order to assess demographic changes over time, I first identified the number of 
patients under follow-up in UK CHIC at the mid-point of each year from 2000-2007. I 
chose the year 2000 as the reference year for these analyses since this is when 
HAART was widely available and recommended for all patients. Further, clinical 
practices may have been somewhat different in the early HAART-era (1996-1999) 
and hence these analyses were restricted to 2000 onwards. In order to be defined 
as under follow-up in a given year, patients had to have at least one viral load and/or 
CD4 count measured in the second half of the year (on or after July 1st) and the 
earliest date of each patient‟s first viral load and CD4 was required to be before July 
1st of that year. Using this criterion, the number of patients under follow-up increased 
from 9041 in 2000 to 14,812 in 2007. Table 3.3.1.1 shows the changing 
characteristics of patients under follow-up in each year. Females now represent 
almost a quarter of the cohort compared to 14.5% in 1996. There has also been an 
increase in the proportion of heterosexual individuals under follow-up in later 
calendar years, whilst the proportion of homosexual individuals appears to be 
declining. In 1996, 75% of the cohort was of white ethnicity, compared to 60% in 
2007. This is consistent with an increasing proportion of black-Africans under follow-
up in later calendar years (23% in 2007 compared to 10% in 1996). Over 75% of 
patients under follow-up were receiving HAART (defined as 3 or more drugs) in 
2007 and over 80% had received HAART at some point whilst under care.
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Table 3.3.1.1: Characteristics of patients under follow-up in each year 
 2000 2001 2002 2003 2004 2005 2006 2007 
No. under follow-up  9041 10230 11373 12648 13781 15003 16709 14812 
Male N (%) 7462 (83) 8280 (81) 9067 (80) 9888 (78) 10654 (77) 11508 (77) 12831 (77) 11380 (77) 
Risk group N (%)               MSM 5954 (66) 6543 (64 ) 7059 (62) 7702 (61) 8242 (60) 8915 (59) 9897 (59) 8640 (58) 
Heterosexual 2138 (24) 2721 (27) 3256 (29) 3868 (31) 4383 (32) 4893 (33) 5447 (33) 4666 (32) 
Other 949 (10) 966 (9) 1058 (9) 1078 (9) 1156 (8) 1195 (8) 1365 (8) 1506 (10) 
Ethnicity N (%)                   White              6507 (72) 7043 (69) 7578 (67) 8148 (64) 8649 (63) 9314 (62) 10246 (61) 8984 (61) 
Black African 1449 (16) 1864 (18) 2257 (20) 2777 (22) 3185 (23) 3516 (23) 3939 (24) 3454 (23) 
Other 1085 (12) 1323 (13) 1538 (14) 1723 (14) 1947 (14) 2173 (14) 2524 (15) 2374 (16) 
On HAART  6249 (69) 7093 (69) 7862 (69) 8905 (70) 9933 (72) 11014 (73) 12451 (74) 11211 (76) 
Started treatment with <3 drugs 2688 (30) 2634 (26) 2562 (23) 2505 (20) 2474 (18) 2428 (16) 2458 (15) 1981 (13) 
Started treatment with >3 drugs 3561 (39) 4459 (44) 5300 (47) 6400 (51) 7459 (54) 8586 (57) 9993 (60) 9230 (62) 
HAART-experienced  7017 (78) 7945 (78) 8819 (78) 9888 (78) 10927 (79) 11963 (80) 13366 (80) 11937 (81) 
NNRTI experienced (%)  4532 (65) 5737 (72) 6679 (76) 7730 (78) 8836 (81) 9654 (81) 10663 (80) 9676 (81) 
PI experienced (%)  4421 (63) 4704 (59) 5022 (57) 5390 (54) 5921 (54) 6648 (56) 7632 (57) 6716 (56) 
Experienced 3 original classes1 
(%) 
2450 (35) 2994 (38) 3385 (38) 3793 (38) 4286 (39) 4715 (39) 5250 (39) 4706 (39) 
1 
NRTIS, NNRTIs and PIs
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3.3.2. CD4 and viral load changes over time 
For all patients under follow-up, the proportion of patients on HAART with viral load 
suppression below 50 copies/mL and the proportion of all patients with a low CD4 
count (<200 cells/mm3) were calculated and are shown in Figure 3.3.2.1. Of those 
receiving HAART, 84% had an undetectable viral load (<50 copies/mL) in 2007, 
compared to 62% in 2000. Amongst all patients under follow-up, the proportion of 
patients with a CD4 count below 200 cells/mm3 decreased from 19% in 2000 to 8% 
in 2007. 
 
Figure 3.3.2.1: Proportion of patients with current CD4 <200 cells/mm3 and 
proportion of patients on HAART with viral load <50 copies/mL  
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3.3.3. Number of regimens received 
The number of regimens patients had received in each calendar year is shown in 
Figure 3.3.3.1. In order to be defined as starting a new regimen, patients had to 
virologically fail their current regimen. Virological failure of a drug was defined as 
having occurred if 2 consecutive viral loads >400 copies/mL were measured in an 
individual, despite at least 4 months of continuous use of the drug. All drugs 
received at the time of failure were also regarded as „failed drugs‟. Patients could 
only experience a new episode of virological failure if they were receiving at least 
one drug which they had not previously failed. 
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The proportion of patients on first-line HAART has steadily increased from 2000 
onwards and was almost 60% in 2007. Consequently, the proportion of patients on 
subsequent regimens has been declining – only 9% of patients were on their third-
line regimen in 2007. 
 
Figure 3.3.3.1: Number of regimens received 
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3.4. The UK HIV Drug Resistance Database 
The UK HIV Drug Resistance Database was established in 2001 as a central 
repository of resistance tests performed as part of routine clinical care in the UK.  
Resistance tests from clinical centres (in the form of blood samples) are sent to 
virology laboratories for analysis. Currently, 14 virology laboratories provide data to 
the study, usually in the form of viral gene sequences. The current database 
contains the results of over 51,000 test results from approximately 36,500 patients. 
Figure 3.4.1 shows the number of resistance tests submitted each year to the 
database, stratified by therapy status. In earlier years, the majority of tests were 
performed in HAART-experienced patients but with new guidelines now in place, 
there has been a steady increase in the number of resistance tests performed in 
HAART-naïve patients. The initial objectives of the study were to estimate the 
prevalence of drug resistance in untreated infections within the UK and describe 
changes over time; to describe the pattern of drug resistance in patients failing 
therapy; and to assess the effect of specific mutations on virological response.  
    98 
 
 
The UK HIV Drug Resistance Database is co-ordinated by the MRC Clinical Trials 
Unit in London and is currently funded by the MRC.  
 
Figure 3.4.1: Number of resistance tests submitted each year to the UK HIV 
Drug Resistance Database, by therapy status and year of sample 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
3.4.1. Data collection and linkage to UK CHIC 
Laboratories provide the results of the resistance tests as full nucleotide sequences 
performed in the previous calendar year for all patients. Data are sent in a variety of 
formats including access databases, Excel spreadsheets and individual FASTA files 
(text-based format for representing either nucleotide sequences or peptide 
sequences, in which base pairs or amino acids are represented using single-letter 
codes). These data are imported into a central SQL database by the study 
coordinator (Esther Fearnhill). The nucleotide sequences are then processed 
through the Stanford University Genotypic Resistance Interpretation Algorithm 
(HIVdb) to obtain aligned sequences, amino acid mutations and drug susceptibility 
data. These are stored in the database along with subtype data from the Rega 
Institute. Data are also collected on patient demographics, clinical details, HAART 
history and laboratory markers at the time of the resistance test. Data checks, such 
as ensuring the reason for the resistance test matches the treatment status of the 
patient, are performed and samples are matched to patients in the UK CHIC 
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database using clinical centre and pseudo-anonymised patient identifiers. Further 
checks are performed, e.g. checking that the date of birth in the resistance database 
matches that in the CHIC database. Given the substantial overlap between the 
patients in the two databases, the clinical information is co-ordinated between the 
studies. There are a total of 15,550 (47.7%) patients in UK CHIC who have 
resistance data in the UK HIV Drug Resistance Database. Amongst patients who 
have had a resistance test, the median number (range) of tests is 1 (1, 16).  
 
3.5. Statistical methods 
The specific statistical methods used in each of the Results chapters are described 
in the appropriate chapter. I have, however, used some generic regression methods 
in all chapters; these are summarised below.  
 
3.5.1. Linear regression 
In situations where there is a single continuous outcome measure per individual 
(dependant variable) y, linear regression is used to predict the value of the outcome 
y, from a set of explanatory variables, x1, x2, x3,…,xn. The magnitude of the effect of 
the explanatory variables on the dependant variable is estimated using a sample of 
observations from the population and this association is assumed to be of the 
following form:  
Expected value of   nn xxxxy ...332211 . 
The parameter estimate for βi gives the impact of a unit increase in xi on y, when all 
other independent variables are kept constant.  
 
3.5.2. Logistic regression 
Logistic regression, like linear regression, is used to investigate the impact of a set 
of explanatory variables on a dependant variable. However, the dependant variable 
y, is not continuously distributed. Instead, it is a binary variable and can only take 
the values 0 and 1. The estimates of βi obtained from the model give the log odds 
ratio for the impact of a unit increase in xi on the probability that y=1, and the 
exponential of βi gives the odds ratio 
 
3.5.3. Poisson regression 
Poisson regression is similar to Logistic regression, in that the event of interest is a 
binary outcome. However, rather than modelling the probability that an event occurs, 
Poisson regression is used to model the rate at which an event occurs. Poisson 
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regression allows for differing follow-up time amongst patients and assumes that the 
rate of an event is constant over time over the whole study period (unless time on 
study is fitted in the model, for example as a categorical variable). The estimates of 
βi obtained from the model give the impact of a unit increase in xi on the log of the 
rate, and the exponential of βi gives the rate ratio. 
 
3.5.4. Cox proportional hazards regression models 
Survival methods, such as the Cox regression model are used when the time to the 
occurrence of an event is of importance. Given that not all individuals will experience 
the event and are likely to have different lengths of follow-up time, data are 
censored, usually at the last known point at which an individual is known to 
experience the event or not. However, these individuals may still experience the 
event at some point in the future and hence we must account for the censored data. 
 
A hazard is calculated for each individual, h(t), and this is the instantaneous risk of 
having an event at any point in time (t), given that the event of interest has not 
already been experienced up until this time point. Generally, it is the hazard ratio 
which is of interest, rather than the hazard itself. The hazard ratio provides an 
estimate of the impact of a unit increase in a factor of interest on the hazard. Cox 
proportional hazard regression models take the following form: 
0            )...exp()()( 11110  txxxthth nn  
Here, h0(t) is the baseline or underlying hazard (usually not of interest in its own 
right, and not estimated in a Cox model) and the estimate of exp(βi) gives the 
hazard ratio for factor xi. 
It is assumed that the multiplicative impact of factor x1 on the hazard remains 
constant, regardless of the current time point – the proportional hazards assumption.  
 
In all regression analyses, all variables which were statistically significant in 
univariable analyses (p<0.10), or were of known clinical significance (e.g. CD4/viral 
load), were included in multivariable analyses. 
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Chapter 4: The impact of transmitted drug-resistance 
on treatment selection and outcome of first-line 
HAART 
4.  
  
4.1. Introduction 
As discussed in Chapter 2.1, transmitted drug resistance (TDR) can compromise an  
individual‟s response to HAART, especially in the context of NNRTI-based regimens 
(189;464-468). The British HIV Association (BHIVA) and the International AIDS 
Society (IAS) treatment guidelines recommend that all newly diagnosed HIV-positive 
individuals have a baseline resistance test performed to determine the presence of 
TDR and inform the selection of first-line HAART (126;130). However, resistance 
concerns are only one of a number of factors that may be considered when 
choosing an initial treatment regimen for a given patient. In particular, concerns 
about possible toxicities and likely adherence, together with patients‟ views on the 
ability of any particular regimen to accommodate lifestyle requirements, and 
hepatitis-B co-infection are major determinants of the selection of first-line regimens. 
In some cases, information about TDR may only become available after the patient 
has started treatment. In other cases, the significance of certain genotypic changes 
(e.g. the presence of T215 revertants) may be missed by the treating physician, 
especially if phenotypic tests are used (469). The overall resilience of the regimen to 
rapidly accumulating drug-resistance – commonly referred to as the “genetic barrier” 
- may also lead to a preference for regimens based on ritonavir-boosted protease 
inhibitors (PI/r) rather than NNRTIs as a compensation for the use of a partially 
active NRTI backbone. These considerations may lead to some patients starting 
treatment regimens that, according to their baseline resistance profile, contain fewer 
than 3 fully-active drugs. The extent to which virological responses to treatment are 
compromised by these choices is unclear. 
 
In this chapter, I investigate TDR amongst patients who underwent genotypic 
resistance testing whilst antiretroviral drug-naïve and subsequently started first-line 
HAART. In this group, I determined the genotypic sensitivity score (GSS) of the 
initial regimen and assessed the impact of GSS on virological outcomes, including 
whether plasma viral load (VL) becomes suppressed to <50 copies/mL and, if so, 
the subsequent risk of virological rebound >400 copies/mL.   
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4.2. Methods 
 
4.2.1. Study population 
Linked data (as described in Section 3.4.1) from the UK HIV Drug Resistance 
Database and the UK CHIC Study were used for these analyses. All patients who 
were antiretroviral naive and subsequently started HAART (defined as a standard 
regimen of >3 drugs including NRTIs in combination with either one NNRTI, one or 
two (including ritonavir) PIs or another NRTI) between 1st January 1999 and 30th 
December 2007 were eligible for analyses (n=13073). January 1999 was chosen as 
the earliest inclusion date as resistance testing in treatment-naïve patients was not 
recommended in routine practice before this date and hence tests were only 
performed on selected individuals. 
Patients receiving combinations without NRTIs, with 2 PIs excluding ritonavir or with 
both PIs and NNRTIs were excluded as these were non-standard treatment 
regimens. Patients were also excluded from analyses if their initial HAART regimen 
contained drugs with recorded start and stop dates but without drug identifiers, i.e. 
„not known‟, „other‟ and „blinded treatment in clinical trial‟ and if they were receiving 
either fusion inhibitors (Maraviroc, T20) or integrase inhibitors (Raltegravir) as these 
were also non-standard regimens. These regimens are likely to have been taken by 
patients who are clinically dissimilar to those on standard regimens and hence 
results obtained from these individuals may not be generalisable.  
In addition, those who had a VL <50 copies/mL before the start date of HAART were 
removed from the dataset as an undetectable pre-HAART VL may be an indication 
of either missing or inaccurate early treatment records. Patients were identified as 
having a routine resistance test performed before starting HAART if the test was 
performed after January 1999 and both the date of the test and the date when the 
result of the resistance test was conveyed to the clinician preceded the date of 
starting HAART. All resistance tests meeting these criteria were analysed (i.e. more 
than 1 test per patient was included if there was more than one test available). The 
results of multiple tests were combined, for example resistance mutations identified 
using the first test but not the second test (and vice-versa) were included in the 
analyses.  
 
4.2.2. Interpreting resistance mutations 
Amongst patients who did have a resistance test performed, mutations indicative of 
TDR were identified according to Shafer‟s  „Resistance surveillance lists‟ compiled in 
2007 and updated in 2009 (183). This is a standardised list of drug resistance 
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mutations used to define transmitted resistance. It includes only those mutations 
which either cause or contribute to drug resistance amongst patients receiving 
HAART and excludes any mutations which occur as polymorphisms amongst 
patients not receiving HAART. The list is particularly useful in epidemiological 
studies where it is otherwise difficult to compare estimates of drug resistance due to 
the high number of (distinct) resistance mutation lists already in existence.  
The Stanford interpretation algorithm (Version 5.1.2) was used to calculate drug 
susceptibility levels. All resistance mutations which were identified using the 
„Resistance surveillance lists‟ and had a Stanford mutation penalty score >0 (each 
drug resistance mutation is assigned a drug penalty score; the total score for each 
drug is derived by adding the scores of each mutation associated with resistance to 
that drug) for each drug were used to calculate the proportion of patients with 
resistance mutations to any drug used as part of their initial HAART regimen, with 
separate analyses for resistance-associated mutations for the NRTIs (NAMs: M41L, 
D67N, K219Q, M184V, L210W, T69D, K219E, K70R, M184I, K65R, D67E, L74V, 
V75M, F77L, K219R, V75T, Y115F, D67G, K70E, L74I, V75A, V75S, F116Y, 
Q151M; TAMs: T215D, T215S, T215C, T215Y, T215E, T215I, T215V, T215F), the 
NNRTIs (nNAMs: K103N, Y181C, K101E, G190A, V106A, V106M, Y188L, K103S, 
G190S, P225H, L100I, K101P, M230L, V179F, Y181V, Y181I, Y188H, Y188C, 
G190E) and the PIs (PRAMs: L90M, M46I, M46L, V82L, F53L, I85V, I47V, I54V, 
G73S, V82A, V32I, N88D, N88S, L23I, D30N, I54L, I54S, L76V, V82T, L24I, I47A, 
G48M, G48V, I50L, I50V, F53Y, I54A, I54M, I54T, G73C, G73T, G73A, V82C, 
V82F, V82M, V82S, N83D, I84A, I84C, I84V).  
 
Using the total drug score, the Stanford algorithm classifies the level of resistance 
into 5 groups: susceptible, potential low-level, low-level, intermediate and high-level. 
In these analyses, the genotypic sensitivity scores were determined by assigning a 
score of 1 to susceptible/potential low-level resistance, 0.5 to low-level/intermediate 
resistance and 0 to high-level resistance. Hence, a patient starting HAART with 3 
drugs and no resistance mutations would have a GSS of 3.  
These analyses were also stratified according to the number of drugs in the initial 
HAART regimens, where low-dose ritonavir was not counted as a separate drug. 
 
4.2.3. Statistical analyses 
Characteristics of patients who started HAART and who had a resistance test 
performed whilst HAART-naive in the study period were compared to those who did 
not have a resistance test performed using Chi-squared and Mann-Whitney tests.  
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Among patients with a resistance test, logistic regression was used to identify 
factors associated with starting a first-line HAART regimen with a GSS score <3. 
Models were adjusted for the following potential confounders: age, gender, ethnicity 
(white, black, „other‟), HIV transmission risk group (MSM, heterosexual, „other‟), HIV-
1 subtype (B, non-B), calendar year of HAART initiation (1999-2001, 2002-2004, 
2005-2007), interval between the last resistance test prior to HAART and the 
HAART start date, pre-HAART CD4 and VL, and type of HAART regimen started 
(PI-based, NNRTI-based or „other‟ [triple NRTIs]). PI-based therapy included both 
non-boosted and ritonavir-boosted PIs (PI/r). 
 
Further analyses using logistic regression were performed in order to investigate 
whether patients with nNAMs were less likely to start HAART on an NNRTI-based 
regimen, whether patients with PRAMs were less likely to start HAART on PI-based 
regimens and whether patients with TAMs were less likely to start HAART with the 
TAM-affected drugs zidovudine, stavudine, abacavir, didanosine and tenofovir.  
Cox regression was used to identify factors associated with the rate of achieving an 
undetectable VL (<50 copies/mL) (patients without baseline and/or follow-up VL 
measurement excluded). Amongst patients who achieved an undetectable VL within 
a year of starting HAART, virological rebound was defined as 2 consecutive VL 
measurements >400 copies/mL or 1 VL >400 copies/mL followed by any treatment 
change. Hazard (rate) ratios of virological rebound were also calculated using Cox 
regression (patients without follow-up VL measurements excluded). In these 
models, GSS was fitted as a continuous variable if a linear trend between GSS and 
the outcome of interest was observed in univariate analyses. 
 
The time to a CD4 increase of 50 cells from start of HAART was also analysed using 
Cox regression. In this analysis, viral load was incorporated as a time-updated 
variable. This again ensured that the effect of GSS on CD4 response was 
independent of VL (VL has been shown to be associated with CD4 response). 
A summary of all outcomes considered and eligibility for each analysis is given in 
Table 4.2.3.1.  
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Table 4.2.3.1: Summary of outcomes considered and eligibility criteria for 
each analysis 
Outcome considered Inclusion criteria 
Differences between those who had a resistance test 
whilst HAART-naive compared to those who did not 
have a resistance test 
All patients starting 
HAART 
Factors associated with starting a first-line HAART 
regimen with GSS <3 
All patients with 
resistance tests 
performed whilst HAART-
naive who subsequently 
started HAART 
Were patients with nNAMS less likely to start NNRTI-
based regimens? 
Patients starting HAART 
with nNAMS 
Were patients with PRAMS less likely to start PI-based 
regimens? 
Patients starting HAART 
with PRAMS 
Factors associated with achieving VL <50 copies/mL Patients with baseline and 
follow-up viral load 
measures 
Factors associated with virological rebound Patients achieving VL <50 
copies/mL within 1 year of 
starting HAART and with 
at least one follow-up VL 
Factors associated with a CD4 cell increase of 50 cells 
from start of HAART 
Patients with baseline and 
follow-up CD4 measures 
 
 
4.2.4. Sensitivity analyses restricted to patients who had their resistance 
test performed within 6 months prior to starting HAART 
As discussed in Chapter 1.8.3, in the absence of therapy, resistance mutations tend 
to fade out over time. Hence, sensitivity analyses were performed in which only 
patients who had their resistance test performed within 6 months prior to starting 
HAART were included. In this analysis, all current resistance mutations present in 
an individual are likely to be identified. The proportion of patients with mutations 
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conferring resistance to the first-line regimen was calculated and time to virological 
response, virological rebound and CD4 increase of >50 cells/mm3 were investigated 
using Cox regression as detailed in Section 4.2.3. 
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4.3. Results 
 
4.3.1. Patients starting HAART 
Of the 32,607 patients in UK CHIC, 13,073 (40.1%) started a HAART regimen 
containing 3 or more drugs from naïve between January 1999 and December 2007. 
Three hundred and sixty-two (2.8%) of these patients were removed from the 
dataset for the following reasons; 245 patients received both PIs and NNRTIs, 73 
patients received >1 PI excluding ritonavir, 30 patients received either unknown 
drugs or fusion/integrase inhibitors and 14 patients did not receive any NRTIs. A 
further 825 (6.3%) patients had a recorded viral load of <50 copies/mL before 
starting HAART and were also removed from the dataset, leaving 11,886 patients 
eligible for analysis. 
 
4.3.1.1. Differences between patients with and without resistance tests 
before starting HAART  
Amongst the 11,886 patients starting HAART from naïve, 2,931 (24.7%) underwent 
pre-HAART resistance testing. Ten of these patients had their first resistance test 
performed before 1999 (before resistance testing was recommended in naïve 
patients) and hence these tests were not considered to be part of routine clinical 
care. Two of these patients had a second resistance test performed after 1999 and 
still before starting HAART and were therefore categorised as having a resistance 
test performed whilst HAART-naive, leaving 2,923 patients with pre-HAART 
resistance tests performed as part of routine clinical care. 
 
Compared to those who did not undergo resistance testing, patients with pre-
HAART resistance tests were more likely to be male (28.2% of males tested vs. 
16.0% of females, p<0.0001), of MSM exposure (33.3% of MSM tested vs. 15.6% of 
heterosexuals, p<0.0001) and of white ethnicity (30.9% of whites tested vs. 15.7% 
of blacks, p<0.0001) (Table 4.3.1.1.1). Patients with pre-HAART resistance tests 
were also more likely to start HAART with a PI/r-regimen (38.9% of those starting 
HAART with PI/r tested vs. 23.1% of those starting HAART with NNRTI-based 
regimens, p<0.0001) and had higher median pre-HAART CD4 counts (210 vs. 173 
cells/mm3, p<0.0001), though no clinical difference was seen in pre-HAART log viral 
loads (4.9 log copies/mL in those with and without pre-HAART resistance tests). 
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Table 4.3.1.1.1: Differences between patients starting HAART with a resistance 
test performed whilst naïve and those without a resistance test performed 
  Resistance test performed 
whilst naive 
P-value 
  No Yes  
N  8963 2923  
Sex N (%) Male 6041 (71.9) 2366 (28.1) <0.0001 
 Female  2922 (84.0) 557 (16.0)  
Ethnicity N (%) White  4189 (69.1) 1877 (30.9) <0.0001 
 Black 3785 (84.3) 705 (15.7)  
 Other 989 (74.4) 341 (25.6)  
HIV transmission risk  MSM 3758 (66.7) 1877 (33.3) <0.0001 
group N (%) Heterosexual 4194 (84.4) 778 (15.6)  
 IDU 277 (82.7) 58 (17.3)  
 Other 734 (77.8) 210 (22.2)  
HAART regimen started NNRTI 6485 (76.9) 1946 (23.1) <0.0001 
 PI/r 1392 (61.1) 885 (38.9)  
 Single PI 637 (95.5) 30 (4.5)  
 NRTI only 449 (87.9) 62 (12.1)  
CD4 count at HAART 
initiation (cells/mm3) 
Median (IQR) 173 (78, 269) 210 (140, 285) <0.0001 
Viral load at HAART 
initiation (log copies/mL) 
Median (IQR) 4.9 (4.3, 5.4) 4.9 (4.3, 5.3) 0.005 
 
 
4.3.2. Baseline characteristics of those with resistance tests before 
starting HAART 
Table 4.3.2.1 shows the baseline characteristics of patients with resistance tests 
before starting HAART. The vast majority of patients (2,436, 83.3%) had only a 
single resistance test performed, though up to 5 tests were performed on some 
HAART-naive individuals. Patients with pre-HAART resistance tests were mostly 
male (80.9%), of white ethnicity (64.2%) and of MSM transmission group (64.2%). 
Testing was more frequent in later calendar years, reflecting the uptake of 
guidelines first introduced in 1999. The median (interquartile-range [IQR]) time 
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between the last resistance test before starting HAART and starting HAART was 1.9 
(0.7, 8.3) months. The majority of patients (76.3%) who started HAART after 6 
months of the date of the resistance test did so in later calendar years (2005-2007) 
and started HAART with an NNRTI-based regimen.  
Two-thirds of all patients started an NNRTI-based regimen and almost one-third a 
PI/r-based regimen. The median CD4 count at start of HAART was lower than that 
at the time of the resistance test (210 vs. 251 cells/mm3), though there was little 
difference between the median log viral loads at these time points (4.9 log copies in 
both groups).  
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Table 4.3.2.1: Baseline characteristics of 2931 patients who initiated first-line 
HAART following a baseline genotypic resistance test 
Total N (%)  2923 (100.0) 
Number of resistance tests before starting 
HAART N (%) 
Median (range) 1 (1, 5) 
Time between last resistance test pre-HAART 
and starting HAART (months) 
Median (IQR) 1.9 (0.7, 8.3) 
Sex N (%) Male 2366 (80.9) 
Ethnicity N (%) White 1877 (64.2) 
 Black 705 (24.1) 
 Other 341 (11.7) 
HIV transmission risk group N (%) MSM 1877 (64.2) 
 Heterosexual 778 (26.6 
 IDU 58 (2.0) 
 Other 210 (7.2) 
Calendar year of resistance test N (%) 1999-2001 141 (4.8) 
 2002-2004 950 (32.5) 
 2005-2007 1832 (62.7) 
Calendar year of starting HAART N (%) 1999-2001 80 (2.7) 
 2002-2004 683 (23.4) 
 2005-2007 2160 (73.9) 
Subtype B virus N (%)  2012 (68.8) 
Age at last resistance test before HAART 
(years) 
Median (IQR) 37 (31, 42) 
CD4 count at last resistance test before 
HAART (cells/mm3) 
Median (IQR) 251 (164, 354) 
CD4 count at HAART initiation (cells/mm3) Median (IQR) 210 (140, 285) 
Viral load at last resistance test before HAART 
(log copies/mL) 
Median (IQR) 4.9 (4.4, 5.3) 
Viral load at HAART initiation (log copies/mL) Median (IQR) 4.9 (4.3, 5.3) 
Initial HAART regimen N (%) NNRTI 1946 (66.6) 
 PI/r 885 (30.3) 
 Single PI 30 (1.0) 
 Nucleoside only 62 (2.1) 
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4.3.3. Prevalence of TDR 
Overall, 272/2923 (9.3% (95% CI: 8.3%, 10.4%) patients had at least one detectable 
mutation indicative of TDR. Table 4.3.3.1 lists the frequency of individual mutations. 
Among NAMs, T215 revertants and M41L were the most frequently detected 
mutations and occurred in 85 (2.9%) and 48 (1.6%) patients respectively. The 
K103N and the L90M mutations were the most commonly detected nNAMs and 
PRAMs respectively, and occurred in 62 (2.1%) and 20 (0.7%) patients; 87/272 
(32.0%) patients had more than 1 mutation. The median (range) number of 
mutations amongst those who had at least one mutation was 1 (1, 14); patients had 
a median of 1 (0, 5) NAM mutations, 0 (0, 4) nNAM mutations and 0 (0, 5) PRAM 
mutations. 
  
The number of patients with at least one detectable mutation indicative of TDR 
increased substantially in later calendar years, from 5 in 2000 to 65 in 2005. 
However, this number appeared to plateau after 2005, with 61 patients identified 
with TDR in 2006 and 66 patients in 2007 (Figure 4.3.3.1). The number of patients 
with NAMs identified increased until 2006, after which a decline was observed (41 
patients with NAMs were identified in 2006, compared to 36 in 2007). There was no 
evidence of a decrease in the number of patients with nNAMs in later calendar 
years, though after 2005, a clear decline was seen in the number of patients with 
PRAMs (15 patients in 2005 compared to 11 in 2006 and 9 in 2007).  
 
Interestingly, if all patients with resistance tests performed whilst HAART-naive 
(including those who never started HAART) were included in the prevalence 
analyses, the number of patients with at least one detectable mutation indicative of 
TDR increased steadily from 1 in 1999 to 179 in 2007. These numbers did not 
appear to plateau as seen in the analysis in which only patients who started HAART 
were included. The number of patients with NAMs and nNAMs also increased from 
1999 to 2007 though the number of patients with PRAMS decreased in 2007 to 34  
(40 in 2006).
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Table 4.3.3.1: Frequency of detection of mutations indicative of transmitted 
drug resistance among 2923 patients, of which 272 had at least one mutationa 
NRTI N (%) NNRTI % Major PI % 
Any 167 (5.7) Any 102 (3.5) Any 61 (2.1) 
T215revb 85 (2.9) K103N 62 (2.1) L90M 20 (0.7) 
M41L 48 (1.6) Y181C 24 (0.8) M46I 9 (0.3) 
T215D 32 (1.1) K101E  14 (0.5) M46L 7 (0.2) 
T215S 26 (0.9) G190A 14 (0.5) V82L 7 (0.2) 
D67N 22 (0.8) V106A 3 (0.1) F53L 6 (0.2) 
K219Q 21 (0.7) V106M 3 (0.1) I85V 6 (0.2) 
M184V 20 (0.7) Y188L 3 (0.1) I47V 3 (0.1) 
L210W 18 (0.6) K103S 2 (0.1) I54V 3 (0.1) 
T215C 13 (0.4) G190S 2 (0.1) G73S 3 (0.1) 
K219N 12 (0.4) P225H 2 (0.1) V82A 3 (0.1) 
T215Y 10 (0.3) L100I 1 (0.0) V32I  2 (0.1) 
T215E 9 (0.3) K101P 1 (0.0) N88D 2 (0.1) 
T69D 7 (0.2) M230L 1 (0.0) N88S 2 (0.1) 
T215I 7 (0.2) V179F    0 (0.0) L23I 1 (0.0) 
T215V 7 (0.2) Y181V 0 (0.0) D30N 1 (0.0) 
K219E 7 (0.2) Y181I 0 (0.0) I54L 1 (0.0) 
K70R 6 (0.2) Y188H 0 (0.0) I54S 1 (0.0) 
T215F 4 (0.1) Y188C 0 (0.0) L76V 1 (0.0) 
M184I 3 (0.1) G190E 0 (0.0) V82T 1 (0.0) 
K65R 2 (0.1)   L24I 0 (0.0) 
D67E 2 (0.1)   I47A 0 (0.0) 
L74V 2 (0.1)   G48M 0 (0.0) 
V75M 2 (0.1)   G48V 0 (0.0) 
F77L 2 (0.1)   I50L 0 (0.0) 
K219R 2 (0.1)   I50V 0 (0.0) 
V75T 1 (0.0)   F53Y 0 (0.0) 
Y115F 1 (0.0)   I54A 0 (0.0) 
D67G 0 (0.0)   I54M 0 (0.0) 
K70E 0 (0.0)   I54T 0 (0.0) 
L74I 0 (0.0)   G73C 0 (0.0) 
V75A 0 (0.0)   G73T 0 (0.0) 
V75S 0 (0.0)   G73A 0 (0.0) 
F116Y 0 (0.0)   V82C 0 (0.0) 
Q151M 0 (0.0)   V82F 0 (0.0) 
    V82M 0 (0.0) 
    V82S 0 (0.0) 
    N83D 0 (0.0) 
    I84A 0 (0.0) 
    I84C 0 (0.0) 
    I84V 0 (0.0) 
 
a 
Patients may have more than one mutation within each drug class and for more than one 
class  
b 
Sum of all patients with at least one T215 revertant 
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Figure 4.3.3.1: Number of patients with at least one mutation, stratified by 
calendar year of starting HAART 
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Of the total number of patients starting HAART, 161 (5.5%) patients had at least one 
detectable mutation associated with resistance to the drugs used in their initial 
HAART regimen (Table 4.3.3.2). This included 142 (4.9%) patients starting NRTIs, 
though this percentage varied by the NRTI received. In addition, 7/259 (2.7%) and 
19/1688 (1.1%) patients who started nevirapine or efavirenz respectively had 
detectable resistance to these drugs. Overall, 15/915 (1.6%) of patients starting a PI 
(boosted or non-boosted) had detectable resistance mutations to the PI in their 
regimen, but this again varied by drug. Eleven patients had mutations associated 
with resistance to both NRTIs and PIs in their initial regimen and a further 11 
patients had mutations associated with resistance to both NRTIs and NNRTIs in 
their initial regimen.  
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Table 4.3.3.2: Proportion of patients starting HAART with one or more 
resistance mutation to any drug used as part of their initial HAART regimen 
 Number of patients 
starting drug as part of 
initial HAART regimen 
N (%)a of patients with 
at least one mutation to 
specific drug 
Total N (%) 2923 (100.0) 161 (5.5) 
Any NRTI 2923 (100.0) 142 (4.9) 
AZT 646 (22.1) 20 (3.2) 
DDI 105 (3.6) 14 (13.3) 
d4T 54 (1.8) 6 (11.1) 
3TC 1662 (56.9) 50 (3.0) 
ABC 880 (30.1) 52 (5.9) 
TDF 1468 (50.2) 70 (4.8) 
FTC 1170 (40.0) 20 (1.7) 
Any NNRTI 1946 (66.6) 26 (1.3) 
NVP 259 (8.9) 7 (2.7) 
EFV 1688 (57.7) 19 (1.1) 
Any PI 915 (31.3) 15 (1.6) 
SQV 141 (4.8) 1 (0.7) 
IDV 1 (0.0) 0 (0.0) 
RTV 885 (30.3) ~ 
NFV 20 (0.7) 1 (0.1) 
APV 1 (0.0) 0 (0.0) 
LPV 474 (16.2) 12 (2.5) 
ATV 224 (7.7) 1 (0.4) 
TPV 2 (0.1) 0 (0.0) 
DRV 12 (0.4) 0 (0.0) 
FPV 40 (1.4) 0 (0.0) 
DDI: didanosine, ABC: abacavir, d4T: stavudine, TDF: tenofovir, 3TC: lamivudine, AZT: 
zidovudine, FTC: emtricitabine, NVP: nevirapine, EFV: efavirenz, SQV: saquinavir, NFV: 
nelfinavir, LPV/r: lopinavir/ritonavir, ATV: atazanavir, TPV: tipranavir, FPV: fosamprenavir, 
IDV: indinavir, APV: amprenavir, DRV: darunavir 
 
No patients received zalcitabine (ddC), delavirdine, etravirine,   
a 
Denominators for percentages are the number of patients starting specific drugs  
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4.3.4. GSS of first-line regimen 
In calculations involving GSS, RTV was not counted as a separate drug. Hence 
patients who were on exactly 3 drugs including RTV, were excluded from all further 
analyses (N=3), leaving 2920 patients in the dataset. Therefore, all patients 
remaining in the dataset were required to have a GSS of >3 to denote a fully active 
regimen.  
 
The GSS of the first-line regimen was 3 in 2747 (94.1%) patients, >3 in 76 (2.6%) 
patients, and <3 in 97 (3.3%) patients, the latter comprising scores of 0.5, 1, 1.5, 2 
and 2.5 in 3 (0.1%), 4 (0.1%), 6 (0.2%), 34 (1.2%) and 50 (1.7%) patients 
respectively. The 7 patients with a GSS of <1 were all receiving NNRTI-based 
regimens (4 were receiving NVP and 3 were receiving EFV). Table 4.3.4.1 shows 
the GSS of patients stratified by the number of drugs received. Of those receiving 3 
drugs, 96.9% of patients had the maximum GSS of 3 and 0.3% of patients had a 
GSS <2. Of those receiving >3 drugs, the majority of patients had a GSS >3 
(86.4%), though around 10% of patients had a GSS between 2 and 3. No patients 
receiving >3 drugs had a GSS below 1.  
 
Table 4.3.4.1: GSS stratified by the number of drugs received as first-line 
HAART 
 Number of drugs received N (%) 
GSS  3 >3 Any 
>3 - 76 (86.4) 76 (2.6) 
3 2745 (96.9) 2 (2.3) 2747 (94.1) 
2.5 47 (1.7) 3 (3.4) 50 (1.7) 
2 29 (1.0) 5 (5.7) 34 (1.2) 
1.5 4 (0.1) 2 (2.3) 6 (0.2) 
1 4 (0.1) 0 (0.0) 4 (0.1) 
0.5 3 (0.1) 0 (0.0) 3 (0.1) 
Total 2832 88 2920 
 
Characteristics of the 97 (3.3%) patients with GSS <3 were compared to the 2823 
(96.7%) patients with GSS >3 (Table 4.3.4.2). A higher proportion of patients with 
GSS <3 were of white ethnicity (75.3% vs. 63.8%), of MSM risk group (72.3% vs. 
63.8%) and had started HAART in earlier calendar years (10.3% vs. 4.6%) 
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compared to those with GSS >3. Patients with GSS <3 were also more likely to 
carry a subtype B virus (80.4% vs. 68.4%) and start HAART with PI-based regimens 
(PI/r: 36.1% vs. 30%, single PI: 3.1% vs. 1.0%) than those with GSS >3. No 
statistical differences were found between CD4 counts and viral loads amongst the 
two groups.  
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Table 4.3.4.2: Characteristics of patients stratified according to whether the 
Genotypic Sensitivity Score (GSS) of the first-line HAART regimen was < or ≥3 
  GSS <3 GSS >3 P-value1 
Total   97 (100.0) 2823 (100.0)  
Gender (%) Male 85 (87.6) 2278 (80.7) 0.09 
Ethnicity (%) White 73 (75.3) 1802 (63.8) 0.02 
 Black African 12 (12.4) 693 (24.5)  
 Other 12 (12.4) 328 (11.6)  
HIV transmission 
group (%) 
MSM 73 (72.3) 1801 (63.8) 0.03 
Heterosexual 15 (15.5) 763 (27.0)  
Other 9 (9.3) 259 (9.2)  
Calendar year of  
resistance test (%) 
1999-2001 10 (10.3) 130 (4.6) 0.0001 
2002-2004 45 (46.4) 905 (32.1)  
2005-2007 42 (43.3) 1788 (63.3)  
Months from 
resistance test to 
start of HAART  
Median (IQR) 1.9  
(0.6, 11.4) 
1.9  
(0.7, 8.3) 
0.86 
Subtype  B 78 (80.4) 1931 (68.4) 0.01 
 Non B 19 (19.6) 892 (31.6)  
Age at time of test 
(years) 
Median (IQR) 37 (31, 41) 37 (31, 43) 0.49 
CD4 count at time of 
resistance test   
Median (IQR) 261  
(195, 386) 
250  
(163, 351) 
0.20 
CD4 count at HAART 
initiation  
Median (IQR) 225 
 (153, 298) 
210 
 (140, 284) 
0.32 
Viral load (VL) at time 
of resistance test  
Median (IQR) 4.8  
(4.3, 5.4) 
4.9  
(4.4, 5.3) 
0.32 
VL at HAART 
initiation  
Median (IQR) 4.8 
 (4.4, 5.4) 
4.9  
(4.3, 5.3) 
0.79 
HAART regimen  NNRTI 46 (47.4) 1900 (67.3) <0.0001 
started N (%) PI/r 35 (36.1) 847 (30.0)  
 PI  3 (3.1) 27 (1.0)  
 Triple NRTI 13 (13.4) 49 (1.7)  
1
 Calculated using Chi-squared or Mann Whitney tests 
CD4 count measured in cell/mm
3
 and VL measured in log10 copies 
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In adjusted analyses, factors significantly associated with a GSS <3 were starting 
HAART in earlier calendar years (Odds ratio (OR) 3.53; 95% Confidence Interval 
(CI): 1.49, 8.34, comparing 1999-2001 with 2005-2007 and 1.60 (0.99, 2.57) 
comparing 2002-2004 with 2005-2007), and starting HAART with a non-NNRTI 
regimen (5.08 (1.40, 18.37) comparing PI- to NNRTI-based regimens, 2.03 (1.27, 
3.23) comparing PI/r- with NNRTI-based regimens and 10.18 (4.26, 24.35) 
comparing triple NRTI- with NNRTI-based regimens).  
 
Given that patients starting HAART with PI-based regimens were more likely to have 
a GSS <3, these patients were investigated in greater detail. Of the 97 patients 
showing a GSS <3, 35 started PI/r-based HAART and 3 started single PI-based 
HAART. Analysing the resistance mutations of these 38 patients, 2 (5.3%) had 
mutations to only the PI in their initial regimen, 7 (18.4%) had mutations to both the 
PI and the NRTI in their initial regimen, and 28 (73.7%) patients had mutations to 
only the NRTIs in their initial regimen. Amongst the 9 patients with resistance 
mutations to PIs, 7 patients had started LPV/r (5 of whom had intermediate 
resistance to the drug), 1 patient had started NFV (with intermediate resistance to 
the drug) and 1 patient had started AZV/r (with intermediate resistance to the drug). 
Amongst the 35 patients with resistance mutations to the NRTIs in their initial 
regimen, the majority of patients (n=26) had mutations to 1 NRTI (most commonly 
ABC (10 patients) and TDF (10 patients), whilst the remaining 9 patients had 
resistance mutations to greater than one NRTI. 
 
In both unadjusted and adjusted models, patients were less likely to start an NNRTI 
if they had any nNAMs detected (adjusted OR=0.16; 95% CI: 0.10, 0.25), whereas 
there was no evidence to suggest that patients with PRAMs were less likely to start 
boosted or non-boosted PI-based regimens (adjusted OR 1.32; 95% CI: 0.74, 2.33). 
Amongst patients with TAMs, in unadjusted analyses patients were less likely to 
start AZT (unadjusted OR: 0.47; 95% CI: 0.24, 0.97) but this effect was non-
significant after adjusting for potential confounders (adjusted OR=0.52; 95% CI: 
0.24, 1.16). No significant relationship was found between having TAMs and starting 
HAART with any of the other TAM-affected drugs, ddI, 3TC, ABC and TDF.  
 
4.3.5. Virological suppression after starting first-line HAART 
Of the 2923 patients, 2785 (95.4%) had follow-up viral-loads measured. There was 
no difference in the sex (p=0.34), ethnicity (p=0.75) or HAART regimen started 
(p=0.32) amongst patients who were included and excluded in the virological 
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suppression analysis. However patients included in this analysis were more likely to 
be of MSM risk group (96.2% of MSMs included compared to 91% of those from 
„other‟ risk groups, p=0.01). No clinical difference was seen in the CD4 count and 
viral load at start of HAART, though p-values suggested borderline significance 
(p=0.07 and 0.10 respectively). Patients included in the analysis were also more 
likely to start HAART in earlier calendar years (99.1% in 2002-2004 compared to 
94.2% in 2005-2007, p<0.0001).  
 
Among the 2785 patients for whom follow-up VL measurements were available, 
2511 (90.2%) patients achieved an undetectable VL (<50 copies/mL) at a (Kaplan-
Meier) median of 3.6 (IQR: 3.5, 3.7) months after starting HAART. Follow-up was 
censored at the date of the last viral load measurement for patients who did not 
achieve an undetectable viral load. The majority of patients who achieved an 
undetectable viral load (1707/2511 (68.0%)) were receiving NNRTI-based regimens; 
751/2511 (29.8%) were receiving PI-based regimens and 53/2511 (2.1%) were 
receiving triple NRTI regimens. Among the 2511 patients who achieved virological 
suppression, the GSS of the regimen started was ≥3 in 2426 (96.6%) patients, 2.5 in 
43 (1.7%) patients, 2 in 32 (1.3%) patients, and <1.5 in 10 (0.4%) patients. Of the 
274 (9.8%) patients who did not achieve virological suppression, the GSS was 4 in 7 
(2.6%) patients, 3 in 259 (94.5%) patients, 2.5 in 4 (1.5%) patients, 2 in 2 (0.7%) 
patients and <1.5 in 2 (0.7%) patients. Some patients did switch therapy prior to 
virological suppression and hence the GSS at time of virological suppression was 
also calculated. Surprisingly, the GSS at time of virological suppression was 
generally lower than the GSS of the initial regimens – 2366 (94.2%) of those who 
achieved VL <50 copies/mL had a GSS of >3, whilst 123 (5.8%) patients had a GSS 
of <3. Patients may have switched drugs due to toxicity, and hence the GSS may 
not have been as important a factor as tolerability when these switches took place.  
 
Amongst the 93 patients with GSS <3, 85 (91.4%) patients achieved virological 
suppression and 8 (8.6%) patients did not achieve virological suppression (Figure 
4.3.5.1). These percentages appeared to be similar to those for patients with GSS 
>3 since they do not take into account censoring. The HAART regimens of the 85 
patients who achieved virological suppression despite a GSS <3 were NNRTI-based 
in 41 patients (17 with NAMs, 15 with nNAMs, and 9 with both NAMs and nNAMs), 
PI-based in 2 patients (1 with PRAMs and 1 with NAMs), PI/r-based in 30 patients (2 
with PRAMs, 22 with NAMs and 6 with NAMs and PRAMs), and triple NRTIs in 12 
patients, 3 of which had NAMs.  
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Of the 8 patients with GSS <3 who did not achieve virological suppression, 4/8 
started NNRTI-based regimens (2 with NAMs and 2 with NAMs and nNAMs). Three 
patients started PI-based regimens (lopinavir/r, nelfinavir and atazanavir/r); none 
had PRAMs whilst all 3 had NAMs. One patient with NAMs started a triple NRTI 
regimen. 
As mentioned in Section 4.3.4, 9 patients with low GSS had resistance to the PIs in 
their initial regimens. Eight of these patients were included in this analysis and all 8 
achieved virological suppression on the regimen they started with. 
 
 
Figure 4.3.5.1: Flow chart outlining those included in the viral suppression 
analysis 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
Table 4.3.5.1 shows the baseline characteristics of the 2785 patients eligible for the 
virological suppression analysis, stratified by whether or not they achieved an 
undetectable viral load after starting HAART. A higher proportion of patients who 
achieved viral suppression were male (81.6% vs. 76.3% of those who did not 
achieve viral suppression), of MSM risk group (65.2% vs. 59.9%) and had their 
resistance tests performed in 2002-2004 (35.6% vs. 13.5%). Patients who started 
HAART with NNRTI-based regimens were also more likely to achieve viral 
suppression (68.0% vs. 54.0% of those on other regimens). 
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In unadjusted analyses, patients with a GSS <3 were significantly less likely to 
achieve viral suppression than those with a GSS >3 (HR=0.72 (0.58, 0.89)). Patients  
were also less likely to achieve viral suppression if they had higher viral loads at 
start of HAART, were receiving a PI-based regimen (compared to NNRTI-based 
regimens), started HAART in earlier calendar years or made any switch in therapy 
before the end of follow-up (Table 4.3.5.2). Patients of black-African ethnicity 
(compared with those of white ethnicity) and of MSM risk group (compared with 
those of heterosexual risk group) were more likely to achieve viral suppression. 
Other than ethnicity and risk group, all of the above variables remained significantly 
associated with viral suppression after adjusting for potential confounders (Table 
4.3.5.2).  
 
In separate analyses where only those patients with GSS >3 were included, there 
was still evidence of a significant association between GSS and viral suppression 
(HR=1.32 (1.14, 1.53) per 1 unit higher). Further analyses in which GSS was 
incorporated as a categorical variable also showed that those with GSS <3 were 
less likely to achieve viral suppression compared to those with a GSS of 3 (0.68 
(0.54, 0.85)) but there was no significant difference amongst patients with GSS >3 
compared to those with GSS of 3 (1.01 (0.78, 1.32)).  
 
An interaction test between calendar year (fitted as a categorical variable) and GSS 
(fitted as a continuous variable) showed no significant association between the two 
(p=0.88).   
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Table 4.3.5.1: Characteristics of patients included in virological suppression 
analysis, stratified by whether or not they achieved an undetectable (<50 
copies/mL) VL after starting HAART (N=2785) 
  VL <50 
copies/mL 
VL >50 
copies/mL 
Total N   2511 (100.0) 274 (100.0) 
GSS <2 10 (0.4) 2 (0.7) 
 2 – 2.5 75 (3.0) 6 (2.2) 
 3 2357 (93.8) 259 (94.5) 
 > 3 69 (2.7) 7 (2.6) 
Sex N (%) Males 2049 (81.6) 209 (76.3) 
Ethnicity N (%) White 1616 (64.4) 176 (64.2) 
 Black 502 (20.0) 56 (20.4) 
 Other 393 (15.6) 42 (15.3) 
Risk group N (%) MSM 1638 (65.2) 164 (59.9) 
 Heterosexual 664 (26.4) 73 (26.6) 
 Other 209 (8.3) 37 (13.5) 
Calendar year of test N (%) 1999-2001 124 (4.9) 12 (4.4) 
 2002-2004 895 (35.6) 37 (13.5) 
 2005-2007 1492 (59.4) 225 (89.1) 
Subtype B 1743 (69.4) 178 (65.0) 
Calendar year of starting  1999-2001 68 (2.7) 8 (2.9) 
HAART N (%)  2002-2004 656 (26.1) 21 (7.7) 
 2005-2007 1787 (71.2) 245 (89.4) 
Age at time of test Median (IQR) 37 (32, 43) 36 (30, 41) 
CD4 count at time of test  Median (IQR) 250 (163, 343) 287 (162, 410) 
CD4 count at HAART initiation  Median (IQR) 210 (140, 280) 220 (141, 322) 
VL at time of test  Median (IQR) 4.9 (4.4, 5.3) 5.0 (4.4, 5.3) 
VL at HAART initiation  Median (IQR) 4.9 (4.3, 5.3) 5.0 (4.3, 5.4) 
HAART regimen started N (%) PI 27 (1.1) 2 (0.7) 
 Boosted PI 724 (28.8) 115 (42.0) 
 NNRTI 1707 (68.0) 148 (54.0) 
 Other 53 (2.1) 9 (3.3) 
 
CD4 measured in cells/mm
3
, VL measured in log10 copies/mL
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Table 4.3.5.2: Factors associated with achieving viral suppression (VL <50 copies/mL) after starting HAART 
  Univariable Multivariable 
  Hazard ratio (95% CI) P-value Hazard ratio (95% CI) P-value 
GSS >3 1 - 1 - 
 <3 0.72 (0.58, 0.89) 0.003 0.68 (0.54, 0.85) 0.001 
Gender Male 0.92 (0.83, 1.01) 0.09 1.01 (0.88, 1.117 0.84 
Ethnicity White 1 - 1 - 
 Black-African 1.18 (1.07, 1.30) 0.001 1.09 (0.93, 1.28) 0.29 
 Other 1.22 (1.09, 1.36) 0.0004 1.14 (1.01, 1.28) 0.03 
HIV transmission risk group MSM 1 - 1 - 
Heterosexual 1.20 (1.09, 1.31) 0.0001 1.10 (0.94, 1.29) 0.22 
Other 0.91 (0.78, 1.07) 0.24 0.85 (0.70, 0.99) 0.04 
Age at resistance test Per 10 years higher 1.03 (0.99, 1.08) 0.12 1.02 (0.98, 1.07) 0.31 
CD4 at start of HAART Per 50 cell higher 1.00 (0.98, 1.01) 0.75 0.99 (0.97, 1.00) 0.07 
Viral load at start of ART Per 1 log higher 0.76 (0.73, 0.80) <0.0001 0.73 (0.70, 0.77) <0.0001 
Regimen started NNRTI 1 - 1 - 
 PI  0.55 (0.38, 0.81) 0.003 0.53 (0.35, 0.79) 0.002 
 PI/r 0.85 (0.78, 0.93) 0.0002 0.77 (0.70, 0.84) <0.0001 
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 Other 0.78 (0.59, 1.03) 0.08 0.80 (0.60, 1.06) 0.12 
Subtype B 1 - 1 - 
 Non B 1.09 (1.00, 1.18) 0.05 0.88 (0.60, 1.06) 0.12 
Calendar year at start 
of HAART 
1999-2001 0.43 (0.34, 0.56) <0.0001 0.39 (0.30, 0.50) <0.0001 
2002-2004 0.72 (0.66, 0.79) <0.0001 0.73 (0.67, 0.81) <0.0001 
2005-2007 1 - 1 - 
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4.3.6. Assigning 1.5 to active PIs (instead of 1) 
It has been suggested that a fully active PI/r should be given a score of 1.5 rather 
than 1 (470). Assigning this score reduced the number of patients with GSS <3, 
from 97 to 75 and increased the number of patients with GSS >3 from 2823 to 2845.  
Using the same definition for viral suppression as outlined above (Section 4.3.5), in 
unadjusted analysis, the HR for patients with a GSS of <3 compared to >3 was 0.72 
(0.56, 0.92). After adjusting for potential confounders, the HR for GSS <3 compared 
to >3 was very similar to that seen in the main analysis (0.66 (0.51, 0.85).  
Since assigning 1.5 to fully active PIs instead of 1 made little difference to the 
adjusted HR (0.66 compared to 0.68 when a score of 1 was assigned), the rest of 
this chapter is based on assigning a score of 1 to fully active PIs.  
 
4.3.7. Virological rebound after achieving viral load suppression 
Among 2379 patients who had achieved virological suppression within a year of 
starting HAART, virological rebound (VL >400 copies/mL on two consecutive 
occasions or 1 VL >400 copies/mL followed by a treatment change) occurred in 228 
(9.6%) patients, at a median 5.9 (2.8, 12.0) months after achieving an undetectable 
VL. Of patients with GSS <3, 80 were included in these analyses, 12 (15.0%) of 
whom experienced virological rebound at a median 3.0 (2.1, 5.0) months. Seven of 
these patients had started HAART with an NNRTI-based regimen; 4 patients had 
resistance mutations to the NNRTI in their initial regimen, 1 patient had mutations to 
the NRTI in the initial regimen and 2 patients had mutations to both the NRTIs and 
the NNRTIs in their initial regimen. Four of the 12 patients experiencing virological 
failure with GSS <3 started HAART on PI-based regimens; 3 of these patients had 
mutations to the NRTIs in their initial regimen, whilst one patient had mutations to 
the PI in their initial regimen. The remaining patient had started HAART on an NRTI-
based regimen and had no resistance mutations.  
 
In univariable analyses, patients with a GSS <3 were at an increased risk of 
experiencing virological rebound, though this effect was not significant (HR=1.49 
(0.83, 2.67), p=0.18). After adjusting for potential confounders, this effect remained 
non-significant (1.64 (0.90, 2.99)). Though most other co-variates appeared to be 
associated with virological rebound in univariable analyses (Table 4.3.7.1), in 
multivariable analyses, only a higher CD4 count at start of HAART, starting HAART 
with a PI-based regimen (compared to an NNRTI-based regimen) and starting 
HAART in earlier calendar years were associated with an increased risk of 
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virological rebound. Older age was associated with a decreased risk of virological 
rebound.   
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Table 4.3.7.1: Factors associated with virological rebound after achieving an undetectable viral load 
  Univariable Multivariable 
  Hazard ratio (95% CI) P-value Hazard ratio (95% CI) P-value 
GSS >3 1 - 1 - 
 <3 1.49 (0.83, 2.67) 0.18 1.64 (0.90, 2.99) 0.11 
Gender Male 0.36 (0.28, 0.48) <0.0001 0.64 (0.41, 1.01) 0.06 
Ethnicity White 1 - 1 - 
 Black-African 1.91 (1.41, 2.59) <0.0001 1.05 (0.65, 1.70) 0.84 
 Other 1.79 (1.27, 2.53) 0.001 1.55 (1.06, 2.26) 0.02 
HIV transmission risk group MSM 1 - 1 - 
Heterosexual 2.18 (1.66, 2.89) <0.0001 1.63 (0.98, 2.71) 0.06 
Other 2.54 (1.61, 4.01) <0.0001 1.65 (0.97, 2.85) 0.07 
Age at resistance test Per 10 years higher 0.63 (0.53, 0.74) 0.0002 0.77 (0.65, 0.91) 0.002 
CD4 at start of HAART Per 50 cell higher 1.15 (1.11, 1.19) <0.0001 1.10 (1.06, 1.15) <0.0001 
Viral load at start of ART Per 1 log higher 0.69 (0.60, 0.78) <0.0001 0.92 (0.78, 1.08) 0.29 
Regimen started NNRTI 1 - 1 - 
 PI  11.48 (6.15, 21.44) <0.0001 4.97 (2.47, 9.99) <0.0001 
 PI/r 3.08 (2.34, 4.05) <0.0001 2.40 (1.78, 3.22) <0.0001 
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 Other 2.21 (1.11, 4.38) 0.02 1.62 (0.80, 3.28) 0.18 
Subtype B 1 - 1 - 
 Non B 1.71 (1.31, 2.22) <0.0001 0.85 (0.54, 1.34) 0.49 
Calendar year at start 
of HAART 
1999-2001 2.90 (1.73, 4.85) <0.0001 3.29 (1.89, 5.75) <0.0001 
2002-2004 1.07 (0.80, 1.44) 0.63 1.22 (0.89, 1.66) 0.22 
2005-2007 1 - 1 - 
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4.3.8. CD4 increase of >50 cells from start of HAART 
Two hundred and forty-one patients did not have follow-up CD4 counts and hence 
were excluded from the analysis of CD4 increases. Patients included were more 
likely to be male (92.3% of males included compared to 89.6% of females, p=0.04), 
of MSM risk group (92.5% of MSMs included compared to 86.7% of others, p=0.02) 
and have started HAART in earlier calendar years (96.2% of those included started 
HAART in 1999-2001 compared to 90.6% in 2005-2007). There was no difference in 
ethnicity (p=0.43) or regimen started (p=0.26) amongst those included and 
excluded. Patients included in this analysis also had lower CD4 counts (210 vs. 243 
cells/mm3, p=0.002) and higher viral loads at HAART initiation (4.9 vs. 4.7 log 
copies/mL, p=0.04). 
 
Of the 2679 patients with CD4 measurements available both at the time of starting 
HAART and after starting HAART, 2508 (93.6%) achieved a CD4 increase of at 
least 50 cells/mm3 from baseline. Patients who did not experience a CD4 increase 
of >50 cells/mm3 had shorter follow-up times (median (IQR) 0.6 (0.2, 1.3) vs. 1.8 
(1.0, 3.0) years) and fewer CD4 measurements (3 (1, 5) vs. 8 (4, 12)).  Amongst the 
171 patients who didn‟t achieve a 50 cell increase, 6 (3.5%) had a GSS <3.  Three 
of these patients had started HAART on NNRTI-based regimens, 2 of whom had 
resistance mutations to the NRTIs in the initial regimen. The remaining 3 patients 
had started HAART on PI/r regimens – all had resistance to the NRTIs in the initial 
regimen and 1 patient had further resistance to the PI in the initial regimen.  
 
Factors associated with more rapidly achieving a CD4 increase of >50 cells/mm3 are 
shown in Table 4.3.8.1. In univariable analyses, patients of male gender and with 
current undetectable viral loads were more likely to experience a CD4 increase. 
Patients of black-African ethnicity (compared to white ethnicity), heterosexual risk 
group (compared to MSM), higher CD4 counts at start of HAART, and those who 
started HAART in earlier calendar years were less likely to experience a CD4 
increase of >50 cells/mm3. Patients starting HAART with PI-based regimens and 
those with non-B subtypes were also less likely to experience a CD4 increase of 
>50 cells/mm3. There was no association between GSS and achieving a CD4 
increase of >50 cells/mm3. After adjusting for potential confounders, only CD4 count 
at start of HAART (HR=0.93 (0.92, 0.94)), starting HAART with PI/r-based regimens 
(1.11 (1.01, 1.22) compared to NNRTI-based regimens), „other‟ ethnicity (0.68 (0.57, 
0.85)) compared to white ethnicity and starting HAART in earlier calendar years 
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(0.74 (0.59, 0.95) comparing 1999-2001 with 2005-2008) remained significantly 
associated with experiencing a CD4 increase of >50 cells/mm3. 
 
Since patients starting HAART with PI/r-based regimens were more likely to achieve 
a CD4 increase than those on NNRTI-based regimens, sensitivity analyses were 
performed to investigate whether this was a robust effect. In the first instance, the 
CD4 threshold was increased to >100 cells/mm3 and >150 cells/mm3 from baseline. 
The HRs for starting HAART with PI/r-based regimens compared to NNRTI-based 
regimens were 1.10 (1.00, 1.21) and 1.17 (1.05, 1.29) respectively.  PI/r-based 
regimen was not significantly associated with a CD4 increase in univariable 
analysis, and only after adjusting for baseline CD4 count did the effect reach 
significance. The median baseline CD4 count amongst those receiving PI/r-based 
regimens was 227 (140, 328) cells/mm3 and for those receiving NNRTI regimens 
was 205 (139, 268) cells/mm3 (p<0.0001). However, a test for interaction between 
first HAART regimen and baseline CD4 count was not significant (p>0.20).  Further, 
the median change in CD4 count for those receiving PI/r-based regimens was 108 
(72, 170) cells/mm3, whilst for those receiving NNRTI-based regimens was 110 (78, 
159) cells/mm3. 
 
Finally, a sensitivity analysis that considered CD4 increases after a year of starting 
HAART was performed. Of the 1621 patients with CD4 counts available within a 
year and 18 months after starting HAART, 1396 (86.1%) patients had achieved a 
CD4 increase of >50 cells/mm3 from baseline. After adjusting for potential 
confounders, PI/r boosted regimen was not found to be significantly associated with  
a CD4 increase from baseline (OR=0.88 (0.63, 1.24)).
    
 
 
    
1
3
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Table 4.3.8.1: Factors associated with achieving a CD4 increase of >50 cells/mm3 after starting HAART 
  Univariable Multivariable 
  Hazard ratio (95% CI) P-value Hazard ratio (95% CI) P-value 
GSS >3 1 - 1 - 
 <3 1.14 (0.91, 1.41) 0.26 1.20 (0.96, 1.50) 0.11 
Gender Male 1.12 (1.01, 1.24) 0.03 0.89 (0.77, 1.03) 0.11 
Ethnicity White 1 - 1 - 
 Black-African 0.87 (0.78, 0.96) 0.01 0.88 (0.75, 1.03) 0.10 
 Other 1.01 (0.91, 1.13) 0.82 0.98 (0.87, 1.10) 0.69 
HIV transmission risk group MSM 1 - 1 - 
Heterosexual 0.87 (0.79, 0.95) 0.002 0.86 (0.74, 1.01) 0.06 
Other 0.75 (0.64, 0.88) 0.001 0.68 (0.57, 0.85) <0.0001 
Age at resistance test Per 10 years higher 0.98 (0.94, 1.03) 0.45 0.96 (0.92, 1.00) 0.07 
CD4 at start of HAART Per 50 cell higher 0.94 (0.92, 0.95) <0.0001 0.93 (0.92, 0.94) <0.0001 
Current VL <50 copies/mL 1.77 (1.11, 2.84) 0.02 1.47 (0.91, 2.36) 0.11 
Regimen started NNRTI 1 - 1 - 
 PI  0.63 (0.43, 0.92) 0.02 0.86 (0.58, 1.26) 0.43 
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 PI/r 1.06 (0.97, 1.15) 0.20 1.11 (1.01, 1.22) 0.02 
 Other 0.93 (0.71, 1.21) 0.57 1.03 (0.78, 1.35) 0.85 
Subtype B 1 - 1 - 
 Non B 0.84 (0.77, 0.91) <0.0001 0.92 (0.80, 1.06) 0.24 
Calendar year at start 
of HAART 
1999-2001 0.70 (0.55, 0.88) <0.0001 0.74 (0.59, 0.95) 0.02 
2002-2004 0.88 (0.80, 0.96) 0.63 0.87 (0.79, 0.96) 0.004 
2005-2008 1 - 1 - 
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4.3.9. Analyses restricted to patients whose resistance test is within 6 
months prior to starting HAART 
Amongst the 2923 patients who had resistance tests performed whist HAART-naïve, 
2023 (69.2%) patients started HAART within 6 months of having had the resistance 
test performed.  Of these patients, 8.8% had at least one resistance mutation 
indicative of TDR and 104 (5.1%) patients had resistance to a drug in their first-line 
regimen. Sixty-five patients (3.2%) had a GSS of <3 and though calendar year was 
not significantly associated with a GSS <3 in adjusted analyses (as it was in the 
main analysis), patients starting HAART with an NRTI-only regimen were at 
increased risk of having a low GSS (7.18 (2.48, 20.79)).  
 
Of the 1947 patients included in the virological suppression analyses, 1766 (90.7%) 
achieved VL <50 copies/mL. In adjusted analyses, patients with a GSS <3 were less 
likely to achieve virological suppression (HR: 0.58 (0.44, 0.77)) – this effect was 
stronger than that seen in the main analyses (0.68 (0.54, 0.85)). One hundred and 
seventy-seven patients experienced virological rebound (10.6%). GSS was not 
associated with virological rebound in adjusted analyses (1.52 (0.70, 3.31)) and this 
effect was weaker than that seen in the main analyses (1.64 (0.90, 2.99)). 
The vast majority (93.7%) of patients who had resistance tests performed within 6 
months prior to starting HAART achieved a CD4 increase of >50 cells/mm3.  Again, 
GSS was not associated with this outcome (1.18 (0.89, 1.55)) and the effect was 
similar to that seen in the main analyses (1.20 (0.96, 1.50)).  
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4.4. Discussion 
This chapter has focussed on the use of genotypic resistance testing among drug-
naïve patients in routine care in the UK. Resistance testing was more commonly 
performed in white MSM compared with other demographic groups during the period 
1999-2007. This finding reflects the overall higher risk of resistance traditionally 
observed in this group relative to heterosexuals, women and persons of black 
ethnicity (181;209). In addition, it is only in recent years that national treatment 
guidelines have started to clearly recommend testing in all newly diagnosed patients 
regardless of risk group and ethnicity (127).  
 
The prevalence of at least one detectable mutation indicative of TDR was 9.3% in 
this cohort, and therefore consistent with previous estimates from the UK and 
elsewhere in Western Europe (206;209;210;214;221;226;464). In particular, the 
prevalence estimate of 9.3% is in line with the largest study analysing rates of 
primary drug resistance across Europe, in which organisers reported a TDR 
prevalence rate of 9.1%. It is also in line with the most recently published studies on 
TDR worldwide, which report rates around 10% (188;203;211;217;471). There was 
also evidence of an increasing trend of TDR prevalence in later calendar years, 
though of note, these analyses are restricted to patients who start HAART and so 
may not be directly comparable to other estimates. Though data on trends over time 
of TDR are conflicting, with some studies showing a declining prevalence, i.e.  the 
UK Collaborative Group on HIV Resistance reports lower rates of TDR in later 
calendar years (12.5% in 2003 and 9.2% in 2004) (214), the findings reported in this 
chapter do consist of more recent data and are consistent with findings from the 
EuroSIDA study in which an upward trend in TDR prevalence was observed from 
2001 to 2004 (6.5% to 9.1%) (163). Brenner et al also reported an increase of TDR 
in Canada (188), from 15.7% in 1997-2001 to 21.2% in 2004-2005. 
 
The TAMs T215rev and M41L for the NRTIs, and the K103N mutation for the 
NNRTIs were the most prevalent mutations, in line with previously published  
findings (181;191;209). Importantly, the majority of patients started first-line HAART 
with a regimen comprising at least 3 fully active drugs. Those starting HAART in 
earlier calendar years and on PI-based regimens were at an increased risk of having 
low GSS. One explanation for the significant calendar year finding may be that in 
earlier years the likely impact of TDR was underappreciated. Patients may have 
been selectively tested, resulting in a higher proportion of patients appearing to have 
TDR. A second explanation is that the choice of HAART drugs was also limited in 
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earlier years. Availability of TDF, in particular, in later calendar years may have 
contributed to the higher GSS seen in this period. This may have reflected the 
evolution of resistance interpretation algorithms, combined with the range of 
available drug options. It should be noted that interpretation systems for genotypic 
drug resistance have evolved significantly over time. I have not attempted to adjust 
for this as I was interested in exploring the impact of GSS using a uniform 
interpretation approach. Hence in a small minority of cases, though the GSS was 
<3, it may have been equal to 3 according to the interpretation system used by the 
clinician at the time of the resistance test.  
 
The lower GSS in patients receiving PI-based regimens compared to NNRTI-based 
regimens was only infrequently related to the presence of PRAMs. Rather, the 
majority of patients in this group had NAMs affecting the NRTIs they received. 
These findings suggest that in a cohort setting where NNRTI-based therapy is the 
generally preferred initial HAART regimen (127), PI/r-based regimens were selected 
specifically in order to compensate for the presence of resistance to the NRTI 
backbone. 
A further consideration is that I used an interpretation algorithm which assigned a 
GSS of 1 to a fully active PI/r. It has been proposed that a fully active PI/r should be 
given a score of 1.5 (470). Using a higher GSS score for PI/r increases the overall 
GSS for each patient with TDR, but had little impact on the number of patients in the 
GSS <3 category (from 97 to 75).  
 
Although some studies (163;188;206) have reported a higher proportion of patients 
who started a PI-based regimen despite having mutations associated with 
resistance to the selected drugs than I found (1.6%), my estimate is in line with 
those reported by most other recently published studies 
(202;204;208;209;214;220;471). This is also true of patients starting NNRTI based 
regimens despite having resistance mutations to the NNRTIs in their initial regimen 
(1.3%) (163;202;209), though again, other studies have reported higher estimates 
(188;204;208;471). The proportion of patients with mutations conferring resistance 
to the NRTIs in the initial regimen is variable across studies, even in recent years, 
ranging from 0.5% reported by Payne et al in 2008 (202) to 10.0% reported by 
Cachay et al in 2007 (208). I found 4.9% of patients had mutations conferring 
resistance to the NRTIs in their initial regimen. This is similar to other recently 
published studies (204;206;209;210;471), albeit utilising a different interpretation list 
to identify resistance mutations. 
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Interestingly, there was no significant association between having TAMs and 
receiving NRTIs that can be affected by these mutations. Although in unadjusted 
analyses, I found that persons with TAMs were less likely to receive zidovudine, this 
effect was not significant after adjusting for potential confounders. This is surprising, 
given the well recognised effect of these mutations on responses to particular drugs 
(469). I did however find that patients with nNAMS were less likely to start NNRTI-
based regimens -  this is consistent with the current understanding of the low 
genetic barrier of such regimens (472).  
 
While only a small minority (3.3%) of patients started regimens with a GSS <3, this 
group of patients experienced reduced virological responses. This effect was still 
significant after adjusting for potential confounders, in particular, starting HAART 
with PI/r-based regimens. This suggests that starting HAART with PI/r (and in 
particular, lopinavir/r in this cohort) did not fully compensate for the presence of 
resistance to the NRTI backbone. This finding is consistent with the superior 
virological activity of lopinavir/r in combination with 2 NRTIs relative to lopinavir/r 
monotherapy in first-line HAART (473). Other studies have shown that TDR has not 
impacted on viral response (189;191;203;211;220), though again, different 
resistance interpretation systems will impact on the comparability of these results. It 
should also be noted that the number of patients in these studies is considerably 
smaller than that in the UK CHIC Study and hence whilst the proportion of patients 
with resistance mutations achieving viral suppression is generally smaller than those 
without mutations achieving viral suppression, there may not have been enough 
power to detect a significant difference. However, some studies have been able to 
detect such an association. Little et al analysed the resistance profiles of 202 
patients in North America and reported a significant association between patients 
having resistance mutations and virological suppression (231). The time to 
virological suppression after starting HAART was longer, whilst the time to 
virological failure was shorter amongst patients with resistance mutations. Similar 
results were reported by Grant et al, also in 2002 (234). The time to virological 
suppression amongst patients with evidence of genotypic mutations was 12 weeks, 
compared to 5 weeks amongst patients without mutations.  
 
In line with previous studies (418;474;475), patients with higher viral loads at start of 
HAART were less likely to achieve virological suppression. Patients starting HAART 
on PI-based regimens compared to NNRTI regimens were also less likely to achieve 
suppression – as discussed earlier, these patients are likely to be carrying NRTI 
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mutations and the use of a PI does not seem to have fully compensated for 
resistance to the NRTI backbone. Earlier calendar year and non-B subtype were 
also associated with a decreased probability of achieving viral suppression. Fewer 
drugs were available in earlier calendar years, some of which were associated with 
high levels of toxicities. Hence, patients receiving HAART in earlier calendar years 
may have received drugs which were not adhered to due to the toxicities associated 
with them. It has been well documented that adherence is a strong predictor of 
virological response to HAART (148-151). There are conflicting reports on the 
association between subtype and virological response. Whilst some studies have 
reported patients of non-B subtype are no less likely to achieve virological 
suppression than those harbouring a subtype B virus (476), other studies have 
reported a significant negative association between these variables (477). Patients 
harbouring non-B subtypes may be those of poorer socio-economic status and 
factors correlated with this status may also affect the levels of virological response. 
Also, the proportion of patients with non-B subtype virus is small in this dataset – 
this is also likely to play a part in the significant finding.  
 
No relationship was seen between the GSS of the first-line regimen and risk of 
virological rebound, though this lack of association may be explained by the small 
number of patients who experienced rebound (<10%). Factors associated with 
virological rebound included younger age, higher pre-HAART CD4 counts and 
starting HAART with either a non-boosted or boosted PI-based regimen compared 
to an NNRTI-based regimen. These observations are mostly consistent with 
previous findings. It has been well documented that patients of older age are likely 
to have a better response to HAART, possibly due to better adherence to 
medication (418;423;475). The effect of CD4 count was surprising as though some 
studies have shown no association between CD4 count and viral rebound (474),  
most studies have shown a positive association between lower CD4 count and 
virological rebound (426;475;478). While the CD4 effect I found may represent a 
chance finding, the number of patients with pre-HAART CD4 counts >350 cells/mm3 
represented less than 15% of the total population and this may somewhat explain 
the association.  
 
The association between starting HAART with PI-based regimens and viral rebound 
is as expected, given the findings discussed above on the resistance profiles of 
these patients. Other factors may also contribute to this finding (i.e. unmeasured 
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confounding), and in particular, it may simply be the case that NNRTI-regimens are 
more efficacious.  
 
Finally, GSS was not significantly associated with a CD4 increase of >50 cells/mm3 
from pre-HAART levels. Patients with higher pre-HAART CD4 counts were less 
likely to achieve a CD4 increase of >50 cells/mm3. This is likely to be explained by 
the greater scope for an increase amongst those with lower pre-HAART counts. This 
finding has been reported in other studies (479;480), though conflicting results have 
also been reported (481;482). It should be noted that though pre-HAART CD4 
counts were found to be significantly associated with a CD4 increase of >50 
cells/mm3 in this chapter, the actual effect was small in magnitude, and hence may 
not have any significant clinical implications.  
 
Patients starting HAART in earlier calendar years were also less likely to achieve a 
CD4 increase of >50 cells/mm3. One possible explanation for this is that the 
importance of adherence may have been less well recognised in earlier years, and 
new methods to improve adherence may have made an impact on 
virological/immunological outcomes in later calendar years (483;484). Improvements 
in drug development, together with better management of drug toxicities may also 
contribute to the higher proportion of patients achieving increases in later calendar 
years. Interestingly, patients receiving PI/r-based regimens were more likely to 
achieve CD4 increases of >50 cells/mm3 than those receiving NNRTI-based 
regimens, despite having higher CD4 counts at the start of HAART. It has been 
reported in some studies that immunological responses are better amongst those 
receiving PI-based regimens than those receiving NNRTI-based regimens (485-
489), however, it is important to note that the significant effect found in my analysis 
may simply be a chance finding. In sensitivity analyses using the CD4 measure after 
a year of initiating HAART, there was no significant association seen between 
HAART regimen and CD4 increase of >50 cells/mm3 from baseline. 
 
In analyses in which only patients who had a resistance test within 6 months prior to 
starting HAART were included, the main results remained in line with those seen in 
the main analyses.  
 
There are limitations to this analysis. Not all patients underwent resistance testing 
prior to starting HAART and selection in favour of white homosexual males was 
clearly evident. Given the data used in this study is derived from an observational 
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cohort study, there may be an effect of unmeasured confounders which may play a 
part in a patient having both a low GSS and a poorer virological outcome on first-line 
HAART. For example, patients with a GSS <3 were less likely to start HAART with 
NNRTI-based regimens. While this suggest adjustments in treatment decisions 
based upon the results of the resistance test, other factors influencing the choice of 
regimen, which may be related to the outcome of interest, may not have been 
captured in this study. Further, I have been unable to fully investigate the viral 
evolution of patients with GSS <3 who experienced virological failure.  
 
4.5. Summary 
In conclusion, I have shown that most but not all patients starting HAART do so on 
fully active regimens. This proportion is likely to increase with the availability of new 
drugs in recent calendar years. However, despite an attempt at compensating for 
the presence of NRTI TDR by using a PI/r-based regimen, patients with a GSS <3 
showed poorer virological outcomes than those starting on fully active regimens. 
These findings indicate that selection of first-line HAART should take into account 
the presence of TDR, together with other recognised predictors of virological 
outcomes. The contribution of NRTI TDR to virological failure of PI/r-based regimens 
has potential clinical significance and warrants further investigation.   
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Chapter 5: Drug resistance testing post-ART 
 
5.  
The main aim of work described in this Chapter is to investigate the impact of 
resistance testing on changes to treatment. I have also included a sub-section 
focussing on patients who commenced PI/r-based HAART after failing a first-line 
NNRTI-based regimen. In this latter Section, I investigate factors associated with 
failing second-line therapy and, in particular, assess the association between the 
number of new/fully active NRTIs in the second-line regimen and virological success 
rates. 
 
5.1. The impact of resistance testing on changes to treatment   
 
5.1.1. Introduction   
Resistance testing is recommended for all HIV-positive patients experiencing 
virological failure of ART to guide changes in therapy (124;490;491). Guidelines also 
state that any changes in therapy amongst ART-experienced patients should be 
guided by the results of a resistance test.  
 
Although there has been an attempt to assess the clinical utility of resistance testing 
using randomised control trials (RCTs), in most instances, randomisation has been 
performed after a decision to switch therapy has already been made (420;492-496).  
Some of these studies have shown little benefit of genotypic resistance testing 
(492;493), instead arguing that adherence and residual treatment options are more 
important predictors of virological response. However, the majority of these trials 
highlight the benefits of genotypic resistance testing in treatment experienced 
patients. For example, Tural et al found that genotypic testing was independently 
associated with achieving viral load (VL) <400 copies/mL at 24 weeks amongst 
those who had experienced virological failure (495). Similarly, results from the 
VIRADAPT trial showed that those who had had genotypic tests performed whilst on 
a failing HAART regimen in order to guide therapy switches had a sustained 
reduction in VL compared to those without resistance tests performed (420;497).  
 
Although guidelines for resistance testing have been in place for some time, few 
studies have assessed the extent to which resistance tests are performed and 
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whether the results of the resistance tests have led to changes in treatment in 
routine clinical practice, or the factors associated with specific changes.  Clinicians 
may decide to change only those drugs for which resistance mutations are present, 
rather than all of the ART drugs in the failing regimen. The level of resistance to the 
current regimen, the line of current ART regimen (first-line, second-line etc) and the 
time since starting ART may all impact on this decision. 
 
In this Chapter, I will first investigate changes made to patients‟ regimens following a 
resistance test result and identify factors associated with switching regimen, with 
particular focus on the genotypic sensitivity score (GSS) of the current regimen and 
the number of regimens previously failed.   
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5.1.2. Methods    
Linked data from the UK HIV Drug Resistance Database (HDRD) and the UK 
Collaborative HIV Cohort (CHIC) Study were used for these analyses.  
 
5.1.2.1. Inclusion criteria 
Patients who had a resistance test performed over the period 1998-2007 whilst on 
therapy were eligible for inclusion in the analysis if they had at least 4 months follow-
up after the date of the result of the resistance test was made available, and if there 
was no change to their regimen between the date when the blood sample was 
drawn for the resistance test and the date when the result of the resistance test 
became available. Chi-squared and Mann-Whitney tests were used to assess 
differences between tests included and excluded from the analyses.  
 
5.1.2.2. Genotypic sensitivity score (GSS) 
The GSS of the current regimen was calculated using the Stanford interpretation 
algorithm (version 5.1.2). Patients with drug-susceptible virus were assigned a 
sensitivity score of one, and those with low-level, intermediate, high-level and very 
high-level resistance were assigned scores 0.75, 0.50, 0.25 and 0 respectively. In 
Chapter 4, these scores were condensed into just 3 groups (GSS of 1, 0.5 and 0), 
but with the higher number of patients in this analysis, I felt it was suitable to use 5 
groups. If ritonavir was used in conjunction with another PI, it was assumed that 
ritonavir was used only as a pharmacologic booster, and hence was not considered 
when calculating the GSS.  
 
5.1.2.3. Defining switches 
For the main analysis, I focussed on whether a switch to the existing regimen 
occurred within 4 months of the date of the resistance test result. Since the definition 
of „switching‟ is arbitrary, I used two different methods to calculate the number of 
patients switching. Using the first method, a patient was defined as having switched 
regimen subsequent to the resistance test if s/he started two or more drugs on the 
same date after the resistance test result. This „strict‟ definition was used in order to 
identify patients who may have substituted only a single drug, perhaps for toxicity 
reasons. Using the second method, a switch was defined as starting or stopping at 
least one drug within 4 months of the resistance test result. This „relaxed‟ definition 
was used to capture all switches made after the resistance test report and may have 
included some switches made for reasons other than drug resistance.  
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5.1.2.4. Statistical methods 
The overall cumulative proportion of patients who switched regimen at any time (not 
restricted to within 4 months of the resistance test result) was estimated using 
Kaplan Meier analyses, stratified by whether or not mutations were present at the 
time of the resistance test. Patient follow-up was censored at the earliest of their last 
VL and the date of the report of any subsequent resistance test. Logistic regression 
(using generalised estimating equations to account for more than one test per 
individual) was used to identify factors independently associated with switching 
regimen within 4 months of the test result.  In these analyses, the following 
covariates were included: GSS of current regimen, age at time of test, ethnicity, 
sex/exposure group, year of resistance test, regimen at resistance test 
(NRTI+NNRTI only, NRTI+PI only, NRTI+PI/r only, NRTI only or Other), CD4 count 
and viral load (VL) at resistance test, whether or not the VL had ever been <50 
copies/mL at any point before the date of the resistance test and the number of 
regimens previously failed. Failure of a regimen was defined as having a VL >200 
copies/mL despite at least one drug in the regimen (which had never been failed in 
the past) having been used continuously for at least 4 months.  
 
If a patient had taken any drugs before January 1996 they were defined as having 
failed one line of ART by this time, and all drugs taken before January 1996 were 
counted as having been failed. I also adjusted for the number of potential drug 
options available to each patient at the time of the resistance test. This was 
determined by calculating the total GSS of the drugs that had not been used up to 
the point of the resistance test, taking into account drug availability at the date of the 
resistance test (drug availability dates are outlined in Table 1.6.1, Chapter 1.6).  
Formal tests for interaction between the effects of (i) regimen at resistance test and 
GSS, (ii) calendar year of resistance test and GSS and (iii) VL at resistance test and 
GSS were also undertaken. 
 
Sensitivity analyses were performed in which only those patients for whom 
resistance mutations (GSS <1 for any drug) were present were included in the 
logistic regression model. Finally, amongst patients who did switch therapy within 4 
months of the resistance test result, I compared the GSS of the old regimen to that 
of the regimen switched to.  
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5.1.3. Results 
 
5.1.3.1. Differences between patients with tests included and excluded         
from the analyses 
In total, 4,722 of the 22,353 UK CHIC patients who started ART before March 2008 
had at least one resistance test performed after starting therapy (8,924 tests in 
total). Over three-quarters of tests (n=7,211, 80.8 %) were performed whilst patients 
were taking ART and, of these, 6,059 (84.0%) were amongst patients who had 
made no change to their regimen between the date of the resistance test and the 
date of the result of the resistance test. After excluding a further 936 tests without 4 
months potential follow-up, 5,123 test results, from 2,567 patients, were included in 
the analyses. Statistically significant differences were detected amongst patients 
who had at least one resistance test included in these analyses and those with no 
resistance tests included, though often the absolute difference was marginal. 
 
Patients with at least one test included in the analyses were more likely to be of 
MSM risk group (56.1% of MSMs had tests included compared to 46.6% of 
heterosexuals, p=<0.0001), of white ethnicity (56.1% of patients of white ethnicity 
had tests included compared to 50.4% of those of black ethnicity, p=0.002) and 
have started ART in earlier calendar years (of those who started ART before 1996, 
65.9% of patients were included in the analyses, compared to 42.1% of patients who 
started ART after 2005, p<0.0001). Patients with tests included were also more 
likely to have failed >5 previous regimens before their first resistance test (81.6% of 
patients who had failed >5 regimens had at least one test included, compared to 
30.5% of those who had failed no previous regimens, p<0.0001), had lower VLs (3.9 
vs. 4.4 log copies/mL, p<0.0001) and higher CD4 counts (283 vs. 260 cells/mm3, 
p<0.0001) at the time of their first resistance test. 
 
5.1.3.2. Characteristics of patients with tests included in the analyses 
Patients had a median (IQR) 42.1 (39.3, 45.6) months of follow-up after the date of 
the report of the resistance test and the results of the resistance test were available 
at a median (IQR) 3.0 (2.0, 4.4) weeks after the resistance test was performed. The 
characteristics of patients with resistance tests included in the analysis are shown in 
Table 5.1.3.2.1, with baseline defined as the date on which the resistance test was 
performed.  The median (range) number of tests per patient was 1 (1, 12) and 
patients had achieved VL <50 copies/mL at some point before the resistance test in 
3069 (59.9%) cases.  A similar number of tests were performed on patients taking 
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an NRTI+NNRTI regimen (1524 (29.8%)) and on those taking a NRTI+PI/r regimen 
(1518 (29.6%)). Over half of tests were performed amongst patients who had 
experienced all 3 of the original drug classes (NRTI, NNRTI and PI) (52.0%) and 
amongst patients who had been taking ART for at least 3 years (70.9%). The 
median (IQR) CD4 and log VL at time of resistance test was 269 (157, 410) 
cells/mm3 and 3.8 (3.1, 4.6) copies/mL respectively. In over 10% of cases, patients 
had failed at least 5 regimens before their resistance test. 
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Table 5.1.3.2.1: Characteristics and demographics of patients who had >1 
resistance test after starting ART 
Total number of resistance tests   5123 
Number of resistance tests per patient Median (range) 1 (1,12) 
Year of starting ART n (%) <1996 1504 (29.4) 
 1996-1998 1939 (37.9) 
 1999-2001 805 (15.7) 
 2002-2004 618 (12.1) 
 2005-2008 257 (5.0) 
Year of resistance test n (%) 1998-2001 1699 (33.2) 
 2002-2004 1761 (34.4) 
 2005-2007 1663 (32.5) 
Regimen at resistance test n (%) NNRTI 1524 (29.8) 
 Single PI 700 (13.7) 
 PI/r 1518 (29.6) 
 Nucleoside only 895 (17.5) 
 Other 486 (9.5) 
Number of classes (NRTI, NNRTI and PI)  1 337 (6.6) 
experienced n (%) 2 2172 (42.4) 
 3 2614 (51.0) 
Drug options available at resistance test 0-3 795 (15.5) 
 4-6 1183 (23.1) 
 7-9 1237 (24.1) 
 >10 1908 (37.2) 
Time since start of ART n (%) <3 months 203 (4.0) 
 4 – 12 months 394 (7.7) 
 1.1 - 3 years 893 (17.4) 
 3.1 - 5 years 1037 (20.2) 
 5.1 – 7 years 894 (17.5) 
 7.1 – 9 years 760 (14.8) 
 >10 years 942 (18.4) 
Ethnicity n (%) White 3206 (62.6) 
 Black 1396 (27.3) 
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 Other 521 (10.2) 
Sex/Exposure n (%) MSM 3062 (59.8) 
 Heterosexual male 673 (13.1) 
 Heterosexual female 909 (17.7) 
 Other 479 (9.4) 
CD4 count at resistance test (cells/mm3) Median (IQR) 269 (157, 410) 
Viral load at resistance test (log copies/mL) Median (IQR) 3.8 (3.1, 4.6) 
Age at resistance test (years) Median (IQR) 35 (31, 45) 
Number of regimens failed before  0 436 (8.5) 
resistance test1 n (%) 1 1410 (27.5) 
 2 1171 (22.9) 
 3 890 (17.4) 
 4 615 (12.0) 
 5 or more 601 (11.7) 
VL <50 copies/mL at any point before 
resistance test n (%)  
Yes 3069 (59.9) 
1 
Failure defined as VL >200 copies/mL despite 4 months of continuous use of any drug. 
Drugs taken before 1996 for >122 days are defined as a line of failure and will not be 
counted as subsequent failures after 1996.  
 
5.1.3.3. GSS at the time of the resistance test 
Table 5.1.3.3.1 shows the GSS at the time of the resistance test, stratified by the 
drug class basis of the current regimen. Amongst resistance tests which were 
performed in those taking an NRTI+NNRTI regimen, the GSS was <1 in 603 
(39.6%) cases, compared to 357 (23.5%) cases in which tests were performed 
amongst those receiving an NRTI+PI/r regimen and 258 (36.9%) cases in which 
tests were performed in those receiving an NRTI+single-PI regimen. The GSS was 
more likely to be >3 amongst tests performed on patients receiving an NRTI-PI/r 
therapy (48.3%) than among those receiving NRTI+NNRTI (26.6%) or NRTI+single 
PI (21.4%) based therapy.  
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Table 5.1.3.3.1: Genotypic sensitivity score (GSS) stratified by regimen at resistance test 
  Regimen at resistance test n (%)  
  NNRTI + NRTIs PI/r + NRTIs PI + NRTIs NRTIs only Other Total 
 N 1524 1518 700 895 486 5123 
 Mean (SD) GSS 2 (1.3) 3 (1.4) 2 (1.2) 2 (1.1) 2 (1.4) 2 (1.4) 
 
GSS 
 
<1 603 (39.6) 357 (23.5) 258 (36.9) 525 (58.7) 203 (41.8) 1946 (38.0) 
1-1.75 342 (22.4) 199 (13.1) 179 (25.6) 188 (21.0) 112 (23.1) 1020 (19.9) 
2-2.75 173 (11.4) 229 (15.1) 113 (16.1) 76 (8.5) 59 (12.1) 650 (12.7) 
3-3.75 340 (22.3) 590 (38.9) 136 (19.4) 67 (7.5) 43 (8.9) 1176 (23.0) 
>4 66 (4.3) 143 (9.4) 14 (2.0) 39 (4.4) 69 (14.2) 331 (6.5) 
SD: Standard deviation 
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5.1.3.4. Switches to regimen at any time after the date of the result of the 
resistance test 
Using the strict definition of a switch, 3471/5123 (67.8%) patients switched therapy 
at a Kaplan-Meier median (95% CI) time of 42 (39, 46) weeks after having received 
the result of the resistance test. Switches were made in 2775/3620 (76.7%) 
instances where mutations were detected and in 696/1503 (46.3%) cases where 
mutations were not detected. Figure 5.1.3.4.1 shows the Kaplan Meier time to 
switching stratified by whether or not mutations were detected. The median (95% 
CI) time to switching was significantly shorter amongst those who had mutations 
detected (26 (24, 30) weeks) compared to those who had no mutations detected 
(102 (93, 115) weeks) (p<0.0001).  
 
Using the relaxed definition of a switch, 4610 (90.0%) patients switched therapy at a 
median (95% CI) 16 (15, 17) weeks after the date of the result of the resistance test. 
Switches were made in 3413/3620 (94.3%) cases at a median (95% CI) 12 (11, 14) 
weeks where mutations were detected and in 1197/1503 (79.6%) cases at a median 
(95% CI) 31 (27, 34) weeks where mutations were not detected (p<0.0001) (Figure 
5.1.3.4.2).  
 
Figure 5.1.3.4.1: Kaplan Meier estimates of the proportion of patients 
switching regimen at any time after resistance test result: strict definition of 
switching 
 
 
 
 
 
         N      5123   2778   1922    1378    978      722     534     403     320  
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Figure 5.1.3.4.2: Kaplan Meier estimates of the proportion of patients 
switching regimen at any time after resistance test result: relaxed definition of 
switching 
 
 
 
 
 
5.1.3.5. Switches to therapy within 4 months of the resistance test result 
Using the strict definition, a switch to therapy occurred in 1,834 (35.8%) cases within 
4 months of the resistance test result. 1550 (42.8%) of resistance tests for which 
resistance mutations were detected were followed by a switch in the next 4 months, 
compared to 284 (18.9%) resistance tests in which mutations were not detected 
(p<0.0001). The number of patients switching therapy within 4 months of the 
resistance test result when using the relaxed definition of a switch was considerably 
higher at 2693 (52.6%). Of those tests for which mutations were detected, 2118 
(58.5%) were followed by a switch in the next 4 months, compared to 575 (38.3%) 
resistance tests in which mutations were not detected (p<0.0001). All subsequent 
analyses are restricted to 4 months follow-up after date of resistance test result. 
 
5.1.3.6. GSS and switches to therapy 
A decreasing trend was seen in the proportion of tests followed by a strict switch 
with increasing GSS of the current regimen; of those with GSS <1, 1-1.75, 2.-2.75, 
3-3.75 and >4, 44.0%, 45.3%, 36.0%, 19.0% and 17.5% of resistance tests were 
followed by a switch within 4 months of the resistance test result (Figure 5.1.3.6.1). 
A similar trend was observed using the relaxed definition of a switch, albeit with 
higher absolute proportions in each category: of those with GSS <1, 1-1.75, 2.-2.75, 
       N   5123   2085   1250     783     513     331     223      142      102  
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3-3.75 and >4, 58.4%, 60.7%, 54.5%, 38.5% and 39.3% of resistance tests were 
followed by a switch within 4 months of the resistance test result (p<0.0001). 
 
Figure 5.1.3.6.1: Proportion of patients who switched regimen within 4 months 
of resistance test result, stratified by GSS  
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5.1.3.7. Future drug options 
Patients had a median of 8 (5, 11) future drug options available. Table 5.1.3.7.1 
shows the available future drug options stratified by the GSS at the time of the 
resistance test. A third of patients with a GSS <1 had 0-3 future drug options 
available, whilst half of those with GSS >4 had >10 future drug options available. 
Generally, the number of future drug options available increased as the GSS of the 
current regimen increased. 
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Table 5.1.3.7.1: Future drug options stratified by GSS at the time of the 
resistance test 
  GSS of current regimen at time of resistance test 
  <1 1-1.75 2-2.75 3-3.75 >4 
Number 
of future 
drug 
options 
available 
0-3 622 (32.0) 102 (10.0) 45 (6.9) 16 (1.4) 10 (3.0) 
4-6 599 (30.8) 253 (24.8) 145 (22.3) 114 (9.7) 72 (21.8) 
7-9 463 (23.8) 288 (28.2) 167 (25.7) 235 (20.0) 84 (25.4) 
>10 262 (13.5) 377 (37.0) 293 (45.1) 811 (69.0) 165 (49.9) 
 
 
5.1.3.8. Differences between those who switched regimen and those who 
did not 
Table 5.1.3.8.1 shows the characteristics of all patients with resistance tests 
included in the analyses, stratified by definition of switch, and by whether or not a 
switch took place. Using the strict definition of switching, no associations were seen 
between year of starting HAART and switching, whilst using the relaxed definition, 
borderline significant associations were identified with in particular, patients being 
less likely to switch in later calendar years. Other than risk group and ethnicity, 
statistically significant associations were identified between all other variables and 
switching, regardless of the definition of switch. However, there were marked 
differences in proportions of patients switching according to the definition used. In 
particular, 20.7% of patients receiving PI/r-based regimens switched therapy under 
the strict definition, compared to 43.4% under the relaxed definition.  
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Table 5.1.3.8.1: Characteristics of patients with resistance tests post-ART according to whether a switch was made to the regimen 
within 4 months of resistance test result 
  Strict1 definition of switching Relaxed2 definition of switching 
  No switch Switch P-value
3 No switch Switch P-value3 
  3289 1834  2430 2693  
Mutations detected n (%) No 1219 (81.1) 284 (18.9) <0.0001 928 (61.7) 575 (38.3) <0.0001 
 Yes 2070 (57.2) 1550 (42.8)  1502 (41.5) 2118 (58.5)  
GSS <1 1089 (56.0) 857 (44.0) <0.0001 809 (41.6) 1137 (58.4) <0.0001 
 1-1.75 558 (54.7) 462 (45.3)  401 (39.3) 619 (60.7)  
 2-2.75 416 (64.0) 234 (36.0)  296 (45.5) 354 (54.5)  
 >3 273 (82.5) 58 (17.5)  924 (61.3) 583 (38.7)  
Year of starting HAART  <1996 968 (64.4) 536 (35.6) 0.36 737 (49.0) 767 (51.0) 0.06 
n (%) 1996-1998 1253 (64.6) 686 (35.4)  918 (47.3) 1021 (52.7)  
 1999-2001 500 (62.1) 305 (37.9)  356 (44.2) 449 (55.8)  
 2002-2004 391 (63.3) 227 (36.7)  282 (45.6) 336 (54.4)  
 2005-2008 177 (68.9) 80 (31.1)  137 (53.3) 120 (46.7)  
Regimen at resistance test  NNRTI + NRTIs 851 (55.8) 673 (44.2) <0.0001 637 (41.8) 887 (58.2) <0.0001 
n (%) Single PI +NRTIs 349 (49.9) 351 (50.1)  267 (38.1) 433 (61.9)  
 PI/r +NRTIs 1203 (79.3) 315 (20.7)  859 (56.6) 659 (43.4)  
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 NRTIs only 552 (61.7) 343 (38.3)  434 (48.5) 461 (51.5)  
 Other 334 (68.7) 152 (31.3)  233 (47.9) 253 (52.1)  
Time between start of HAART  <3 months 142 (70.0) 61 (30.0) <0.0001 109 (53.7) 94 (46.3) <0.0001 
and resistance test (months)  3.1 – 12 months 216 (54.8) 178 (45.2)  145 (36.8) 249 (63.2)  
N (%) 1.1 - 3 years 521 (58.3) 372 (41.7)  373 (41.8) 520 (58.2)  
 3.1 - 5 years 658 (63.5) 379 (36.6)  470 (45.3) 567 (54.7)  
 5.1 – 7 years 592 (66.2) 302 (33.8)  427 (47.8) 467 (52.2)  
 7.1 – 9 years 525 (69.1) 235 (30.9)  409 (53.8) 351 (46.2)  
 >10 years 635 (67.4) 307 (32.6)  497 (52.8) 445 (47.2)  
CD4 at resistance test 
(cells/mm3) 
Median (IQR) 290 (172, 430) 243 (137, 370) <0.0001 290 (172, 430) 250 (140, 390) <0.0001 
Viral load at resistance test 
(log copies/mL) 
Median (IQR) 3.7 (3.1, 4.5) 4.0 (3.4, 4.6) <0.0001 3.8 (3.1, 4.5) 3.9 (3.3, 4.6) <0.0001 
Age at start of HAART (years) Median (IQR) 40 (35, 45) 39 (35, 44) 0.07 40 (35, 45) 39 (35, 44) 0.004 
Number of drugs  3 530 (58.4) 377 (41.6) <0.0001 435 (48.0) 472 (52.0) <0.0001 
experienced 4-6 905 (59.0) 629 (41.0)  654 (42.6) 880 (57.4)  
 7-9 977 (66.1) 502 (33.9)  686 (46.4) 793 (53.6)  
 10-12 636 (72.0) 247 (28.0)  482 (54.6) 401 (45.4)  
 13-15 199 (75.4) 65 (24.6)  144 (54.6) 120 (45.5)  
 >15 42 (75.0) 14 (25.0)  29 (51.8) 27 (48.2)  
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Number of classes 1 223 (66.2) 114 (33.8) <0.0001 181 (53.7) 156 (46.3) <0.0001 
experienced  2 1262 (58.1) 910 (41.9)  938 (43.2) 1234 (56.8)  
 3 1804 (69.0) 810 (31.0)  1311 (50.2) 1303 (49.9)  
Ethnicity n (%) White 2088 (65.1) 1118 (34.9) 0.20 1520 (47.4) 1686 (52.6) 0.97 
 Black 873 (62.5) 523 (37.5)  665 (47.6) 731 (52.4)  
 Other 328 (63.0) 193 (37.0)  245 (47.0) 276 (53.0)  
Sex/Exposure n (%) MSM 1981 (64.7) 1081 (35.3) 0.50 1429 (46.7) 1633 (53.3) 0.15 
 Heterosexual (m) 417 (62.0) 256 (38.0)  312 (46.4) 361 (53.6)  
 Heterosexual (f) 577 (63.5) 332 (36.5)  440 (48.4) 469 (51.6)  
 Other 314 (65.6) 165 (34.5)  249 (52.0) 230 (48.0)  
Number of regimens failed  0 121 (72.9) 45 (27.1) 0.07 99 (59.6) 67 (40.4) 0.01 
before resistance test n  1 606 (66.0) 312 (34.0)  464 (50.5) 454 (49.5)  
(%) 2 606 (61.5) 379 (38.5)  456 (46.3) 529 (53.7)  
 3 596 (63.4) 344 (36.6)  434 (46.2) 506 (53.8)  
 4 537 (63.9) 304 (36.1)  395 (47.0) 446 (53.0)  
 5 823 (64.7) 450 (35.3)  582 (45.7) 691 (54.3)  
VL <50 copies/mL at any  No 1284 (62.5) 770 (37.5) 0.04 944 (46.0) 1110 (54.0) 0.08 
point before resistance test Yes 2005 (65.3) 1064 (34.7)  1486 (48.4) 1583 (51.6)  
1
 Starting at least two drugs within 4 months of the resistance test result;
 2
 Starting/stopping at least one drug within 4 months of the resistance test result;       
3 
Obtained by Chi-Squared/Mann-Whitney tests  
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5.1.3.9. Factors associated with switching regimen 
With the exception of mutations detected, number of drugs experienced and number 
of classes experienced, all variables in Table 5.1.3.8.1 were included in logistic 
regression analyses. I chose to include GSS in the models, as opposed to whether 
mutations were, or were not detected, since GSS better captures clinically relevant 
resistance carried by patients. The number of drugs/classes experienced is 
somewhat captured by the number of regimens previously failed. I felt the latter 
variable was also more clinically relevant and hence did not include the former 
variables due to co-linearity with the number of regimens failed. In univariable 
analyses, using the strict definition of switching, the GSS of the current regimen was 
a significant predictor of switching regimen within 4 months of the resistance test 
result (OR (95% CI) for GSS <1 compared to >3: 3.43 (2.93, 4.02)). Patients 
receiving PI/r-based regimens were less likely to switch than those receiving NNRTI-
based regimens (0.33 (0.28, 0.39)), as were patients who had failed a greater 
number of previous regimens (0.92 (0.88, 0.95) per additional regimen). A reduced, 
albeit still significant, effect of GSS was seen when using the relaxed definition of 
switching (2.23 (1.94, 2.56) for GSS <1 compared to >3). Patients receiving PI/r-
based regimens were again less likely to switch than those receiving NNRTI-based 
regimens (0.55 (0.48, 0.64)), as were patients who had failed a greater number of 
previous regimens (0.94 (0.91, 0.98) per additional regimen). 
  
After adjusting for other possible confounders, the GSS of the current regimen was 
a significant predictor of switching regimen within 4 months of the resistance test 
result, regardless of the definition used for switching (4.82 (3.92, 5.93) and 2.91 
(2.42, 3.51) for GSS <1 compared to GSS >3 using the strict definition and relaxed 
definition, respectively, Table 5.1.3.9.1). Using the strict definition, patients with 
fewer drug options were less likely to switch (0.46 (0.34, 0.61) comparing 0-3 drug 
options with >10 drug options), whilst no association was seen between the number 
of regimens previously failed and switching regimen (0.98 (0.92, 1.05) per additional 
failed regimen). Tests performed amongst patients receiving PI/r-based regimens 
were less likely to result in a switch than those performed on patients receiving 
NNRTI-based regimens (0.47 (0.39, 0.56)), whilst tests performed on those 
receiving  single PI-based regimens were more likely to result in a switch than those 
performed on patients receiving NNRTI-based regimens (1.41 (1.16, 1.72)).  Lower 
CD4 count at time of resistance test (2.06 (1.74, 2.44) for those with CD4<200 
cells/mm3 compared to CD4>350 cells/mm3 and higher VL (0.36 (0.27, 0.49) 
comparing VL <400 with VL >100,000 copies/mL) at the time of the resistance test 
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were also independently associated with switching regimen. Patients who had 
achieved viral suppression (at any time point, not necessarily on the regimen they 
were failing) before having the resistance test performed were more likely to switch 
regimens than those who had not (1.27 (1.10, 1.47)).  
 
Estimates using the relaxed definition of switching were generally in the same 
direction as those obtained using the strict definition of switching, though were less  
pronounced and hence closer to one in most cases. 
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Table 5.1.3.9.1: Independent factors associated with switching regimen, stratified by definition of switching 
 Strict definition1 Relaxed definition2 
 OR (95% CI) P-value OR (95% CI) P-value 
GSS at time of resistance <1 4.82 (3.92, 5.93) <0.0001 2.91 (2.42, 3.51) <0.0001 
test 1-1.75 4.09 (2.02, 3.14)  2.73 (1.57, 2.33)  
 2-2.75 2.52 (2.02, 3.14)  1.24 (1.09, 1.42)  
 >3 1  1  
Drug options remaining 0-3 0.46 (0.34, 0.61) <0.0001 0.59 (0.45, 0.77) <0.0001 
 4-6 0.85 (0.68, 1.07)  0.94 (0.76, 1.16)  
 7-9 0.91 (0.75, 1.11)  0.90 (0.75, 1.08)  
 >10 1  1  
Age  Per 10 years older 0.99 (0.91, 1.07) 0.81 0.94 (0.88, 1.02) 0.13 
Year of resistance test  <1999 1 0.68 1 0.81 
 1999-2001 0.94 (0.76, 1.17)  0.96 (0.78, 1.19)  
 2002-2003 0.97 (0.77, 1.23)  1.01 (0.81, 1.26)  
 2004-2005 1.06 (0.82, 1.37)  0.93 (0.73, 1.19)  
 2006-2007 0.93 (0.69, 1.23)  0.90 (0.69, 1.17)  
Regimen at resistance test  NNRTI + NRTIs 1 <0.0001 1 <0.0001 
 PI/r + NRTIs 0.47 (0.39, 0.56)  0.77 (0.66, 0.91)  
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 Single PI + NRTIs 1.41 (1.16, 1.72)  1.22 (1.00, 1.49)  
 NRTIs only 0.68 (0.56, 0.81)  0.69 (0.58, 0.83)  
 Other 0.72 (0.56, 0.92)  0.95 (0.76, 1.20)  
Time between start of  <3 1.04 (0.69, 1.57) 0.01 1.23 (0.85, 1.78) <0.0001 
ART and resistance test  4 – 24 1.44 (1.13, 1.83)  1.77 (1.41, 2.23)  
(months) 25 – 36 1.30 (1.01, 1.69)  1.51 (1.18, 1.93)  
 37 – 60 1.08 (0.88, 1.31)  1.30 (1.08, 1.56)  
 61 – 84 0.97 (0.80, 1.17)  1.17 (0.98, 1.40)  
 >84 1  1  
Ethnicity White 1 0.86 1 0.84 
 Black 1.06 (0.86, 1.29)  0.95 (0.79, 1.14)  
 Other/unknown 1.03 (0.83, 1.28)  0.99 (0.81, 1.21)  
Sex/Exposure  MSM 1 0.51 1 0.10 
 Heterosexual male 1.13 (0.90, 1.41)  1.02 (0.82, 1.25)  
 Heterosexual female 1.02 (0.82, 1.28)  0.93 (0.76, 1.14)  
 Other/unknown 0.91 (0.73, 1.14)  0.78 (0.64, 0.96)  
Number of regimens failed 
before resistance test 
Per 1 regimen greater 0.98 (0.92, 1.05) 0.55 1.00 (0.94, 1.06) 0.97 
CD4 at resistance test <200 2.06 (1.74, 2.44) <0.0001 1.69 (1.44, 1.97) <0.0001 
cells/mm3 200-350 1.35 (1.15, 1.59)  1.13 (0.97, 1.30)  
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 >350 1  1  
 Missing 1.20 (0.66, 2.15)  1.25 (0.73, 2.14)  
VL <50 copies/mL before 
resistance test 
Yes 1.27 (1.10, 1.47) 0.001 1.24 (1.09, 1.42) 0.001 
VL at resistance test <400 copies/mL 0.36 (0.27, 0.49) <0.0001 0.47 (0.37, 0.62) <0.0001 
 401-1000 copies/mL 0.76 (0.56, 1.02)  0.81 (0.61, 1.07)  
 1001-10,000 copies/mL 0.68 (0.55, 0.84)  0.78 (0.63, 0.96)  
 10,000-30,000 copies/mL 0.82 (0.65, 1.04)  0.79 (0.63, 0.98)  
 30,000-100,000 copies/mL 0.78 (0.61, 0.99)  0.81 (0.64, 1.02)  
 >100,000 copies/mL 1  1  
 Missing  0.56 (0.42, 0.76)  0.62 (0.47, 0.81)  
1
 Starting at least two drugs within 4 months of the resistance test result
 
2
 Starting/stopping at least one drug within 4 months of the resistance test result
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5.1.3.10. Interactions with GSS 
A significant interaction was identified between regimen at the time of the resistance 
test and the GSS (fitted as a continuous variable, likelihood ratio test p=0.04 and 
p=0.01 using strict and relaxed definitions respectively), after adjusting for other 
variables. This was mainly driven by the „other‟ regimen category – amongst those 
with a GSS of 0, those who were receiving other regimens were less likely to switch 
their regimen than those receiving NNRTI-containing regimens (OR=0.54, 
p<0.0001), but this effect attenuated as the GSS increased (OR for interaction=1.32, 
p=0.001). The ORs (95% CIs) for „other‟ regimen when the GSS was <1, 1-1.75, 2-
2.75 and >3 were 0.74 (0.50, 1.09), 0.59 (0.35, 0.98), 0.37 (0.17, 0.80) and 1.25 
(0.70, 2.21) respectively. 
 
There was also a significant interaction between calendar year and GSS (p=0.03 
and 0.001 using the strict and relaxed definitions respectively).  Patients with 
resistance tests performed in later calendar years were more likely to switch 
regimen when they had a GSS of 0 (OR=1.55 comparing resistance tests performed 
between 2004 and 2005 to before 1999, p=0.01) but this effect was reduced as the 
GSS increased (OR for interaction=0.75, p=0.003). The ORs (95% CIs) comparing 
resistance tests performed between 2004 and 2005 to before1999 when the GSS 
was <1, 1-1.75, 2-2.75 and >3 were 0.95 (0.65, 1.39), 1.52 (0.85, 2.70), 0.91 (0.41, 
2.01) and 0.98 (0.47, 2.05) respectively 
 
There was no significant interaction between VL at resistance test and GSS 
(p=0.93). 
 
5.1.3.11. Restricting analyses to only those with mutations detected 
I then considered analyses in which patients without detectable resistance mutations 
were removed from the dataset.  Of the 3,620 patients remaining in the dataset, 
1,550 (42.8%) made a switch (strict definition) to their regimen within 4 months of 
the resistance test result. The proportion of patients with GSS <1, 1-1.75, 2-2.75 
and >3 who switched regimen were 44.1%, 45.6%, 37.4% and 43.9%, respectively. 
Factors associated with switching regimen in univariable and multivariable analyses 
are shown in Table 5.1.3.11.1. The independent association between GSS and 
probability of switching regimen was weakened compared to the main analysis, but 
was still significant (2.08 (1.41, 3.08)) for GSS <1 compared to GSS >3). The 
number of future drug options available (0.42 (0.31, 0.58) for 0-3 drugs compared to 
>10 drugs) was also still independently associated with switching regimen after 
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adjusting for potential confounders. Patients who had resistance tests performed 
whilst receiving a PI/r regimen were less likely to switch regimen than those 
receiving an NNRTI-based regimen (0.43 (0.34, 0.54)), whilst those who were 
receiving a single PI-based regimen were more likely to switch (1.35 (1.08, 1.68)). 
Patients who had failed a greater number of regimens before having a resistance 
test performed were less likely to switch in univariable analyses (0.81 (0.78, 0.85) 
per additional failed regimen) but this association was not significant after adjusting 
for potential confounders (0.96 (0.89, 1.03)).  
 
Similar results were seen when using the relaxed definition of switching. Of the 
3,620 patients with mutations detected, 2118 (58.5%) switched regimen within 4 
months of the resistance test result. Patients with a GSS <1 were more likely to 
switch (1.45 (1.01, 2.07) compared to GSS >3), though again, this estimate was 
weaker that that seen in the main results.  
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Table 5.1.3.11.1: Factors associated with a strict switch of regimen, restricted to those who had mutations detected (N=3620) 
 Univariable analyses Multivariable analyses 
 OR (95% CI) P-value OR (95% CI) P-value 
GSS at time of resistance <1 1.80 (1.27, 2.53) 0.0001 2.08 (1.41, 3.08) <0.0001 
test 1-1.75 1.91 (1.34, 2.72)  1.71 (1.16, 2.54)  
 2-2.75 1.36 (0.93, 1.98)  1.09 (0.72, 1.64)  
 >3 1  1  
Drug options remaining 0-3 0.43 (0.35, 0.52) <0.0001 0.42 (0.31, 0.58) <0.0001 
 4-6 0.72 (0.60, 0.86)  0.73 (0.57, 0.94)  
 7-9 0.74 (0.62, 0.89)  0.77 (0.62, 0.97)  
 >10 1  1  
Age  Per 10 years older 0.95 (0.88, 1.03) 0.21 1.04 (0.95, 1.14) 0.38 
Year of resistance test  <1999 1 0.30 1 0.65 
 1999-2001 0.95 (0.77, 1.18)  0.97 (0.77, 1.23)  
 2002-2003 0.87 (0.71, 1.07)  0.96 (0.75, 1.24)  
 2004-2005 0.97 (0.78, 1.21)  1.14 (0.86, 1.52)  
 2006-2007 0.79 (0.62, 1.02)  1.02 (0.73, 1.42)  
Regimen at resistance test  NNRTI + NRTIs 1 <0.0001 1 <0.0001 
 PI/r + NRTIs 0.32 (0.27, 0.39)  0.43 (0.34, 0.54)  
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 Single PI + NRTIs 1.09 (0.89, 1.34)  1.35 (1.08, 1.68)  
 NRTIs only 0.61 (0.51, 0.74)  0.64 (0.52, 0.78)  
 Other 0.43 (0.33, 0.54)  0.64 (0.48, 0.84)  
Time between start of  <3 2.82 (1.75, 4.53) <0.0001 1.67 (0.95, 2.94) 0.02 
ART and resistance test  4 – 24 2.35 (1.90, 2.90)  1.57 (1.18, 2.08)  
(months) 25 – 36 1.61 (1.26, 2.05)  1.20 (0.89, 1.61)  
 37 – 60 1.29 (1.08, 1.56)  1.07 (0.86, 1.35)  
 61 – 84 1.13 (0.93 1.37)  1.00 (0.81, 1.24)  
 >84 1  1  
Ethnicity White 1 0.004 1 0.99 
 Black 1.30 (1.12, 1.52)  1.00 (0.80, 1.26)  
 Other/unknown 1.12 (0.90, 1.40)  0.99 (0.78, 1.26)  
Sex/Exposure  MSM 1 0.01 1 0.74 
 Heterosexual male 1.35 (1.10, 1.66)  1.16 (0.90, 1.50)  
 Heterosexual female 1.25 (1.04, 1.50)  1.05 (0.81, 1.37)  
 Other/unknown 1.16 (0.92, 1.47)  1.05 (0.81, 1.36)  
Number of regimens failed 
before resistance test 
Per 1 regimen greater 0.81 (0.78, 0.85) <0.0001 0.96 (0.89, 1.03) 0.24 
CD4 at resistance test <200 1.84 (1.57, 2.16) <0.0001 2.16 (1.78, 2.62) <0.0001 
cells/mm3 200-350 1.35 (1.14, 1.59)  1.38 (1.15, 1.65)  
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 >350 1  1  
 Missing 1.63 (0.85, 3.11)  1.31 (0.66, 2.62)  
VL <50 before resistance 
test 
Yes 0.95 (0.83, 1.08) 0.44 1.29 (1.10, 1.52) 0.002 
VL at resistance test <400 copies/mL 0.32 (0.23, 0.44) <0.0001 0.35 (0.24, 0.52) <0.0001 
 401-1000 copies/mL 0.68 (0.50, 0.93)  0.68 (0.48, 0.97)  
 1001-10,000 copies/mL 0.71 (0.56, 0.90)  0.68 (0.52, 0.89)  
 10,000-30,000 copies/mL 0.79 (0.61, 1.03)  0.78 (0.58, 1.04)  
 30,000-100,000 copies/mL 0.82 (0.62, 1.08)  0.79 (0.58, 1.05)  
 >100,000 copies/mL 1  1  
 Missing  0.62 (0.44, 0.86)  0.57 (0.40, 0.82)  
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5.1.3.12. GSS of new regimen compared to GSS of old regimen 
Finally, amongst the patients who did make a switch to their therapy within 4 months 
of the resistance test result, the GSS of the new regimen was calculated and 
compared to the GSS of the regimen taken at the time of the resistance test (old 
regimen). Amongst those who made a strict switch to therapy (n=1834) and had an 
old regimen GSS of <1, 12% still had a GSS <1 after switching regimens (Table 
5.1.3.12.1). Forty-five percent had a new GSS of 1-1.75 and 35% had a new GSS of 
2-2.75. Only 7% of patients had a new GSS >3. Most patients with an old GSS of 1-
1.75 had a new GSS of >2, though I did identify 4 patients who had a new GSS of 
<1 and 12 patients who had a new GSS of 1-1.75. Amongst patients with an old 
GSS >2, most patients had a new GSS at least that of the old regimen. However, a 
third of patients with an old GSS >4 had a new GSS <4.  
Using the relaxed definition of switching, 30% of patients with an old GSS <1 had a 
new GSS of <1 after switching therapy (Table 5.1.3.12.2). Of those with an old GSS 
of 1-1.75, 18% still had a new GSS of 1-1.75. Around 14% of patients with an old 
GSS of >2 had a new GSS <2.  
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Table 5.1.3.12.1: GSS of regimen at resistance test (old regimen) stratified by 
GSS of regimen switched to (new regimen) (N=1834): strict definition of 
switching 
Overall mean (SD) increase in GSS from old to new regimen: 1.2 (0.9) 
   GSS of new regimen n (%) 
  Mean 
increase 
<1 1-1.75 2-2.75 3-3.75 >4 
GSS of 
old 
regimen 
<1 1.4 103 (12) 384 (45) 304 (35) 64 (7) 2 (0) 
1-1.75 1.5 4 (1) 55 (12) 222 (48) 155 (33) 26 (6) 
2-2.75 1.0 1 (0) 13 (6) 51 (22) 121 (52) 48 (20) 
3-3.75 0.5 0 (0) 2 (1) 16 (7) 114 (51) 91 (41) 
>4 0.1 0 (0) 1 (2) 1 (2) 18 (31) 38 (65) 
 
 
 
Table 5.1.3.12.2: GSS of regimen at resistance test (old regimen) stratified by 
GSS of regimen switched to (new regimen) (N=2693): relaxed definition of 
switching 
Overall mean (SD) increase in GSS from old to new regimen: 1.0 (1.0) 
   GSS of new regimen n (%) 
  Mean 
increase 
<1 1-1.75 2-2.75 3-3.75 >4 
GSS of 
old 
regimen 
<1 1.2 341 (30) 426 (37) 304 (27) 64 (6) 2 (0) 
1-1.75 1.3 69 (11) 111 (18) 258 (42) 155 (25) 26 (4) 
2-2.75 0.8 31 (8) 20 (6) 89 (25) 166 (47) 48 (14) 
3-3.75 0.4 58 (13) 5 (1) 33 (7) 211 (46) 146 (32) 
>4 -0.1 12 (9) 3 (2) 3 (2) 32 (25) 80 (62) 
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5.1.4. Discussion 
These analyses were restricted to patients who had a resistance test performed 
whilst receiving ART, and in whom the result of the resistance test was made 
available to the clinician within 4 months of the date of the test. An added restriction 
that patients did not change therapy between the date of the resistance test and the 
date when the result was received was also enforced. This strict criterion was used 
in order to assess changes made to therapy based on the outcome of the resistance 
test, rather than changes made for other reasons, such as tolerability, pill burden 
and virological failure. I used two different definitions of a switch to therapy since 
there is no gold-standard definition. The strict definition (starting at least 2 new 
drugs) is perhaps more likely to be linked with the result of the resistance test as it 
excludes patients who switched a single drug, perhaps for toxicity reasons. 
However, clinicians do sometimes switch patients with resistance mutations to 
single PI (Personal communication, Gazzard) therapy or make switches to only 
those drugs for which resistance mutations are present. These cases will have been 
captured in the relaxed definition of a switch.   
 
The definition of a switch impacted considerably on the proportion of tests which 
were identified as being followed by a switch within 4 months of the resistance test 
result. Using the strict definition, 36% of tests were followed by a switch, compared 
to 56% when using the relaxed definition. This suggests a substantial number of 
patients only made a single change to their regimen within 4 months of the 
resistance test result. In both cases, patients with mutations detected had an 
increased likelihood of switching and, in particular, the proportion of patients 
switching decreased as the GSS of the current regimen increased. Interestingly, the 
difference in the proportion of patients making a switch using the strict and relaxed 
definitions was less pronounced if the GSS of the current regimen was low 
(difference in proportion of patients switching regimen with GSS <1=14%; difference 
in proportion of patients switching regimen with GSS >3=21%).  
 
A third of patients with low GSS (<1) to the current regimen had only 0-3 future drug 
options available. This may explain why some patients with low GSS did not switch 
regimens, and amongst those that did, the reason for the equally low GSS of the 
new regimen. Those with higher current GSS had a greater number of future drug 
options available and were hence likely to have experienced fewer previous failures. 
The number of regimens previously failed was not associated with switching 
regimen after adjusting for potential confounders, though in univariable analyses, 
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was associated with a decreased risk of switching. It is likely that the variable 
consisting of the number of future drug options confounded the relationship between 
the number of previous regimens failed and switching regime, explaining the lack of 
significance of the number of previous regimens failed in multivariate analyses.  
 
A low GSS at the time of the resistance test was independently associated with an 
increased risk of switching, with absolute estimates stronger using the strict 
definition of switching. These results are in line with findings from other studies 
(420;495;496) and both national and international guidelines (124;491) which have 
stated the importance of resistance testing and GSS before switching regimens. The 
estimates are likely to be lower when using the relaxed definition of switching as 
GSS may not be the main reason that patients switched therapy – for example, 
patients may have switched a single drug for toxicity reasons.  
 
The number of drug options available was also significantly associated with 
switching, with the risk of switching decreasing as the number of drug options 
decreased. This has also been shown in other studies (420;495;496). Further, in 
contrast to findings from the ARGENTA trial, I found GSS to be associated with 
switching regimen, even after adjusting for the number of drug options available 
(492). In fact, the effect of GSS was stronger after adjusting for the availability of 
drug options. Patients with low GSS may not switch regimen because of few 
options, but when the number of options is taken into account, a larger effect of GSS 
is expected. 
  
Interestingly, I also found patients who had previously attained an undetectable VL 
were more likely to switch regimen compared to those who had not achieved 
virological suppression. It is well recognised that adherence is associated with 
virological suppression (152;498-500) and hence clinicians may be more willing to 
switch regimens in those patients they perceive to have proven themselves to have 
been adherent than those with adherence issues. These findings are also in line 
with those reported by Cingolani et al (492) as discussed above. Patients with 
higher VLs and lower CD4 counts at the time of the resistance test were also more 
likely to switch regimen, indicating that together with GSS, VL and CD4 count are 
key indicators in influencing the decision to switch. This is well recognised and 
previous analyses from the UK CHIC Study have also shown that these indicators 
are associated with rapid switching after viral rebound (501). Although I did not 
restrict these analyses to those who experienced viral rebound, it is likely that the 
    170 
 
 
majority of resistance tests were performed for this reason, and in general 
resistance tests are only performed if the VL is above 200-500 copies/mL. 
 
The type of regimen being taken at the time of the resistance test was also 
significantly associated with switching regimens. In particular, tests performed whilst 
patients were receiving boosted PI regimens were less likely to be followed by a 
switch whilst those performed amongst patients taking a single PI-based regimen 
were more likely to be followed by a switch compared to those performed in patients 
receiving NNRTI- based regimens, even after adjusting for GSS. Although PI/r 
based regimens are usually recommended as second-line regimens (124), and 
hence patients receiving these regimens may have fewer treatment options 
available, this effect remained highly significant after adjusting for both number of 
prior failures and number of drug options available. In the event that these patients 
have already failed an NNRTI-based regimen, other NNRTIs are usually not a 
feasible option (although not necessarily the case with Etravirine), since a single 
mutation (L100I, Y181C, Y181I, G190A) can cause class-specific resistance. It is 
also well recognised that resistance accumulation on PI/r-based regimens is quite 
slow, which may also explain the reluctance in switching patients to other regimens. 
Single PI-based regimens are sub-optimal in the HAART era and hence clinicians 
may be more inclined to switch therapy amongst patients receiving such regimens. 
This is likely to be particularly evident amongst patients who started therapy in 
earlier calendar years and did not have the full range of ART drugs available that 
are accessible today.  
 
Patients with a shorter time period between starting ART and having a resistance 
test performed were at an increased risk of switching. Those who had been on ART 
for shorter time periods are likely to have a higher number of drug options available, 
resulting in a higher probability of switching. These patients, and in particular those 
who had a resistance test performed within 3 months of starting ART, may also have 
been infected with a resistant virus. Though guidelines state that all newly infected 
HIV patients should have a resistance test before starting ART, this only became 
routine around 2004 (127). Patients starting ART in earlier calendar years are 
unlikely to have had a resistance test performed before starting therapy, and hence 
may be more likely to switch soon after starting ART, in an attempt to suppress the 
virus from the outset. 
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Although the year in which the resistance test was performed was not found to be 
significantly associated with switching, either using the strict or relaxed definition of 
switching, there was a significant interaction between calendar year of resistance 
test and GSS. Patients who had resistance tests performed in later calendar years 
were more likely to switch if their GSS was 1-1.75 compared to >2. This effect was 
significant even after adjusting for the number of future drug options available. One 
explanation for this effect is that drugs in earlier calendar years were less potent, 
with higher levels of toxicities, so clinicians/patients may have been less willing to 
switch regimen despite a low GSS.  
 
The association between GSS and probability of switching regimen was weakened, 
but was still significant when analyses were restricted to those who carried 
resistance mutations. This is to be expected, given that the overall range of GSS will 
be smaller when restricting to patients with mutations detected. Interestingly, 
patients who had failed a greater number of regimens before having a resistance 
test performed were less likely to switch in univariable analyses but after adjusting 
for potential confounders, this effect was reversed. Given that the number of future 
drug options was the main variable which caused this reversal, the most likely 
explanation for this reversal is that patients with a higher number of prior failures 
were more likely to have fewer drug options available. However, after adjusting for 
the number of future drug options available, we would expect a higher probability of 
switching with a greater number of previous failures for reasons outlined earlier in 
this Discussion.    
 
When using the strict definition of switching, over 10% of patients with a GSS of <1 
still had a GSS of <1 after switching. This increased to over 30% when using the 
relaxed definition of switching. Though these patients may have had limited future 
drug options available, it is likely (particularly in the latter case) that patients did not 
switch solely to increase the number of active agents in their regimen, but instead to 
either „simplify‟ their regimen, or to reduce the number of toxic drugs in their 
regimen. This may be particularly true in later calendar years, when newer more 
tolerable drugs were readily available. 
 
There are limitations to this analysis. Firstly, my definition of „current drug options‟ is 
based on the GSS of available drugs not yet experienced at the date of the 
resistance test. Of note, I do not have data on previous experimental use of drugs 
which may have some impact on these analyses. It is also possible that in some 
    172 
 
 
cases, a previous resistance test may have revealed a mutation which has since 
disappeared from the majority virus, so clinicians may be aware of limitations in drug 
options that are not captured by my measure. Though statistically, I could have used 
cumulative genotype results to somewhat deal with this issue, I felt that this was 
diverting from the initial question I was trying to answer, i.e. whether individual 
resistance tests are followed by a switch. Clinicians may not have results of previous 
tests to hand, especially in the case where patients were seen at more than one 
clinic. Further, tolerability issues, such as previous drug intolerance and 
cardiovascular/renal toxicities of particular drugs may also factor in decisions to 
switch. It is also possible that some resistance tests may not have had the date of 
the result recorded, despite being made available to the clinician. Tests excluded 
from the analyses may have had some impact on the results seen.  
 
In relation to the data I have available, I have shown that the GSS of the current 
regimen is a strong predictor of switching regimen within 4 months of the resistance 
test result, regardless of which definition of switching is used.  When using the strict 
definition of switching, fewer than half of all those with GSS <2 switch within 4 
months of the test result, and amongst those that do switch, 12% with an old GSS of 
<1 continue to have a GSS of <1 after switching therapy. These patients are highly 
ART-experienced and have few treatment options available. Given that those with 
fewer options are less likely to switch, these results show that the need for drugs 
from both existing classes and new classes continues to exist.   
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5.2. Outcomes of second-line ART when switching from NNRTI to PI/r 
 
5.2.1. Introduction    
A 3-drug combination of two NRTIs with an NNRTI is the most widely prescribed 
regimen for first-line therapy worldwide (124). Despite marked improvements in 
antiretroviral therapy in recent calendar years, in terms of efficacy, tolerability and 
adherence, treatment failures continue to occur.  After failure on an NNRTI-based 
regimen, most second-line combinations are PI/r-based.  In the case of virological 
failure of a first-line regimen, current guidelines advise switching to at least 2 active 
agents (preferably 3), where a drug‟s activity is predicted based on results from a 
resistance test and knowledge of the drugs that a patient was receiving during the 
first-line regimen.  However, the potency and high genetic barrier of PI is such that 2 
additional fully active nucleoside drugs may not be necessary.  PI/r such as 
lopinavir/ritonavir and darunavir/ritonavir have shown high rates of virologic efficacy 
as monotherapy (84;409;502), although virological success rates are better for 
induction-maintenance strategies than when PI/r are used as initial therapy (503). 
Trials investigating the efficacy of PI/r and single NRTI combinations are planned or 
ongoing (504).   
 
If second-line ART efficacy is not dependent on NRTI activity then this could have 
far-reaching implications, in particular for resource-limited settings.  Currently, 
routine viral load monitoring remains inaccessible to many patients in developing 
countries and hence the diagnosis of virological failure may be delayed resulting in 
accumulation of drug resistance mutations.  NRTI resistance may be of less concern 
with PI/r-based second-line HAART although this must be balanced by the risks of 
transmission of resistant virus and resistance to other classes (i.e. NNRTI). 
 
In practice, approaches differ between clinics with respect to how many fully active 
agents are selected for second-line PI/r based therapy.  If two fully active NRTIs are 
not required for second-line PI/r, savings could be made both in terms of drug cost 
but also short- and long-term ART-related toxicity.  Zidovudine, for example, is one 
of the few NRTIs that remain fully active after failing NNRTI-based HAART with a 
3TC-containing backbone (lamivudine and emtricitabine are now recommended 
NRTI backbone components in all first-line regimens) so long as no TAMs have 
developed, but is associated with mitochondrial toxicities including lipoatrophy.   
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In this Section I investigate whether it is necessary to include two fully active NRTIs 
in a second-line PI/r-based regimen after first-line NNRTI failure. In particular, I will 
identify factors associated with failing second-line therapy and focus on the impact 
of the number of new or fully active NRTI included with second-line therapy on 
virological success rates. 
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5.2.2. Methods 
 
5.2.2.1. Inclusion criteria 
All HIV-positive patients who commenced first-line NNRTI-based HAART (defined 
as at least two NRTIs with an NNRTI (and no PI component)) and who subsequently 
experienced virological failure (defined as HIV-RNA >200 copies/mL after at least 4 
months of therapy) were eligible for inclusion if they switched to second-line PI/r-
based therapy after failure.  
Patients with VLs <200 copies/mL at date of switch (defined using last VL prior to 
switching), those with less than 4 months follow-up after the start of second-line 
therapy and those who failed a new NRTI between failing the first-line NNRTI 
regimen and starting the second-line PI/r regimen were excluded from this analysis. 
 
5.2.2.2. Definition of virological failure and GSS 
When analysing responses to second-line therapy, virological failure was also 
defined as HIV-RNA >200 copies/mL after 4 months of continuous use of a PI/r. I 
decided to use only one VL >200 copies/mL to define failure of the second-line 
regimen (as opposed to two VL >200 copies/mL as in the previous analysis) to be 
consistent with the definition of failure of first-line regimens. In this analysis, patients 
who switched regimen before experiencing virological failure were not excluded. In 
order to analyse the impact of the predicted activity level of NRTIs in the second-line 
regimen, a GSS was calculated for the new regimen based on the Stanford 
algorithm (version 5.1.2). Patients were assigned a GSS as described in Section 
5.1.2.2; drug-susceptible viral strains were assigned a sensitivity score of one, and 
those with low-level, intermediate, high-level and very high-level resistance were 
assigned scores 0.75, 0.50, 0.25 and 0 respectively. These sensitivity scores were 
then summed for each drug in the regimen. 
 
5.2.2.3. Statistical analyses 
A Kaplan-Meier analysis was performed to describe time to failure of the second-line 
regimen and Cox regression to identify factors associated with second-line 
virological failure. In these initial analyses, patients were not required to have a 
resistance test performed as it was the number of new drugs started that was the 
focus of the analysis. Models were adjusted for the following potential confounders: 
age at start of second-line HAART, time from failing first-line to starting second-line 
HAART, number of new NRTIs started at second-line HAART, ethnicity, 
sex/exposure, year of starting second-line HAART, whether the VL was <200 
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copies/mL between failing first-line and before starting second-line, CD4 at start of 
second-line HAART (per 50 cells higher) and VL at start of second-line HAART (per 
1 log higher). Chi-squared and Mann-Whitney tests were used to identify differences 
amongst patients who did and did not have a resistance test performed. Logistic 
regression was used to identify factors associated with having a resistance test 
performed and Cox regression was used to identify factors associated with 
virological failure amongst those with resistance tests.  
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5.2.3. Results  
 
5.2.3.1. Patient disposition 
During the study period (January 1999 to December 2007) 9285 subjects 
commenced NNRTI-based first-line HAART, and of these 1692 (18.2%) experienced 
virological failure according to the definition outlined above.  Only 65% of patients 
experiencing virological failure started new drugs (n=1103) after the date of failure. 
Of these, 700 did not meet the inclusion criteria (Figure 5.2.3.1.1); 502 patients 
started non-PI/r based regimens, 100 patients who did start PI/r-based regimens 
had VL <200 copies/mL at start of second-line therapy, 56 patients had less than 4 
months follow-up after starting second-line PI/r and 42 patients failed a new NRTI 
after failing their 1st line NNRTI-based regimen and before starting their second-line 
PI/r-based regimen. This left 403 patients eligible for the analysis. Not all 403 
patients had resistance data available; those who did not were removed from 
analyses requiring resistance data. 
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Figure 5.2.3.1.1: Patient disposition 
 
 
5.2.3.2. Baseline characteristics  
Baseline characteristics are described in Table 5.2.3.2.1. AZT and 3TC (either in 
combination with each other or with other NRTIs) were the most frequently received 
NRTIs at first-line failure, whilst TFV was most frequently received at start of 
second-line. Over a half of patients started 2 or more NRTIs at second-line HAART. 
Median (IQR) CD4 cell count at start of second-line therapy was 213 (124, 310) 
cells/mm3 and median (IQR) VL 4.4 (3.6, 5.0) log copies/mL. Most patients initiated 
lopinavir/ritonavir (59.3%) or atazanavir/ritonavir (23.1%) based second-line therapy 
and a total of 216 (53.6%) patients underwent genotypic resistance testing.  
Patients starting  
new drugs 2nd line 
(n = 1103) 
Started PI/r  
regimen 2nd line 
(n = 601) 
Started non-PI/r 
regimen 2nd line 
(n = 502) 
 
 
 
Unboosted PI  45 
New NNRTI  138 
New NRTI only 318 
Other   1 
 
Excluded 
HIV-RNA <200 at 2nd line 100 
<4 months follow-up  56 
Failed new NRTI between 
1st and 2nd line   42 
Eligible for analysis 
(n = 403) 
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Table 5.2.3.2.1: Characteristics of patients starting second-line PI/r-based 
therapy 
Patients starting second-line PI/r HAART  403 
Time to failing first-line HAART (months) Median (IQR) 9.4 (5.3, 20.0) 
NRTIs taken at first-line failure n (%) AZT 216 (53.6) 
 DDC 1 (0.2) 
 DDI 87 (21.6) 
 d4T 62 (15.4 
 3TC 308 (76.4) 
 ABC 62 (15.4) 
 TFV 65 (16.1) 
 FTC 26 (6.5) 
NRTIs taken at second-line n (%) AZT 129 (32.0) 
 DDC 1 (0.2) 
 DDI 134 (33.2) 
 d4T 36 (8.9) 
 3TC 144 (35.7) 
 ABC 143 (35.5) 
 TFV 255 (63.3) 
 FTC 36 (8.9) 
New NRTIs started at second-line n (%) 0 69 (17.1) 
 1 113 (28.0) 
 >2 221 (54.8) 
Year of starting second-line n (%) 1999-2001 195 (48.4) 
 2002-2004 164 (40.7) 
 2005-2007 44 (10.9) 
Ethnicity n (%) White 161 (40.0) 
 Black  206 (51.1) 
 Other 36 (8.9) 
Risk group n (%) MSM 154 (38.2) 
 Heterosexual 214 (53.1) 
 Other 35 (8.7) 
VL <200 between first and second-line HAART n (%) 63 (15.6) 
    180 
 
 
CD4 at start first-line (cells/mm3) Median (IQR) 150 (54, 220) 
VL at start first-line (log10 copies/mL) Median (IQR) 5.1 (4.6, 5.5) 
CD4 at start second-line (cells/mm3) Median (IQR) 213 (124, 310) 
VL at start second-line (log10 copies/mL) Median (IQR) 4.4 (3.6, 5.0) 
 
 
5.2.3.3. Factors associated with virological failure of second-line HAART 
Of the 403 patients starting second-line PI/r HAART, 181 (44.9%) experienced 
virological failure, after a median of 42 months (Figure 5.2.3.3.1).  
 
Figure 5.2.3.3.1: Kaplan-Meier estimate of the proportion of patients failing 
second-line PI/r 
 
 
Factors associated with virological failure are presented in Table 5.2.3.3.1. In 
univariable analyses, patients of black ethnicity (HR 1.56 (95% CI: 1.14, 2.13)) 
compared with white ethnicity), heterosexual risk group (2.03 (1.39, 2.97) and 1.86 
(1.27, 2.72) for heterosexual males and females respectively, compared with MSM) 
and those with higher VLs at start of second-line HAART (1.37 (1.20, 1.56) per 1 log 
increase) were at an increased risk of virological failure. Patients with higher CD4 
counts at start of second-line HAART were less likely to experience virological 
failure (0.86 (0.81, 0.91) per 50 cells higher).  
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Factors found from multivariable analyses to be independently associated with 
virological failure were heterosexual risk group (1.93 (1.17, 3.20); p=0.01 and 2.33 
(1.35, 4.02); p=0.002 for heterosexual males and females, respectively, compared 
with MSM) and VL at start of second-line (1.23 (1.06, 1.42); p=0.01 per 1 log 
higher).  Higher CD4 cell count at start of second-line regimen was associated with 
a reduced risk of virological failure (0.89 (0.83, 0.94); p<0.001 per 50 cells/mm3 
higher).  There was a trend towards increased risk of virological failure of second-
line therapy with each month increase between time of failure and switch (1.01 
(1.00, 1.03); p=0.07 per month). The number of new NRTIs included in the second-
line regimen was not associated with virological outcome; compared to individuals 
with 2 or more new NRTIs, the hazard ratios for virological failure were 0.83 (0.51, 
1.33; p=0.44) and 1.11 (0.79, 1.56; p=0.56) for those receiving 0, or 1 new NRTI, 
respectively.  When number of new NRTIs was analysed as a continuous variable 
the HR for virological failure was 1.00 per new NRTI (0.82, 1.21; p=0.99). 
  
  
     
 
 
    
1
8
2 
Table 5.2.3.3.1: Associations between various factors and virological failure from univariable and multivariable analyses 
  Univariable Multivariable 
  HR (95% CI) P-value HR (95% CI) P-value 
Age at start of second-line Per 10 years older 1.02 (0.83, 1.26) 0.83 1.08 (0.86, 1.34) 0.52 
Time from failing first-line to starting second-line HAART Per month longer 1.01 (0.99, 1.02) 0.35 1.01 (1.00, 1.03) 0.07 
Number of new NRTIs started at second-line 0 0.80 (0.51, 1.25) 0.32 0.83 (0.51, 1.33) 0.44 
 1 1.07 (0.77, 1.48) 0.70 1.11 (0.79, 1.56) 0.56 
 >2 1 - 1 - 
Ethnicity White 1 - 1 - 
 Black 1.56 (1.14, 2.13) 0.01 0.95 (0.60, 1.51) 0.95 
 Other 0.61 (0.31, 1.23) 0.17 0.52 (0.24, 1.12) 0.52 
Sex/Exposure MSM 1 - 1 - 
 Heterosexual male 2.03 (1.39, 2.97) 0.0003 1.93 (1.17, 3.20) 0.01 
 Heterosexual female 1.86 (1.27, 2.72) 0.002 2.33 (1.26, 4.02) 0.002 
 Other 1.79 (1.06, 3.03) 0.03 1.59 (0.62, 2.80) 0.11 
Year of starting second-line Per 1 year later 0.94 (0.86, 1.01) 0.10 0.94 (0.86, 1.02) 0.15 
VL <200 after failing first-line and before starting second-line 0.86 (0.57, 1.31) 0.47 0.76 (0.47, 1.24) 0.28 
CD4 at second-line (cells/mm
3
) Per 50 cells higher 0.86 (0.81, 0.91) <0.0001 0.89 (0.83, 0.94) <0.0001 
VL at second-line (copies/mL) Per 1 log10 higher 1.37 (1.20, 1.56) <0.0001 1.23 (1.06, 1.42) 0.01 
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5.2.3.4. Resistance testing prior to switch 
When comparing patients who did (n=216) and did not (n=187) undergo resistance 
testing prior to switch, patients who did not have a resistance test had significantly 
lower median CD4 cell count at virological failure (220 vs. 287 cell/mm3; p=0.01) and 
were less likely to have ever achieved viral suppression, defined as VL less than 
500 copies/mL, on first-line HAART (43.8% vs. 56.2%; p=0.05) than those who did 
have a test.  Patient characteristics according to resistance testing status are shown 
in Table 5.2.3.4.1. 
 
Table 5.2.3.4.1: Characteristics of patients stratified by whether or not they 
had a resistance test after failing first-line HAART and before starting second-
line 
Resistance test performed No Yes P-value 
N  187 216  
Age at failing first-line 
(yrs) 
Median (IQR) 35          
(31, 39) 
36          
(32, 40) 
0.31 
Ethnicity n (%) White 73 (45.3) 88 (54.7) 0.73 
 Black 99 (48.1) 107 (51.9)  
 Other 15 (41.7) 21 (58.3)  
Sex/Exposure n (%) MSM 69 (44.8) 85 (55.2) 0.06 
 Heterosexual male 59 (56.7) 45 (43.3)  
 Heterosexual female 47 (42.7) 63 (57.3)  
 Other 12 (34.3) 23 (65.7)  
VL <500 before starting second-line n (%) 137 (43.8) 176 (56.2) 0.05 
Year of failing first-line n  1999-2001 54 (49.1) 56 (50.9) 0.16 
(%) 2002-2004 90 (49.5) 92 (50.6)  
 2005-2008 43 (38.7) 168 (61.3)  
CD4 at failing first-line 
(cells/mm3) 
Median (IQR) 220      
(124, 349) 
287      
(168, 390) 
0.01 
Log VL at failing first-line 
(copies/mL) 
Median (IQR) 4.0        
(3.1,  4.8) 
3.7        
(3.0, 4.5) 
0.08 
  
In multivariable analyses, only log VL at first-line failure was associated with having 
a resistance test performed; patients with higher viral loads were less likely to have 
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a resistance test performed (OR: 0.80 (95% CI: 0.63, 1.00), p=0.05 per 1 log 
higher). 
 
5.2.3.5. NRTI GSS and risk of virological failure amongst patients with   
resistance tests performed 
Amongst the 216 patients with resistance tests performed prior to switching 
regimen, the NRTI GSS for the new regimen was <1, 1.25-1.75 and >2 in 15%, 33% 
and 49% of patients respectively. In univariable analysis, there was no statistical 
difference in NRTI GSS between patients who failed second-line PI/r therapy and 
those who achieved and maintained virological suppression (HR for experiencing 
virological failure: 0.73 (0.39, 1.34) and 0.74 (0.46, 1.17) for patients with GSS <1 
and GSS 1-1.75 respectively, compared to those with a GSS >2). When NRTI GSS 
was included in a multivariable analysis adjusted for potential confounders, it was 
not associated with virological failure: HR for virological failure compared to subjects 
with GSS ≥2 was 0.73 (p=0.34) and 0.70 (p=0.16) for subjects with NRTI GSS of ≤1 
and 1.25-1.75, respectively. When NRTI GSS was included in to the multivariable 
model as a continuous variable there was, again, no association with virological 
failure (1.14 (0.76, 1.72) per 1 unit higher). 
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5.2.4. Discussion  
This analysis was performed on a very specific subset of patients, with the aim of 
investigating whether two fully active NRTIs in a second-line PI/r-based regimen are 
necessary. In this analysis there was a wide degree of variability in the number of 
new and active NRTIs started as part of second PI/r line; however, I found no 
association between the number of new NRTIs, nor the number of fully active 
NRTIs, and virological failure of a second-line PI/r-based regimen.   
 
These findings are consistent with data presented recently indicating that, amongst 
individuals with the M184V mutation, and therefore resistance to lamivudine (3TC) 
and emtricitabine (FTC), outcomes on a PI/r were similar regardless of number of 
NRTIs (505); in a retrospective observational analysis, patients receiving 3TC/FTC 
with a PI/r and one other NRTI were as likely to achieve virological suppression as 
those receiving 2 NRTI  + PI/r +/- 3TC/FTC.  Possible explanations are the inherent 
potency of PI/r rendering the number of new or active NRTIs less important. This is 
supported by the high rates of efficacy when PI/r is issued as monotherapy; any 
benefit of including active NRTIs in the combination is small in comparison to the 
efficacy of PI/r alone.  LPV/r monotherapy, the most studied single PI/r strategy to 
date, is associated with higher rates of viral suppression when used as a 
simplification option in already virologically suppressed patients than as initial 
therapy.  Most patients in this analysis switched directly from failing therapy and had 
lower viral load levels than patients starting first-line HAART.  This may explain the 
relatively low rates of virological failure found - by 12 months of starting second-line 
HAART, only a quarter of patients had experienced virological failure.  
 
There is also the possibility that there was a benefit of active NRTIs in terms of 
efficacy but that this was masked by lower adherence rates in those with more 
active NRTIs in the regimen.  Regimens with at least 2 active NRTIs were more 
likely to include zidovudine than those with fewer than 2 (39% of regimens with >2 
active NRTIs included ZDV compared to 31% of regimens with <2 active NRTIs) 
and thus side effects may have resulted in lower adherence rates; unfortunately 
adherence data is not collected in the UK CHIC Study, so it is difficult to evaluate 
this hypothesis.  Although not statistically significant, there was a numerically lower 
risk of virological failure in patients with NRTI GSS less than 2 compared to those 
with a GSS of 2 or greater.  In order to definitively address the question of the 
number of nucleosides needed a randomized trial is required, in order to rule out 
confounding secondary to adherence or other factors.   
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Notably, of the 1103 individuals who started a new second-line regimen after failing 
NNRTI-based HAART, 138 started a new NNRTI and 318 started a new NRTI only. 
In these cases, it may be possible that clinicians were modifying the initial regimen 
not in relation to virological failure, but perhaps due to toxicity or adherence issues. 
It is also possible that clinicians may be reluctant for patients to switch to PI/r-based 
regimens because of adherence issues.   
 
Though these findings do have the limitations of low statistical power, recognised by 
the wide confidence intervals for the effect of number of new drugs and GSS, 
ultimately these findings could be of global importance.  With scarce second-line 
ART options in resource-limited settings, minimising the number of agents required 
for second-line therapy could yield large benefits in terms of toxicity, tolerability, 
adherence and, of course, cost.  However, in resource-rich settings, with access to 
regular monitoring (including resistance testing), these data support the possible use 
of second-line PI/r regimens containing fewer than 2 active NRTI. 
 
   
5.3. Summary 
In this Chapter I have shown that the definition of „switching‟ impacts considerably 
on the proportion of patients identified as having switched regimen. However, 
regardless of using a strict or relaxed definition, the GSS of the current regimen is a 
strong predictor of whether patients make a switch following the result of a 
resistance test, even after adjusting for the number of future drug options available. 
The second Section of this Chapter investigates the need for 3 fully active drugs 
amongst patients on second-line PI/r-based HAART. The number of new NRTIs and 
the NRTI GSS was not associated with virological failure of second-line HAART. 
Although the relaxed definition I used for switching in the first Section initially 
appeared to be somewhat too broad, results from the second Section suggest that 
switching a single component, i.e. NNRTI to PI/r can still be beneficial.  
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Chapter 6: Is a single ALT>200 IU sufficient to define 
an alanine transaminase (ALT) flare in HIV-positive 
populations? 
6.  
  
In this Chapter I will focus on ALT elevations. Though several factors may contribute 
to rises in ALT, these rises have also been linked to HAART in various studies. I 
have chosen to focus on ALT elevations as opposed to other toxicities associated 
with HAART since there is currently no consensus on what constitutes an ALT flare, 
i.e. an abnormally high value of ALT. Since ALT is regularly measured in most 
centres in UK CHIC, it is possible to investigate ALT elevations and distinguish 
these random fluctuations in ALT level from ALT flares within the CHIC dataset.  
 
6.1. Introduction  
Several studies have suggested that HAART may cause a rise in ALT levels (269-
275;506-508). ALT elevations range in both severity and duration. The definition of 
an ALT „flare‟ is varied. Some definitions include new ALT elevations which persist, 
while others refer only to transient elevations which return to baseline or normal 
levels. Some definitions are based on a single ALT measurement >50 IU (276;509) 
and others use the definition of Grade 3/4 hepatotoxicity from the AIDS Clinical Trial 
Group (ACTG) (>5 times upper limit of normal (283)). The extent to which such 
increases in ALT level are due to immune reconstitution, non-treatment related 
events, or random fluctuations has not been previously explored.  
 
Chronic infection with hepatitis C virus (HCV) or hepatitis B virus (HBV) is an 
independent risk factor for liver damage in HIV-positive patients (269;279;283;286-
288;510). However, there is no consensus on the relative impact of hepatitis status, 
HAART use and CD4 count in determining the risk of ALT flares. 
 
The aim of this analysis was to derive a definition of an ALT flare which may be 
useful in understanding the causes and significance of ALT elevations in the HIV-
treated population, by investigating the frequency and time course of ALT elevations 
in untreated HIV-positive patients without hepatitis co-infection.  I used this derived 
definition to identify factors that were associated with the risk of an ALT flare 
amongst both naïve and treatment experienced patients. Finally, I compared the 
strength of these associations with those identified when using a commonly utilized 
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definition of an ALT flare (ACTG Grade 3 hepatotoxicity) (270;271;279;285;511;512) 
with the aim of identifying any factors which may be given too little or too much 
importance when using the common definition of an ALT flare.  
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6.2. Methods 
 
6.2.1. Patient population 
Patients with ALT measurements recorded after 1996 were included in the analyses. 
Differences between those included and excluded were tested using Chi-squared 
and Mann Whitney tests.  
 
6.2.2. Justifying the need for an ALT flare definition to be restricted to 
HAART-naive patients 
In the first part of this analysis, I crudely verified the relationship between ALT 
elevations and HAART status. This was done in order to justify the need for the 
definition of an ALT flare to be solely based on HAART-naïve patients, i.e. to 
exclude the impact of HAART on ALT levels. I compared the frequency and duration 
of ALT elevations using a series of different thresholds (100, 120, 140, 160, 180 and 
200 IU) to define an elevation, stratifying analyses by HAART status and HBV 
and/or HCV status.  
Patients were classified in three (non-mutually exclusive) groups: patients who had 
never had a positive HBV/HCV test (including those who were never tested, i.e. 
those with negative/unknown HBV/HCV status); patients who had been tested for 
HBV/HCV co-infection and never had a positive HBV/HCV test (i.e. those with 
negative HBV/HCV status only); patients who had tested positive to HBV/HCV at 
least once. Positive HBV status was defined as having a positive HBV surface 
antigen result. 
 
For each individual, an episode of ALT elevation started when ALT levels first 
increased above the defined threshold (with the start date estimated by linear 
interpolation between the date of the first ALT level above the threshold and the 
date of the preceding ALT measurement to try to account for the issue of interval 
censoring) and ended when ALT levels fell below the threshold (end date estimated 
by linear interpolation between the date when ALT levels first fell below the 
threshold and the date of the preceding ALT measurement). Patients were stratified 
according to whether or not they had started HAART at the date of the ALT 
elevation. For those who had not yet started HAART, ALT measurements from Jan 
1996 to the earliest of the date of starting HAART and the date of the last ALT 
measurement were eligible for inclusion.  
After patients had started HAART, ALT measurements from the date of starting 
HAART to the date of the last ALT measurement were eligible for inclusion. If ALT 
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levels did not fall below the threshold, the episode was censored at the date of the 
last ALT measurement for patients who did not start HAART and at the earliest of 
the date of starting HAART and the date of the last ALT measurement for patients 
who did start HAART.  The proportion of ALT elevation episodes that were 
sustained for two or more consecutive ALT measurements was described. 
In these analyses, patients whose first HBV/HCV test was positive were defined as 
being HBV/HCV-positive from the start of their follow-up.  
 
6.2.3. Defining an ALT flare using data from HAART-naive and HBV/HCV-
negative patients  
Given the results of the above analysis (reported in Sections 6.3.2 - 6.3.4), all 
subsequent analyses in relation to defining an ALT flare were restricted to HAART-
naïve patients.  Poisson regression was used to verify the association between 
HBV/HCV status and ALT elevation, with follow-up starting from date of first ALT 
measurement after 1996 and ending at the earliest of date of starting HAART and 
last ALT measurement. Analyses were then restricted to patients who were HBV 
and HCV-negative or who had unknown hepatitis status at the time of their ALT 
measurement. The frequency and duration of ALT elevation was calculated using 
linear interpolation as described above. The number of episodes lasting 0.5 months 
or longer, 1 month or longer, 3 months or longer and 6 months or longer was 
described. As a further summary measure, patient follow-up was split into 3 month 
intervals and the mean ALT measurement in each 3 month interval was calculated.  
 
A subset of these patients tested positive for hepatitis at a later date, so sensitivity  
analyses were also performed in which I additionally excluded any patients who had 
ever had a positive HBV/HCV test and then further excluded patients who had never 
been tested. Using these results (Section 6.3.7), a definition of an ALT flare, based 
on untreated, HBV/HCV-negative patients was derived, which was used in all 
subsequent analyses (2 consecutive ALTs >200 IU, measured >2 weeks apart).  
 
6.2.4. Identifying factors associated with ALT flares 
Poisson regression was used to identify factors associated with my newly derived 
definition of an ALT flare. In these analyses, all patients were included, regardless of 
treatment and hepatitis status.  In patients who did not experience a flare, follow-up 
was calculated from the date of the first ALT measurement after 1996 and censored 
at the date of death or the last clinic visit. Amongst patients who experienced an 
ALT flare, follow-up was calculated from the date of the first ALT measurement after 
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1996 and ended on the date of experiencing the flare. For those who had a flare 
which resolved, follow-up began again from the first ALT measurement after 
resolution of the flare (ALT<200 IU). 
 
The following potential confounders were considered: sex, exposure (MSM, 
heterosexual, other/unknown), ethnicity (white, black, other/unknown), current CD4 
count, current viral load, current age, current calendar year, previous AIDS 
diagnosis, number of prior of ALT measurements, HCV diagnosis, HBV diagnosis, 
current HAART regimen (didanosine/stavudine (ddI/d4T) with nevirapine (NVP), 
ddI/d4T without NVP, NVP without ddI/d4T and „other‟) and any ritonavir (RTV) use. 
These specific regimens were selected as the drugs included have been reported to 
be associated with ALT flares (270;272;276). The number of prior ALT 
measurements has also been associated with ALT flares (273); this covariate may 
be a surrogate for the frequency of attendance or monitoring at a clinical centre. It 
was hypothesised that positive hepatitis status may impact on CD4 counts and on 
treatment regimen, and hence interactions between hepatitis status and both 
treatment and CD4 count were explored and analyses were stratified by these 
variables where appropriate. 
 
6.2.5. Comparing the derived definition with the definition commonly 
used in the literature 
Poisson regression was also used to identify factors associated with experiencing 
an ALT flare when categorised using the most common definition in the literature (a 
single ALT >200 IU). These estimates were compared to those calculated above. 
The rationale for this comparison was that the RRs obtained using the standard 
definition may differ to those using the derived definition, due to issues such as 
monitoring bias.  
 
Finally, the association between ALT flares (fitted as a time updated covariate, 
current flare yes/no) and all-cause mortality was explored using Kaplan Meier 
analyses and Cox regression. Again, estimates using both the derived definition and 
the most commonly found definition in the literature were compared.  Patients 
were followed from the date of the first ALT measurement after 1996 until the date of 
last clinical follow-up. Analyses were adjusted for the following confounders: current 
CD4 count, current viral load, current age, ethnicity, exposure group and number of 
prior ALT flares.  
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6.3. Results 
 
6.3.1. Differences between those who have an ALT measurement 
recorded after 1996 and those without a measurement recorded 
after 1996 
ALT measurements recorded after 1996 were available in 19,707 (60.4%) of the 
total 32,607 patients. Patients without measurements were more likely to be female 
(51.4% of females had no available ALT measurements compared to 48.6% of 
females with ALT measurements, p<0.0001), of black ethnicity (55.8% had no ALT 
measurements recorded compared to 44.2% of patients with ALT measurements, 
p<0.0001) and of heterosexual risk group (51.2% had no ALT measurements, 
compared to 48.8% with ALT measurements, p<0.0001). Patients without 
measurements available were also less likely to have started HAART (31.8% vs. 
68.2%) and less likely to have ever had a positive HBV/HCV test (5.7% vs. 94.3%).  
 
Amongst the 19,707 patients who did have available ALT measurements, the 
median number of measurements per patient was 14 (IQR: 4, 28) at a mean 
duration of 141 (SD: 149) days apart.  
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Table 6.3.1.1: Differences between those who did and those who did not have 
an ALT measurement recorded after 1996 
  Patients with ALT 
measurements after 1996 
P-value 
  No Yes  
  12900 19707  
Sex Males 8863 (35.8) 15888 (64.2) <0.0001 
 Females 4037 (51.4) 3819 (48.6)  
Ethnicity White 5981 (31.5) 13008 (68.5) <0.0001 
 Black 5233 (55.8) 4149 (44.2)  
 Other 1686 (39.8) 2550 (60.2)  
Risk group MSM 4857 (28.6) 12103 (71.4) <0.0001 
 Heterosexual 5297 (51.2) 5056 (48.8)  
 Other 2746 (51.9) 2548 (48.1)  
Started HAART No 6206 (53.8) 5338 (46.2) <0.0001 
 Yes 6694 (31.8) 14369 (68.2)  
HBV/HCV-positive No 12761 (42.3) 17398 (57.7) <0.0001 
 Yes 139 (5.7) 2309 (94.3)  
 
 
6.3.2. ALT measurements in HAART-naive and HAART-experienced 
patients who are not known to be HBV or HCV-positive  
Table 6.3.2.1 shows the frequency and duration of elevated ALT episodes for a 
range of different thresholds amongst HAART-naive, HBV/HCV-negative patients. 
Similar results are shown in Table 6.3.2.2 for HAART-experienced, HBV/HCV-
negative patients. In both the untreated and the treated groups, the proportion of 
patients with at least one ALT measurement above each threshold decreases as the 
threshold increases. This is also true of the number of episodes above each 
threshold. Amongst HAART-naive patients, the proportion of patients with at least 2 
consecutive measurements above each threshold also decreases as the threshold 
increases, but this is not true for the HAART-experienced patients.  
Although the general trends are similar in both groups, the actual proportions are 
considerably different. The proportion of patients with at least one ALT 
measurement above each threshold drops from 10.5% for ALT levels >100 IU to 
       194 
 
 
3.5% for ALT levels >200 IU amongst HAART-naive patients, but these proportions 
are much higher amongst HAART-experienced patients (22.8% for ALT levels >100 
IU and 7.9% for ALT levels >200 IU).  Not much variation was seen between the 
groups in the proportion of episodes in which the ALT level was sustained above the 
threshold of interest for 2 consecutive measurements. However, as a proportion of 
the total number of patients under follow-up in each group, HAART-experienced 
patients were more likely to have 2 consecutive ALT measurements above each 
threshold than HAART-naive patients (5.5% for ALT levels >100 IU in HAART-naive 
patients compared to 16.9% in HAART-experienced patients).  In the group of 
HAART-experienced patients there were also a considerably higher maximum 
number of episodes above each threshold, at around 15-18 for at least one patient, 
whilst the patient with the maximum number of episodes among HAART-naive 
patients had only 5 episodes above each threshold. The median duration of 
episodes was slightly lower in the HAART-naïve group for ALT levels >180 IU, but 
was higher for ALT levels >180 IU. 
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Table 6.3.2.1: Frequency and duration of elevated ALT episodes when using a series of different ALT thresholds amongst patients 
who were HAART-naïve and HBV/HCV-negative or of unknown status (patients who had never tested positive for HBV or HCV) 
throughout follow-up (N=12564) 
                
ALT 
threshold 
(IU) 
N (%) 
patients with 
> 1 ALT 
above 
threshold 
No. of 
episodes 
Sustained for >2 
consecutive 
measurements 
N (% of episodes) 
No. of episodes of > 2 
consecutive measurements 
per patient   
Median (Range) 
Duration (days) of each 
episode of > 2 consecutive 
measurements 
Median (IQR) 
ALT >100 1323 (10.5) 1709 691 (40.4) 1 (1,5) 96 (26, 243) 
ALT >120 985 (7.8) 1256 500 (39.8) 1 (1,4) 85 (23, 226) 
ALT >140 786 (6.3) 985 378 (38.4) 1 (1,4) 74 (23, 202) 
ALT >160 638 (5.1) 788 309 (39.2) 1 (1,3) 73 (20, 193) 
ALT >180 529 (4.2) 639 241 (37.7) 1 (1,3) 73 (18, 187) 
ALT >200 440 (3.5) 517 196 (37.9) 1 (1,3) 69 (20, 183) 
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Table 6.3.2.2: Frequency and duration of elevated ALT episodes when using a series of different ALT thresholds amongst patients 
who were HAART-experienced and HBV/HCV-negative or of unknown status (patients who had never tested positive for HBV or HCV) 
throughout follow-up (N=11783) 
  
ALT 
threshold 
(IU) 
N (%) 
patients with 
> 1 ALT 
above 
threshold 
No. of episodes Sustained for >2 
consecutive 
measurements 
N (% of episodes) 
No. of episodes of > 2 
consecutive measurements 
per patient   
Median (Range) 
Duration (days) of each 
episode of > 2 consecutive 
measurements 
Median (IQR) 
ALT >100 2689 (22.8) 4925 1995 (40.5) 1 (1,16) 109 (49, 215) 
ALT >120 2066 (17.5) 3490 1423 (40.8) 1 (1,15) 93 (42, 189) 
ALT >140 1642 (13.9) 2649 1067 (40.3) 1 (1,17) 84 (37, 182) 
ALT >160 1321 (11.2) 2058 851 (41.4) 1 (1,17) 81 (33, 165) 
ALT >180 1097 (9.3) 1686 688 (40.8) 1 (1,18) 72 (34, 148) 
ALT >200 930 (7.9) 1385 563 (40.6) 1 (1,16) 64 (31, 126) 
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6.3.3. ALT measurements in HAART-naive and HAART-experienced 
patients who are known to be HBV and HCV-negative  
Similar analyses were performed amongst patients who had had at least one HBV 
and HCV test after 1996. Analyses were restricted to patients who had never had a 
positive HBV/HCV test result and hence were known to be HBV/HCV-negative. 
Results of these analyses are shown in Table 6.3.3.1 and Table 6.3.3.2. Although 
the absolute numbers under follow-up were lower in both groups, the proportions of 
patients with at least one ALT measurement and with at least two consecutive ALT 
measurements above each threshold were very similar to those seen in patients of 
negative or unknown hepatitis status. A considerably higher proportion of HAART-
experienced patients experienced ALT elevations than HAART-naive patients and 
these occurred more frequently amongst the former group. Since the results of this 
analysis are similar to those obtained from pooling together hepatitis-negative 
patients and those with unknown status, I believe that to classify not tested patients 
as HBV/HCV-negative was a reasonable assumption to make. 
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Table 6.3.3.1:  Frequency and duration of elevated ALT episodes when using a series of different ALT thresholds amongst patients 
who were HAART-naive and known to be HBV/HCV-negative (patients who had had at least one HBV/HCV test and had not ever tested 
positive) throughout follow-up (N=10094) 
  
ALT 
threshold 
(IU) 
N (%) 
patients with 
> 1 ALT 
above 
threshold 
No. of episodes Sustained for >2 
consecutive 
measurements 
N (% of episodes) 
No. of episodes of > 2 
consecutive measurements 
per patient   
Median (Range) 
Duration (days) of each 
episode of > 2 consecutive 
measurements 
Median (IQR) 
ALT >100 1071 (10.6) 1368 562 (41.1) 1 (1,5) 90 (23, 220) 
ALT >120 809 (8.0) 1021 415 (40.6) 1 (1,4) 76 (21, 211) 
ALT >140 647 (6.4) 806 315 (38.1) 1 (1,4) 68 (20, 183) 
ALT >160 527 (5.2) 643 263 (40.9) 1 (1,3) 68 (18, 180) 
ALT >180 433 (4.3) 519 208 (40.1) 1 (1,3) 68 (18, 171) 
ALT >200 361 (3.6) 426 170 (39.9) 1 (1,3) 67 (18, 174) 
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Table 6.3.3.2:  Frequency and duration of elevated ALT episodes when using a series of different ALT thresholds amongst patients 
who were HAART-experienced and known to be HBV/HCV-negative (patients who had had at least one HBV/HCV test and had not ever 
tested positive) throughout follow-up (N=9952) 
  
ALT 
threshold 
(IU) 
N (%) 
patients with 
> 1 ALT 
above 
threshold 
No. of episodes Sustained for >2 
consecutive 
measurements 
N (% of episodes) 
No. of episodes of > 2 
consecutive measurements 
per patient   
Median (Range) 
Duration (days) of each 
episode of > 2 consecutive 
measurements 
Median (IQR) 
ALT >100 2304 (23.2) 4203 1689 (40.2) 1 (1,16) 109 (49, 210) 
ALT >120 1759 (17.7) 2964 1193 (40.2) 1 (1,15) 92 (41, 186) 
ALT >140 1408 (14.2) 2251 902 (40.1) 1 (1,17) 84 (37, 178) 
ALT >160 1130 (11.4) 1739 728 (41.9) 1 (1,17) 80 (33, 160) 
ALT >180 942 (9.5) 1432 598 (41.8) 1 (1,18) 70 (34, 141) 
ALT >200 801 (8.1) 1190 493 (41.4) 1 (1,16) 63 (29, 123) 
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6.3.4. ALT measurements in HAART-naive and HAART-experienced 
patients who have had a positive HBV/HCV test result 
In the analyses presented below, only patients who had tested positive for either 
HBV or HCV were included. As anticipated, the proportion of patients with either 
one or two consecutive ALT measurements above each threshold was significantly 
higher than in the HBV/HCV-negative populations. Again, HAART-experienced 
patients experienced a greater number of ALT elevations than HAART-naive 
patients (33.3% with at least one ALT >200 IU compared to 16% in HAART-naive 
patients). This difference was particularly noticeable when comparing the overall 
proportion of patients who experienced at least 2 consecutive measurements above 
each threshold (29.3% for ALT >200 IU compared to 11.4% in HAART-naive 
patients). The frequency of episodes was similar amongst the two populations 
whilst episodes appeared to last longer amongst HAART-naive patients than in 
HAART-experienced patients. 
 
        
 
 
    
2
0
1 
Table 6.3.4.1:  Frequency and duration of elevated ALT episodes when using a series of different ALT thresholds amongst patients 
who are HAART-naive and known to be HBV/HCV-positive (N=1644) 
  
ALT 
threshold 
(IU) 
N (%) 
patients with 
> 1 ALT 
above 
threshold 
No. of episodes Sustained for >2 
consecutive 
measurements 
N (% of episodes) 
No. of episodes of > 2 
consecutive measurements 
per patient   
Median (Range) 
Duration (days) of each 
episode of > 2 consecutive 
measurements 
Median (IQR) 
ALT >100 556 (33.8) 795 420 (52.8) 1 (1,6) 157 (70, 326) 
ALT >120 460 (28.0) 654 333 (50.9) 1 (1,5) 144 (63, 280) 
ALT >140 391 (23.8) 545 267 (49.0) 1 (1,4) 137 (58, 264) 
ALT >160 344 (20.9) 464 226 (48.7) 1 (1,4) 135 (57, 243) 
ALT >180 298 (18.1) 397 201 (50.6) 1 (1,3) 115 (56, 224) 
ALT >200 267 (16.2) 348 188 (54.0) 1 (1,4) 101 (55, 216) 
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Table 6.3.4.2: Frequency and duration of elevated ALT episodes when using a series of different ALT thresholds amongst patients 
who are HAART-experienced and known to be HBV/HCV-positive (N=1791) 
ALT 
threshold 
(IU) 
N (%) 
patients with 
> 1 ALT 
above 
threshold 
No. of episodes Sustained for >2 
consecutive 
measurements 
N (% of episodes) 
No. of episodes of > 2 
consecutive measurements 
per patient   
Median (Range) 
Duration (days) of each 
episode of > 2 consecutive 
measurements 
Median (IQR) 
ALT >100 990 (55.3) 2259 1240 (54.9) 1 (1,7) 148 (77, 276) 
ALT >120 884 (49.4) 1920 1015 (52.9) 1 (1,8) 129 (69, 240) 
ALT >140 799 (44.6) 1635 823 (50.3) 1 (1,6) 121 (67, 214) 
ALT >160 713 (39.8) 1410 705 (50.0) 1 (1,7) 102 (60, 187) 
ALT >180 652 (36.4) 1231 608 (49.4) 1 (1,5) 94 (54, 174) 
ALT >200 596 (33.3) 1072 525 (49.0) 1 (1, 5) 89 (52, 154) 
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6.3.5. Verifying the relationship between hepatitis status and ALT 
elevations in HAART-naive patients 
Given the above results which clearly show that HAART-experienced patients are 
more likely to experience ALT elevations, regardless of which ALT threshold is used, 
the following analyses were restricted to HAART-naive patients only. Rate-ratios for 
patients who were HCV-positive (compared to HCV-negative) and HBV-positive 
(compared to HBV-negative) in relation to experiencing 2 or more consecutive ALT 
measurements above each threshold are shown in Table 6.3.5.1. In these analyses, 
patients were defined to be HBV/HCV-positive from the start of follow-up if their first 
HBV/HCV test was positive.  In unadjusted analyses, patients who were HCV-
positive were 4-5 times more likely to experience ALT elevations than patients who 
were HCV-negative, regardless of the threshold used. The rate-ratios increased 
linearly with increasing ALT thresholds. After adjusting for potential confounders, 
positive HCV status was generally still strongly associated with ALT elevations, 
though the magnitude of the estimates were smaller than in the unadjusted 
analyses. In particular, no association was seen between positive HCV status and 
ALT elevations >200 IU (p=0.26).  
 
Similar results were seen when analysing HBV status and ALT elevations. Higher 
ALT thresholds were associated with higher rate ratios of experiencing an ALT 
elevation for positive HBV status (compared to negative), and the magnitude of 
these estimates, though still highly significant, were smaller after adjusting for 
potential confounders. In addition, the increase in risk associated with positive HBV 
status was smaller than that of positive HCV status, regardless of the threshold 
used.  
 
In sensitivity analyses, the date of positive hepatitis status was taken as the date of 
the first positive HBV/HCV test result (as opposed to start of follow-up if the first 
hepatitis test result was positive). In these analyses, the rate-ratios for positive HCV 
status were slightly higher than those in the previous analyses (Table 6.3.5.2) and a 
linear trend (rate-ratios increasing as ALT threshold increases) was evident even 
after adjusting for potential confounders. Positive HCV status, regardless of which 
threshold was used, was still also highly associated with the risk of experiencing 
ALT elevations.  The HBV results were very similar to those seen in Table 6.3.5.1, 
again confirming that patients with positive HBV tests were more likely to experience 
ALT elevations than those with negative HBV tests. This analysis also shows that 
any bias caused by potential misclassification of person-time in the previous 
  204 
 
 
analyses (defining patients as HBV/HCV-positive if their first test is positive), is likely 
to be negligible, although results suggest that associations may have been slightly 
underestimated. 
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Table 6.3.5.1: Rate-ratios for patients who are HCV-positive (vs. HCV-negative) and HBV-positive (vs. HBV-negative) in relation to 
predicting ALT elevation (defined as >2 consecutive measurements above each threshold) in HAART-naïve patients (n=14242) 
(Patients defined as HBV/HCV-positive from start of follow-up if first HBV/HCV test is positive)  
ALT 
threshold 
(IU) 
No. of 
episodes 
above 
threshold 
Rate-ratios (95% CI1)  for HCV+ vs. HCV- in 
predicting ALT rises 
Rate-ratios (95% CI1)  for HBV+ vs. HBV- in predicting 
ALT rises 
  Unadjusted P-value Adjusted P-value Unadjusted P-value Adjusted P-value 
>100 1111 4.67 
(4.02, 5.44) 
<0.0001 1.31 
(1.06, 1.61) 
0.01 2.99 
(2.57, 3.48) 
<0.0001 1.86 
(1.58, 2.19) 
<0.0001 
>120 833 4.74 
(3.99, 5.64) 
<0.0001 1.63 
(1.31, 2.03) 
<0.0001 2.94 
(2.47, 3.50) 
<0.0001 1.58 
(1.31, 1.91) 
<0.0001 
>140 645 4.72 
(3.88, 5.74) 
<0.0001 2.10 
(1.66, 2.66) 
<0.0001 2.80 
(2.29, 3.42) 
<0.0001 1.65 
(1.33, 2.05) 
<0.0001 
>160 535 5.18 
(4.18, 6.42) 
<0.0001 1.85 
(1.42, 2.40) 
<0.0001 2.71 
(2.18, 3.38) 
<0.0001 1.92 
(1.50, 2.45) 
<0.0001 
>180 442 5.27 
(4.19, 6.64) 
<0.0001 1.88 
(1.39, 2.53) 
<0.0001 2.86 
(2.26, 3.63) 
<0.0001 1.62 
(1.24, 2.12) 
0.004 
>200 384 5.54 
(4.34, 7.07) 
<0.0001 0.75 
(0.69, 1.35) 
0.26 3.03 
(2.36, 3.89) 
<0.0001 0.97 
(0.69, 1.35) 
0.26 
1 
CI: Confidence interval 
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Table 6.3.5.2: Rate-ratios for patients who are HCV-positive (vs. HCV-negative) and HBV-positive (vs. HBV-negative) in relation to 
predicting ALT elevation (defined as >2 consecutive measurements above each threshold) in HAART-naive patients (n=14242) 
(Patients defined as HBV/HCV-positive from date of first positive HBV/HCV test result)  
ALT 
threshold 
(IU) 
No. of 
episodes 
above 
threshold 
Rate-ratios (95% CI1)  for HCV+ vs. HCV- in 
predicting ALT rises 
Rate-ratios (95% CI1)  for HBV+ vs. HBV- in predicting 
ALT rises 
  Unadjusted P-value Adjusted P-value Unadjusted P-value Adjusted P-value 
>100 1111 5.53 
(4.71, 6.48) 
<0.0001 1.68 
(1.38, 2.04) 
<0.0001 2.91 
(2.46, 3.43) 
<0.0001 1.77 
(1.48, 2.11) 
<0.0001 
>120 833 5.80 
(4.85, 6.94) 
<0.0001 1.65 
(1.32, 2.07) 
<0.0001 2.81 
(2.32, 3.40) 
<0.0001 1.47 
(1.19, 1.82) 
0.0003 
>140 645 6.02 
(4.92, 7.37) 
<0.0001 2.32 
(1.83, 2.96) 
<0.0001 2.60 
(2.08, 3.24) 
<0.0001 1.47 
(1.15, 1.88) 
0.0002 
>160 535 6.54 
(5.25, 8.16) 
<0.0001 2.20 
(1.69, 2.86) 
<0.0001 2.46 
(1.92, 3.14) 
<0.0001 1.72 
(1.31, 2.26) 
<0.0001 
>180 442 6.74 
(5.33, 8.54) 
<0.0001 2.24 
(1.66, 3.01) 
<0.0001 2.72 
(2.10, 3.53) 
<0.0001 1.49 
(1.11, 2.00) 
0.01 
>200 384 7.06 
(5.50, 9.07) 
<0.0001 3.69 
(2.72, 5.00) 
<0.0001 2.80 
(2.13, 3.69) 
<0.0001 0.79 
(0.54, 1.14) 
0.21 
1 
CI: Confidence interval 
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6.3.6. Moving towards a definition of an ALT flare using data from 
HAART-naive and HBV/HCV-negative patients 
Given the above results, only patients who were HAART-naive and HBV/HCV-
negative were included in further analyses to define an ALT flare. Table 6.3.6.1 
shows the frequency and duration of ALT elevation episodes in patients who were 
HAART-naive and HBV/HCV-negative or of unknown status at the time of their ALT 
measurement. Of the 14,208 patients included in this analysis, 11.3% had at least 
one ALT >100 IU, whilst 4.1% had at least one ALT >200 IU. 7.2% of patients had 2 
consecutive ALT measurements >100 IU and only 2.3% of patients had 2 
consecutive ALT measurements >200 IU. 25% of patients had an episode lasting 
around 4 weeks, whilst the median duration of episodes was around 3 months.  
 
In sensitivity analyses, patients who had ever had a positive HBV or HCV test were 
excluded. The results of these analyses have been shown previously in Table 
6.3.2.1. A slightly smaller proportion of patients experienced ALT elevations above 
each threshold than those seen in Table 6.3.6.1, suggesting that some patients who 
tested positive for HBV/HCV after the date of their ALT measurement may have 
been positive at the time of their ALT measurement but did not have a hepatitis test 
to confirm this. The median duration of episodes was shorter amongst the subset of 
patients with subsequent positive HBV/HCV tests excluded. Again, this may be 
explained by patients in the former analyses not being picked up as HBV/HCV-
positive early enough, so in analyses in which patients are known not to be 
HBV/HCV-positive, the duration of ALT elevations is likely to be shorter.  
 
In the last set of sensitivity analyses, patients who had not had a HBV or HCV test 
were also excluded (Table 6.3.3.1). Again, this table was shown previously when 
comparing HAART-naive to HAART-experienced patients. Results were very similar 
to the above analyses, suggesting that patients with unknown hepatitis status were 
likely to be HBV/HCV-negative.  
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Table 6.3.6.1: ALT elevation episodes amongst patients who were HAART-naïve and HBV/HCV-negative or of HBV/HCV unknown 
status at time of ALT measurements (N=14208) 
 
ALT 
threshold 
(IU) 
N (%) patients 
with > 1 ALT 
above threshold 
No. of episodes Sustained for >2 
consecutive 
measurements                 
N (% of episodes) 
No. of episodes of > 2 
consecutive measurements 
per patient                      
Median (Range) 
Duration (days) of each 
episode of > 2 consecutive 
measurements                  
Median (IQR) 
ALT >100 1601 (11.3) 2504 857 (34.2) 1 (1,5) 108 (36, 270) 
ALT >120 1220 (8.6) 1910 633 (33.1) 1 (1,4) 100 (32, 250) 
ALT >140 987 (7.0) 1530 484 (31.6) 1 (1,4) 92 (30, 225) 
ALT >160 815 (5.7) 1252 400 (31.9) 1 (1,3) 92 (28, 209) 
ALT >180 684 (4.8) 1036 325 (31.4) 1 (1,3) 88 (28, 364) 
ALT >200 581 (4.1) 865 277 (32.0) 1 (1,3) 84 (29, 207) 
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The duration of ALT elevations was analysed in greater detail amongst the 3 groups of 
patients described in this sub-section. Amongst patients who were not known to be 
HBV/HCV-positive at the time of their ALT measurement, the proportion of patients 
experiencing episodes lasting >2 weeks was around 85% (Table 6.3.6.2). The 
proportion of patients experiencing episodes lasting longer than 1 month, 3 months 
and 6 months decreased as the ALT threshold increased. For ALT elevations >200 IU, 
87.0%, 73.6%, 46.6% and 28.9% of patients experienced episodes lasting longer than 
2 weeks, 1 month, 3 months and 6 months respectively.  
 
Amongst patients who had never had a positive HBV/HCV test result, trends were 
similar to the above analyses, though the proportions calculated were slightly lower 
(Table 6.3.6.3). Of the 196 ALT elevation episodes >200 IU, 84.2%, 68.4%, 44.9% and 
27.6% lasted longer than 2 weeks, 1 month, 3 months and 6 months respectively.  
Little difference was seen in the results when analyses were restricted to patients who 
had had at least one HBV/HCV test (Table 6.3.6.4).  
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Table 6.3.6.2: Duration of elevations amongst patients who were HAART-naïve and HBV/HCV-negative or of HBV/HCV unknown status 
at time of ALT measurements (N=14208) 
ALT 
threshold 
(IU) 
No. of 
episodes1 
above 
threshold 
Episodes lasting >2 
weeks 
N (%) 
Episodes lasting 
>1 month 
N (%) 
Episodes lasting >3 
months 
N (%) 
Episodes lasting >6 
months 
N (%) 
>100 857 755 (88.1) 663 (77.3) 471 (55.0) 301 (35.1) 
>120 633 548 (86.6) 477 (75.4) 335 (52.9) 218 (34.4) 
>140 484 416 (85.9) 361 (74.6) 241 (49.8) 152 (31.4) 
>160 400 340 (85.0) 290 (72.5) 198 (49.5) 119 (29.8) 
>180 325 277 (85.2) 237 (72.9) 154 (47.4) 94 (28.9) 
>200 277 241 (87.0) 204 (73.6) 129 (46.6) 80 (28.9) 
1 
Defined as 2 consecutive ALT values above each threshold 
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Table 6.3.6.3: Duration of elevations amongst patients who were HAART-naïve and HBV/HCV-negative or of unknown status 
throughout follow-up (had never tested positive for HBV/HCV) (N=12564) 
ALT 
threshold 
(IU) 
No. of 
episodes1 
above 
threshold 
Episodes lasting >2 
weeks 
N (%) 
Episodes lasting 
>1 month 
N (%) 
Episodes lasting >3 
months 
N (%) 
Episodes lasting >6 
months 
N (%) 
>100 691 602 (87.1) 519 (75.1) 367 (53.1) 234 (33.9) 
>120 500 424 (84.8) 359 (71.8) 252 (50.4) 168 (33.6) 
>140 387 318 (82.2) 268 (69.3) 178 (46.0) 115 (29.7) 
>160 309 256 (82.8) 212 (68.6) 147 (47.6( 90 (29.1) 
>180 241 199 (82.6) 165 (68.5) 109 (45.2) 66 (27.4) 
>200 196 165 (84.2) 134 (68.4) 88 (44.9) 54 (27.6) 
1 
Defined as 2 consecutive ALT values above each threshold 
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Table 6.3.6.4: Duration of elevations amongst patients who were HAART-naïve and known to be HBV/HCV-negative throughout follow-
up (had at least one HBV/HCV test and had never tested positive) (N=10094) 
ALT  
threshold 
(IU) 
No. of 
episodes1 
above 
threshold 
Episodes lasting >2 
weeks 
N (%) 
Episodes lasting >1 
month 
N (%) 
Episodes lasting >3 
months 
N (%) 
Episodes lasting >6 
months 
N (%) 
>100 562 483 (85.9) 413 (73.5) 284 (50.5) 173 (30.8) 
>120 415 347 (83.6) 292 (70.4) 201 (48.4) 129 (31.1) 
>140 315 261 (82.9) 216 (68.6) 142 (45.1) 86 (27.3) 
>160 263 216 (82.1) 175 (66.5) 118 (44.9) 69 (26.2) 
>180 208 170 (81.7) 137 (65.9) 91 (43.8) 51 (24.5) 
>200 170 143 (84.1) 113 (66.5) 74 (43.5) 43 (25.3) 
1 
Defined as 2 consecutive ALT values above each threshold 
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As a final summary measure, patient follow-up was split into 3-month intervals and 
the mean ALT measurement in each 3-month and 6-month interval was calculated.  
The number of patients known to be HBV and HCV-negative, with at least one mean 
3-monthly and 6-monthly ALT measurement above each threshold is shown in Table 
6.3.6.5.  
 
Table 6.3.6.5: Duration of elevations amongst patients who were HAART-naïve 
and known to be HBV/HCV-negative throughout follow-up (had at least one 
HBV/HCV test and had never tested positive) (N=10094) 
ALT 
threshold 
(IU) 
N (%) patients with 
> 1 ALT above 
threshold                
N (%)               
Patients with > 1 
mean ALT over 3 
month period             
N (%) 
Patients with > 1 
mean ALT over 
6 month period             
N (%) 
>100 1071 (10.6) 641 (6.4) 138 (1.4) 
>120 809 (8.0) 451 (4.5) 95 (0.9) 
>140 647 (6.4) 360 (3.6) 56 (0.6) 
>160 527 (5.2) 288 (2.9) 43 (0.4) 
>180 433 (4.3) 230 (2.3) 34 (0.3) 
>200 361 (3.6) 187 (1.9) 28 (0.3) 
 
The proportion of patients with a mean ALT measurement sustained over 3 and 6 
months decreased as the ALT threshold increased, suggesting that flares of 
duration longer than 3 months are uncommon. For ALT levels >200 IU, 1.9% and 
0.3% of patients had a sustained mean ALT for 3 and 6 months respectively.  
 
6.3.7. Definition of an ALT flare 
Amongst the HAART-naïve, HBV/HCV-negative/unknown population, 1601 (11.3%) 
patients had at least one ALT >100 IU compared to 581 (4.1%) patients with at least 
one ALT >200 IU. Only 277 (2.3% of the total group) of these patients had 2 
consecutive ALT measurements above this level. The majority of these patients 
(87.0%) had a sustained episode of >2 weeks, though three-quarters of patients had 
a sustained episode for >1 month. The lower quartile for the duration of these 
elevations was 29 days, though this was lower in the sensitivity analyses in which 
only patients who were known to be HBV/HCV-negative were included (18 days). 
Based on this information, I defined an individual as having an ALT flare if s/he had 
2 consecutive ALT measurements >200 IU measured at least 14 days apart. I chose 
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14 days since 25% of the population had an ALT elevation >200 IU which lasted 18 
days (lower quartile of duration of episode), and hence these patients were more 
likely to have a clinic appointment at 2 weeks, rather than at 18 days apart. Further, 
almost 90% of patients had a sustained ALT elevation of >2 weeks, suggesting that 
a gap of 2 weeks between measurements was the minimum that was needed for a 
stringent definition of an ALT flare.  
 
In sensitivity analyses, I defined an ALT flare as 2 consecutive ALT measurements 
>200 IU measured at least 30 days apart. This time period was chosen since the 
lower quartile for the duration of an ALT elevation was around 30 days, regardless 
of the threshold used. In addition, three-quarters of the patient population had a 
sustained flare lasting >1 month.  
 
6.3.8. ALT flares (defined as at least 2 ALTs >200 IU, >14 days apart) in 
the overall population (HAART-naive and HAART-experienced, 
HBV/HCV-negative and HBV/HCV-positive) 
 
6.3.8.1. Differences between those who experienced an ALT flare and those 
who did not 
Of the 19,707 patients with >1 ALT measurement available after 1996, 17,634 
(89.5%) patients had at least 2 measurements recorded after 1996.  
807 (4.6%) patients had at least one ALT-flare using the proposed definition of an 
ALT flare (2 consecutive measurements >200 IU, >14 days apart). Of those that 
resolved this first flare, 165 patients (20.4%) experienced at least 2 ALT flares. 
Patients who experienced ALT flares were more likely to be male (5.2% of males vs. 
1.9% of females experienced an ALT flare, p<0.0001), of „other‟ risk group (5.5% vs. 
2.2% of MSMs and 4.6% of heterosexuals, p<0.0001) and of „other‟ ethnicity (5.5% 
vs. 2.1% of white ethnicity and 3.7% of black ethnicity, p<0.0001). Patients 
experiencing ALT flares also had a shorter median duration between ALT 
measurements (2.2 vs. 2.8 months, p<0.0001), were more likely to be HCV-positive 
(47.0% vs. 3.9% of HCV-negative, p<0.0001) and were more likely to be HBV-
positive (40.0% vs. 3.9% of HBV-negative, p<0.0001) than those who did not 
experience ALT flares. Furthermore, 5.3% of patients who had started HAART-
experienced ALT flares compared to 2.2% of patients who had not yet started 
HAART (p<0.0001).  
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6.3.8.2. Baseline characteristics of patients who experienced an ALT flare  
Baseline characteristics of patients who experienced an ALT flare are shown in 
Table 6.3.8.2.1. In total, patients contributed 1031 episodes of ALT flares to the 
analysis. Each episode lasted an average 3.7 months and the median peak ALT 
measurement recorded during the episode was 531 IU. ALT flares occurred mainly 
within white males, of MSM risk group, at a median CD4 count and viral load of 363 
cells/mm3 and 368 copies/mL respectively. There was no difference in the duration 
between ALT measurements amongst those who were HAART-naive and those who 
had started HAART (2.0 months). 21.9% of patients who had experienced an ALT 
flare were HCV-positive, whilst 16.7% of patients were HBV-positive. Patients who 
were HCV-negative had a slightly longer duration between ALT measurements than 
those who were HCV-positive, though the absolute difference was minimal (2.2 vs. 
2.1 months). Almost a third of patients were not receiving any treatment at the time 
of the ALT flare, whilst another third were receiving regimens not containing d4T/ddI 
or NVP and a fifth of patients experiencing an ALT flare were receiving d4T/ddI 
without NVP. 
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Table 6.3.8.2.1: Characteristics of patients experiencing an ALT flare (2 
consecutive ALTs >200 IU, >14 days apart) 
Total number of patients N 17634 
No. of patients with flare N (%) 807 (4.6) 
No. of episodes N 1031 
Age at start of flare (years) Median (IQR) 39 (34, 44) 
CD4 count at start of flare (cells/mm3) Median (IQR) 363 (210, 533) 
Viral load at start of flare (copies/mL) Median (IQR) 368 (50, 23400) 
Sex N (%) Males 956 (92.7) 
 Females 75 (7.3) 
Ethnicity N (%) White 837 (81.2) 
 Black 86 (8.3) 
 Other 108 (10.5) 
Exposure N (%) MSM 784 (76.0) 
 Heterosexual  122 (11.8) 
 Other 125 (12.1) 
No. of prior ALT measurements  Median (IQR) 13 (5, 26) 
Duration between ALT measurements 
before starting HAART(months) 
Median (IQR)  2.0 (0.8, 3.4) 
Duration between ALT measurements after 
starting HAART(months) 
Median (IQR)  2.0 (1.5, 2.7) 
HCV-positive1 prior to flare N (%) 226 (21.9) 
HBV-positive prior to flare N (%) 172 (16.7) 
Duration between ALT measurements 
before amongst HCV-negative patients 
(months) 
Median (IQR) 2.2 (1.5, 3.0) 
Duration between ALT measurements 
before amongst HCV-positive patients 
(months) 
Median (IQR) 2.1 (1.4, 2.8) 
Maximum ALT measurement (IU) Median (IQR) 531 (361, 962) 
Duration of flare (months) Median (IQR)  3.7 (2.2, 7.0) 
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1
Defined from date of first positive test  
 
6.3.8.3. Rates of ALT flares  
The number of events, person-years (pys) and crude rates of ALT flares for each 
potential covariate are shown in Table 6.3.8.3.1. The overall rate of ALT flares was 
1.02 (95% CI: 0.96, 1.09) /100 pys. This is somewhat lower than the crude risk of an 
ALT flare shown in Table 6.3.6.1 (277/14208=1.9%). This is to be expected as ALT 
flares of shorter duration (<14 days) were included in the crude risk calculations. 
Rates of ALT flares were higher amongst patients of younger age (1.11/100 pys for 
<35 years), those with CD4 counts below 200 cells/mm3 (1.71/100 pys) and those 
with detectable viral loads (1.23/100 pys). Patients seen in earlier calendar years 
(1.60/100 pys), those with positive HBV/HCV status (2.02 and 3.74/100 pys 
respectively) and those on HAART regimens including d4T or DDI (1.56/100 pys) 
also had higher rates of ALT flares than those seen in the overall population.  
  
The crude rates of ALT-flares stratified by hepatitis and treatment status are shown 
in Table 6.3.8.3.2. Patients co-infected with HBV/HCV had higher flare rates than 
those not co-infected, though HBV/HCV-positive HAART-experienced patients had 
lower rates than HBV/HCV-positive HAART-naive patients. Similar results were 
seen after removing patients with unknown hepatitis status (Table 6.3.8.3.3). In 
these analyses, patients of HBV/HCV-negative status had lower ALT flare rates than 
those seen if patients of unknown hepatitis status were included.  
 
AIDS within 6 weeks after flare Yes 329 (31.9) 
HAART regimen  d4T/ddI without 
NVP 
216 (21.0) 
 d4T/ddI with NVP 84 (8.2) 
 NVP without 
d4T/ddI 
98 (9.5) 
 Other regimens 319 (30.9) 
 Currently off 
treatment 
314 (30.5) 
 Any RTV 279 (27.1) 
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Table 6.3.8.3.1: Events, person-years and crude rates (95% CI) of ALT flares  
 Person years Events Rate (95% CI) 
Total  1031/100827 1.02 (0.96, 1.09) 
Current age (years) >35 312/27998 1.11 (0.99, 1.24) 
 35-50 490/46203 1.06 (0.97, 1.15) 
 >50 229/26626 0.86 (0.75, 0.97) 
Current CD4 count  <200 239/14006 1.71 (1.49, 1.92) 
(cells/mm3) 200-349 231/24334 0.95 (0.83, 1.07) 
 350-449 227/25725 0.88 (0.77, 1.00) 
 >500 308/35747 0.86 (0.77, 0.96) 
 Missing  26/1015 2.56 (1.58, 3.55) 
Nadir CD4 count <50 224/18693 1.20 (1.04, 1.36) 
(cells/mm3) 50-199 362/36864 0.98 (0.88, 1.08) 
 200-349 247/25951 0.95 (0.83, 1.07) 
 >350 172/18305 0.94 (0.80, 0.94) 
 Missing 26/1015 2.56 (1.58, 3.55) 
Current viral load <50 353/49852 0.71 (0.63, 0.78) 
(copies/mL) >50 576/46917 1.23 (1.13, 1.33) 
 Missing 102/4058 2.51 (2.03, 3.00) 
Current calendar year 1996-2000 378/23646 1.60 (1.44, 1.76) 
 2001-2004 392/40974 0.96 (0.86, 1.05) 
 >2005 261/36207 0.72 (0.63, 0.81) 
Sex Males 956/84169 1.14 (1.06, 1.21) 
 Females 75/16658 0.45 (0.35, 0.55) 
Ethnicity White 837/72433 1.16 (1.08, 1.23) 
 Black 86/17610 0.49 (0.38, 0.59) 
 Other 108/10785 1.00 (0.81, 1.19) 
Exposure N (%) MSM 784/68372 1.15 (1.07, 1.23) 
 Heterosexual  122/22128 0.55 (0.45, 0.65) 
 Other 125/10328 1.21 (1.00, 1.42) 
No. of prior ALT  <10 427/41124 1.04 (0.94, 1.14) 
measurements 10-20 263/27932 0.94 (0.83, 1.06) 
 >20 341/31771 1.07 (0.96, 1.19) 
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In sensitivity analyses, patients whose first HBV/HCV test was positive were defined 
as HBV/HCV-positive from the start of follow-up. Rates of ALT flares stratified by 
treatment and hepatitis status for these patients are shown in Table 6.3.8.3.4 and 
Table 6.3.8.3.5. In analyses in which patients of unknown hepatitis status were 
included, the rates of ALT flares were lower than those seen when positive hepatitis 
status was defined from the first positive HBV/HCV test. After excluding patients of 
unknown hepatitis status, rates of ALT flares were similar to those seen in Table 
6.3.8.3.3 amongst HBV/HCV-negative patients, though were lower for HAART-naïve 
HBV/HCV-positive patients and higher for HAART-experienced HBV/HCV-positive 
patients.  
HCV status at flare  Positive 223/5965 3.74 (3.25, 4.23) 
 Negative 424/56358 0.75 (0.68, 0.82) 
 Unknown 384/38505 1.00 (0.90, 1.10) 
HBV status at flare Positive 175/8676 2.02 (1.72, 2.32) 
 Negative 535/60924 0.88 (0.80, 0.95) 
 Unknown 321/31227 1.03 (0.92, 1.14) 
Time since start of  HAART-naive 320/28496 1.03 (0.92, 1.15) 
HAART < 3 years  396/29427 1.14 (1.02, 1.26) 
 > 3 years 315/42904 0.91(0.82, 1.00) 
AIDS diagnosis at time  Yes 320/25516 1.25 (1.12, 1.39) 
Of flare No 711/75311 0.94 (0.88, 1.01) 
HAART regimen  No d4T/ddI/NVP 280/33528 0.84 (0.74, 0.93) 
 d4T/ddI with NVP 85/5463 1.56 (1.23, 1.89) 
 NVP without d4T/ddI 95/10891 0.87 (0.70, 1.05) 
 d4T/ddI without NVP 254/19417 1.31 (1.15, 1.47) 
 Currently off 
treatment 
317/31528 1.01 (0.90, 1.12) 
Any prior RTV  Yes 270/21858 1.24 (1.09, 1.38) 
experience No 761/78970 0.96 (0.90, 1.03) 
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Table 6.3.8.3.2: Events, person-years and rates (95% CI) of ALT flares stratified by hepatitis status (including unknown) and HAART 
status: Patients defined as HBV/HCV-positive from first date of positive test result 
 All HBV/HCV-negative/unknown HBV/HCV-positive 
  HAART-naive HAART-experienced HAART-naive HAART-experienced 
Events 1031 148 386 165 332 
Person-years 100827 24117 63068 3210 10432 
Rate (95% CI) 
/100 person years 
1.02 (0.96, 1.09) 0.61 (0.51, 0.71) 0.61 (0.55, 0.67) 5.14 (4.36, 5.93) 3.18 (2.84, 3.52) 
 
 
Table 6.3.8.3.3: Events, person-years and rates (95% CI) of ALT flares stratified by known hepatitis status and HAART status: Patients 
defined as HBV/HCV-positive from first date of positive test result 
 All HBV/HCV-negative HBV/HCV-positive 
  HAART-naive HAART-experienced HAART-naive HAART-experienced 
Events 689 44 148 165 332 
Person-years 58835 10718 34476 3210 10432 
Rate (95% CI) 
/100 person years 
1.17 (1.08, 1.26) 0.41 (0.29, 0.53) 0.43 (0.36, 0.50) 5.14 (4.36, 5.93) 3.18 (2.84, 3.52) 
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Table 6.3.8.3.4: Events, person-years and rates (95% CI) of ALT flares stratified by hepatitis status (including unknown) and HAART 
status: Patients defined as HBV/HCV-positive from start of follow-up if first test is positive 
 
 All HBV/HCV-negative/unknown HBV/HCV-positive 
  HAART-naive HAART-experienced HAART-naive HAART-experienced 
Events 1031 126 336 188 404 
Person-years 100827 23338 61662 4013 11814 
Rate (95% CI) 
/100 person years 
1.02 (0.96, 1.09) 0.54 (0.45, 0.63) 0.55 (0.49, 0.60) 4.69 (4.02, 5.35) 3.42 (3.09, 3.75) 
 
Table 6.3.8.3.5: Events, person-years and rates (95% CI) of ALT flares stratified by known hepatitis status and HAART status: Patients 
defined as HBV/HCV-positive from start of follow-up if first test is positive 
 
 All HBV/HCV-negative HBV/HCV-positive 
  HAART-naive HAART-experienced HAART-naive HAART-experienced 
Events 761 44 148 188 381 
Person-years 61021 10718 34476 4013 11814 
Rate (95% CI) 
/100 person years 
1.12 (1.03, 1.20) 0.41 (0.29, 0.53) 0.43 (0.36, 0.50) 4.69 (4.02, 5.35) 3.42 (3.09, 3.75) 
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6.3.8.4. Factors associated with ALT flares  
Table 6.3.8.4.1 shows the unadjusted and adjusted factors associated with 
experiencing an ALT flare. In univariable analyses, patients aged above 50 years 
(RR=0.77 (95% CI: 0.65, 0.92) vs. <35 years), those of female sex (0.40 (0.31, 0.50) 
compared to male sex), of black ethnicity (0.42 (0.34, 0.53) compared to white 
ethnicity) and of heterosexual risk group (0.48 (0.40, 0.58) compared to MSM) were 
less likely to experience ALT flares. Current CD4 count was linearly associated with 
the risk of an ALT flare; patients with lower current CD4 counts were more likely to 
experience ALT flares than those with higher current CD4 counts (1.98 (1.67, 2.35) 
for CD4 counts <200 compared to >500 cells/mm3). A similar trend was observed 
with nadir CD4 count. Patients with detectable VLs (1.73 (1.52, 1.98) comparing >50 
copies/mL to <50 copies/mL), those seen in earlier calendar years (2.20 (1.89, 2.60) 
comparing patients seen in 1996-2000 to those seen after 2005), those with positive 
HBV and HCV status (2.30 (1.94, 2.72) and 4.97 (4.23, 5.84) respectively) and 
patients currently receiving d4T/ddI containing regimens (1.86 (1.46, 2.38) and 1.57 
(1.32, 1.86) comparing d4T/ddI with NVP and d4T/ddI without NVP to regimens not 
containing d4T/ddI) were at an increased risk of experiencing an ALT flare. Patients 
who had had any prior RTV experience were also more likely to experience an ALT 
flare (1.28 (1.12, 1.47)).  
 
With the exception of nadir CD4 count and current calendar year, all variables 
remained significantly associated with the risk of an ALT flare after adjusting for 
potential confounders. A linear association was seen between the nadir CD4 count 
and the risk of an ALT flare, but this association did not reach statistical significance. 
Positive HCV status remained highly associated with ALT flares (4.99 (4.18, 5.96)), 
as did regimens containing d4T/ddI with NVP (1.73 (1.34, 2.24)) and d4T/ddI without 
NVP (1.22 (1.02, 1.47)). Patients receiving regimens containing NVP without 
d4T/ddI were also at an increased risk of experiencing an ALT flare (1.50 (1.18, 
1.92)).  Patients who had been receiving HAART for >3 years were less likely to 
experience ALT flares (0.62 (0.47, 0.80)) compared to those who were HAART-
naive. Patients receiving HAART for <3 years were more likely to experience ALT 
flares than HAART-naive patients, though this association was not significant in 
adjusted analyses.   
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Table 6.3.8.4.1: Factors associated with experiencing an ALT flare (2 consecutive ALTs>200 IU, > 14 days apart) from adjusted and 
unadjusted Poisson regression analyses 
  Unadjusted RR (95% CI)1 Adjusted RR (95% CI) 
  RR (95% CI) P-value RR (95% CI) P-value 
Current age (years) >35 1 - 1 - 
 35-50 0.95 (0.83, 1.10) 0.49 0.95 (0.82, 1.11) 0.53 
 >50 0.77 (0.65, 0.92) 0.003 0.81 (0.67, 0.97) 0.02 
Current CD4 count  <200 1.98 (1.67, 2.35) <0.0001 1.31 (1.04, 1.65) 0.02 
(cells/mm3) 200-349 1.10 (0.93, 1.31) 0.27 0.92 (0.75, 1.12) 0.41 
 350-449 1.02 (0.86, 1.22) 0.79 0.93 (0.78, 1.12) 0.45 
 >500 1 - 1 - 
 Missing  2.97 (1.99, 4.43) <0.0001 Excluded2 
Nadir CD4 <50 1.28 (1.05, 1.56) 0.02 0.86 (0.63, 1.17) 0.33 
 50-199 1.05 (0.87, 1.25) 0.64 0.92 (0.71, 1.18) 0.51 
 200-349 1.01 (0.83, 1.23) 0.90 1.00 (0.80, 1.24) 0.97 
 >350 1 - 1 - 
 Missing  2.73 (1.80, 4.12) <0.0001 Excluded 
Current viral load <50 1 - 1 - 
(copies/mL) >50 1.73 (1.52, 1.98) <0.0001 1.82 (1.54, 2.14) <0.0001 
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 Missing 3.55 (2.85, 4.42) <0.0001 3.50 (2.60, 4.72) <0.0001 
Current calendar year 1996-2000 2.20 (1.89, 2.60) <0.0001 1.16 (0.98, 1.37) 0.08 
 2001-2004 1.33 (1.13, 1.55) 0.0004 1.16 (0.98, 1.37) 0.09 
 >2005 1 - 1 - 
Sex  Male 1 - 1 - 
 Female 0.40 (0.31, 0.50) <0.0001 0.49 (0.37, 0.65) <0.0001 
Ethnicity  White 1 - 1 - 
 Black 0.42 (0.34, 0.53) <0.0001 0.64 (0.49, 0.84) 0.001 
 Other 0.87 (0.71, 1.06) 0.16 0.96 (0.78, 1.18) 0.72 
Exposure  MSM 1 - 1 - 
 Heterosexual  0.48 (0.40, 0.58) <0.0001 0.91 (0.70, 1.17) 0.45 
 Other 1.05 (0.87, 1.27) 0.57 0.71 (0.57, 0.88) 0.002 
No. of prior ALT  <10 1 - 1 - 
measurements 10-20 0.91 (0.78, 1.06) 0.21 1.09 (0.93, 1.28) 0.30 
 >20 1.03 (0.90, 1.19) 0.65 1.32 (1.10, 1.55) 0.002 
HCV status prior to flare  Negative 1 - 1 - 
 Positive 4.97 (4.23, 5.84) <0.0001 4.99 (4.18, 5.96) <0.0001 
 Unknown 1.33 (1.15, 1.52) <0.0001 1.01 (0.85, 1.21) 0.90 
HBV-positive prior to flare  Negative 1 - 1 - 
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 Positive 2.30 (1.94, 2.72) <0.0001 1.73 (1.45, 2.07) <0.0001 
 Unknown 1.17 (1.02, 1.34) 0.03 1.26 (1.06, 1.50) 0.01 
Time since start of HAART HAART-naive 1 - 1 - 
 < 3 years  1.20 (1.03, 1.39) 0.02 1.14 (0.91, 1.44) 0.26 
 > 3 years 0.65 (0.56, 0.76) <0.0001 0.62 (0.47, 0.80) 0.0003 
AIDS diagnosis prior to flare  Yes 1.33 (1.16, 1.52) <0.0001 1.16 (0.99, 1.36) 0.06 
HAART regimen  No d4T/ddI/NVP 1 - 1 - 
 d4T/ddI with NVP 1.86 (1.46, 2,38) <0.0001 1.73 (1.34, 2.24) <0.0001 
 NVP without d4T/ddI 1.04 (0.83, 1.32) 0.71 1.50 (1.18, 1.92) 0.001 
 d4T/ddI without NVP  1.57 (1.32, 1.86) <0.0001 1.22 (1.02, 1.47) 0.03 
 Currently off treatment 1.20 (1.03, 1.41) 0.02 0.82 (0.65, 1.04) 0.10 
Any prior RTV experience  Yes 1.28 (1.12, 1.47) 0.001 1.58 (1.34, 1.87) <0.0001 
1 
RR: rate-ratios, CI: confidence intervals 
2
 Missing categories were excluded due to co-linearity between current and nadir CD4 counts
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6.3.8.5. Sensitivity analyses and interactions between hepatitis status and 
treatment status, and between CD4 status and treatment status 
In sensitivity analyses, patients with unknown hepatitis status were excluded from 
the multivariable regression model. The adjusted rate ratio for positive HCV status 
was higher (5.99 (4.95, 7.24)) in these analyses, but was lower for positive HBV 
status (1.53 (1.26, 1.87)). If positive hepatitis status was defined from the start of 
follow-up amongst patients whose first HBV/HCV test result was positive, rate-ratios 
for both positive HBV status (2.08 (1.77, 2.44)) and positive HCV status (5.29 (4.48, 
6.23)) were higher than those seen in the main analyses.  
 
A significant interaction was identified between known HCV status and current 
regimen (p=0.01). Analyses were therefore stratified by current regimen and rate-
ratios for positive HCV status were identified. Though positive HCV status was 
associated with the risk of an ALT flare, regardless of which regimen patients were 
receiving, the rate-ratio was significantly lower for those currently off treatment (4.47 
(3.18, 6.28)) than those receiving treatment (RRs ranging from 6.41 to 7.17 
depending on which regimen was being received).  
In contrast, there was no significant interaction between current CD4 count and 
current regimen (p>0.15), or between HBV status and current regimen (p=0.31).  
 
6.3.9. ALT flares (defined as at least 2 consecutive ALTs >200 IU, >30 
days apart)  
In sensitivity analyses, an ALT flare was defined as experiencing at least 2 ALTs 
>200 IU, at least 30 days apart. Consistent with the result that the longer the 
duration of sustained elevation, the rarer the event (Table 6.3.6.2), the number of 
patients experiencing an ALT flare using this definition (N=644, 3.6%), was lower 
than that seen in Section 6.3.8 in which a flare was defined as at least 2 ALTs >200 
IU, >14 days apart (4.6%).  
 
6.3.9.1. Characteristics of patients experiencing and ALT flare; 2   
consecutive ALTs >200 IU, >30 days apart 
A total of 803 episodes of ALT flares using this definition occurred; characteristics of 
patients experiencing an ALT flare were generally similar to those seen using the 
definition in the main analyses (Table 6.3.9.1.1). Patients in this analysis did have a 
higher VL at the time of the flare (400 vs. 368 copies/mL in the main analysis), were 
more likely to be HCV-positive (24.2% vs. 21.9% in the main analysis) and, as 
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expected, had a longer flare duration (median 4.8 vs. 3.7 months in the main 
analysis) than those patients included in the main analyses. 
 
Table 6.3.9.1.1: Characteristics of patients at the time of each ALT flare 
Total number of patients N 17634 
No. of patients with flare N (%) 644 (3.7) 
No. of episodes N 803 
Age at start of flare (years) Median (IQR) 39 (34, 44) 
CD4 count at start of flare (cells/mm3) Median (IQR) 370 (210, 540) 
Viral load at start of flare (copies/mL) Median (IQR) 400 (50, 29200) 
Sex N (%) Males 745 (92.8) 
 Females 58 (7.2) 
Ethnicity N (%) White 663 (82.6) 
 Black 43 (5.4) 
 Other 97 (12.1) 
Exposure N (%) Homosexual 603 (75.1) 
 Heterosexual  91 (11.3) 
 Other 109 (13.6) 
No. of prior ALT measurements  Median (IQR) 13 (5, 26) 
Duration between ALT measurements 
before starting HAART (months) 
Median (IQR)  2.0 (0.9, 3.5) 
Duration between ALT measurements after 
starting HAART (months) 
Median (IQR)  2.0 (1.5, 2.8) 
HCV-positive1 prior to flare N (%) 194 (24.2) 
HBV-positive prior to flare N (%) 132 (16.4) 
Duration between ALT measurements 
amongst HCV-negative patients (months) 
Median (IQR) 2.3 (1.5, 3.1) 
Duration between ALT measurements 
amongst HCV-positive patients (months) 
Median (IQR) 2.1 (1.4, 2.8) 
Maximum ALT measurement (IU) Median (IQR) 521 (357, 945) 
Duration of flare (months) Median (IQR)  4.8 (3.1, 8.0) 
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Defined from date of first positive test  
 
6.3.9.2. Events, person-years and rates (95% CI) of ALT flares  
The overall rate of an ALT flare using this definition was 0.80 (0.74, 0.85) / 100 pys. 
As expected, this was somewhat lower that seen in the main analysis (1.02/100 
pys). As before, patients who were HBV/HCV-positive had higher rates of ALT flares 
than those who were HBV/HCV-negative/unknown, though amongst the positive 
group, HAART-experienced patients had lower rates than HAART-naïve patients 
(Table 6.3.9.2.1). There was little difference in the rate of ALT flares between 
HAART-naive and HAART-experienced patients in the HBV/HCV-negative group. 
Since the overall rate of an ALT flare was lower in these analyses, the group-
specific rates were also lower compared to the main analyses. Crude rates for other 
variables are shown in Table 6.3.9.2.2. Again, in general, the rates were lower, but 
were in line with the findings in the main analyses. 
AIDS within 6 weeks after flare Yes 265 (33.0) 
HAART regimen  d4T/ddI without 
NVP 
153 (19.1) 
 d4T/ddI with NVP 67 (8.3) 
 NVP without 
d4T/ddI 
79 (9.8) 
 Other regimens 261 (32.5) 
 Currently off 
treatment 
243 (30.3) 
 Any RTV 218 (27.1) 
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Table 6.3.9.2.1: Events, person-years and rates (95% CI) of ALT flares (2 consecutive ALTs >200 IU, >30 days apart) stratified by 
hepatitis status1 and HAART status 
 All HBV/HCV-negative/unknown HBV/HCV-positive 
  HAART-naive HAART-experienced HAART-naive HAART-experienced 
Events 803 110 300 129 264 
Person-years 100881 24132 63088 3218 10443 
Rate (95% CI) /100 
person years 
0.80 (0.74, 0.85) 0.46 (0.37, 0.54) 0.48 (0.42, 0.53) 4.00 (3.32, 4.70) 2.53 (2.83, 2.53) 
1 
Patients defined as positive from first date of positive test result 
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Table 6.3.9.2.2: Events, person-years and crude rates (95% CI) of ALT flares (2 
consecutive ALTs >200 IU, >30 days apart) 
 Person years Events Rate (95% CI) 
Total  803/100881 0.80 (0.74, 0.85) 
Current age (years) >35 253/28011 0.90 (0.7, 1.02) 
 35-50 392/46227 0.85 (0.76, 0.93) 
 >50 158/26642 0.59 (0.50, 0.69) 
Current CD4 count  <200 182/14011 1.30 (1.11, 1.49) 
(cells/mm3) 200-349 175/24354 0.72 (0.61, 0.83) 
 350-449 178/25738 0.69 (0.59, 0.79) 
 >500 249/35762 0.70 (0.61, 0.78) 
 Missing  19/1016 1.87 (1.03, 2.71) 
Nadir CD4 count <50 174/18693 0.93 (0.79, 1.07) 
(cells/mm3) 50-199 279/36883 0.76 (0.67, 0.85) 
 200-349 196/25972 0.76 (0.65, 0.86) 
 >350 135/18317 0.74 (0.61, 0.86) 
 Missing 19/1016 1.87 (1.03, 2.71) 
Current viral load <50 269/49868 0.54 (0.48, 0.60) 
(copies/mL) >50 455/46950 0.97 (0.88, 1.06) 
 Missing 79/4063 1.94 (1.52, 2.37) 
Current calendar year 1996-2000 287/23657 1.21 (1.07, 1.35) 
 2001-2004 310/41001 0.76 (0.67, 0.84) 
 >2005 206/36223 0.57 (0.49, 0.65) 
Sex N (%) Males 745/84222 0.89 (0.82, 0.95) 
 Females 58/16659 0.35 (0.26, 0.44) 
Ethnicity N (%) White 663/72470 0.92 (0.85, 0.99) 
 Black 62/17619 0.35 (0.26, 0.44) 
 Other 78/10792 0.72 (0.56, 0.88) 
Exposure N (%) Homosexual 603/68420 0.88 (0.81, 0.95) 
 Heterosexual  91/22130 0.41 (0.33, 0.50) 
 Other 109/10331 1.06 (0.86, 1.25) 
No. of prior ALT  <10 333/41146 0.81 (0.72, 0.90) 
measurements 10-20 204/27949 0.73 (0.63, 0.83) 
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 >20 266/31786 0.84 (0.74, 0.94) 
HCV status at flare  Positive 188/5971 3.15 (2.70, 3.60) 
 Negative 314/56389 0.56 (0.50, 0.62) 
 Unknown 301/38521 0.78 (0.69, 0.87) 
HBV status at flare Positive 130/8690 1.50 (1.24, 1.75) 
 Negative 423/60947 0.69 (0.63, 0.76) 
 Unknown 250/31244 0.80 (0.70, 0.90) 
Time since start of  HAART-naive 245/28519 0.86 (0.75, 0.97) 
HAART < 3 years  315/29440 1.07 (0.95, 1.19) 
 > 3 years 243/42921 0.57 (0.50, 0.64) 
AIDS diagnosis at time  Yes 256/25516 1.00 (0.88, 1.13) 
of flare No 547/75365 0.73 (0.67, 0.79) 
HAART regimen  No d4T/ddI/NVP 236/33543 0.70 (0.61, 0.79) 
 d4T/ddI with NVP 70/5463 1.28 (0.98, 1.58) 
 NVP without d4T/ddI 75/10894 0.69 (0.53, 0.84) 
 d4T/ddI without NVP 179/19427 0.92 (0.79, 1.06) 
 Currently off 
treatment 
243/31554 0.77 (0.67, 0.87) 
Any prior RTV  Yes 210/21866 0.96 (0.83, 1.09) 
experience No 593/79015 0.75 (0.69, 0.81) 
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6.3.9.3. Factors associated with ALT flares (2 consecutive ALTs >200 IU, 
>30 days apart) 
Table 6.3.9.3.1 shows factors associated with ALT flares in unadjusted and adjusted 
analyses. In unadjusted analyses, trends were in line with those seen in the main 
analyses, with estimates generally being very close to those seen in Table 6.3.8.4.1 
(albeit less precise). Estimates were slightly stronger for positive HCV status (5.65 
(4.72, 6.77) compared to 4.97 (4.23, 5.84) in the main analysis), though the 
confidence intervals did overlap.  
 
In adjusted analyses, though estimates were in the same direction as those seen in 
the main analyses, they were generally weaker. However, the rate ratio for positive 
HCV status was again stronger than that seen in the main analyses (5.53 (4.54, 
6.75) vs. 4.99 (4.18, 5.96) in the main analysis).  
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Table 6.3.9.3.1: Factors associated with experiencing an ALT flare (2 consecutive ALTs>200 IU, > 30 days apart) from adjusted and 
unadjusted Poisson regression analyses  
  Unadjusted RR (95% CI)1 Adjusted RR (95% CI) 
  RR (95% CI) P-value RR (95% CI) P-value 
Current age (years) >35 1 - 1 - 
 35-50 0.94 (0.80, 1.10) 0.43 0.90 (0.76, 1.07) 0.23 
 >50 0.66 (0.54, 0.80) <0.0001 0.66 (0.53, 0.82) 0.0001 
Current CD4 count  <200 1.87 (1.54, 2.26) <0.0001 1.16 (0.89, 1.51) 0.26 
(cells/mm3) 200-349 1.03 (0.85, 1.25) 0.75 0.83 (0.66, 1.04) 0.10 
 350-449 0.99 (0.82, 1.20) 0.95 0.89 (0.73, 1.09) 0.25 
 >500 1 - 1 - 
 Missing  2.69 (1.68, 4.28) <0.0001 Excluded 
Nadir CD4 <50 1.26 (1.01, 1.58) 0.04 0.92 (0.65, 1.29) 0.62 
 50-199 1.03 (0.84, 1.26) 0.80 0.96 (0.72, 1.28) 0.77 
 200-349 1.02 (0.82, 1.27) 0.83 1.04 (0.81, 1.34) 0.75 
 >350 1 - 1 - 
 Missing  2.54 (1.57, 4.10) 0.0001 Excluded 
Current viral load <50 1 - 1 - 
(copies/mL) >50 1.80 (1.55, 2.09) <0.0001 1.99 (1.65, 2.39) <0.0001 
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 Missing 3.60 (2.80, 4.63) <0.0001 3.74 (2.67, 5.25) <0.0001 
Current calendar year 1996-2000 2.13 (1.78, 2.55) <0.0001 1.15 (0.90, 0.46) 0.26 
 2001-2004 1.33 (1.11, 1.59) 0.002 1.16 (0.96, 1.40) 0.13 
 >2005 1 - 1 - 
Sex  Male 1 - 1 - 
 Female 0.39 (0.30, 0.51) <0.0001 0.46 (0.33, 0.64) <0.0001 
Ethnicity  White 1 - 1 - 
 Black 0.38 (0.30, 0.50) <0.0001 0.58 (0.42, 0.79) 0.001 
 Other 0.79 (0.62, 1.00) 0.05 0.86 (0.68, 1.10) 0.23 
Exposure  Homosexual 1 - 1 - 
 Heterosexual  0.47 (0.37, 0.58) <0.0001 0.90 (0.67, 1.20) 0.47 
 Other 1.20 (0.98, 1.47) 0.08 0.78 (0.61, 0.90) 0.03 
No. of prior ALT  <10 1 - 1 - 
measurements 10-20 0.90 (0.76, 1.07) 0.25 1.09 (0.90, 1.31) 0.37 
 >20 1.03 (0.88, 1.21) 0.68 1.34 (1.10, 1.64) 0.004 
HCV status prior to flare  Negative 1 - 1 - 
 Positive 5.65 (4.72, 6.77) <0.0001 5.53 (4.54, 6.75) <0.0001 
 Unknown 1.40 (1.20 1.64) <0.0001 1.12 (0.91, 1.37) 0.29 
HBV-positive prior to flare  Negative 1 - 1 - 
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 Positive 2.16 (1.77, 2.63) <0.0001 1.63 (1.33, 2.00) <0.0001 
 Unknown 1.15 (0.99, 1.35) 0.07 1.20 (0.98, 1.46) 0.07 
Time since start of HAART HAART-naive 1 - 1 - 
 < 3 years  1.25 (1.05, 1.47) 0.01 1.18 (0.91, 1.52) 0.22 
 > 3 years 0.66 (0.55, 0.79) <0.0001 0.61 (0.45, 0.82) 0.001 
AIDS diagnosis prior to flare  Yes 1.38 (1.19, 1.60) <0.0001 1.26 (1.06, 1.50) 0.01 
HAART regimen  No d4T/ddI/NVP 1 - 1 - 
 d4T/ddI with NVP 1.82 (1.39, 2.38) <0.0001 1.67 (1.26, 2.21) 0.0004 
 NVP without d4T/ddI 0.98 (0.75, 1.27) 0.87 1.43 (1.09, 1.87) 0.01 
 d4T/ddI without NVP  1.31 (1.08, 1.59) 0.01 1.00 (0.81, 1.23) 0.98 
 Currently off treatment 1.09 (0.92, 1.31) 0.32 0.73 (0.56, 0.96) 0.02 
Any prior RTV experience  Yes 1.28 (1.09, 1. 05) 0.002 1.60 (1.32, 1.93) <0.0001 
1 
RR: rate-ratios, CI: confidence interval  
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6.3.10. Comparing the derived definition of an ALT flare to a commonly 
used definition in the literature (1 ALT >200 IU) 
Using the single ALT >200 IU definition for an ALT flare (commonly used in the 
literature; Chapter 2.2.1), 2280 patients had experienced at least one ALT flare, 
contributing 3,602 episodes of ALT flares to the analysis. The overall rate of an ALT 
flare using this definition was 3.60 (3.48, 3.71)/100 pys. This was considerably 
higher than the rate calculated when using the 2 consecutive ALTs >200 IU, >14 
days apart‟ definition. Table 6.3.10.1 shows factors independently associated with 
ALT flares when using the 1 ALT >200 IU definition and when using the 2 
consecutive ALTs >200 IU, >14 days apart definition. Stronger associations were 
seen between current CD4 count and ALT flares when using the 1 ALT >200 IU 
definition (1.75 (1.54, 1.98) comparing CD4 <200 cells/mm3 to CD4 >500 cells/mm3 
compared to 1.31 (1.04, 1.65) when using the derived definition) and weaker 
associations were seen between positive HCV status and ALT flares (3.41 (3.07, 
3.78) compared to 4.99 (4.18, 5.96) using the derived definition). Weaker 
associations were also seen between current regimen and ALT flares when using 
the 1 ALT >200 IU definition.  
 
Given the stronger associations seen between CD4 count and ALT flares when 
using the 1 ALT >200 IU definition, the frequency of CD4 measurements was 
calculated for patients with an ALT flare and for those who did not experience an 
ALT flare (using the 1 ALT >200 IU definition).  Patients experiencing an ALT flare 
had a median 31 (18, 44) CD4 measurements during follow-up, whilst those not 
experiencing an ALT flare had a median 19 (8, 31) CD4 measurements during 
follow-up. Since data on patient visits is not collected in the UK CHIC Study, CD4 
counts can be used as a surrogate marker for patient visits. This suggests that 
patients with ALT flares may have been monitored more frequently than those 
without ALT flares and it is possible that the association between CD4 count and 
risk of flares using the 1 ALT >200 IU definition could simply be explained by this 
difference in monitoring. 
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Table 6.3.10.1: Adjusted rate ratios of ALT flares in the whole population using 2 different definitions of an ALT flare using a Poisson 
regression model 
  1 ALT >200 IU 2 ALTs >200 IU, >14 days apart 
  RR (95% CI) P-value RR (95% CI) P-value 
Current age (years) >35 1 - 1 - 
 35-50 0.93 (0.86, 1.00) 0.01 0.95 (0.82, 1.11) 0.53 
 >50 0.74 (0.67, 0.82) <0.001 0.81 (0.67, 0.97) 0.02 
Current CD4 count  <200 1.75 (1.54, 1.98) <0.0001 1.31 (1.04, 1.65) 0.02 
(cells/mm3) 200-349 1.06 (0.94, 1.18) 0.27 0.92 (0.75, 1.12) 0.41 
 350-449 0.95 (0.86, 1.05) 0.79 0.93 (0.78, 1.12) 0.45 
 >500 1 - 1 - 
Nadir CD4 <50 0.95 (0.80, 1.12 0.51 0.86 (0.63, 1.17) 0.33 
 50-199 0.95 (0.83, 1.10) 0.52 0.92 (0.71, 1.18) 0.51 
 200-349 1.02 (0.90, 1.15) 0.79 1.00 (0.80, 1.24) 0.97 
 >350 1 - 1 - 
Current viral load <50 1 - 1 - 
(copies/mL) >50 1.55 (1.42, 1.70) <0.0001 1.82 (1.54, 2.14) <0.0001 
 Missing 2.88 (2.47, 3.37) <0.0001 3.50 (2.60, 4.72) <0.0001 
Current calendar year 1996-2000 1.59 (1.42, 1.79) <0.0001 1.16 (0.98, 1.37) 0.08 
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 2001-2004 1.34 (1.22, 1.48) <0.0001 1.16 (0.98, 1.37) 0.09 
 >2005 1 - 1 - 
Sex  Male 1 - 1 - 
 Female 0.62 (0.54, 0.71) <0.0001 0.49 (0.37, 0.65) <0.0001 
Ethnicity  White 1 - 1 - 
 Black 0.69 (0.60, 0.78) <0.0001 0.64 (0.49, 0.84) 0.001 
 Other 0.94 (0.84, 1.05) 0.28 0.96 (0.78, 1.18) 0.72 
Exposure  MSM 1 - 1 - 
 Heterosexual  1.08 (0.95, 1.23) 0.24 0.91 (0.70, 1.17) 0.45 
 Other 0.91 (0.82, 1.02) 0.11 0.71 (0.57, 0.88) 0.002 
No. of prior ALT  <10 1 - 1 - 
measurements 10-20 1.21 (1.11, 1.32) <0.0001 1.09 (0.93, 1.28) 0.30 
 >20 1.61 (1.46, 1.77) <0.0001 1.32 (1.10, 1.55) 0.002 
HCV status prior to flare  Negative 1 - 1 - 
 Positive 3.41 (3.07, 3.78) <0.0001 4.99 (4.18, 5.96) <0.0001 
 Unknown 1.04 (0.95, 1.14) 0.40 1.01 (0.85, 1.21) 0.90 
HBV-positive prior to flare  Negative 1 - 1 - 
 Positive 1.64 (1.49, 1.81) <0.0001 1.73 (1.45, 2.07) <0.0001 
 Unknown 1.17 (1.07, 1.28) 0.001 1.26 (1.06, 1.50) 0.01 
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Time since start of HAART HAART-naive 1 - 1 - 
 < 3 years  1.10 (0.97, 1.24) 0.12 1.14 (0.91, 1.44) 0.26 
 > 3 years 0.63 (0.55, 0.72) <0.0001 0.62 (0.47, 0.80) 0.0003 
AIDS diagnosis prior to flare  Yes 1.20 (1.11, 1.31) <0.0001 1.16 (0.99, 1.36) 0.06 
HAART regimen  No d4T/ddI/NVP 1 - 1 - 
 d4T/ddI with NVP 1.40 (1.22, 1,61) <0.0001 1.73 (1.34, 2.24) <0.0001 
 NVP without d4T/ddI 1.18 (1.03, 1.35) 0.02 1.50 (1.18, 1.92) 0.001 
 d4T/ddI without NVP  1.06 (0.97, 1.17) 0.21 1.22 (1.02, 1.47) 0.03 
 Currently off treatment 0.87 (0.77, 0.98) 0.02 0.82 (0.65, 1.04) 0.10 
Any prior RTV experience  Yes 1.35 (1.23, 1.48) 0.001 1.58 (1.34, 1.87) <0.0001 
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6.3.10.1. Association between ALT flares and mortality 
In total, 1666 (9.5%) patients died after having previously had at least one ALT 
measurement. Patients were stratified according to whether or not they experienced 
an ALT flare using both the derived definition (2 consecutive ALTs >200 IU, >14 
days apart) and the standard definition (1 ALT>200 IU). Kaplan-Meier plots stratified 
by whether or not patients had a flare are shown in Figure 6.3.10.1.1 and in Figure 
6.3.10.1.2. When using the derived definition of an ALT flare, no difference in 
mortality rates were seen amongst those who did experience an ALT flare and those 
who did not (log-rank p=0.86). Mortality rates at 1 year, 3 years, 5 years and 10 
years after the first ALT measurement were 3.2%, 6.2%, 8.6% and 14.6% 
respectively for those who did not experience an ALT flare and 0.5%, 4.9%, 8.0% 
and 15.5% respectively for those who did experience an ALT flare.  
 
However, when using the standard definition of an ALT flare found in the literature (1 
ALT >200 IU), patients who experienced ALT flares were found to be at increased 
risk of death than those who did not experience an ALT flare (p<0.0001). Mortality 
rates at 1 year, 3 years, 5 years and 10 years after the first ALT measurement for 
these patients were 3.1%, 5.9%, 8.2% and 13.8% respectively for those who did not 
experience an ALT flare and 3.2%, 7.5%, 10.9% and 19.1% respectively for those 
who did experience an ALT flare. 
 
The association between current ALT flares (time-updated) and death was explored 
using Cox regression. In unadjusted analyses, patients with an ALT flare using the 
standard definition of 1 ALT >200 IU were over 3 times more likely to die than those 
who did not have an ALT flare (HR=3.73 (2.92, 4.76)). However, when using the 
derived definition, the hazard ratio was reduced to 1.97 (1.12, 3.48). After adjusting 
for potential confounders, using the standard definition of an ALT flare, patients 
experiencing ALT flares were still at an increased risk of death than those without 
ALT flares (2.10 (1.62, 2.72)).  Using the derived definition of an ALT flare, this 
association was no longer significant (1.27 (0.71, 2.26)).  
 
Interestingly, monitoring bias did not appear to explain the difference in hazard 
ratios seen above. Patients who died did have fewer CD4 counts than those who did 
not die (median 8 vs. 19) though this can be explained by the longer follow-up time 
in the latter period. The median number of CD4 counts per year was similar in both 
groups (4.0 (3.1, 5.0) and 4.0 (2.1, 5.9) amongst those who did not die and those 
who died respectively). The absolute number of ALT measurements was also similar 
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amongst those who did not die (16 (67, 29)) and those who died (15 (6, 32)). 
However, the difference in the average number of ALT measurements per year in 
the two groups suggested that monitoring bias may partly explain the difference in 
hazard-ratios for death when using different definitions of ALT flares. Patients who 
did not die had a median 4 (2, 5) ALT measurements per year, whilst those who did 
die had a median 7 (4, 17) measurements per year. This suggests that the sickest 
patients (i.e. those who eventually died) were being monitored more frequently and 
were hence more likely to have a single ALT >200 IU recorded.    
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Figure 6.3.10.1.1: Kaplan Meier estimates of the proportion of patients who 
died after their first ALT measurement, stratified by whether or not they had a 
flare (2 ALTs >200 IU, >14 days apart) 
 
 
Figure 6.3.10.1.2: Kaplan Meier estimates of the proportion of patients who 
died after their first ALT measurement, stratified by whether or not they had a 
flare (1 ALT >200 IU) 
0
0.05
0.1
0.15
0.2
0.25
0 2 4 6 8 10 12
Years since first ALT measurement
C
u
m
u
la
ti
v
e
 %
No flare
Flare
 
  
  
  
0 
0.05 
0.1 
0.15 
0.2 
0.25 
0 2 4 6 8 10 12 
Years since first ALT measurement 
C
u
m
u
la
ti
v
e
 %
 
No flare 
Flare 
r  since first ALT measur ment 
meemmeasurement 
   243 
 
 
6.4. Discussion 
Though one ALT measurement above 200 IU is frequently used as an indication of 
an ALT rise in the HIV treated population, it is not known whether such an increase 
is a genuine reason for concern, or whether it is a random fluctuation, possibly due 
to non-treatment related events/chance alone. In this Chapter, I first justified the 
need for the definition of an ALT flare to be derived from untreated HBV/HCV-
negative patients. HAART-experienced patients, and those with positive HBV/HCV 
status experienced greater ALT rises than HAART-naive patients and this was 
confirmed by a series of descriptive analyses. Using data from untreated HBV/HCV-
negative patients, I established that up to 4.1% (depending on how HBV/HCV-
positive is defined) of patients also experience single ALT values above this limit 
(200 IU). Furthermore, patients may experience such rises on multiple occasions, 
suggesting that rather than reflecting a genuine adverse effect of treatment, many of 
these episodes may be due to another cause or may be random ALT fluctuations. 
 
The derived definition of an ALT flare of 2 consecutive measurements >200 IU, at 
least 2 weeks apart is more stringent than the standard definition of only 1 ALT >200 
IU and hence it is less likely that random fluctuations will be defined as flares. The 
definition based on confirmed values above a threshold is likely to be more accurate 
than that based on a single value. The 2 week duration was chosen for several 
reasons outlined in sub-section 6.3.7, but it also mirrors clinical practice, to the 
extent that the occurrence of such laboratory abnormalities is likely to prompt an 
early repeat test. Using this definition, I found that 4.6% of all patients, including 
those who were HAART-experienced and/or HBV/HCV-positive, with at least two 
ALT measurements experienced one or more ALT flares. Cicconi et al. in 2007 
reported a slightly higher percentage (5.2%), most likely due to both their different 
definition of an ALT flare (>3.5 times the baseline ALT value) and the higher 
prevalence of HCV-positive patients in Italy (287). Many studies focus only on 
treatment-experienced patients; using the derived definition, 5% of treatment-
experienced patients had an ALT flare.  Whilst this was somewhat in line with 
estimates from some studies (281;308;316), it was lower than that reported in others 
(275;285;315).   
 
Patients who experienced an ALT flare in these analyses were generally males, of 
white ethnicity and MSM risk group, in line with the demographics of the CHIC 
dataset as a whole. There was no difference in the duration between ALT 
measurements amongst HAART-naive and HAART-experienced patients, 
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suggesting that the decision to perform an ALT test was not dependent on whether 
or not patients had started HAART. However, ALT tests were performed more often 
on HCV-positive patients than HCV-negative patients, possibly reflecting more 
frequent monitoring in the HCV-positive population.  
 
Interestingly, crude rates of ALT flares amongst those co-infected with HBV/HCV 
were lower amongst treatment-experienced patients than those who were treatment 
naïve. One possible reason for this is that naïve patients tend to have lower CD4 
counts and this, in turn, may be associated with a higher risk of liver disease (305). 
Though there was no significant interaction between treatment status and CD4 
count, it is possible that there was not enough power to detect such an interaction 
and there may have been a stronger association between CD4 count and ALT flares 
amongst HAART-naive patients than HAART-experienced patients. Other studies 
have reported such an association between CD4 count and liver disease, albeit 
using different definitions of liver disease (312;313). Low CD4 counts have also 
been reported to be associated with death from liver disease (310). A second 
possible explanation is that ART experienced patients may have been exposed to 
drugs such as lamivudine and emtricitabine which are known to have activity against 
HBV, which may reduce the apparent impact of HBV on ALT levels.    
 
In multivariable analyses, patients taking NVP (either with ddI/d4T or without) and 
those taking RTV were at increased risk of ALT flares, consistent with results from 
other studies (272;276).  Both positive HCV and HBV status were associated with 
ALT flares and this too has been well documented (269;270;286). However, unlike 
findings reported by Cicconi et al (287) a significant interaction between hepatitis 
status and current regimen was identified. A stronger association between positive 
HCV status and ALT flares was seen amongst patients receiving treatment, 
regardless of which ART drugs were being received, than amongst those currently 
not receiving treatment. Though this does suggest that the effect of HAART on ALT 
flares is stronger amongst the HCV-positive patient population than the HCV-
negative population, a third of HCV-positive patients were not receiving any 
treatment at the time of the ALT flare, which may also impact on this finding.  
 
Patients who were on treatment for longer periods of time were less likely to have 
ALT flares, unlike Martinez et al. who found the risk of an ALT flare was increased 
by 10% (p=0.02) for each additional year since starting treatment (275). This 
difference is likely to be explained by the inclusion criteria applied in the latter study; 
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patients were required to have started NVP-based HAART and NVP was found to 
be a risk factor for ALT flares in our study.  
 
The risk of an ALT flare was lower amongst patients of older age, those with 
undetectable viral loads and those with higher current CD4 counts. These findings 
are consistent with other studies (313-315). Though the effect of nadir CD4 count 
was significant in univariable analyses, it ceased to be signifcant after adjustment for 
current CD4 count, suggesting the latter is a stronger predictor of ALT flares. The 
effect of calendar year was also not signficant after adjusting for other variables, 
albeit there being a trend towards a higher risk of ALT flares in earlier calendar 
years. This is likely to be due to improved toxicities of antiretroviral drugs in later 
calendar years, and the reduced usage of drugs such as d4T and ddI which are 
known to be associated with ALT flares.  
 
Patients with a higher number of prior ALT measurements were at an increased risk 
of an ALT flare. These patients were likely to have been closely monitored in 
anticipation of ALT rises and were perhaps also more likely to be HCV-positive, 
given the shorter duration between ALT measurements amongst HCV-positive 
patients discussed earlier in this Section.  
 
In sensitivity analyses, a more stringent definition of an ALT flare was applied, such 
that the duration between the 2 consecutive ALTs >200 IU was required to be at 
least 30 days apart. Although trends were generally in line with those seen in the 
main analysis, a stronger association was observed between HCV-positive status 
and ALT flares. This implies that HCV-positive patients experience flares of longer 
duration than HCV-negative patients, and therefore perhaps of greater severity.  
 
The main limitation of these analyses is that it is not possible to control for 
unmeasured confounding, such as that resulting from alcohol consumption, which 
has been reported as predictive of ALT flares (307). The UK CHIC dataset also does 
not yet have information on other non-HIV related drugs that may have an impact on 
ALT levels, such as acetaminophen. However, this is unlikely to affect the 
conclusions when comparing the different definitions of an ALT flare. Comparing the 
derived definition of an ALT flare to that usually reported in the literature highlights 
the importance of differentiating between ALT flares and isolated ALT elevations. 
The stronger relationships seen between CD4 count and ALT flares when using a 
wider, less stringent definition of an ALT flare may lead to unnecessary concern by 
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both clinicians and patients when analysing CD4 count, whilst the role of treatment 
regimen, viral load and hepatitis status may not be given enough significance.  
In particular, these issues accentuate the need to consider monitoring bias when 
analysing outcomes such as ALT flares, as associations between known risk factors 
may be under- or over-estimated if using a definition based on a single ALT value. In 
these analyses, patients with ALT flares had a higher number of CD4 
measurements during follow-up than those without ALT flares, suggesting that 
patients with flares were likely to be more closely monitored than those without 
flares. Hence, the probability of patients having a lower CD4 count at the time of the 
flare is likely to be greater amongst patients who do experience ALT rises.  
 
All-cause mortality was only significantly associated with ALT flares when using the 
1 ALT >200 IU definition, and not when using the derived definition. This was true 
when categorising patients as ever experiencing a flare/not experiencing a flare, as 
well as when analysing flares as a time-updated variable. Given that a single ALT 
value >200 IU was strongly associated with mortality, further work is required to 
assess the reasons why the derived definition was not as strong a predictor of 
mortality as the standard definition of an ALT flare. In hindsight, I would have 
performed the mortality analyses in the first instance, i.e. exploring differing 
definitions of ALT flares as shown in the first part of this chapter as predictors of 
mortality. This would result in a definition of an ALT flare which was focussed 
around a strong clinical endpoint. However, the current method used does have the 
advantage of detailed descriptive analyses. Analyses on all-cause mortality are 
likely to lack specificity, resulting in weaker associations with variables such as ALT. 
Data on all-cause mortality are poor; causes of death are often not provided and 
hence it is difficult to distinguish liver-related mortality from other causes. Another 
issue with analyses surrounding all-cause mortality is that if ALT levels are elevated, 
clinicians are likely to intervene and therefore prevent death. Hence death itself is 
unlikely to capture all liver associated problems. Finally, the number of deaths in the 
UK CHIC cohort is relatively low and therefore it is likely that all-cause mortality 
analyses are lacking in power.    
 
In conclusion, the findings presented in this chapter do suggest that in cases where 
new solitary ALT measurements >200 IU are measured, a second test should be 
performed to confirm the measurement. The use of two consecutive ALTs >200 IU, 
measured >2 weeks apart, may more reliably identify the causes and significance of 
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ALT elevations and may prove more useful in exploring liver function tests 
abnormalities. 
 
6.5. Summary 
The definition of an ALT flare in the current literature varies, though there is 
emphasis on a definition based on a single ALT >200 IU. In this chapter, I have 
shown that such a definition may not represent a genuine ALT flare, but rather 
random fluctuations in ALT. Using data from HAART-naïve, HBV/HCV-negative 
patients, I derived an alternative definition of an ALT flare; 2 consecutive ALT 
measurements >200 IU, at least 2 weeks apart. Factors associated with this 
proposed definition were compared to those associated with the standard definition 
in the literature. CD4 count was found to be a stronger predictor of ALT flares using 
the standard definition, whilst weaker associations were seen between treatment 
regimen, current viral load and hepatitis status and ALT flares, compared to those 
when using the derived definition. The association between ALT flares and all-cause 
mortality was also accentuated when using the standard definition of an ALT flare. 
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Chapter 7: The impact of increased duration of viral 
suppression, prior treatment failures and prior 
treatment interruptions on viral rebound rates 
amongst patients with viral suppression 
7.  
  
7.1. Introduction 
The ultimate goal of HAART is to fully suppress HIV replication, currently judged as 
attaining a plasma viral load of less than 50 copies/mL, as this minimizes the risk of 
resistance evolution and results in the greatest potential for immune recovery (482). 
Viral rebound is often associated with emergence of HIV with resistance (260;513). 
With accumulating regimen failures, the attainment of full viral suppression becomes 
more difficult (514), and failure to achieve this  can result in immunological decline 
(515).  Factors associated with an increased rate of viral rebound include pre-
HAART use of NRTIs as single or dual therapy (413;414;417;418;430;516), use of 
particular antiretroviral drugs (422;430) and poor adherence to medication (412). 
Lower rates of viral rebound have also been reported with increased duration of 
virological suppression (413;414;517). In the EuroSIDA cohort in 2,444 patients, the 
overall rate of viral rebound during the first six months after initial full suppression 
was 33.5/100 pys follow-up, compared with 8.6/100 pys in those who were 
suppressed for greater than 24 months (430). 
 
Whilst the number of patients interrupting treatment may have declined since 
findings of an increased risk of clinical progression in patients who interrupt therapy 
(449), patients continue to consider the option of temporarily discontinuing 
treatment, largely with the aim of minimising the unwanted side effects and/or 
inconvenience of HAART.  It has been shown that patients who have interrupted 
HAART have a raised risk of drug resistance and increased immuno-suppression 
(439;440;455;459;460;518-521), though many patients are able to suppress viral 
load upon restarting therapy (445;450;451).  
However, the risk of subsequent viral rebound in these patients has not been 
previously explored. If resistant virus has emerged following treatment interruptions 
this may have been archived in latently infected cells and might only emerge at 
some later time point when such cells become activated. The association between 
pre-HAART use of nucleoside mono or dual therapy and a raised risk of rebound in 
people with viral suppression is likely to be due to such a mechanism.  
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In this Chapter, I will investigate the frequency of treatment interruptions amongst 
patients who have started HAART, and will determine whether prior episodes of 
treatment interruptions are associated with a raised risk of viral rebound in 
individuals who have attained virological suppression. I will also determine whether 
the rate of viral rebound decreases with increasing duration of viral suppression 
regardless of prior failure and, if so, whether rebound rates in patients who have 
previously failed one or more regimens ultimately decline to levels as low as those 
seen in patients receiving first-line therapy if they are able to re-suppress viral load 
on a new regimen.   
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7.2. Methods 
 
7.2.1. Proportion of time spent on treatment amongst all patients and 
description of treatment interruptions amongst patients who had 
started HAART 
The proportion of follow-up time spent on treatment was calculated for all patients, 
by dividing the time spent on treatment by the number of days patients were under 
follow-up. These analyses were stratified by calendar year in order to distinguish 
whether the results of the SMART Study had influenced the proportion of time spent 
receiving treatment. Amongst patients who had started HAART, the number of 
interruptions, the regimen interrupted (NNRTI/PI/r/PI/Other) and the regimen 
restarted were described. The viral load and CD4 count at time of interruption was 
also calculated. 
   
7.2.2. Selection of patients for inclusion in viral rebound analysis 
In the main analysis, all patients who achieved a viral load of <50 copies/mL while 
receiving HAART (defined as any treatment combination including three or more 
drugs) were eligible to enter the analyses. Differences between patients receiving 
HAART and achieving an undetectable viral load and those receiving HAART and 
not achieving an undetectable viral load were described using Chi-squared and 
Mann Whitney tests. 
Patients were followed from the date when their viral load first fell below 50 
copies/mL while on HAART until the time of viral rebound (defined as two 
consecutive viral load values >400 copies/mL or one viral load value >400 
copies/mL followed by starting two or more new drugs).  Patient follow-up was 
censored (i.e. patients were removed from the risk set for the analysis) prior to this 
point if the patient discontinued or reduced HAART to fewer than three drugs, or on 
the date of the patient‟s last viral load. Patients who experienced viral rebound or 
whose follow-up was censored on discontinuation/reduction of HAART re-entered 
the analysis if they subsequently re-suppressed their viral load to <50 copies/mL. 
The rate of viral rebound was calculated by dividing the total number of events (viral 
rebounds) by the person time spent in a particular category. 
 
7.2.3. Defining failure history at the start of each period of suppression 
At the start of each period of viral suppression, the patient‟s viral failure history was 
assessed and the patient was categorised as having experienced virological failure 
to 0, 1, 2, 3, or 4 or more prior regimens.  Patients who were antiretroviral naïve 
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when they started HAART and those with pre-HAART NRTI exposure were 
included. Any treatment taken before January 1996 counted as having failed one 
regimen, regardless of viral load.  From January 1996, having a viral load of ≥400 
copies/mL, whilst receiving any treatment and not having been off treatment in the 
previous 4 months counted as a regimen failure. Each time a viral load of ≥400 
copies/mL was obtained whilst being on a regimen containing at least one drug (and 
having been on that drug for over 4 months) that the patient had not previously 
failed was counted as an additional regimen failure.  Patients who had temporarily 
been removed from the risk set after discontinuing HAART were not classified as 
having failed that regimen as long as they had not met the definition of failure at the 
time of discontinuation; thus, if these patients subsequently re-entered the analysis 
their number of failed regimens remained unchanged.  Patient follow-up in the 
analysis was stratified according to the length of time a patient‟s viral load had been 
suppressed in the current episode of viral suppression; for individuals re-entering 
the risk set after treatment discontinuation/reduction, the clock was reset such that 
this length started once again from zero. Thus each patient could contribute multiple 
viral suppression episodes to the analysis. The allocation of pys is further described 
in Figure 7.2.4.1.   
 
7.2.4. Statistical methods 
The relationship between the duration of each viral suppression episode, calendar 
year of entry into a viral suppression episode and number of regimens previously 
failed was analysed by stratifying the crude rates of viral rebound by the number of 
regimens previously failed and the duration of viral suppression/calendar year of 
entry into a viral suppression episode. Poisson regression was used to determine 
the impact of the duration of viral suppression, the number of previous regimens 
failed and the number of prior treatment interruptions (discontinuation of all therapy 
for at least 2 weeks, followed by restart of therapy) on viral rebound. In addition to 
the total number of prior interruptions, the regimen interrupted/restarted and the viral 
load at time of interruption  (i.e. the number of interruptions that had previously 
occurred whilst the viral load was detectable, undetectable or not known) were also 
considered as potential predictors of viral rebound. The following potential predictors 
were also considered: current antiretroviral regimen (backbone NRTIs and „third‟ 
drug), calendar year, age, ethnicity (white, black African or other), sex, risk group 
(MSM, heterosexual, other), viral load at initiation of ART, time since initiation of 
ART and CD4 count at the start of the period of viral suppression. An interaction 
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variable between number of previous regimens failed and duration of suppression 
was also incorporated in the model. 
 
As each person could contribute more than one period of follow-up (and viral 
rebound) to the analysis, rate ratios were also estimated using generalized 
estimating equations to fit univariable and multivariable Poisson regression models, 
allowing for multiple events in the same individuals.  
    
 
 
    
2
5
3 
Figure 7.2.4.1: Example of allocation of person-years of follow-up for a hypothetical individual 
   Patient starts             Viral         Patient starts                                            Patient stops   Patient re-starts 
  1
st
 line HAART                   rebound          2
nd
 line HAART                                               HAART                       HAART 
                                                                                      Time    
         
 
Time 
VL <50 copies/mL 
            
                              VL<400 copies/mL 
Start of patient 
follow-up 
 
 
              
Patient re-enters analysis 
(start of second period of 
follow-up) 
p-yrs 
End of first 
episode of 
patient follow -
up              
p-yrs 
         
  
  
         
  
  
p-yrs 
 
  
Viral load measurement 
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7.3. Results 
 
7.3.1. Time spent on treatment in the whole population 
The proportion of time patients spent on treatment each year is shown in Figure 
7.3.1.1. In 1996, only a quarter of time under follow-up was spent on treatment. This 
increased to almost 70% in 1999 but dropped to 55% in the year 2000. The results 
of the SMART trial were published in 2006, and though time spent on treatment has 
increased since then, this increase was actually evident from 2000 onwards. In 
2008, over 70% of time under follow-up was spent receiving treatment. The 
proportion of patients under follow-up who had not yet started treatment decreased 
from 60.8% in 1996 to 21.9% in 2008. The proportion of patients who had 
interrupted treatment also decreased over time and stood at 6.5% in 2008.  
 
Figure 7.3.1.1: Proportion of time under follow-up each year spent on 
treatment, not yet started treatment and treatment interruptions 
0
10
20
30
40
50
60
70
80
90
100
19
96
19
97
19
98
19
99
20
00
20
01
20
02
20
03
20
04
20
05
20
06
20
07
20
08
%
 o
f 
ti
m
e 
sp
en
t 
o
n
 t
re
at
m
en
t
ART interrupted
No ART
On ART
 
 
  
 
7.3.2. Treatment interruptions amongst patients who had started HAART 
Amongst the 20,036 patients who had started HAART between 1996 and 2008, a 
quarter (n=4936, 24.6%) interrupted treatment at least once whilst under follow-up. 
           Year under follow-up 
8700 9257 8527 9585 12352 13636 15013 16268 17720 19368 20474 20310 9569 
              Patients under follow-up 
 
Patients under      8700  9257  8527  9585  12352 13636 15013 16268 17720 19368 20474 20310 9569 
follow-up  
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The total number of interruptions recorded was 7,801. The median number of 
interruptions per patient was 1 (range: 1, 13) and the median duration of each 
treatment interruption was just under 5 months (4.8 (IQR: 2.0, 12.0)). Characteristics 
of patients at the time of each interruption, together with details of regimen 
interrupted and restarted are shown in Table 7.3.2.1. Patients interrupted treatment 
for the first time at a median 1.2 years after starting HAART and subsequent 
interruptions were a median 1.6 years apart. A higher proportion of interruptions 
took place between 2000-2003, after which the proportions of interruptions 
decreased. Most interruptions were made by patients of male sex, MSM exposure 
and white ethnicity. The median age at interruption was 38 years.  
 
Of those who interrupted therapy, over a third of patients interrupted an NNRTI-
based regimen (of whom 36.1% restarted the same regimen and 29.6% restarted a 
PI/r-based regimen). Over a quarter of patients (26.7%) interrupted a PI/r-based 
regimen (of whom 28.9% restarted the same regimen and 12.9% restarted an 
NNRTI-based regimen). Treatment interruptions were made whilst patients‟ viral 
loads were a median 1154 copies/mL and CD4 counts were a median 300 
cells/mm3. Patients restarted therapy with a median viral load of 63,400 copies/mL 
and a median CD4 count of 190 cells/mm3.  
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Table 7.3.2.1: Characteristics of patients at start of each treatment interruption 
Patients who interrupted treatment at least once 4936 
Total number of treatment interruptions N 
(%) 
 7801 (100.0) 
Time from start of HAART to interruption (years) Median (IQR) 2.1 (0.7, 4.3) 
Regimen interrupted n (%) NNRTI 2897 (37.1) 
Restarted same regimen n (%)   897 (31.0) 
Restarted n (%) NNRTI 1635 (56.4) 
 PI/r 857 (29.6) 
 PI 122 (4.2) 
 Other 283 (9.8) 
Regimen interrupted n (%) PI/r 2080 (26.7) 
Restarted same regimen n (%)  601 (28.9) 
Restarted n (%) NNRTI 269 (12.9) 
 PI/r 1456 (70.0) 
 PI 105 (5.1) 
 Other 250 (12.0) 
Regimen interrupted n (%) PI 1335 (17.1) 
Restarted same regimen n (%)  196 (14.7) 
Restarted n (%) NNRTI 407 (30.5) 
 PI/r 337 (25.2) 
 PI 364 (27.3) 
 Other 227 (17.0) 
Regimen interrupted n (%) Other 1489 (19.1) 
Restarted same regimen n (%)  225 (11.7) 
Restarted n (%) NNRTI 365 (24.5) 
 PI/r 449 (30.1) 
 PI 116 (7.8) 
 Other 559 (37.5) 
Year of interruption n (%) 1996-1999 2042 (26.2) 
 2000-2003 3221 (41.3) 
 2004-2008 2538 (32.5) 
Number of viral load measurements between Median (IQR) 1 (1,3) 
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interruption and restart 
Viral load at interruption (copies/mL) Median (IQR) 1154 (50, 38080) 
Viral load at restart (copies/mL) Median (IQR) 63400 
(10000,203481) 
Number of CD4 count measurements between 
interruption and restart 
Median (IQR) 2 (1,3) 
CD4 at interruption (cells/mm3) Median (IQR) 300 (160, 475) 
CD4 at restart (cells/mm3) Median (IQR) 190 (93, 300) 
Sex n (%) Males 5810 (74.5) 
 Females 1991 (25.5) 
Ethnicity n (%) White 4813 (61.7) 
 Black 2337 (30.0) 
 Other 651 (8.4) 
Exposure n (%) MSM 4318 (55.4) 
 Heterosexual 2620 (33.6) 
 Other 863 (11.1) 
Age at interruption (years) Median (IQR) 38 (33, 43) 
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7.3.3. Differences between those included and excluded from viral 
rebound analyses 
17,743/20,036 (88.6%) patients who started HAART achieved VL <50 copies/mL at 
a median 6.1 (6.0, 6.3) months after initiation of therapy. Although differences 
amongst patients who did and did not achieve VL <50 copies/mL were statistically 
significant, the absolute differences were of limited clinical significance (Table 
7.3.3.1). 
Compared to patients who started HAART and did not achieve VL <50 copies/mL, 
patients with VL <50 copies/mL after starting HAART were more likely to be of male 
sex (88.9% of males achieved VL <50 copies/mL compared to 87.6% of women, 
p=0.001), of MSM exposure (90.3% of MSMs achieved VL <50 copies/mL compared 
to 88.8% of heterosexuals and 79.4% of those from „other‟ exposure groups, 
p<0.0001) and had lower viral loads at HAART initiation (58,600 copies/mL 
compared to 64,729 copies/mL, p=0.01). Patients who achieved VL <50 copies/mL 
after starting HAART also had marginally higher CD4 counts at start of HAART (190 
vs. 180 cells/mm3, p=0.002) and were more likely to start HAART on an NNRTI-
based regimen than those who did not achieve VL <50 copies/mL after starting 
HAART (91.4% of patients starting HAART with an NNRTI-based regimen achieved 
VL <50 copies/mL compared to 85.4% of those who started HAART on PI/r-based 
regimens, p<0.0001). Finally, patients starting HAART in 2000-2003 appeared to be 
more likely to achieve VL <50 copies/mL after starting HAART than those starting 
HAART before 2000 and after 2003. Though the absolute difference was small, one 
possible explanation for this is that patients starting HAART in later calendar years 
may not have enough follow-up time to achieve VL <50 copies/mL. 
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Table 7.3.3.1: Differences between those who started HAART and achieved VL 
<50 copies and those who didn’t achieve VL <50 copies 
  VL >50 
copies/mL 
VL <50 
copies/mL 
P-value 
  2293 17743  
Sex  Males 1681 (11.1) 13405 (88.9) 0.001 
 Females 612 (12.4) 4338 (87.6)  
Ethnicity White 1332 (11.2) 10582 (88.8) 0.17 
 Black  702 (11.6) 5362 (88.4)  
 Other 259 (12.6) 1799 (87.4)  
Exposure MSM 1056 (9.7) 9830 (90.3) <0.0001 
 Heterosexual 770 (11.2) 6117 (88.8)  
 Other  467 (20.6) 1796 (79.4)  
Year of  1996-1999 975 (12.9) 6566 (87.1) <0.0001 
starting 2000-2003 542 (8.8) 5625 (91.2)  
HAART 2004-2008 776 (12.3) 5552 (87.7)  
VL at start of 
HAART 
Median (IQR) 64729 
(10319, 224100) 
58600 
(9754, 198000) 
0.01 
CD4 at start Median (IQR) 180 (63, 297) 190 (94, 290) 0.002 
of HAART     
1st line  NNRTI 945 (8.6) 10061 (91.4) <0.0001 
regimen PI/r 526 (14.6) 3089 (85.4)  
 PI 591 (15.2) 3302 (84.8)  
 Other 231 (15.2) 1291 (84.8)  
 
  
7.3.4. Characteristics of patients included in the viral rebound analyses 
The 17,743 patients included in the viral rebound analyses contributed a total of 
22,965 unique viral suppression episodes (median 1 episode, range 1 to 11 per 
person). Most patients included in the analysis were of male sex, white ethnicity and 
MSM risk group. A quarter of patients had a CD4 count below 200 cells/mm3 at the 
start of the viral suppression episode and 39.2% of patients had failed at least one 
regimen before entering the viral suppression episode. Of the 22,965 viral 
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suppression episodes, 5,198 (22.6%) were in individuals who had interrupted 
therapy prior to the start of the episode. The characteristics of the patients included 
in the analysis at the start of each viral suppression episode, stratified according to 
whether or not the patient had previously interrupted therapy, are shown in Table 
7.3.4.1. In general, patients who had interrupted therapy were more likely to be of 
white ethnicity, to have attained viral suppression in later calendar years and had 
failed a greater number of previous regimens than those who did not interrupt 
therapy prior to the viral suppression episode. Patients who had interrupted therapy 
were also more likely to have received mono/dual therapy before receiving HAART.  
 
Of the 8,024 treatment interruptions that occurred prior to the start of the viral 
suppression episode (Table 7.3.4.2), 37.5% were interruptions of NNRTI-based 
regimens, 23.3% of PI/r-based regimens and 19.9% of single PI-based regimens. 
The remaining 19.3% of treatment interruptions occurred amongst patients receiving 
„other‟ regimens, for example, NRTI only regimens and regimens containing both 
PIs and NNRTIs.  Of the 3,009 NNRTI interruptions, 27.1% ended with the patient 
restarting the same NNRTI and the same proportion (27.1%) ended with the patient 
restarting a different NNRTI. A slightly higher proportion of patients (29.2%) 
restarted therapy with a PI/r-based regimen. Of the 1,870 PI/r interruptions, 25.9% 
ended with the patient restarting the same PI/r, 38.8% ended with patients starting a 
different PI/r and 15.7% ended with patients starting an NNRTI-based regimen. The 
median duration of each treatment interruption was 5.7 (IQR: 2.5, 13.0) months and 
treatment interruptions were initiated at a median CD4 count of 281 (152, 457) 
cells/mm3 and median viral load of 2150 (56, 32,000) copies/mL. Patients restarted 
treatment with a median CD4 count of 190 (97, 290) cells/mm3 and median viral 
load of 67,900 (16,221, 192,036) copies/mL. 
    
 
 
    
2
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Table 7.3.4.1: Patient characteristics at the start of each viral suppression episode, stratified by whether or not patients had had prior 
treatment interruptions 
   Treatment interruption prior to start of viral suppression 
episode 
  Total Yes No 
N  22965 5198 17767 
Age (years) Median (IQR) 38 (33, 44) 39 (35, 45) 38 (33, 44) 
CD4 count (cells/mm3) <200 5679 (24.7) 1324 (25.5) 4355 (24.5) 
 200-349 7086 (30.9) 1605 (30.9) 5481 (30.9) 
 350-499 5183 (22.6) 1203 (23.1) 3980 (22.4) 
 >500 4478 (19.5) 1044 (20.1) 3434 (19.3) 
 Missing 539 (2.4) 22 (0.4) 517 (2.9) 
Ethnicity, n (%) White 13866 (60.4) 3288 (63.3) 10578 (59.5) 
 Black  6872 (29.9) 1488 (28.6) 5384 (30.3) 
 Other 2227 (9.7) 422 (8.1) 1805 (10.2) 
Risk group, n (%) MSM 12928 (56.3) 3032 (58.3) 9896 (55.7) 
 Heterosexual 7805 (34.0) 1668 (32.1) 6137 (34.5) 
 Other 2232 (9.7) 498 (9.6) 1734 (9.8) 
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Male sex, n (%)  17334 (75.5) 3861 (74.3) 13473 (75.8) 
Year of viral  1996-2000 6343 (27.6) 933 (18.0) 5410 (30.5) 
suppression, n (%) 2001-2004 9069 (39.5) 2250 (43.3) 6819 (38.4) 
 2005 onwards 7553 (32.9) 2015 (38.8) 5538 (31.2) 
Number of previous  0 13951 (60.8) 1655 (31.8) 12296 (69.2) 
regimens failed, 1 4112 (17.9) 1364 (26.2) 2748 (15.5) 
n (%) 2 2353 (10.3) 935 (18.0) 1418 (8.0) 
 3 1358 (5.9) 600 (11.5) 758 (4.3) 
 4 677 (3.0) 361 (6.9) 316 (1.8) 
>5 514 (2.2) 283 (5.4) 231 (1.3) 
Receipt of mono/dual therapy prior to 
HAART, n (%) 
6284 (27.4) 2108 (40.6) 4176 (23.5) 
Suppression episode 1 17743 (77.3) 2053 (39.5) 15690 (88.3) 
 2 2176 (17.0) 2176 (41.9) 1719 (9.7) 
 3 966  (4.2) 682 (13.1) 284 (1.6) 
 >4 361 (1.6) 287 (5.5) 74 (0.4) 
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Table 7.3.4.2: Patient characteristics at the time of each treatment interruption 
(TI) 
  N (%) 
Total number of treatment interruptions1 N (%) 8024 (100) 
Number of interruptions Median (range) 1 (1, 11) 
Treatment status at start and end of interruption  
Interrupted NNRTI regimen N (%)  3009 (37.5) 
Restarted same NNRTI regimen 814 (27.1) 
Restarted different NNRTI regimen 816 (27.1) 
Restarted PI/r regimen 880 (29.2) 
Restarted PI regimen 168 (5.6) 
Restarted Other regimen 331 (11.0) 
Interrupted PI/r regimen N (%)   1870 (23.3) 
Restarted same PI/r regimen 485 (25.9) 
Restarted different PI/r regimen 725 (38.8) 
Restarted PI regimen 118 (6.3) 
Restarted NNRTI regimen 294 (15.7) 
Restarted Other regimen 248 (13.3) 
Interrupted PI regimen N (%)  1600 (19.9) 
Restarted same PI regimen 234 (14.6) 
Restarted different PI regimen 191 (11.9) 
Restarted PI/r regimen 367 (22.9) 
Restarted NNRTI regimen 542 (33.9) 
Restarted Other regimen 266 (16.6) 
Interrupted Other regimen N (%)  1545 (19.3) 
Restarted same Other regimen 225 (14.6) 
Restarted different Other regimen 330 (21.4) 
Restarted PI/r regimen 419 (27.1) 
Restarted PI regimen 135 (8.7) 
Restarted NNRTI regimen 436 (28.2) 
Duration of TI (months) Median (IQR) 5.7 (2.5, 13.0) 
CD4 count at start of TI 
(cells/mm3) 
Median (IQR) 281 (152, 457) 
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CD4 count at end of TI 
(cells/mm3) 
Median (IQR) 190 (97, 290) 
Number of CD4 counts between 
interrupting and restarting ART 
Median (IQR) 2 (1, 4) 
Viral load at start of TI 
(copies/mL) 
Median (IQR) 2150 (56, 32000) 
Viral load at end of TI (copies/mL) Median (IQR) 67900  
(16221, 192036) 
Number of VL measurements 
between interrupting and 
restarting treatment 
Median (IQR) 2 (1, 4) 
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7.3.5. Person-years, events and rates 
Patients were followed for a median 66,053 pys. In total 4,078 viral rebound events 
occurred over follow-up, giving an overall rebound rate of 6.17 (95% CI: 5.98, 6.36) 
per 100 pys. Table 7.3.5.1 shows the number of events and pys, together with the 
viral rebound rate and 95% CI for a range of demographic and other variables. The 
viral rebound rate was higher amongst females (compared to males), those of black 
ethnicity (compared to white ethnicity) and those of „other‟ risk groups (compared to 
MSM). Patients who had received mono/dual therapy prior to HAART, those who 
were under follow-up in earlier calendar years and those with lower CD4 counts also 
had higher viral rebound rates. The rate of viral rebound linearly increased as the 
number of regimens previously failed increased, as the number of previous viral 
rebounds increased and as the number of prior treatment interruptions increased. 
The rebound rate also varied considerably according to the NRTI combination and 
the „third‟ drug used in regimens. Patients receiving d4T/ddI had the highest 
rebound rate, whilst those receiving FTC/TFV NRTI combinations had the lowest 
rebound rate. In terms of the „third‟ drug used in regimens, patients receiving 
unboosted SQV had the highest rebound rates and those receiving EFV had the 
lowest rebound rates. Viral rebound rates decreased as the time since start of 
HAART increased and as the duration of viral suppression increased.  
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Table 7.3.5.1: Events, person-years and rates (95% CI) of viral rebound, 
stratified by demographic and other variables 
 Events/ person- years Rate (95% CI) 
Total  4078/66053 6.17 (5.98, 6.36) 
Sex Male 3052/52459 5.82 (5.61, 6.02) 
 Female 1026/13594 7.55 (7.09, 8.01) 
Ethnicity White 2442/43260 5.65 (5.42, 5.87) 
 Black 1299/16893 7.69 (7.27, 8.11) 
 Other 337/5901 5.71 (5.10, 6.32) 
Risk group MSM 2274/40895 5.56 (5.33, 5.79) 
 Heterosexual 1388/19691 7.05 (6.68, 7.42) 
 Other 416/5467 7.61 (6.88, 8.34) 
Mono/dual therapy No 2309/45097 5.12 (4.91, 5.33) 
received  Yes 1769/20956 8.44 (8.05, 8.83) 
Calendar year 1996-2000 1109/8181 13.56 (12.76, 14.35) 
 2001-2004 1697/27265 6.22 (5.93, 6.52) 
 2005 onwards 1272/30607 4.16 (3.93, 4.38) 
Number of regimens  0 1409/35708 3.95 (3.74, 4.15) 
previously failed 1 992/14489 6.85 (6.42, 7.27) 
 2 741/8257 8.97 (8.33, 9.62) 
 3 502/4397 11.42 (10.42, 12.42) 
 4 239/2081 11.49 (10.03, 12.94) 
 >5 195/1122 17.38 (14.94, 19.82) 
Current CD4 count  <200 826/6449 12.81 (11.93, 13.68) 
(cells/mm
3
) 200-349 1156/15056 7.68 (7.24, 8.12) 
 350-499 962/17443 5.51 (5.17, 5.86) 
 >500 1113/26899 4.14 (3.90, 4.38) 
 Missing 21/207 10.15 (5.81, 14.48) 
Number of prior 0 2901/54407 5.33 (5.14, 5.53) 
treatment interruptions 1 758/8615 8.80 (8.17, 9.42) 
 2 258/2069 12.47 (10.95, 13.99) 
 >3 161/961 16.75 (14.17, 19.34) 
NRTI combination  AZT/3TC 966/19918 4.85 (4.54, 5.16) 
 AZT/DDI 123/1414 8.70 (7.16, 10.24) 
   267 
 
 
 d4T/3TC 589/6350 9.28 (8.53, 10.03) 
 d4T/ddI 350/2416 14.49 (12.97, 16.00) 
 AZT/ABC 30/370 8.11 (5.21, 11.01) 
 TFV/3TC 224/5602 4.00 (3.48, 4.52) 
 ABC/3TC 220/7443 2.96 (2.57, 3.35) 
 TFV/DDI 231/2395 9.65 (8.40, 10.89) 
 FTC/TFV 167/6284 2.66 (2.25, 3.06) 
 Other 1178/13861 8.50 (8.01, 8.98) 
“Third” drug EFV 478/18077 2.64 (2.41, 2.88) 
 NVP 796/15766 5.05 (4.70, 5.40) 
 SQV 76/449 16.93 (12.12, 20.73) 
 IDV 178/1829 9.73 (8.30, 11.16) 
 NFV 450/3678 12.23 (11.10, 13.37) 
 RTV 39/485 8.04 (5.52, 10.56) 
 AZV 28/365 7.67 (4.83, 10.51) 
 IDV/r 97/1119 8.67 (6.94, 10.39) 
 SQV/r 265/3120 8.49 (7.47, 9.52) 
 LPV/r 497/7373 6.74 (6.15, 7.33) 
 AZV/r 217/3986 5.44 (4.72, 6.17) 
 ABC 629/7275 8.65 (7.97, 9.32) 
 ETR 4/114 3.51 (0.96, 8.98) 
 Other 325/2417 13.45 (11.98, 14.91) 
Time since start of <1.0 year 585/7331 7.98 (7.33, 8.63) 
HAART 1.1-3.0 years 1348/18576 7.26 (6.87, 7.64) 
 3.1-5.0 years 938/15682 5.98 (5.60, 6.36) 
 >5.0 years 1207/24464 4.93 (4.66, 5.21) 
Duration of viral  <1.0 year 2232/19975 11.17 (10.71, 11.64) 
suppression 1.1-3.0 years 1260/22865 5.51 (5.21, 5.81) 
 3.1-5.0 years 386/12989 2.97 (2.68, 3.27) 
 >5.0 years 200/10223 1.96 (1.69, 2.23) 
Number of previous 0 3199/58212 5.50 (5.30, 5.69) 
viral rebounds 1 666/6586 10.11 (9.34, 10.88) 
 2 163/1035 15.75 (13.33, 18.17) 
 3 37/186 19.89 (13.48, 26.30) 
 >4 13/35 37.14 (19.78, 63.51) 
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7.3.6. Number of regimens previously failed and duration of viral 
suppression/calendar year of entry into viral suppression episode 
Table 7.3.6.1 shows the rates of viral rebound according to both the number of 
regimens previously failed and duration of viral suppression. Within the first year of 
viral suppression, the rate of viral rebound was 6.57/100 pys (95% CI: 6.11, 7.03) in 
patients who had not failed treatment previously, rising to 29.38/100 pys (24.21, 
34.56) in patients who had failed five or more regimens. Viral rebound rates 
decreased progressively with increased duration of viral suppression despite one or 
more previous episodes of failure. In patients who had failed one or more 
antiretroviral combinations and remain suppressed after 5 years, rebound rates fell 
to levels nearly as low as those seen in patients who had never experienced 
virological failure.  After 1-3 years of suppression the rate of rebound was 3.31/100 
pys (95% CI: 3.00, 3.63) in naïve and 13.11/100 pys (95% CI: 9.51, 16.71) in 
patients who had failed >5 regimens; and after >5 years, the corresponding rebound 
rates were 1.54/100 pys (95% CI: 1.16, 1.92) and 3.64/100 pys (95% CI: 0.99, 9.31). 
 
The association between the number of regimens previously failed and the calendar 
year of entering an episode of viral suppression was also investigated (Table 
7.3.6.2). Although rebound rates increased as the number of regimens previously 
failed increased, regardless of calendar year, viral rebound rates decreased 
progressively with later calendar year, despite one or more previous episodes of 
failure.  
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Table 7.3.6.1: Events/ person-years and rates (95% CI) stratified by number of regimens previously failed and duration of viral 
suppression 
 Duration of viral suppression 
Number of regimens 
previously failed 
 
< 1 year 
 
1-3 years 
 
3-5 years 
 
> 5 years 
0 783/11914 430/12978 132/6662 64/4153 
 6.57 (6.11, 7.03) 3.31 (3.00, 3.63) 1.98 (1.64, 2.32) 1.54 (1.16, 1.92) 
1 523/3739 324/4713 92/3063 53/2973 
 13.99 (12.79, 15.19) 6.87 (6.13, 7.62) 3.00 (2.39, 3.62) 1.78 (1.30, 2.26) 
2 394/2104 221/2606 73/1738 53/1810 
 18.73 (16.88, 20.58) 8.48 (7.36, 9.60) 4.20 (3.24, 5.16) 2.93 (2.14, 3.72) 
3 268/1220 162/1488 53/881 19/807 
 21.97 (19.34, 24.60) 10.89 (9.21, 12.56) 6.02 (4.40, 7.64) 2.35 (1.42, 3.68) 
 4 140/578 72/691 20/444 7/370 
 24.22 (20.21, 28.23) 10.42 (8.01, 12.83) 4.50 (2.53, 6.48) 1.89 (0.76, 3.90) 
> 5 124/422 51/389 16/201 4/110 
 29.38 (24.21, 34.56) 13.11 (9.51, 16.71) 7.96 (4.55, 12.93) 3.64 (0.99, 9.31) 
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Table 7.3.6.2: Events, person-years and rates (95% CI) stratified by number of regimens previously failed and year of entry of viral 
suppression episode 
 
 Year of entering an episode 
Number of regimens 
previously failed 
1996-2000 2001-2004 2005-2008 
0 326/3513 601/14341 482/17853 
 9.28 (8.27, 10.29) 4.19 (3.86, 4.53) 2.70 (2.46, 2.94) 
1 311/2337 400/6055 281/6096 
 13.31 (11.83, 14.79) 6.61 (5.96, 7.25) 4.61 (4.07, 5.15) 
2 264/1466 288/3600 189/3192 
 18.01 (15.84, 20.18) 8.00 (7.08, 8.92) 5.92 (5.08, 6.77) 
3 146/636 221/1943 135/1818 
 22.96 (19.23, 26.68) 11.37 (9.87, 12.87) 7.43 (6.17, 8.68) 
 4 46/175 105/909 88/997 
 26.29 (18.69, 33.88) 11.55 (9.34, 13.76) 8.83 (6.98, 10.67) 
> 5 16/53 82/418 97/652 
 30.19 (15.40, 44.98) 19.62 (15.37, 23.86) 14.88 (11.92, 17.84) 
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7.3.7. Factors associated with viral rebound 
In univariable analyses (Table 7.3.7.1), patients who had interrupted treatment at 
least once prior to their viral suppression episode had an 89% greater chance of 
experiencing viral rebound than those who had no prior treatment interruptions. 
When the number of prior treatment interruptions was fitted as a categorical variable 
(0, 1, 2, >3 prior treatment interruptions), the relative rate of viral rebound increased 
as the number of interruptions increased; compared to those with no prior treatment 
interruptions, rate-ratios for patients with 1, 2 and >3 prior treatment interruptions 
were 1.65 (95% CI: 1.77, 2.03), 2.34 (2.06, 2.66) and 3.14 (2.68, 3.68) respectively. 
Rate-ratios also increased linearly as the number of previous regimens failed 
increased (4.40 (3.79, 5.11) comparing failing >5 regimens to 0 regimens) and 
decreased linearly as the duration of viral suppression increased (5.71 (4.94, 6.60) 
comparing patients whose viral load was suppressed for <1 year to >5 years). 
Females (compared to males), patients of black ethnicity (compared to white 
ethnicity), of heterosexual/other risk group (compared to MSM) of younger age and 
those who had received mono/dual therapy before starting HAART were more likely 
to experience viral rebound. Patients under follow-up in later calendar years, those 
with higher current CD4 counts, with no prior AIDS diagnosis and patients who had 
experienced fewer episodes of viral rebound in the past were less likely to 
experience viral rebound. The regimen that patients were currently receiving was 
also a strong predictor of viral rebound. In particular, patients receiving d4T/ddI as 
their NRTI-backbone were 3 times as likely to experience viral rebound than those 
receiving AZT/3TC and those receiving unboosted SQV as the „third‟ drug were over 
6 times as likely to experience viral rebound than those receiving EFV.   
In multivariable analyses, categorical variables were fitted as continuous variables if 
a linear effect was evident in univariable analyses. After adjusting for potential 
confounders, patients who had interrupted therapy at least once before their viral 
suppression episode had a 30% higher risk of experiencing viral rebound than those 
who had no prior treatment interruptions (Table 7.3.7.1). When the number of 
treatment interruptions was fitted as a categorical variable, compared to those who 
had no treatment interruptions, the rate-ratios for patients with 1, 2 and >3 prior 
treatment interruptions were 1.22 (1.12, 1.33), 1.46 (1.28, 1.67) and 1.62 (1.39, 
1.92) respectively (Figure 7.3.7.1).  
Patients with a higher number of previous regimens failed (1.27 (1.23, 1.31) per 
additional regimen failed) were at an increased risk of viral rebound, whilst those 
who maintained viral suppression for longer periods of time were at a reduced risk of 
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viral rebound (0.80 (0.79, 0.82) per 1 year higher). Patients of black ethnicity 
(compared to white ethnicity) were also at an increased risk of viral rebound, though 
sex and risk group were no longer significantly associated with viral rebound. 
Patients of older age, those seen in later calendar years and those with lower CD4 
counts were still at a reduced risk of viral rebound, after adjusting for other 
confounders. Compared to receiving an AZT/3TC NRTI combination, patients 
receiving AZT/DDI, d4T/3TC, d4T/ddI and TFV/DDI had a higher risk of viral 
rebound whilst those receiving ABC/3TC and FTC/TFV had a lower risk of viral 
rebound. Other than etravirine (taken by only 136 patients), patients receiving any 
other third drug were at increased risk of viral rebound compared to patients 
receiving EFV.  
The test for interaction between number of past regimens failed and time under 
suppression was statistically significant with a p-value of 0.01.  Thus, although 
rebound rates were higher in those with a greater number of previously failed 
regimens, this effect waned with increased duration of suppression. The relative rate 
of rebound, estimated separately after stratifying by the number of regimens failed 
according to time with viral suppression is shown in Table 7.3.7.1.  Patients who had 
remained virologically suppressed for less than one year had a 27% (1.27 (1.22–
1.33)) increased chance of viral rebound per extra regimen failed. This decreased to 
16% (1.16 (1.00, 1.34) in those who remain suppressed for >5 years. 
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Figure 7.3.7.1: Adjusted rate-ratios (and 95% CIs) according to the number of 
prior treatment interruptions 
 
 
 
 
 
 
 
 
 
 
Figure 7.3.7.2: Adjusted rate-ratios (and 95% CIs) for number of previous 
regimens failed (per 1 regimen higher), stratified by years under viral 
suppression 
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Table 7.3.7.1: Factors associated with viral rebound from univariable and multivariable analyses 
  Univariable Multivariable 
  RR (95% CI) P-value RR (95% CI) P-value 
Prior treatment interruption No 1 <0.0001 1 <0.0001 
 Yes 1.89 (1.77, 2.03)  1.30 (1.20, 1.40)  
Number of prior 0 1 <0.0001 Co-linear with  
treatment interruptions 1 1.65 (1.52, 1.79)  „prior treatment  
 2 2.34 (2.06, 2.66)  Interruption‟  
 >3 3.14 (2.68, 3.68)    
Number of regimens  0 1 <0.0001 1.27 (1.23, 1.31) <0.0001 
previously failed 1 1.74 (1.60, 1.88)  Per extra regimen  
 2 2.27 (2.08, 2.49)  failed  
 3 2.89 (2.61, 3.20)    
 4 2.91 (2.65, 3.34)    
 >5 4.40 (3.79, 5.11)    
Duration of viral  <1.0 year 5.71 (4.94, 6.60) <0.0001 0.80 (0.79, 0.82) <0.0001 
Suppression 1.1-3.0 years 2.82 (2.43, 3.27)  Per 1 year higher  
 3.1-5.0 years 1.52 (1.28, 1.80)    
 >5.0 years 1    
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Sex Male 1 - 1 0.61 
 Female 1.30 (1.21, 1.39) <0.0001 0.98 (0.88, 1.08)  
Ethnicity White 1 <0.0001 1 <0.0001 
 Black 1.36 (1.27, 1.46)  1.29 (1.17, 1.43)  
 Other 1.01 (0.90, 1.13)  1.00 (0.89, 1.12)  
Risk group MSM 1 <0.0001 1 0.09 
 Heterosexual 1.27 (1.19, 1.36)  1.08 (0.97, 1.20)  
 Other 1.37 (1.23, 1.52)  1.13 (1.01, 1.27)  
Current age (years) <35 1 <0.0001 0.76 (0.73, 0.79) <0.0001 
 35-45 0.73 (0.68, 0.79)  Per 10 years older  
 >45 0.47 (0.43, 0.51)    
Mono/dual therapy No 1 <0.0001 1 0.14 
received  Yes 1.65 (1.55, 1.75)  0.94 (0.86, 1.02)  
Calendar year 1996-2000 3.26 (3.01, 3.54) <0.0001 0.95 (0.93, 0.97) <0.0001 
 2001-2004 1.50 (1.39, 1.61)  Per 1 year later  
 2005 onwards 1    
Current CD4 count  <200 3.10 (2.83, 3.39) <0.0001 1.83 (1.67, 2.02) <0.0001 
(cells/mm3) 200-349 1.86 (1.71, 2.01)  1.37 (1.26, 1.49)  
 350-499 1.33 (1.22, 1.45)  1.15 (1.05, 1.25)  
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 >500 1  1  
 Missing 2.45 (1.59, 3.78)  1.32 (0.86, 2.04)  
NRTI combination  AZT/3TC 1 <0.0001 1 <0.0001 
 AZT/DDI 1.79 (1.49, 2.16)  1.39 (1.15, 1.68)  
 d4T/3TC 1.91 (1.73, 2.12)  1.23 (1.10, 1.37)  
 d4T/ddI 2.99 (2.64, 3.38)  1.59 (1.40, 1.82)  
 AZT/ABC 1.67 (1.16, 2.40)  1.42 (0.98, 2.05)  
 TFV/3TC 0.82 (0.71, 0.95)  0.92 (0.79, 1.07)  
 ABC/3TC 0.61 (0.53, 0.71)  0.86 (0.74, 1.00)  
 TFV/DDI 1.99 (1.72, 2.30)  1.22 (1.04, 1.43)  
 FTC/TFV 0.55 (0.46, 0.65)  0.75 (0.63, 0.90)  
 Other 1.75 (1.61, 1.91)  1.16 (1.05, 1.28)  
“Third” drug EFV 1 <0.0001 1 <0.0001 
 NVP 1.91 (1.70, 2.14)  1.87 (1.67, 2.10)  
 SQV 6.40 (5.02, 8.15)  3.32 (2.59, 4.27)  
 IDV 3.68 (3.10, 4.37)  2.07 (1.72, 2.49)  
 NFV 4.63 (4.07, 5.26)  2.88 (2.51, 3.30)  
 RTV 3.04 (2.19, 4.21)  1.68 (1.20, 2.34)  
 AZV 2.90 (1.98, 4.25)  2.35 (1.60, 3.45)  
 IDV/r 3.28 (2.64, 4.08)  1.78 (1.42, 2.23)  
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 SQV/r 3.21 (2.76, 3.73)  2.01 (1.72, 2.36)  
 LPV/r 2.55 (2.25, 2.89)  1.57 (1.38,1.80)  
 AZV/r 2.06 (1.75, 2.42)  1.72 (1.45, 2.05)  
 ABC 3.27 (2.90, 3.68)  2.29 (2.02, 2.59)  
 ETR 1.33 (0.50, 3.56)  0.48 (0.18, 1.29)  
 Other 5.08 (4.42, 5.85)  2.85 (2.45, 3.31)  
Time since start of <1.0 year 1.62 (1.47, 1.79) <0.0001 - - 
HAART 1.1-3.0 years 1.47 (1.36, 1.59)    
 3.1-5.0 years 1.21 (1.11, 1.32)    
 >5.0 years 1    
Prior AIDS diagnosis Yes 1.22 (1.14, 1.30) <0.0001 1.03 (0.96, 1.10) 0.39 
Number of previous 0 1 <0.0001 1.12 (1.05,1.20) 0.001 
viral rebounds 1 1.84 (1.69, 2.00)  Per 1 previous  
 2 2.87 (2.45, 3.35)  rebound higher  
 >3 4.13 (3.12, 5.46)    
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7.3.8. Association between duration of treatment interruption and viral 
rebound 
Though the median duration of a treatment interruption was just under 6 months, 
2,956 (36.8%) interruptions were shorter than 3 months and a further 1,676 (20.9%) 
lasted for between 3 and 6 months. The remaining 3,392 (42.3%) interruptions were 
longer than 6 months. The risk of viral rebound increased linearly as the number of 
interruptions increased, for all durations of treatment interruptions. In univariable 
analyses, compared to those who had never interrupted therapy for less than 3 
months (i.e. those who interrupted therapy for longer than 3 months), patients who 
made 1 interruption that was shorter than 3 months had a 77% higher risk of viral 
rebound (1.77 (1.61, 1.95)), whilst those who had interrupted therapy at least twice 
for less than 3 months were over twice as likely to experience viral rebound (2.13 
(1.75, 2.58)). Compared to patients who had never interrupted therapy for 3-6 
months, patients who had 1 previous treatment interruption for this period of time 
were twice as likely to experience viral rebound (2.05 (1.83, 2.30)), whilst those who 
had 2 or more previous interruptions were 3 times as likely to experience viral 
rebound (3.07 (2.35, 4.06)). Finally, patients who had interrupted therapy once for 
>6 months had a 74% increased risk of viral rebound compared to those who had 
never interrupted therapy for >6 months (1.74 (1.58, 1.91)), and those who had 
interrupted therapy 2 or more times had a 2.6 times increased risk of viral rebound 
(2.60 (2.14, 3.14)).  
After adjusting for potential confounders, including demographics, number of 
regimens previously failed and the number of treatment interruptions of different 
durations, all the above estimates were still significantly associated with viral 
rebound (Table 7.3.8.1). 
In sensitivity analyses, the total duration of treatment interruptions was calculated. 
For example, a patient who had interrupted treatment on two occasions for 3 months 
and 6 months respectively had a total duration of 9 months of treatment interruption. 
In univariable analyses, the risk of viral rebound increased by 5% per 3 month 
increase in total duration of prior interruptions (1.05 (1.04, 1.06)). Though this 
estimate was weaker after adjusting for potential confounders, it still remained 
statistically significant (1.03 (1.02, 1.04)).   
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Table 7.3.8.1: Independent associations between duration of treatment 
interruptions and viral rebound (obtained by fitting 3 separate models) 
  RR (95% CI) P-value 
Number of prior treatment  0 1 0.005 
interruptions lasting <3 months 1 1.18 (1.06, 1.30)  
 >2 1.15 (0.94, 1.41)  
Number of prior treatment  0 1 <0.0001 
interruptions lasting 3 -6 months 1 1.32 (1.17, 1.48)  
 >2 1.49 (1.13, 1.99)  
Number of prior treatment  0 1 <0.0001 
interruptions lasting >6 months 1 1.27 (1.15, 1.41)  
 >2 1.47 (1.21, 1.80)  
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7.3.9. Viral load at time of prior treatment interruptions  
The number of treatment interruptions was also considered after stratification by the 
viral load at the time of the interruption. The total number of interruptions at an 
undetectable viral load (<400 copies/mL) was 2,207 (27.5%), whilst 3,250 (40.5%) 
interruptions were made when the viral load was above 400 copies/mL. In 
univariable analyses, patients who interrupted treatment once with a detectable viral 
load were almost twice as likely to experience viral rebound than those who had 
never interrupted therapy with a detectable viral load (1.97 (1.80, 2.14)). This 
estimate increased to 2.77 (2.34, 3.25) amongst patients who had interrupted 
therapy at least twice whilst having a detectable viral load. Patients interrupting 
therapy once with an undetectable viral load were 36% more likely to experience 
viral rebound (1.36 (1.21, 1.54)) compared to those who had never interrupted 
therapy with an undetectable viral load and this increased to 52% for those who had 
interrupted therapy at least twice with an undetectable viral load (1.52 (1.12, 2.08)). 
Interestingly, 2,567 (32.0%) interruptions to therapy were made without having a 
viral load measure recorded at time of interruption. Patients with 1 prior interruption 
had a 79% higher risk of viral rebound compared to those with no prior interruptions 
with missing viral loads, whilst those with at least 2 prior interruptions were over 3 
times as likely to experience viral rebound. In multivariable analyses, interrupting 
treatment at an undetectable viral load was no longer significantly associated with 
viral rebound (1.07 (0.94, 1.21) and 0.92 (0.67, 1.26) comparing 1 prior treatment 
interruption and 2 or more prior treatment interruptions at an undetectable viral load 
to no prior treatment interruptions at an undetectable viral load, p=0.50). However, 
patients who had one prior interruption at a detectable viral load had a 28% higher 
risk of viral rebound compared to those who had no prior treatment interruptions at a 
detectable viral load (1.28 (1.16, 1.41)), whilst those who had 2 or more prior 
interruptions at a detectable viral load had a 49% higher risk of viral rebound (1.49 
(1.25, 1.78)) (p<0.0001). Patients with missing viral loads at treatment interruption 
were also more likely to experience viral rebound compared to those without any 
prior interruptions whilst the viral load was unknown (1.24 (1.11, 1.39) and 1.76 
(1.44, 2.15) for one interruption and 2 or more interruptions respectively, compared 
to no interruptions whilst the viral load was unknown). 
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Table 7.3.9.1: Independent associations between viral load at treatment 
interruption and viral rebound (obtained by fitting 3 separate models) 
  RR (95% CI) P-value 
Number of prior treatment  0 1 0.50 
interruptions at VL <400 copies/mL 1 1.07 (0.94, 1.21)  
 >2 0.92 (0.67, 1.26)  
Number of prior treatment  0 1 <0.0001 
interruptions at VL >400 copies/mL 1 1.28 (1.16, 1.41)  
 >2 1.49 (1.25, 1.78)  
Number of prior treatment  0 1 <0.0001 
interruptions at a missing VL 1 1.24 (1.11, 1.39)  
 >2 1.76 (1.44, 2.15)  
 
7.3.10. Regimen and viral load at time of prior treatment interruptions 
The regimen at the time of the treatment interruption was initially fitted in a separate 
model to the models assessing the viral load at treatment interruption (Table 
7.3.10.1). In univariable analyses, the risk of viral rebound increased with the 
number of prior treatment interruptions for those receiving NNRTI-, PI/r- and PI-
based regimens. The strongest effect was seen amongst patients taking PI/r-based 
regimens; patients with 2 or more prior interruptions of a PI/r-based regimen were 
over 3 times as likely to experience viral rebound compared to those with no prior 
interruptions of a PI/r based regimen. These effects remained statistically significant 
after adjusting for potential confounders. Patients with 2 or more interruptions of an 
NNRTI-based regimen had a 46% increased risk of viral rebound compared to those 
with no prior interruptions, whilst those interrupting a PI/r-based regimen on 2 or 
more occasions had a 54% higher risk of viral rebound. Patients interrupting a single 
PI-based regimen on 2 or more occasions had a 20% higher risk of viral rebound 
compared to those with no prior interruptions of a single PI-based regimen.  In 
multivariable analyses, the number of interruptions remained linearly associated with 
viral rebound. Again, the strongest effect was seen amongst patients who had 
interrupted a PI/r regimen on more than 2 occasions (1.54 (1.20, 1.98) compared to 
no prior interruptions of a PI/r-based regimen).  
Given that a detectable viral load at interruption was significantly associated with 
viral rebound, this variable was fitted in the same model as the regimen interrupted 
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variable. After adjusting for the regimen interrupted, having a detectable viral load at 
the time of the treatment interruption was no longer associated with the risk of viral 
rebound, whilst interrupting NNRTI or PI/r based regimens remained significantly 
associated with the risk of viral rebound (Table 7.3.10.1). However, these analyses 
may have been confounded with the regimen that patients subsequently restarted.  
Thus, sub-group analyses were performed separately among those who were 
receiving a NNRTI-based regimen at the time of viral suppression and those who 
were receiving a PI/r-based regimen and focused on prior treatment interruptions 
taken whilst the viral load was detectable (Table 7.3.10.2).  
    
   
 
 
    
2
8
3 
Table 7.3.10.1: Univariable and multivariable estimates of the impact of regimen and viral load at interruption on risk of viral rebound 
  Univariable Multivariable 
  RR (95% CI) P-value RR (95% CI) P-value 
Model 1: Regimen at interruption     
Number of NNRTI-based 0 1 <0.0001 1 0.002 
regimen interruptions 1 1.65 (1.49, 1.82)  1.18 (1.03, 1.36)  
 >2 2.71 (2.21, 3.32)  1.46 (1.17, 1.82)  
Number of PI/r-based 0 1 <0.0001 1 0.0004 
regimen interruptions 1 1.96 (1.73, 2.23)  1.24 (1.07, 1.45)  
 >2 3.31 (2.61, 4.20)  1.54 (1.20, 1.98)  
Number of PI-based  0 1 <0.0001 1 0.03 
regimen interruptions 1 1.78 (1.59, 1.98)  1.20 (1.04, 1.38)  
 >2 2.30 (1.67, 3.17)  1.23 (0.88, 1.72)  
Number of „Other‟-based  0 1 <0.0001 1 0.44 
regimen interruptions 1 0.55 (0.51, 0.59)  0.94 (0.82, 1.08)  
 >2 1.42 (1.06, 1.89)  1.12 (0.84, 1.51)  
Model 2: Detectable VL and regimen at interruption    
Number of interruptions 0   1 0.16 
    
   
 
 
    
2
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at detectable viral load 1   1.11 (0.99, 1.25)  
 >2   1.14 (0.90, 1.44)  
Number of NNRTI-based 0   1 0.04 
regimen interruptions 1   1.13 (0.97, 1.32)  
 >2   1.37 (1.07, 1.75)  
Number of PI/r-based 0   1 0.01 
regimen interruptions 1   1.20 (1.02, 1.41)  
 >2   1.47 (1.11, 1.93)  
Number of PI-based  0   1 0.18 
regimen interruptions 1   1.15 (0.99, 1.34)  
 >2   1.17 (0.83, 1.64)  
Number of „Other‟-based  0   1 0.62 
regimen interruptions 1   0.95 (0.82, 1.10)  
 >2   1.07 (0.79, 1.46)  
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Among those receiving a NNRTI-based regimen, those who had previously 
interrupted at least one NNRTI regimen at a detectable viral load had a 71% 
increased rate (adjusted RR 1.71 (1.17, 2.50)) of viral rebound compared to those 
patients who had never interrupted therapy. The rate of rebound among patients 
who had interrupted only non-NNRTI-based regimens at detectable viral load levels 
was only 18% higher (1.18 (0.86, 1.61)) compared to that in patients who had never 
previously interrupted therapy and was not statistically significant. In contrast, 
among patients who were currently on a PI/r-based regimen, those who had 
previously interrupted a PI/r-based regimen with a detectable viral load had a 59% 
increased rate (1.71 (1.17, 2.50)) of viral rebound compared to those patients who 
had never interrupted therapy. Patients in this group who had interrupted only non-
PI/r-based regimens at a detectable viral load had a rate of viral rebound that was 
18% (1.18 (0.98, 1.41)) higher than that among patients who had never interrupted 
therapy. 
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Table 7.3.10.2: Independent estimates from sub group analyses:  Patients currently receiving NNRTI based regimens and those 
currently receiving PI/r based regimens 
 
Univariable Multivariable 
 
RR (95% CI) P-value RR (95% CI) P-value 
Patients currently on an NNRTI regimen 
    
No prior interruptions 1 <0.0001 1 0.06 
At least one interruption of a NNRTI regimen at a detectable viral load 2.41 (1.67, 3.48)  1.71 (1.17, 2.50)  
No interruption of a NNRTI at a detectable viral load, but interruption 
of other regimens at a detectable viral load 
1.96 (1.46, 2.64)  1.18 (0.86, 1.61)  
No interruption at a detectable viral load, but at least one interruption 
at an undetectable viral load 
1.14 (0.82, 1.59)  1.11 (0.79, 1.56)  
Patients currently on an PI/r regimen 
    
No prior interruptions 1 <0.0001 1 0.004 
At least one interruption of a PI regimen at a detectable viral load 2.14 (1.68, 2.73)  1.59 (1.23, 2.05)  
No interruption of a PI at a detectable viral load, but interruption of 
other regimens at a detectable viral load 
1.42 (1.20, 1.68)  1.18 (0.98, 1.41)  
No interruption at a detectable viral load, but at least one interruption 
at an undetectable viral load 
1.07 (0.84, 1.36)  0.98 (0.77, 1.25)  
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7.4. Discussion 
Following the publication of the SMART trial (522) it has been anticipated that the 
proportion of follow-up time spent on treatment may rise. In these analyses, I have 
shown that the proportion of time spent on treatment has been increasing steadily in 
the last 10 years. In this dataset, information is only available up until early 2008 and 
hence it is likely that the proportion of time spent on treatment has continued to rise. 
Further, as the results of the SMART trial are incorporated into treatment guidelines, 
it is possible that the rise in the proportion of time spent on treatment may be at a 
higher rate than previously seen. However, the proportion of new patients who are 
diagnosed early may also impact on these results, i.e. the proportion of time spent 
on treatment may decrease if a larger number of patients under follow-up are 
diagnosed early and do not start treatment until their CD4 counts are below 
guideline recommendations.  
 
However, amongst those who have started HAART, a quarter of patients interrupted 
all treatment for greater than two weeks at least once whilst under follow-up. 
Interestingly, the proportion of interruptions decreased in later calendar years. This 
may be explained by a greater awareness of the consequences of interrupting 
treatment, especially in light of the results from the SMART trial. Amongst those who 
interrupted therapy, a higher proportion of patients (36%) interrupted an NNRTI 
regimen than a PI/r regimen (27%). This is not surprising given that NNRTI-based 
regimens are the most commonly used regimens within the CHIC cohort. A third of 
patients restarted the same NNRTI regimen, suggesting that the interruption 
amongst these patients was not due to viral rebound or resistance to the NNRTI, but 
rather just a break from therapy. However, 30% of patients did restart a PI/r-based 
regimen, suggesting that these patients may have had resistance to the NNRTI in 
their regimen. Patients were still being monitored whilst on a treatment break, 
evident from the number of CD4 counts and viral loads during the interruption. 
 
Though previous studies have reported the short to medium-term effects of 
interrupting therapy (439;445;450;455;459;460;518-520;522), the long-term effects 
of treatment interruptions among those who subsequently achieve an undetectable 
viral load has not previously been investigated. Further, many studies have 
identified factors associated with viral rebound, but no study to date has specifically 
focussed on the effect of the duration of viral suppression on the rate of viral 
rebound in relation to the antiretroviral regimens previously failed. These analyses 
included patients who are representative of the UK CHIC population as a whole as 
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most patients were male, of white ethnicity and MSM risk group. Patients who had 
interrupted treatment prior to the viral suppression episode had similar 
demographics and CD4 counts to those without prior interruptions but were more 
likely to have received mono/dual therapy before receiving HAART and were also 
more likely to have failed regimens before entering the viral suppression episode. 
This suggests that prior interruptions were not simply a break in treatment, but were 
due to resistance mutations surfacing and hence a change in antiretroviral therapy 
being implemented. This is further supported by the fact that only a quarter of 
patients restarted the same regimen at the end of their treatment interruption. 
Patients who had previously interrupted while their viral load was detectable (>400 
copies/mL) had up to a 49% higher chance of rebounding, even after controlling for 
the duration of viral suppression.  In contrast, there was no evidence to suggest that 
interrupting therapy at a viral load of <400 copies/mL was associated with a raised 
risk of viral rebound 
 
Other studies focusing on rates of viral suppression after interrupting therapy 
(455;520) have demonstrated that interruption of treatment at an undetectable viral 
load is generally associated with a lower rate of suppression compared to 
continuous therapy. It should be noted that these analyses focus solely on those 
patients with a suppressed viral load while on therapy.  In particular, patients who 
have previously interrupted therapy must have re-attained viral suppression on 
restarting therapy to be included in these analyses.  Thus, a selected group of 
patients with better adherence who may be expected to have better long-term 
outcomes may have been included. 
 
The results in this Chapter show that the rebound rate increases as the number of 
prior treatment interruptions with detectable viral load increases. These findings may 
be a consequence of the higher risk of resistance evolution in patients who had 
previously interrupted HAART(459).  Resistance mutations may have been archived 
during the period when drug levels were low immediately after interruption, as well 
as in the period before interruption when the viral load was detectable.   Yerly et al 
reported that the M184V/I mutation is frequently selected during repeated treatment 
interruptions (460), consistent with results from Schweighardt et al, who concluded 
that repeated treatment interruptions of certain antiretroviral drug regimens may lead 
to the development of drug resistance (521).  It is also possible that prior detectable 
viral load while on therapy, with the consequent evolution of resistance, is the main 
reason for the association, rather than the interruption itself. These hypotheses 
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would be consistent with our findings of a higher rate of viral rebound in those who 
had previously interrupted an NNRTI with a detectable viral load and then restarted 
the same class of drug, which appeared to be larger than the corresponding level of 
increased risk for those who had interrupted a PI/r among those on a PI/r, and which 
may be a consequence of the longer half-life of the NNRTI class. 
A lower rate of archived resistance is expected in patients who interrupt their 
therapy when their viral load levels are undetectable due to the reduced opportunity 
for replication of virus in the presence of sub-optimal drug levels. The findings of a 
lack of association between interruption of therapy at undetectable viral loads and 
subsequent viral rebound are consistent with this.  
 
However, these findings might also be explained by confounding by adherence, in 
that patients who have previously interrupted HAART may be those who are 
generally less adherent to HAART and hence are more likely to experience viral 
rebound, either due to the emergence of resistance or to the presence of sub-
optimal drug levels.  If so then the explanation for the lack of relationship between 
treatment interruptions at undetectable viral loads and viral rebound may be that 
those patients who interrupted treatment at undetectable viral loads and then 
managed to re-suppress their viral load on restarting treatment may generally have 
better adherence levels than those who interrupt at a detectable viral load and may 
therefore be more likely to maintain viral suppression.  
 
In these analyses, I have also shown that though viral rebound rates increased with 
the number of regimens previously failed they declined progressively with increased 
duration of viral suppression. Within the first year of viral suppression, the rate of 
rebound ranged from 6.57/100 pys in patients on first-line therapy, to 1.54/100 pys 
in patients who had failed five or more regimens. However, this large difference in 
viral rebound rate observed between those on first-line and heavily treatment-
experienced patients was substantially reduced with increasing time with 
suppression and there appeared to be little difference in the rebound rate observed 
in patients who remained suppressed for >5 years. 
 
These results showing that viral rebound rates decrease progressively with 
increased duration of viral suppression are consistent with data from other 
observational cohorts (413;414;429).  This is likely to be due to a selection effect, 
whereby patients who are able to suppress their virus for the longest periods tend to 
be those who are most adherent to therapy and those who experience fewest drug 
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toxicities. Further, these patients are likely to be those who achieve the highest 
plasma drug concentrations and have the fewest pre-existing drug resistance 
mutations. It has also been reported that patients who are able to suppress their 
viral load to <50 copies/mL for longer durations of time, are likely to experience even 
lower viral load decreases, to <3 copies/mL (523).  
 
Other factors associated with viral rebound are consistent with those reported in 
other studies. In accordance with the results of a previous study (478), these results 
indicate that a lower baseline CD4 count was a significant predictor of viral rebound. 
One potential explanation is that levels of some drugs are not maintained at optimal 
levels in those with low CD4 counts, due to poorer drug absorption or other factors.  
The finding that black ethnicity was associated with an increased risk of viral 
rebound is consistent with other studies (414;422). This may, in part, be related to 
socio-economic issues. Older age was found to be a significant predictor of a better 
response. In other areas of medicine, older age is generally associated with poorer 
adherence to therapy. However, the converse appears to be the case in HIV, and 
younger age has been associated with poorer responses to therapy (423). The 
reasons for these associations are unclear, however social or behavioural factors 
may play an important role. Calendar year was also associated with an increased 
risk of viral rebound, whereby patients commencing therapy in earlier calendar years 
were at increased risk of viral rebound. These patients are more likely to have had 
prior exposure to NRTI mono or dual therapy and have accumulated mutations 
associated with drug resistance. Further, in recent calendar years, antiretroviral 
drugs have improved considerably and are now associated with fewer toxicities. 
Hence patients starting HAART in later calendar years may be more adherent, 
hence reducing the risk of viral rebound.  
 
Current drug regimen was also a strong predictor of viral rebound. In particular, 
patients receiving d4T/ddI as an NRTI combination were at an increased risk of viral 
rebound when compared to patients receiving AZT/3TC. Both d4T and DDI have 
been associated with peripheral neuropathy and pancreatitis and hence it is possible 
that patients receiving these drugs may not be as adherent as those receiving other 
NRTI backbone combinations. The newer NRTI drug combinations (i.e. those with 
fewer toxicities and less pill burden), for example ABC/3TC and FTC/TFV were 
associated with a reduced risk of viral rebound, further supporting this explanation. 
With regards to the „third‟ drug in the regimen, patients receiving PIs (single or 
ritonavir-boosted) were at an increased risk of viral rebound compared to those 
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receiving EFV. One possible explanation for this is that PI-based therapy is now 
generally used as second-line therapy and hence patients receiving these regimens 
are likely to have failed previous regimens. Patients receiving NVP were also at an 
increased risk of viral rebound compared to those receiving EFV.  Although other 
studies have reported similar results (100;102;103;430;524), 2NN, a large 
randomised trial comparing EFV and NVP did not verify this finding (104).  EFV was, 
however, seen as favourable when analyses were restricted to patients who had 
taken at least one dose of the drug they were assigned to.  
 
It is important to note that in these analyses in particular, unmeasured confounding, 
such as that due to adherence, has not been controlled for. Adherence is likely to 
play a key part in both the decision to interrupt treatment as well as the risk of 
subsequent viral rebound. Furthermore, findings of a non-significant relationship 
between the number of treatment interruptions taken whilst the viral load was 
undetectable and viral rebound, should be interpreted cautiously, given the relatively 
small number of such interruptions.  
 
The results in this Chapter show that there may be long term effects of treatment 
interruption that are present even if viral suppression is subsequently achieved.  
Among those with suppressed viral load on HAART, those who have previously 
interrupted therapy while having a raised viral load may be at increased risk of 
subsequent viral rebound and hence should be monitored regularly.  It is important 
that the potential negative long-term effects of interrupting therapy (both in terms of 
the risk of clinical events and long-term viral failure) are taken into account when the 
decision to interrupt is being made, even if the short-term effects appear to be 
minimal. Amongst patients who do achieve viral suppression, previous failure is 
associated with a higher rate of viral rebound, but the likelihood of rebound declines 
with the duration of suppression. Achievement of viral suppression in a patient with 
previous multiple failures is followed by a period of high risk of rebound that requires 
careful management. Both clinicians and patients can be encouraged that 
regardless of previous treatment failure, rebound rates fall to levels approaching 
those of patients on first-line therapy after 5 years of suppressive therapy. 
 
7.5. Summary 
Although the proportion of time spent on treatment has increased over the last 10 
years, a quarter of patients starting HAART are likely to interrupt treatment at some 
point whilst under follow-up. Though some of these interruptions are simply a 
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treatment break, most patients restart a different regimen. Patients interrupting 
therapy whilst their viral load is detectable, who subsequently restart ART and 
achieve viral suppression are more likely to experience viral rebound than those with 
viral suppression who have not previously interrupted ART. However, patients 
maintaining viral suppression for long periods of time are less likely to experience 
viral rebound, regardless of both the number of prior treatment interruptions and the 
number of regimens previously failed. 
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Chapter 8: Association between laboratory 
abnormalities and mortality 
8.  
  
8.1. Introduction 
Though patients with HIV who are successfully treated now have near normal life 
expectancies as a result of antiretroviral treatment, adverse events associated with 
therapy are of growing concern.  Table 1.6.1 in Chapter 1 lists common and rare 
side effects associated with each of the antiretroviral drugs available.  
 
Results from the Swiss HIV Cohort Study (525) indicate that patients with laboratory 
abnormalities are at increased risk of mortality; those with clinical abnormalities are 
more likely to either change or discontinue treatment. However, these results were 
based on a cross-sectional analysis and hence the effect of adverse events over 
time on mortality and treatment modification could not be assessed.  Further, in the 
Swiss Study, an overall score was calculated by summing up individual scores 
(calculated by assigning 4 points to each serious abnormality, 3 points to each 
severe abnormality, 2 points to each moderate abnormality and 1 point to each mild 
abnormality, based on the Table for Grading Severity of Adult Adverse Experiences 
(283)) of 11 adverse laboratory parameters (haemoglobin, absolute neutrophil 
count, platelet count, creatinine, urate, alanine aminotransferase, alkaline 
phosphatase, bilirubin, amylase, creatinine phosphokinase and lactate). This did not 
allow distinction between those abnormalities which may have contributed more to 
the overall score (and therefore overall risk) than other abnormalities. 
 
In this Chapter, I investigate the association between laboratory abnormalities and 
mortality. In addition to applying the cut-offs used in the Table for Grading Severity 
of Adult Adverse Experiences to score laboratory abnormalities, I will explore 
several other methods of assigning a score to these abnormalities and choosing 
appropriate cut-offs for these scores to represent high risk.  In addition to the 
laboratory markers discussed above, I will also include CD4 and viral load in all 
analyses as both are well recognised predictors of mortality.   
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8.2. Methods 
 
8.2.1. Laboratory data checks 
Although laboratory data received from centres is checked and cleaned before the 
dataset is made available for analysis, the number of different tests performed and 
the centre-specific decision to perform these tests results in a highly variable 
database of laboratory tests. Some centres provide very little or no laboratory data 
at all, whilst others provide data on a wide range of toxicity measures. Centres may 
also provide laboratory data infrequently in one calendar period, but routinely in 
another. In order to describe these irregularities and hence reduce the impact of 
selection bias (i.e. centres providing laboratory measures in only those patients with 
abnormal values or in those perceived to be at high risk), I calculated the proportion 
of patients with laboratory measurements in each calendar year and at each CHIC 
centre. Further, the proportion of patients seen at each centre with laboratory 
measurements available was stratified by calendar year in order to identify any 
centre-specific irregularities. Based on these results, years in which the proportion of 
patients with laboratory measures were very low, and centres at which these 
variables were not measured routinely on all patients, were excluded from the 
analysis.  
 
Differences between the number of laboratory measurements and the duration 
between measurements before and after starting HAART were described. When 
analysing the number of laboratory measurements prior to starting HAART, follow-
up began on date of entry to CHIC and ended at the earliest date of starting HAART 
and 31st December 2007. When analysing the number of laboratory markers after 
starting HAART, follow-up began on date of starting HAART and ended on 31st 
December 2007. 
 
Factors associated with having each laboratory measurement in the years 2000 
(start of follow up, see Section 8.2.2) and 2007 (last complete year of follow up) 
were identified. These latter analyses were performed in order to highlight any 
potential biases that may occur in later analyses (deriving a laboratory score). 
Separate models were fitted for each laboratory measurement and adjusted for the 
following potential predictors: ethnicity, risk-group, age at start of year, sex, CD4 
count at start of year, VL at start of year, and prior laboratory measurement (none, 
abnormal, normal, with measurements being defined as abnormal using the Table 
for Grading the Severity of Adverse Events (283)). Analyses were also adjusted for 
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whether or not patients had started HAART in the year in question to capture the 
possibility of more frequent monitoring around the time of HAART initiation.   
 
8.2.2. Inclusion criteria 
For patients to be included in the main analyses, they must have started HAART in 
or after the year 2000. This time point was chosen since monitoring practices have 
changed considerably since the early HAART era, as have treatment strategies and 
the type of patient under follow-up (in the early HAART era, patients were more 
likely to have experienced mono/dual NRTIs before starting HAART). Patients were 
also required to have at least one laboratory measurement within 2 years of starting 
HAART (the first of each laboratory measurement in this period was defined  as the 
„baseline‟ measurement), including at least one CD4 count and one viral load 
measurement, as these variables have been consistently shown to be associated 
with mortality. Laboratory measurements considered are shown in Section 8.2.3. 
Patients who died within 3 months of first being seen at a CHIC clinic were 
excluded.  
 
Differences between patients who started HAART and had laboratory 
measurements available and those who did not have laboratory measurements 
available (and were hence excluded from the analyses) were investigated using Chi-
squared and Mann Whitney tests. 
 
8.2.3. Deriving a laboratory score to predict mortality 
Several methods were used to derive a laboratory score that could efficiently predict 
mortality within 2 years of starting HAART. The following laboratory markers were 
included in the analyses: alanine aminotransferase (ALT), albumin (ALB), amylase 
(AMY), aspartate transaminase (AST), alkaline phosphatase (ALK), bilirubin (BIL), 
cholesterol (CHL), creatinine (CRE), creatinine phosphokinase (CPK) gamma 
glutamyl transpeptidase (GGT), glucose (GLU), haemoglobin (HAE), high-density 
lipoprotein (HDL), low-density lipoprotein (LDL), triglycerides (TRI) and urea (URE).  
Patients who were under follow up for at least two years, or had died within 2 years 
of starting HAART, were included in the analyses. I used a validation method to 
assess the accuracy of the derived scores. The dataset was randomly partitioned 
into a training set (70% of the data) and a validation set (the remaining 30% of the 
data); all analyses were initially performed on the training set and then validated on 
the validation set. Harrell‟s C-statistic was used to assess the ability of the score to 
discriminate between those who died and those who were alive after 2 years of 
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starting HAART.  A value of greater than 0.5 suggests that the score is able to 
discriminate between the two groups, with values close to 1 indicating better 
discriminatory ability. Patients were also stratified according to the deciles of the 
score distributions; observed and expected numbers of deaths in each strata were 
compared with the Hosmer-Lemeshow statistic (p>0.05 indicates no evidence of 
lack of fit). These statistics were also performed on the validation sets to assess 
model adequacy.  
Only baseline laboratory measurements at start of HAART were considered. The 
different approaches taken to derive a score are outlined below.  
 
8.2.3.1. Stratifying baseline laboratory measurements by quintiles 
(Approach A) 
In the first instance, I split the distribution of each laboratory variable into quintiles 
and calculated the proportion of deaths in each stratum. For most variables, a score 
of 1 was assigned to the lowest stratum and 5 to the highest. The exceptions to this 
were ALB, HAE and HDL, where a high measurement is considered better than a 
lower measurement. Hence a score of 1 was assigned to the highest stratum and 5 
to the lowest for these three variables. The total score was calculated by adding up 
the individual scores for each laboratory measurement. Patients with missing 
baseline laboratory measurements were assigned a score of 1 for each 
measurement (i.e. these patients were considered to have a low risk). The overall 
score was split into quintiles and associations between this score and mortality was 
assessed using logistic regression.   
 
8.2.3.2. Using continuous baseline laboratory measures (Approach B) 
These analyses were similar to those described above. However, the laboratory 
measures were not split into categorical variables, but rather, the continuous 
baseline measures were used instead. The estimates from a multivariable logistic 
regression model were used to derive an overall laboratory score to predict 
mortality. Sensitivity and specificity of the chosen score were calculated. Patients 
with missing baseline laboratory measures were excluded from these analyses.  
 
8.2.3.3. Principal component analysis (Approach C) 
Principal component analysis is a method of reducing the number of variables 
included in a regression model. Variables which are correlated to some degree are 
reduced into a smaller number of principal components which account for most of 
the variance in the observed variables. For example, all variables which measure 
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liver function may be correlated into one new variable. A linear combination of 
weighted observed variables forms a principal component. Ideally, the first 
component extracted accounts for a large amount of total variance and each 
subsequent component accounts for progressively smaller amounts of variance. In 
these analyses, I retained all components which cumulatively accounted for at least 
70% of the total variance. Other methods of selecting the components to keep 
included the following: 
1. Retain all components with an eigenvalue >1 
2. The scree test – plot eigenvalues and look for a „break‟ between the components. 
Retain all components that appear before the break 
3. Remove any variables which „load‟ significantly onto more than one component. 
In these analyses, a loading is defined as significant if its absolute value is greater 
than 0.40. Variables which significantly load onto more than one variable are not 
measuring either component efficiently.   
4. Ensure there are at least 3 variables which „load‟ on to a component, i.e. each 
component is made up of at least 3 variables which share the same conceptual 
meaning 
Further details of how to select principal components can be found on the following 
website: http://support.sas.com/publishing/pubcat/chaps/55129.pdf).  
 
I initially performed these analyses on only those patients who had all baseline 
laboratory measures available. I then excluded AMY and GLU from the analyses as 
a large proportion of patients had these measurements missing. In the final step, I 
also excluded HDL and LDL from the analyses in an attempt to increase the number 
of patients in the analysis.  
 
8.2.3.4. Replicating the Swiss score (Approach D) 
In these analyses, the Swiss toxicity score (525) was replicated using the CHIC 
dataset. ALT, ALK, ALB, AMY, BIL, CRE, HAE and URE were used to derive the 
score. Though lactate, CPK, neutrophil count and platelet count were also used in 
the Swiss score, these variables are not routinely collected in UK CHIC and hence 
were not used to derive the overall score.  
Each laboratory measure was stratified and scored according to the Table for 
Grading Severity of Adult Adverse Experiences. Serious severe abnormalities were 
a given a score of 4, severe abnormalities a score of 3, moderate abnormalities a 
score of 2 and mild abnormalities a score of 1. Scores were summed to provide an 
overall score. Logistic regression was used to assess the association between this 
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overall score and death. Patients who did not have baseline laboratory values 
measured, and those with measures that did not meet the criteria to be defined as 
having a „mild‟ toxicity were given a score of 0 for each particular laboratory variable. 
The rationale for assigning a score of 0 to those without laboratory values measured 
was that patients who reported no adverse events may have been less likely to have 
a laboratory measurement. Hence, though not always the case, it is likely that their 
laboratory values were in the normal range. In sensitivity analyses, only patients 
with all baseline laboratory measures were included.   
 
8.2.3.5. Six-month risk of mortality 
The approaches described above aim to predict the long-term risk of mortality.  
I used two of these approaches to derive a score for the short-term risk of mortality, 
i.e. a six month risk of mortality. These were Approach B (using continuous baseline 
measures) and Approach D (replicating the Swiss score).  In the former method, all 
available laboratory markers were used (not just baseline) and a score was derived 
using the estimates of the regression model. In the latter method, a score was 
assigned to the time-updated laboratory variables and this score was fitted in a 
regression model. I did not use Approach A as splitting the laboratory measures into 
quintiles did not give a convincing significant association between the overall score 
and mortality. The same was true for Approach C (principal component analysis).  
 
In order to use the continuous measures at baseline approach to assess short-term 
mortality, patient follow-up was split into 6-month periods. The association between 
laboratory measurements at the start of each period and mortality within 6 months 
was assessed using logistic regression, taking into account multiple records from 
each patient (by using generalised estimating equations). Significant variables in the 
multivariable model were used to derive a score as previously described.  
 
In the second method, using Approach D, the Swiss score was updated at the start 
of each 6-month interval. Again, logistic regression was used to assess the 
association between the overall score and mortality.  
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8.3. Results 
 
8.3.1. Laboratory data checks 
 
8.3.1.1. Proportion of patients with laboratory measurements in each 
calendar year 
CD4 and VL are routinely measured markers and were hence analysed separately 
from the laboratory markers discussed below. The proportion of patients with CD4 
counts in each year of follow-up steadily increased from 69% in 1996 to 86% in 
2007 (Table 8.3.1.1.1). Though the proportion of patients under follow-up with 
recorded VL measurements was low in 1996 (27%), in 1997 it was 71% and this 
increased to 93% in 2007.  
 
Table 8.3.1.1.1: Proportion of patients with CD4 and VL measurements 
stratified by year under follow-up 
Year under 
follow-up 
Number of patients under 
follow-up 
% of patients with at least one 
measurement in each year 
  CD4 VL 
1996 8791 69 27 
1997 9330 73 71 
1998 10327 78 79 
1999 11342 81 81 
2000 12441 83 78 
2001 13740 85 81 
2002 15111 86 83 
2003 16381 87 86 
2004 17816 87 87 
2005 19468 88 88 
2006 20570 91 93 
2007 20451 91 93 
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The proportions of patients with at least one laboratory measurement in each year, 
stratified by year of follow-up, are shown in Table 8.3.1.1.2. Generally, over 50% of 
patients had at least one laboratory measurement. However, the proportion of 
patients with specific laboratory measurements was highly variable across all 
calendar years and there was little evidence to suggest that a higher proportion of 
patients had laboratory measurements in later calendar years as may have been 
expected. In most years, over 50% of patients had the following measurements: 
ALT, ALB, ALK, BIL, CRE, and HAE. Around 40% of patients had CHL, TRI and 
URE measured, and around 30% of patients had HDL, LDL, AMY and GLU 
measured. Less than 30% of patients had AST, CPK, LAC and GGT measured in 
most calendar years.  
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Table 8.3.1.1.2: Proportion of patients with laboratory measurements stratified by year under follow-up 
Year  Patients under follow-up  % of patients with at least one laboratory measurement in each year 
  N Any 
measure 
ALT ALB AMY AST ALK BIL CHL CPK 
1996 8791 48 41 38 10 17 44 44 2 2 
1997 9330 50 43 40 10 14 47 47 4 2 
1998 10327 55 48 45 18 13 53 53 23 2 
1999 11342 59 52 45 33 12 57 57 41 2 
2000 12441 71 63 53 41 12 68 68 51 3 
2001 13740 72 65 56 42 13 70 70 56 4 
2002 15111 73 65 58 41 13 71 71 51 4 
2003 16381 73 65 61 38 15 71 71 44 4 
2004 17816 66 57 57 32 14 63 63 51 4 
2005 19468 55 47 53 19 13 54 54 46 5 
2006 20570 55 46 53 18 13 53 53 47 6 
2007 20451 51 43 50 16 8 50 50 42 5 
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Table 8.3.1.1.2 continued 
Year  Patients under follow-up % of patients with at least one laboratory measurement in each year 
 N CRE GGT GLU HAE HDL LAC LDL TRI URE 
1996 8791 44 17 8 47 0 0 0 2 32 
1997 9330 46 20 13 49 1 0 1 4 30 
1998 10327 52 21 20 53 3 0 3 20 38 
1999 11342 56 22 23 57 5 2 5 37 42 
2000 12441 65 25 26 70 12 17 11 47 53 
2001 13740 64 28 30 71 17 20 16 51 54 
2002 15111 71 27 35 72 23 9 22 48 57 
2003 16381 71 28 35 72 27 3 27 44 58 
2004 17816 63 25 35 65 28 9 28 51 47 
2005 19468 54 22 34 55 39 4 38 45 41 
2006 20570 53 21 33 54 43 1 41 46 42 
2007 20451 50 17 30 50 41 1 31 41 45 
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8.3.1.2. Proportion of patients with laboratory measurements at each 
clinical centre 
The proportion of patients with laboratory measurements in each calendar year was 
lower than anticipated, particularly in later calendar years. Since the denominator 
used was all patients under follow-up, I next stratified the proportion of patients with 
laboratory measurements by clinical centre to identify any centres which did not 
provide laboratory measurements. These proportions are shown in Table 8.3.1.2.1. 
Although the proportions do differ by laboratory marker, i.e. some centres provide 
data on some laboratory markers and not on others, it was apparent that four 
centres provided very little data on laboratory markers at all (centres 107, 109, 110 
and 111). Infact, it is extremely likely that the laboratory data provided from these 4 
centres was actually from patients who had been seen at more than one clinic and 
hence did have some laboratory measurements on their records (i.e. recorded by 
another clinic which did provide laboratory data to CHIC).  
 
Given that patients seen at these clinics contributed to the proportions in Table 
8.3.1.1.2, I recalculated the proportion of patients with a laboratory measurement in 
each calendar year, after removing all patients seen at any of the above 4 centres 
(Table 8.3.1.2.2). I also restricted analyses to the year 2000 onwards for the 
reasons outlined in Section 8.2.2. The proportion of patients with at least one 
laboratory measurement increased from around 50% (before excluding the 4 
centres) to above 60%. However, this proportion appeared to decline from 2000 
(80%) to 2007 (62%).  This decline was evident in all laboratory variables.   
 
To investigate this further, I stratified patients by both the year of follow-up and the 
clinical centre they were attending. Tables showing the proportion of patients at 
each centre with laboratory measurements stratified by calendar year are provided 
in Appendix A.  Whilst a decline in the proportion of patients having specific 
laboratory measurements from 2000 to 2007 was evident in some centres, the 
overall proportion of patients with at least one laboratory measurement increased in 
all but one centre. In Centre 103 however, the proportions of patients with any 
laboratory markers measured in the years 2000-2007 were 75%, 76%, 76%, 77%, 
54%, 20%, 16% and 8% respectively. Hence it was apparent that from 2004 
onwards, we had not received the full laboratory dataset from this centre. This 
contributed wholly to the overall decline in proportions seen in Table 8.3.1.2.2. 
Hence, in all further analyses, patient follow-up was censored at December 2003 
amongst patients seen at Centre 103. 
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Table 8.3.1.2.1: Proportion of patients with toxicity measurements at each centre  
Centre Patients under follow-up  % of patients with at least one laboratory measurement in each year 
 N ALT ALB AMY AST ALK BIL CHL CPK CRE 
101 2137 82 83 47 9 84 84 79 15 83 
102 4361 90 90 74 24 90 90 80 33 90 
103 8438 66 54 50 19 66 66 46 1 66 
104 4750 82 82 24 5 82 82 71 8 81 
105 2945 20 87 79 2 87 87 78 1 86 
106 3023 92 92 4 91 92 92 83 1 92 
107 2879 9 8 5 3 9 9 8 1 9 
108 915 87 84 78 8 87 87 52 78 87 
109 1304 7 7 3 3 7 7 6 1 7 
110 1013 5 6 2 2 6 6 5 1 6 
111 842 3 3 2 1 3 3 3 0 3 
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Table 8.3.1.2.1 continued 
Centre Patients under follow-up  % of patients with at least one laboratory measurement in each year 
 N GGT GLU HAE HDL LAC LDL TRI URE 
101 2137 12 78 84 78 12 78 73 84 
102 4361 44 78 91 63 9 52 80 68 
103 8438 29 10 66 9 34 9 46 65 
104 4750 26 61 85 68 11 68 71 82 
105 2945 86 43 86 58 17 58 78 66 
106 3023 91 86 91 77 24 76 83 92 
107 2879 4 6 9 6 2 6 8 8 
108 915 2 2 87 0 7 30 30 71 
109 1304 5 6 7 5 2 5 6 7 
110 1013 3 4 6 5 1 5 5 5 
111 842 2 2 3 2 1 2 3 3 
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Table 8.3.1.2.2: Proportion of patients with toxicity measurements stratified by year under follow-up (excluding patients seen at 
centres 107, 109, 110, 111 and years 1996-1999) 
Year  Patients under follow-up  % of patients with at least one laboratory measurement in each year 
 N Any ALT ALB AMY AST ALK BILI CHL CPK 
2000 10884 80 63 53 41 12 68 68 51 3 
2001 11922 82 65 56 42 13 70 70 56 4 
2002 13007 83 65 58 41 13 71 71 51 4 
2003 14044 83 65 61 38 15 71 71 44 4 
2004 15087 76 57 57 32 14 63 63 51 4 
2005 16089 65 47 53 19 13 54 54 46 5 
2006 16792 66 46 53 18 13 53 53 47 6 
2007 16448 62 43 50 16 8 50 50 42 5 
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Table 8.3.1.2.2. continued 
Year  Patients under follow-up  % of patients with at least one laboratory measurement in each year 
 N GGT GLU HAE HDL LAC LDL TRI URE 
2000 12441 71 63 53 41 12 68 68 51 
2001 13740 72 65 56 42 13 70 70 56 
2002 15111 73 65 58 41 13 71 71 51 
2003 16381 73 65 61 38 15 71 71 44 
2004 17816 66 57 57 32 14 63 63 51 
2005 19468 55 47 53 19 13 54 54 46 
2006 20570 55 46 53 18 13 53 53 47 
2007 20451 51 43 50 16 8 50 50 42 
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8.3.2. Frequency, duration and value of laboratory measurements pre and 
post HAART 
The frequency and duration of laboratory measurements stratified according to 
HAART status (pre-HAART and post-HAART) amongst the 24,166 patients eligible 
for analyses are shown in Table 8.3.2.1. For all laboratory markers, a higher number 
of measurements were observed post-HAART than pre-HAART.  This rise was 
particularly evident for the liver function tests ALT (median number of 
measurements increased from 4 whilst not receiving HAART to 16 after receiving 
HAART), ALB (3 to 13), and ALK (4 to 17). The median number of BIL and HAE 
measurements also increased substantially in the post-HAART period.  
The duration between measurements was shorter after patients had started HAART 
for all toxicity measurements, other than AST (duration was longer post-HAART) 
and URE, for which the median duration between measurements was the same, 
though the upper quartile was shorter than that seen in the pre-HAART period (3.4 
vs. 4 months).  
 
The value of most laboratory markers was higher post-HAART than pre-HAART. 
The exceptions to this were ALT, AMT and AST. Amongst the markers which did 
increase after the start of HAART, the biggest increase was seen for ALK and GGT.   
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Table 8.3.2.1: Frequency and duration of laboratory measurements before and after starting HAART 
 Number of measures per patient 
(Median (IQR)) 
Duration (months) between 
measurements (Median (IQR)) 
Value of measurement 
(Median (IQR)) 
Laboratory 
marker 
Pre-HAART Post-HAART Pre-HAART Post-HAART Pre-HAART Post-HAART 
ALT 4 (2, 8) 16 (7, 28) 2.4 (0.7, 4.2) 2.2 (0.9, 3.3) 29 (20, 45) 24 (17, 37) 
ALB 3 (1, 8) 13 (5, 25) 2.4 (0.7, 4.1) 2.3 (0.9, 3.4) 41 (37, 44) 44 (41, 46) 
AMY 2 (1, 4) 8 (3, 15) 3.2 (1.8, 6.4) 2.9 (1.6, 4.4) 70 (51, 95) 65 (49, 89) 
AST 3 (1, 8) 7 (2, 20) 1.5 (0.4, 3.4) 2.0 (0.8, 3.3) 30 (24, 40) 26 (21, 34) 
ALK  4 (1, 8) 17 (7, 29) 2.4 (0.7, 4.1) 2.2 (0.2, 3.3) 72 (59, 90) 85 (69, 106) 
BIL 3 (1, 8) 17 (7, 29) 2.5 (0.7, 4.2) 2.2 (0.9, 3.3) 8 (6, 11) 8 (6, 11) 
CHL 2 (1, 4) 10 (4, 17) 3.4 (2.1, 6.4) 3.0 (1.8, 4.2) 4 (3, 5) 5 (4, 5) 
CRE 3 (1, 8) 17 (7, 28) 2.3 (0.5, 4.1) 2.1 (0.8, 3.3) 80 (70, 90) 81 (72, 91) 
GGT 2 (1, 6) 6 (2, 17) 2.5 (0.7, 4.2) 2.4 (0.8, 3.7) 31 (18, 60) 39 (25, 79) 
GLU 2 (1, 4) 9 (4, 18) 2.9 (0.9, 5.3) 2.8 (1.4, 4.1) 5 (4, 5) 5 (4, 5) 
HAE 4 (2, 9) 17 (8, 29) 2.2 (0.6, 3.9) 2.1 (0.8, 3.3) 13 (12, 14) 14 (12, 15) 
HDL 2 (1, 4) 8 (4, 14) 3.2 (1.8, 6.0) 3.0 (1.8, 4.6) 1 (1, 1) 1 (1, 2) 
LDL 2 (1, 3) 6 (3, 13) 3.3 (1.8, 6.0) 3.0 (1.8, 4.3) 2 (2, 3) 3 (2, 3) 
TRI 2 (1, 4) 10 (5, 17) 3.4 (2.1, 6.4) 3.0 (1., 4.2) 1 (1, 2) 1 (1, 2) 
URE 3 (1, 8) 11 (4, 23) 2.1 (0.5, 4.0) 2.1 (0.7, 3.4) 4 (3, 5) 5 (4, 6) 
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8.3.3. Factors associated with having a laboratory measurement 
Factors associated with having a laboratory measurement in the year 2000 were 
identified and compared to those associated with having a laboratory measurement 
in 2007. Separate models were fitted for each laboratory measurement. Since CD4 
count and VL were routinely measured since 2000 (Table 8.3.1.1.1), separate 
models were not fitted for these markers. However, models for all other laboratory 
markers were adjusted for both CD4 count and VL.  
 
In univariable analyses, having started HAART was positively associated with 
having a laboratory measurement in 2000 for all laboratory markers, apart from ALT 
and URE. The strongest association was seen for ALB (OR=1.53 (95% CI: 1.34, 
1.75)). These associations remained significant after adjusting for potential 
confounders (ethnicity, risk, sex, age at start of year, CD4 at start of year, VL at start 
of year, status of prior laboratory measurement (normal, abnormal, missing)) – the 
strongest association between having started HAART and having a laboratory 
measurement was seen for TRI (2.87 ((2.46, 3.36)). These associations also 
remained significant when the outcome was changed to having a laboratory 
measurement in 2007. However, in these analyses, the strongest associations 
between having started HAART and having a laboratory measurement were seen 
for AMY (2.85 (2.45, 3.31)).  
 
Having a prior abnormal laboratory measurement (defined using the Table for 
Grading the Severity of Adverse Events (283)) was also independently associated 
with a higher chance of having a laboratory measurement in both 2000 and 2007. 
This was true for all laboratory measurements, other than ALB and HDL cholesterol. 
In both 2000 (0.43 (0.37, 0.49)) and 2007 (0.39 (0.33, 0.45)), having a prior 
abnormal ALB measurement was associated with a reduced risk of having an ALB 
measurement. A prior abnormal HDL measurement was not significantly associated 
with having a HDL measurement in 2000 (1.07 (0.76, 1.53)).  
 
The associations between black ethnicity and having a laboratory measurement 
were similar in 2000 and 2007, with the exception of AMY and URE. Patients of 
black ethnicity had a lower risk of having an AMY measurement in 2000 (0.69 (0.58, 
0.83)) compared to those of white ethnicity, but a higher risk of having an AMY 
measurement in 2007 (1.16 (1.01, 1.34)). Similarly, patients of black ethnicity had a 
lower risk of having an URE measurement in 2000 (0.81 (0.68, 0.96)) compared to 
those of white ethnicity, but a higher risk of having an URE measurement in 2007 
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(1.23 (1.09, 1.40)). Lipids, such as CHL and TRI were less likely to be measured in 
females in 2000; this association remained significant in multivariable analyses. 
However, in 2007, no association was seen between gender and lipid 
measurements.  
 
Interestingly, the independent associations between heterosexual risk group 
(compared to MSM) and laboratory measurements differed considerably from 2000 
to 2007. In 2000, patients of heterosexual risk group were less likely to have the 
following laboratory measurements: CHL (0.72 (0.59, 0.88)), TRI (0.69 (0.57, 0.84)) 
and URE (0.71 (0.59, 0.86)). No association was seen between heterosexual risk 
group and the following laboratory measurements: ALT, AMY, ALK, BIL, GLU, HAE, 
HDL and LDL. However, other than GLU and HDL, for all laboratory markers, 
heterosexual risk group increased the chances of having a laboratory measurement 
in 2007. Weak associations were seen between age and having a laboratory 
measurement both in 2000 and 2007 – older age was significantly associated with 
having a GLU, HDL, LDL and TRI measurement in 2007.  
 
Finally, in univariable analyses, longer duration of follow-up was significantly 
associated with having a laboratory measurement in the year 2000 for most 
laboratory markers, the exceptions being HDL and LDL. Interestingly, this was not 
the case in 2007. In univariable analyses, longer duration of follow-up was 
associated with a decreased likelihood of having most laboratory markers measured 
in 2007. In multivariable analyses, both in 2000 and 2007, longer duration of follow-
up was generally associated with a decreased likelihood of having a laboratory 
measurement. Adjustment for a prior abnormal measurement was the main variable 
which caused the effect of duration of follow-up to be reversed in 2000. 
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Table 8.3.3.1: Factors associated with having a laboratory measurement in 2000 from multivariable logistic regression 
  ALT ALB AMY ALK BIL CHL CRE 
  Odds Ratio (95% CI) 
Ethnicity White 1 1 1 1 1 1 1 
 Black 0.72 
 (0.57, 0.90) 
1.31 
 (1.10, 1.56) 
0.69                                
(0.58, 0.83) 
1.33
(0.99, 1.78) 
1.35 
(1.01, 1.81) 
1.32 
(1.10, 1.58) 
1.07 
(0.82, 1.38) 
 Other 1.29  
(1.00, 1.68) 
1.20  
(1.00, 1.43) 
0.90                                 
(0.75, 1.08) 
1.10
(0.82, 1.46) 
1.08 
(0.81, 1.44) 
1.18 
(0.97, 1.43) 
0.91 
(0.70, 1.17) 
Risk MSM 1 1 1 1 1 1 1 
 Heterosexual 0.84 
(0.66, 1.07) 
1.56  
(1.29, 1.89) 
1.04 
 (0.86, 1.26) 
1.17 
(0.85, 1.61) 
1.16 
(0.84, 1.58) 
0.72 
(0.59, 0.88) 
1.34 
(1.01, 1.78) 
 Other 0.88 
 (0.77, 1.00) 
0.69 
 (0.33, 0.76) 
0.82 
 (0.75, 0.90) 
0.87 
(0.75,1.02) 
0.87 
(0.74, 1.01) 
1.22 
(1.11, 1.33) 
0.78 
(0.68, 0.90) 
Age Per 10 years 
higher 
1.11       
(1.02, 1.21) 
1.01                 
(0.95, 1.08) 
1.04                                  
(0.98, 1.12) 
1.08
(0.97, 1.19) 
1.07 
(0.97, 1.19) 
1.10 
(1.02, 1.18) 
1.09 
(0.99, 1.19) 
Started HAART Yes vs. No 1.96       
(1.61, 2.39) 
1.64              
(1.41, 1.92) 
2.70                                     
(2.31, 3.15) 
2.57
(1.98, 3.35) 
2.54 
(1.96, 3.30) 
2.79 
(2.38, 3.27) 
2.85 
(2.27, 3.58) 
Sex Female vs. male 0.96       
(0.76, 1.22) 
0.86                        
(0.71, 1.05) 
0.71                                
(0.58, 0.85) 
0.77
(0.56, 1.05) 
0.81 
(0.59, 1.10) 
0.68 
(0.60, 0.82) 
0.75 
(0.57, 1.00) 
CD4 at start of year Per 50 cells 
higher 
1.02      
(1.00, 1.03) 
0.99             
(0.98, 1.00) 
0.97                                 
(0.96, 0.98) 
1.00
(0.99, 1.02) 
1.00 
(0.98, 1.02) 
0.97 
(0.96, 0.98) 
0.99 
(0.98, 1.01) 
VL at start of year Per 1 log higher 1.20       
(1.13, 1.27) 
1.15             
(1.10, 1.20) 
0.93                                  
(0.89, 0.97) 
1.11
(1.03, 1.19) 
1.12 
(1.05, 1.20) 
0.87 
(0.83, 0.91) 
1.04 
(0.98, 1.11) 
Status of prior  Normal 1 1 1 1 1 1 1 
laboratory 
measurement 
Abnormal 1.79       
(1.35, 2.39) 
0.43                    
(0.37, 0.49) 
1.67                                      
(1.10, 2.54) 
2.42
(1.49, 3.93) 
2.45 
(1.75, 3.45) 
2.14 
(1.74, 2.63) 
2.09 
(1.18, 3.69) 
(Within 3 years) No measurement 0.06       
(0.05, 0.07) 
0.20              
(0.18, 0.23) 
0.06                                      
(0.05, 0.07) 
0.07
(0.06, 0.09) 
0.09 
(0.07, 0.11) 
0.14 
(0.12, 0.17) 
0.05 
(0.04, 0.06) 
Duration of follow-up 
at start of year 
Per 1 year 
increase 
0.89 
(0.86, 0.93) 
0.94 
(0.91, 0.97) 
0.98 
(0.95, 1.01) 
0.93 
(0.89, 0.98) 
0.93 
(0.89, 0.98) 
1.02 
(0.99, 1.06) 
0.90 
(0.86, 0.94) 
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Table 8.3.3.1 continued 
  GLU HAE HDL LDL TRI URE 
  Odds Ratio (95% CI) 
Ethnicity White 1 1 1 1 1 1 
 Black 1.01 
(0.84, 1.21) 
1.26 
(0.91, 1.74) 
0.89 
(0.69, 1.14) 
0.91 
(0.70, 1.18) 
1.66 
(1.39, 1.99) 
0.81 
(0.68, 0.96) 
 Other 1.73 
(1.44, 2.07) 
0.90 
(0.67, 1.21) 
0.67 
(0.51, 0.89) 
0.68 
(0.51, 0.91) 
1.44 
(1.19, 1.75) 
0.78   
(0.65, 0.93) 
Risk MSM 1 1 1 1 1 1 
 Heterosexual 0.88 
(0.72, 1.07) 
1.35 
(0.95, 1.91) 
0.96 
(0.73, 1.25) 
1.00 
(0.76, 1.30) 
0.69 
(0.57, 0.84) 
0.71 
(0.59, 0.86) 
 Other 0.83 
(0.76, 0.90) 
1.00 
(0.86, 1.17) 
1.08 
(0.96, 1.22) 
1.06 
(0.94, 1.20) 
1.38 
(1.26, 1.51) 
1.51 
(1.38, 1.64) 
Age Per 10 years 
higher 
1.12 
(1.05, 1.20) 
1.05 
(0.94, 1.18) 
1.07 
(0.98, 1.17) 
1.02 
(0.93, 1.11) 
1.05 
(0.98, 1.12) 
1.08 
(1.01, 1.16) 
Started HAART Yes vs. No 2.32 
(1.99, 2.71) 
1.93 
(1.46, 2.55) 
1.62 
(1.34, 1.96) 
1.63 
(1.34, 1.99) 
2.87 
(2.46, 3.36) 
1.53 
(1.31, 1.80) 
Sex Female vs. male 0.82 
(0.68, 1.00) 
0.80 
(0.57, 1.13) 
0.69 
(0.53, 0.91) 
0.71 
(0.54, 0.94) 
0.78 
(0.64, 0.94) 
0.94 
(0.78, 1.13) 
CD4 at start of year Per 50 cells 
higher 
1.00 
(0.99, 1.01) 
1.00 
(0.98, 1.02) 
0.98 
(0.96, 1.00) 
0.98 
(0.97, 1.00) 
0.98 
(0.97, 0.99) 
1.01 
(1.00, 1.02) 
VL at start of year Per 1 log higher 1.07 
(1.03, 1.12) 
1.22 
(1.13, 1.31) 
1.18 
(1.11, 1.24) 
1.19 
(1.12, 1.26) 
0.88 
(0.84, 0.92) 
1.21 
(1.16, 1.26) 
Status of prior  Normal 1 1 1 1 1 1 
laboratory 
measurement 
Abnormal 1.73 
(1.42, 2.12) 
1.39 
(0.80, 2.43) 
1.07 
(0.76, 1.53) 
1.95 
(1.36, 2.82) 
3.28 
(2.13, 5.05) 
3.18 
(2.20, 4.60) 
(Within 3 years) No measurement 0.07 
(0.06, 0.08) 
0.10 
(0.08, 0.12) 
0.03 
(0.02, 0.04) 
0.04 
(0.03, 0.05) 
0.09 
(0.08, 0.10) 
0.10  
(0.08, 0.11) 
Duration of follow-up 
at start of year 
Per 1 year 
increase 
0.90 
(0.87, 0.93) 
0.94 
(0.89, 0.99) 
0.91 
(0.87, 0.95) 
0.90 
(0.87, 0.94) 
1.03 
(0.99, 1.06) 
0.87 
(0.84, 0.90) 
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Table 8.3.3.2: Factors associated with having a laboratory measurement in 2007 from multivariable logistic regression 
  ALT ALB AMY ALK BIL CHL CRE 
  Odds Ratio (95% CI) 
Ethnicity White 1 1 1 1 1 1 1 
 Black 0.68 
 (0.59, 0.78) 
1.24 
 (1.06, 1.46) 
1.16                                 
(1.01, 1.34) 
1.19
(1.02, 1.38) 
1.23 
 (1.05, 1.43) 
1.51  
(1.32, 1.72) 
1.16 
(1.00, 1.35) 
 Other 1.34  
(1.16, 1.55) 
1.30  
(1.10, 1.52) 
1.51                                  
(1.31, 1.74) 
1.29
(1.11, 1.50) 
1.25 
 (1.07, 1.45) 
1.39   
(1.21, 1.58) 
1.28 
(1.10, 1.49) 
Risk MSM 1 1 1 1 1 1 1 
 Heterosexual 1.32  
(1.13, 1.54) 
1.43  
(1.20, 1.71) 
1.23 
 (1.05, 1.43) 
1.57  
(1.32, 1.86) 
1.57  
(1.32, 1.86) 
1.18   
(1.01, 1.36) 
1.56 
(1.31, 1.84) 
 Other 0.82 
 (0.76, 0.89) 
0.70 
 (0.64, 0.77) 
0.61 
 (0.57, 0.65) 
0.68 
 (0.63, 0.75) 
0.70  
(0.64, 0.76) 
0.87  
(0.81, 0.93) 
0.68 
(0.63, 0.75) 
Age Per 10 years 
higher 
1.01       
(0.96, 1.06) 
1.00                 
(0.95, 1.06) 
0.99                                  
(0.94, 1.05) 
0.99                                    
(0.93, 1.04) 
0.99                           
(0.94, 1.05) 
1.04
(0.99, 1.09) 
0.98 
(0.93, 1.03) 
Started HAART Yes vs. No 1.36       
(1.15, 1.61) 
1.85              
(1.51, 2.28) 
2.85                                     
(2.45, 3.31) 
1.67                                
(1.37, 2.04) 
1.78                                        
(1.46, 2.17) 
2.24
(1.90, 2.63) 
1.67 
(1.37, 2.04) 
Sex Female vs. male 1.26       
(1.09, 1.46) 
1.31                        
(1.09, 1.56) 
0.99                                  
(0.86, 1.14) 
1.17                              
(0.99, 1.39) 
1.25                                
(1.05, 1.48) 
0.92
(0.79, 1.06) 
1.17 
(0.99, 1.39) 
CD4 at start of year Per 50 cells 
higher 
1.03       
(1.02, 1.04) 
1.01             
(1.00, 1.02) 
1.01 
 (0.99, 1.02) 
1.01                                           
(1.01, 1.02) 
1.02
(1.01, 1.03) 
1.00  
(0.99, 1.01) 
1.02 
(1.01, 1.03) 
VL at start of year Per 1 log higher 1.19       
(1.14, 1.24) 
1.19              
(1.14, 1.25) 
1.14                                  
(1.09, 1.19) 
1.15                              
(1.10, 1.20) 
1.16
(1.11, 1.21) 
1.04  
(1.00, 1.08) 
1.15  
(1.10, 1.20) 
Status of prior  Normal 1 1 1 1 1 1 1 
laboratory 
measurement 
Abnormal 2.96       
(2.65, 3.29) 
0.39                    
(0.33, 0.45) 
1.68                                      
(1.41, 2.01) 
1.45                          
(1.14, 1.84) 
3.18
(2.82, 3.58) 
2.66  
(2.41, 2.94) 
1.67  
(1.36, 2.05) 
(Within 3 years) No measurement 0.08       
(0.07, 0.09) 
0.05              
(0.04, 0.05) 
0.09                                       
(0.08, 0.10) 
0.10
 (0.09, 0.11) 
0.13     
(0.12, 0.15) 
0.17  
(0.15, 0.18) 
0.10 
(0.09, 0.11) 
Duration of follow-up 
at start of year 
Per 1 year 
increase 
0.82 
 (0.81, 0.83)      
0.80  
(0.78, 0.81) 
0.89 
 (0.88, 0.90) 
0.80  
(0.79, 0.82) 
0.80  
(0.79, 0.81) 
0.86  
(0.85, 0.87) 
0.80  
(0.79, 0.81) 
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Table 8.3.3.2 continued 
  GLU HAE HDL LDL TRI URE 
  Odds Ratio (95% CI) 
Ethnicity White 1 1 1 1 1 1 
 Black 0.88 
 (0.76, 1.02) 
1.07 
 (0.92, 1.24) 
1.49 
(1.29, 1.72) 
1.20 
(1.06, 1.35) 
1.51  
(1.32, 1.73) 
1.44 
(1.27, 1.63) 
 Other 1.50  
(1.130, 1.73) 
1.25  
(1.07, 1.45) 
1.39 
(1.20, 1.61) 
0.60 
(0.53, 0.68) 
1.40 
(1.23, 1.60) 
1.23 
(1.09, 1.40) 
Risk MSM 1 1 1 1 1 1 
 Heterosexual 1.00  
(0.85, 1.17) 
1.51  
(1.27, 1.78) 
1.19 
(1.01, 1.40) 
1.03 
(0.89, 1.18) 
1.21 
(1.04, 1.41) 
1.21 
(1.05, 1.39) 
 Other 0.97 
 (0.89, 1.05) 
0.67 
 (0.61, 0.73) 
0.83 
(0.77, 0.90) 
1.03 
(0.96, 1.10) 
0.84 
(0.78, 0.91) 
0.93  
(0.87, 1.00) 
Age Per 10 years 
higher 
1.10       
(1.04, 1.16) 
0.99                 
(0.94, 1.04) 
1.17 
(1.10, 1.23) 
1.10 
(1.05, 1.15) 
1.11 
(1.06, 1.17) 
0.97 
(0.93, 1.02) 
Started HAART Yes vs. No 2.64       
(2.25, 3.11) 
1.77              
(1.44, 2.17) 
2.49  
(2.10, 2.95) 
2.59 
(2.24, 3.01) 
2.34 
(1.99, 2.77) 
1.32 
(1.12, 1.54) 
Sex Female vs. male 1.15       
(0.99, 1.35) 
1.09                        
(0.92, 1.29) 
0.95 
(0.81, 1.11) 
1.04 
(0.92, 1.19) 
0.97 
(0.84, 1.12) 
0.96 
(0.83, 1.10) 
CD4 at start of year Per 50 cells 
higher 
1.02       
(1.01, 1.03) 
1.02             
(1.01, 1.03) 
1.00 
(0.99, 1.01) 
0.99 
(0.98, 0.99) 
1.01 
(1.00, 1.02) 
1.01 
(1.00, 1.01) 
VL at start of year Per 1 log higher 1.10       
(1.06, 1.15) 
1.18              
(1.12, 1.23) 
0.99  
(0.95, 1.03) 
0.93  
(0.90, 0.97) 
1.00 
(0.96, 1.04) 
1.05 
(1.01, 1.09) 
Status of prior  Normal 1 1 1 1 1 1 
laboratory 
measurement 
Abnormal 2.83       
(2.47, 3.25) 
1.82                    
(1.43, 2.31) 
1.36 
(1.20, 1.55) 
1.90 
(1.72, 2.11) 
2.46 
(2.03, 2.99) 
3.17 
(2.74, 3.66) 
(Within 3 years) No measurement 0.06       
(0.05, 0.06) 
0.08              
(0.07, 0.09) 
0.05 
(0.05, 0.06) 
0.16 
(0.14, 0.17) 
0.09 
(0.08, 0.10) 
0.73 
(0.65, 0.81) 
Duration of follow-up 
at start of year 
Per 1 year 
increase 
0.92 
(0.01, 0.93)        
0.80  
(0.79, 0.81) 
0.88 
(0.87, 0.89) 
0.91 
(0.90, 0.92) 
0.86 
(0.85, 0.88) 
0.86 
(0.85, 0.87) 
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8.3.4. Patients included in the main analyses 
All patients who had at least one laboratory marker measured after starting HAART 
and after the year 2000 were eligible for inclusion in the main analyses. After 
excluding patients seen at any of the 4 centres without toxicity data (n=6038), those 
who died within 3 months of first being seen (n=348), patients seen at Centre 103 
after 2004 (n=2385) and patients who started HAART before 2000 (n=14753), 9083 
patients were left in the dataset.  
Patients without CD4 counts and VLs within 2 years after starting HAART were also 
excluded (n=1391), and finally, those without a laboratory measurement within 2 
years after starting HAART were removed from the dataset (n=258).  The total 
number of patients included in the analyses was 7,434 (22.8% of the whole CHIC 
dataset).  
 
I assessed differences between those patients who started HAART and did have 
laboratory measurements available after the start of HAART, and those who started 
HAART without laboratory measurements available (Table 8.3.4.1). This latter group 
was chosen as the comparison group to those included in the analyses as the focus 
of this analysis was on patients starting HAART without laboratory measurements 
available. Only differences in ethnicity and risk group were of statistical significance.  
 
Patients included in the main analyses mostly started HAART on NNRTI-based 
regimens (66.8%) and were mostly naïve to therapy at start of HAART (88.6%). The 
median duration of follow-up was 2.5 (1.1, 4.3) years, and median CD4 and log VL 
were 216 (120, 350) cells/mm3 and 4.6 (4.1, 5.2) copies respectively. 
 
Among this subset with at least one laboratory measurement, over 70% of patients 
had at least one measure of most laboratory variables within 2 years of starting 
HAART (the exceptions being AMY, AST, GLU, HDL and LDL). However, only 57% 
of patients had an AMY measure, 23% had an AST measure and 62% had a GLU 
measure (Table 8.3.4.2). The median number of measurements varied according to 
each laboratory variable. ALK, BIL, CRE and HAE were most frequently measured 
(Median: 11 measurements), whilst AMY, AST and GLU were least frequently 
measured. The median duration between measurements was similar for all 
measures, at 2-3 months.   
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Table 8.3.4.1: Differences between those who started HAART with laboratory 
measurements and those who started HAART without laboratory 
measurements available after starting HAART 
  Laboratory measurements after 
HAART 
P-value 
  No Yes  
N  258 7434  
Sex N (%) Male  198 (76.7) 5384 (72.4) 0.13 
 Female 60 (23.3) 2050 (27.6)  
Ethnicity N (%) White 159 (61.6) 4067 (54.7) 0.03 
 Black 65 (25.2) 2466 (33.2)  
 Other 34 (13.2) 901 (12.1)  
Exposure N (%) MSM 146 (56.6) 3765 (50.7) 0.004 
 Heterosexual  75 (29.1) 2878 (38.7)  
 Other 37 (14.3) 791 (10.6)  
Year of starting 2000-2002 110 (42.6) 3096 (41.7) 0.36 
HAART N (%) 2003-2004 76 (29.5) 1973 (26.5)  
 2005-2007 72 (27.9) 2365 (31.8)  
Age at HAART (years) Median (IQR) 37 (32, 42) 37 (32, 43) 0.90 
CD4 at HAART 
(cells/mm3) 
Median (IQR) 215 (120, 339) 216 (120, 350) 0.98 
VL at HAART (log 
copies/mL) 
Median (IQR) 4.6 (4.1, 5.2) 4.6 (4.1, 5.2) 0.70 
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Table 8.3.4.2: Description of laboratory measurements amongst patients 
included in the analyses 
Laboratory 
measure-
ment 
Patients with at 
least 1 measure 
after HAART N 
(%) 
Number of measures 
per patient (Median 
(IQR) 
Duration between 
measurements 
(Median (IQR)) 
(months) 
ALT 6314 (84.9) 8 (3, 17) 2.3 (0.9, 3.3) 
ALB 6900 (92.8) 9 (3, 17) 2.3 (0.9, 3.4) 
AMY 4252 (57.2) 1 (0, 6) 2.8 (1.5, 4.1) 
AST 1687 (22.7) 0 (0, 0) 2.1 (0.9, 3.2) 
ALK  7314 (98.4) 11 (5, 19) 2.3 (0.9, 3.3) 
BIL 7313 (98.4) 11 (5, 18) 2.3 (0.9, 3.3) 
CHL 6317 (85.0) 6 (2, 12) 3.0 (1.6, 4.0) 
CRE 7286 (98.0) 11 (5, 18) 2.3 (0.9, 3.3) 
GLU 4570 (61.5) 2 (0, 9) 2.8 (1.3, 3.9) 
HAE 7402 (99.6) 11 (5, 19) 2.2 (0.9, 3.3) 
HDL 4529 (60.9) 3 (0, 9) 3.0 (1.6, 4.1) 
LDL 4395 (59.1) 3 (0, 8) 3.0 (1.6, 4.2) 
TRI 6129 (82.5) 6 (2, 12) 3.0 (1.6, 4.1) 
URE 6308 (84.9) 6 (2, 14) 2.2 (0.8, 3.4) 
CD4 7434 (100.0) 10 (5, 17) 2.8 (1.6, 3.6) 
VL 7434 (100.0) 10 (5, 17) 2.8 (1.4, 3.7) 
 
 
 
8.3.5. Association between laboratory measurements and mortality within 
2 years of starting HAART 
Of the 7434 patients with at least one toxicity measurement after starting HAART, 
6121 (82.3%) patients had at least two years follow-up from start of HAART. 
Amongst these patients, 151 (2.5%) died within two years of starting HAART (and 
after having at least one laboratory measurement). Several methods were used to 
derive a score, based on the baseline laboratory measurements (the first 
measurements within 2 years of starting HAART), to predict mortality.  
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8.3.5.1. Scoring laboratory measurements according to quintiles of 
laboratory values (Approach A) 
In this crude analysis, laboratory values were split into quintiles and the number of 
deaths occurring in each quintile was calculated. A score of 1 was assigned to the 
first quintile, 2 to the second, 3 to the third, 4 to the fourth and 5 to the fifth for most 
laboratory measurements. The exceptions to this were ALB, HAE, HDL and CD4 
count, for which the scoring system was reversed (5 assigned to first quintile, 4 to 
second etc) to allow for a low value being of more concern than a high value. 
Patients with missing baseline values were given a score corresponding to the 
optimal value (1 for most laboratory measures and 5 for ALB, HAE, HDL and CD4). 
Table 8.3.5.1.1 shows the proportion of deaths occurring in each quintile, of each 
laboratory variable. 
 
Table 8.3.5.1.1: Number of deaths within 2 years of starting HAART stratified 
by quintiles of laboratory measure 
Laboratory measure at start of HAART N Deaths N (%) 
ALT IU 0-17 1113 25 (2.2) 
 18-24 1082 25 (2.3) 
 25-32 1013 23 (2.3) 
 33-48 1037 26 (2.6) 
 >48 1011 29 (3.4) 
 Missing 865 23 (1.7) 
ALB g/L 0-37 1349 87 (6.4) 
 38-40 1085 23 (2.1) 
 41-42 1038 13 (1.3) 
 43-45 1357 12 (1.1) 
 >45 844 6 (0.9) 
 Missing 448 10 (2.5) 
AMY U/L 0-48 773 23 (3.0) 
 49-62 707 20 (2.8) 
 63-77 733 14 (1.9) 
 78-100 721 24 (3.3) 
 >100 731 20 (2.7) 
 Missing 2456 50 (2.0) 
ALK U/L 0-59 1283 17 (1.3) 
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 60-70 1227 15 (1.2) 
 71-82 1152 20 (1.7) 
 83-100 1165 25 (2.1) 
 >100 1197 72 (6.0) 
 Missing 97 2 (2.0) 
BIL mg/dL 0-5 1716 35 (2.0) 
 6 800 12 (1.5) 
 7-8 1330 37 (2.8) 
 9-11 1055 24 (2.3) 
 >11 1123 41 (3.7) 
 Missing 97 2 (2.1) 
CHL mmol/L 0-3.7 1109 30 (2.7) 
 3.8-4.3 1122 24 (2.1) 
 4.4-4.8 932 13 (1.4) 
 4.9-5.5 1028 21 (2.0) 
 >5.5 1020 14 (1.4) 
 Missing 910 49 (5.4) 
CRE mmol/L 0-69 1294 46 (3.6) 
 70-77 1175 25 (2.1) 
 78-85 1252 25 (4.4) 
 86-94 1146 24 (2.1) 
 >94 1138 29 (2.5) 
 Missing 116 2 (1.7) 
GLU mmol/L 0-4.3 904 12 (1.3) 
 4.4-4.7 784 13 (1.7) 
 4.8-5.0 673 15 (2.2) 
 5.1-5.6 738 9 (1.2) 
 >5.6 677 23 (3.4) 
 Missing 2345 79 (3.4) 
HAE gm/dL 0-11.0 1234 63 (5.1) 
 11.1-12.4 1256 36 (2.9) 
 12.5-13.5 1287 22 (1.7) 
 13.6-14.4 1157 17 (1.5) 
 >14.4 1175 13 (1.1) 
 Missing 12 0 (0.0) 
   321 
 
 
HDL mmol/L 0-0.9 822 13 (1.6) 
 1.0-1.1 801 13 (1.6) 
 1.2-1.3 732 11 (1.5) 
 1.4-1.5 530 7 (1.3) 
 >1.5 710 7 (1.0) 
 Missing 2526 100 (4.0) 
LDL mmol/L 0-1.9 810 10 (1.2) 
 2.0-2.3 616 14 (2.3) 
 2.4-2.8 778 12 (1.5) 
 2.9-3.4 715 7 (1.0) 
 >3.4 627 7 (1.1) 
 Missing 2575 101 (3.9) 
TRI mmol/L 0-1.00 1110 19 (1.7) 
 1.10-1.35 916 16 (1.7) 
 1.36-1.80 1071 15 (1.4) 
 1.81-2.50 969 21 (2.2) 
 >2.50 992 29 (2.9) 
 Missing 1063 51 (4.8) 
URE mmol/L 0-3.4 1081 32 (3.0) 
 3.5-4.2 1121 24 (2.1) 
 4.3-4.8 907 17 (1.9) 
 4.9-5.7 1039 23 (2.2) 
 >5.7 1026 38 (3.7) 
 Missing 947 17 (1.8) 
CD4 count (cells/mm3) 0-98 1228 57 (4.6) 
 99-180 1268 28 (2.2) 
 181-250 1224 21 (1.7) 
 251-393 1179 14 (1.2) 
 >393 1222 31 (2.5) 
VL (log copies/mL) 0-3.9 1188 34 (2.9) 
 4.0-4.4 1303 33 (2.5) 
 4.5-4.9 1168 20 (1.7) 
 5.0-5.4 1312 31 (2.4) 
 >5.4 1150 33 (2.9) 
Equal groups may not be observed as tied values are assigned the same quintile 
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There was evidence of a decrease in the proportion of deaths as the values of ALB, 
HAE and HDL increased, and an increase in the proportion of deaths as the values 
of ALT, ALK and GLU increased, though there were no other obvious associations 
between laboratory measurement quintiles and death. Scores were summed; the 
median total score was 42 (IQR: 37, 46) (minimum possible score=15 and maximum 
possible score=75). The total score was split into quintiles and fitted as a covariate 
in logistic regression models, in which the outcome was mortality by 2 years after 
starting HAART (Table 8.3.5.1.2). In univariable analyses, a linear relationship was 
observed between the total score and death – patients with a higher total score were 
at a greater risk of mortality. Though this linear relationship was also broadly evident 
after adjusting for potential confounders, in particular, age at start of HAART, 
associations were weaker than those seen in univariable analyses.   
 
Table 8.3.5.1.2: Univariable and multivariable odds ratios (OR) for score 
quintiles from logistic regression 
Quintile  Score N Dead Univariable OR Multivariable 
OR 
1 13-31 1249 18 (1.4) 0.40 (0.23, 0.72) 0.48 (0.27, 0.87) 
2 32-34 1327 24 (1.8) 0.51 (0.30, 0.86) 0.60 (0.35, 1.02) 
3 35-37 1392  25 (1.8) 0.50 (0.30, 0.85) 0.57 (0.34, 0.97) 
4 38-41 940 33 (3.5) 1 1 
5 >41 1213 51 (4.2) 1.21 (0.77, 1.89) 1.08 (0.69, 1.71) 
 
The c-statistic from the multivariable model was 0.72 and the Hosmer-Lemeshow p-
value was 0.41, indicating that there was no evidence of a lack of fit of the model.  
 
In sensitivity analyses, only those patients who had all laboratory measurements 
available at baseline were included (n=811). Ten patients (1.2%) died within 2 years 
of starting HAART in this subset. Again the total score was split into quintiles – the 
second and third quintile was merged as no deaths occurred in the third quintile.  
No association was seen between total score and mortality in univariable analyses 
(Table 8.3.5.1.3), though there was evidence of an increased risk of mortality for 
patients with very low and very high scores. Of note, this analysis had very low 
power, with only ten deaths occurring in this population. 
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Table 8.3.5.1.3: Univariable odds ratios (OR) for score quintiles amongst 
patients who had all baseline laboratory measurements available (N=811) 
Quintile  Score N Dead  Univariable OR 
1 15-33 203 5 (2.5) 3.86 (0.45, 33.41) 
2 and 3 34-40 322 1 (0.3) 0.48 (0.03, 7.67) 
4 41-43 154 1 (0.7) 1 
5 >43 132 3 (2.3) 3.56 (0.37, 34.62) 
   
8.3.5.2. Using baseline laboratory measures (continuous variables) to 
derive a cut-off score (Approach B) 
In these analyses, the training set (70% of the randomly selected data) was used in 
the first instance (n=4302).  Laboratory measures were fitted into regression models 
as continuous variables. Patients without any baseline laboratory measurements 
were excluded from these analyses. The multivariable analyses included data from 
2284 patients. This was considerably higher than the number of patients included in 
the sensitivity analyses in Section 8.3.5.1 (number of patients with all laboratory 
measurements=811) as only 8/13 laboratory measurements were included in the 
multivariable analyses (Table 8.3.5.2.1). The odds ratios for mortality within 2 years 
of starting HAART from univariable and multivariable regression models are shown 
in Table 8.3.5.2.1. In univariable analyses, a 1 unit increase in ALB, CHL and HAE 
was associated with a reduced risk of mortality. An increase in ALK, BIL, GLU, TRI 
and URE was associated with an increased risk of mortality. After adjusting for 
potential confounders, including CD4 count and VL (as these variables are of known 
clinical significance) ALB was still associated with a decreased risk of mortality, 
whilst TRI was associated with an increased risk of mortality.  
 
The overall score was calculated by summing the significant parameter estimates 
from the logistic regression model (i.e. the estimated logarithms of the ORs). CD4 
count and VL were also included in this score. Using this method, the median score 
was -4.65 and the c-statistic of the model was 0.81.  
 
Two approaches were taken to choose a cut-off value for the score. In the first 
instance, differences in the mean score amongst those who died (-3.90) and those 
who did not die within 2 years of starting HAART (-4.65) were assessed using a t-
test (p<0.0001). Given this significant result, I used the mean score of those who did 
die as a cut-off value. The number of patients experiencing mortality stratified by the  
    
 
 
    
3
2
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Table 8.3.5.2.1: Odds ratios (OR) for baseline laboratory measures (continuous)  in relation to death within 2 years of starting HAART 
from univariable and multivariable  
Laboratory measurement Univariable Multivariable 
 OR (95% CI) P-value OR (95% CI) P-value 
ALT (10 unit increase) 1.00 (0.99, 1.03) 0.99 -  
ALB (1 unit increase) 0.85  (0.82, 0.87) <0.0001 0.90 (0.84, 0.96) 0.002 
AMY (10 unit increase) 1.02 (0.98, 1.05) 0.36 -  
ALK (10 unit increase) 1.02 (1.01, 1.03) 0.0002 1.02 (1.00, 1.04) 0.12 
BIL (10 unit increase) 1.17 (1.06, 1.29) 0.003 1.04 (0.86, 1.26) 0.69 
CHL (1 unit increase) 0.78 (0.62, 0.97) 0.03 0.81 (0.62, 1,07) 0.15 
CRE (10 unit increase) 0.99 (0.92, 1.06) 0.72 -  
GLU (1 unit increase) 1.16 (1.03, 1.30) 0.02 1.12 (0.96, 1.31) 0.14 
HAE (1 unit increase) 0.72 (0.65, 0.78) <0.0001 0.89 (0.74, 1.08) 0.24 
HDL (1 unit increase) 0.57 (0.25, 1.32) 0.19 -  
LDL (1 unit increase) 0.76 (0.52, 1.11) 0.16 -  
TRI (1 unit increase) 1.15 (1.03, 1.29) 0.01 1.21 (1.02, 1.44) 0.03 
URE (1 unit increase) 1.09 (1.03, 1.16) 0.004 0.96 (0.86, 1.07) 0.43 
CD4 count (50 cells increase) 1.00 (0.99, 1.00) 0.10 1.00 (0.99, 1.00) 0.47 
VL (1 log increase) 1.02 (0.85, 1.23) 0.84 1.41 (0.98, 2.02) 0.06 
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mean score of those who died (-3.90) is shown in Table 8.3.5.2.2. The sensitivity of 
the -3.90 cut off was 60.5% and specificity was 80.8%.  
 
Table 8.3.5.2.2: Number of patients experiencing mortality within 2 years of 
starting HAART, stratified by mean score of those who died (-3.90) 
 Mortality within 2 years of starting HAART 
Overall score> -3.90 Yes No 
Yes 26 431 
No 17 1810 
Total 43 2241 
 
In an alternative method of choosing a cut-off, I used the 10th percentile of the score 
amongst those who died (-5.68). This value was chosen as it would allow most 
patients with a score above this threshold to be correctly classified as having died.  
The sensitivity of this cut-off was 97.7%, but this was at the cost of the specificity, 
which was 10.1%.  
 
The observed and expected number of deaths (stratified by score decile) in the 
training and validation datasets are shown in Table 8.3.5.2.3. Generally, the 
observed and expected deaths were well matched. The 10th decile was the 
exception, with the expected number being lower than the observed number in the 
training set but higher than the observed number in the validation set, though the 
absolute difference was small. The Hosmer-Lemeshow p-value was >0.05 in the 
training dataset, indicating the there was no strong evidence of a lack of fit. 
However, in the validation dataset, the p-value was 0.04, suggesting that the model 
did not fit as well as it did in the training dataset.  
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Table 8.3.5.2.3: Expected and observed number of deaths stratified by score 
deciles 
 Training dataset Validation dataset 
Deciles N Expected Observed N Expected Observed 
1 228 1 1 105 0 1 
2 230 1 0 80 0 1 
3 222 1 0 104 1 2 
4 233 2 2 112 1 2 
5 224 2 3 70 1 0 
6 238 3 1 94 1 2 
7 222 3 5 98 1 1 
8 230 4 5 95 2 3 
9 231 6 7 103 3 1 
10 226 13 19 104 6 1 
All  2284 36 43 965 16 14 
Hosmer-
Lemeshow 
p-value 
0.45 0.04 
 
 
8.3.5.3. Principal component analyses (Approach C) 
In the first instance, only those patients with all baseline laboratory measures in the 
training dataset were included (n=560, 13.0%). I did not attempt to include CD4 and 
VL in the principal component analyses as both these variables have been shown to 
be independently associated with mortality and hence I felt they should be 
covariates in regression models in their own right. Using the eigenvalue >1 criterion, 
6 components were retained. The scree plot showed a large break between factors 
3 and 4, implying that only the first 3 components should be retained. However, only 
43% of the variance was accounted for with just the first 3 components – 7 
components were needed to account for at least 70% of the variance. Components 
6 and 7 had eigenvalues of <1 and hence only 5 components were retained, 
accounting for 61% of the total variance. Variables significantly loading onto each 
component are shown below. HDL was not assigned to a specific component as it 
loaded significantly onto more than one component.  
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Component 1: CHL, LDL 
Component 2: ALB, AMY, HAE 
Component 3: CRE, URE 
Component 4: GLU, TRI 
Component 5: ALT, ALK, BIL 
 
Although variables which are likely to be correlated have been grouped into the 
same component, 3 components had fewer than 3 variables. This did not meet the 
original selection criteria (outlined in Section 8.2.3.3) and suggests that the solution 
is not satisfactory or interpretable. Hence, I did not validate this solution on the 
validation set.  
 
I then excluded AMY and GLU from the analysis as a high proportion of patients had 
either one or both of these variables missing. The total number of patients with all 
baseline measures available increased to 2018 (46.9%). Five components were 
retained using the eigenvalue >1 criterion and the cumulative variance of these 5 
components was just over 70% (70.3%). There was also evidence of a break 
between the 5th and 6th component in the scree plot. ALK loaded significantly onto 
more than one component and was hence not assigned to any single component. 
Variables significantly loading onto each factor are shown below: 
  
Component 1: CHL, LDL 
Component 2: ALB, HAE 
Component 3: CRE, URE 
Component 4: ALT, BIL 
Component 5: HDL, TRI 
 
Again, though similar variables have been grouped together, there are fewer than 3 
variables associated with each component, suggesting that this solution is also 
unsatisfactory. For this reason, the validation dataset was not used to validate the 
solution.  
 
Finally, I also removed HDL and LDL from the analysis to increase the number of 
patients with baseline measures available. This increased the number of patients in 
the dataset to 2623 (61.0%). Four components were retained in using the 
eigenvalue >1 criterion, though 5 components were needed to account for over 70% 
of the total variance. The scree plot showed a gap between the 4th and 5th 
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component and hence I decided to retain only 4 components, despite the cumulative 
variance accounting for only 60.9% of the total variance. The variables associated 
with each of the four factors are shown below. Again, ALK loaded significantly onto 
more than one component and was hence not assigned to any single component.  
 
Component 1: ALB, HAE 
Component 2: ALT, BIL 
Component 3: CHL, TRI 
Component 4: CRE, URE 
 
Again, most components are associated with only 2 variables. Similar variables 
were grouped together, and despite this solution not being optimum (since fewer 
than 3 variables are associated with most components), I decided to proceed with 
assigning scores to patients based on the above components.   
 
The components are a linear equation of all the standardised laboratory variables 
(denoted by the prefix „STD_‟). To standardise a variable, the mean of the variable is 
subtracted from it (resulting in a mean of 0) and then the variable is divided by its 
standard deviation (resulting in a standard deviation of 1). Equations for each 
component (extracted from the principal component analysis) are given below:   
 
Component 1: (-0.02*STD_ALT) + (0.52*STD_ALB) + (-0.26*STD_ALK) + 
(0.09*STD_BIL) + (0.01*STD_CHL) + (0.01*STD_CRE) + (0.52*STD_HAE) + (-
0.02*STD_TRI) + (0.001*STD_URE) 
 
Component 2: (0.55*STD_ALT) + (-0.02*STD_ALB) + (0.32*STD_ALK) + 
(0.53*STD_BIL) + (-0.10*STD_CHL) + (0.004*STD_CRE) + (0.11*STD_HAE) + 
(0.04*STD_TRI) + (-0.01*STD_URE) 
 
Component 3: (-0.03*STD_ALT) + (0.02*STD_ALB) + (0.16*STD_ALK) + (-
0.08*STD_BIL) + (0.60*STD_CHL) + (-0.13*STD_CRE) + (0.01*STD_HAE) + 
(0.56*STD_TRI) + (0.10*STD_URE) 
 
Component 4: (-0.005*STD_ALT) + (-0.02*STD_ALB) + (-0.06*STD_ALK) + 
(0.02*STD_BIL) + (-0.07*STD_CHL) + (0.72*STD_CRE) + (0.02*STD_HAE) + 
(0.05*STD_TRI) + (0.62*STD_URE) 
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Each component has larger multiples of the variables it is associated with than the 
other variables in the equation. For example, in Component 1, ALB and HAE are 
both weighted by 0.52, whilst all the other variables are weighted by lower values.  
 
Amongst the 2623 patients included in this analysis, 49 (1.9%) patients died within 2 
years of starting HAART. Table 8.3.5.3.1 shows the odds ratios in relation to death 
from univariable and multivariable analyses for each of the four components.  
In univariable analyses, only Component 1 (ALB, HAE) was significantly associated 
with mortality. Hence only this Component was retained in multivariable analysis. 
After adjusting for potential confounders, Component 1 remained significantly 
associated with mortality. The c-statistic of the model was 0.77 indicating a good 
ability of the score to discriminate between those who died and those who did not. 
The significant estimates of the multivariable regression model were used to derive 
an overall score as previously described.   
 
Table 8.3.5.3.1:  ORs for components derived from principal component 
analysis in relation to mortality within 2 years of starting HAART 
 Univariable Multivariable1 
 OR (95% CI) P-value OR (95% CI) P-value 
Component 1 0.55 (0.45, 0.67) <0.0001 0.49 (0.38, 0.62) <0.0001 
Component 2 1.10 (0.91, 1.32) 0.32 Excluded  
Component 3 1.08 (0.82, 1.40) 0.59 Excluded)  
Component 4 1.07 (0.93, 1.22) 0.36 Excluded)  
1
Adjusted for ethnicity, risk group, viral load at start of HAART, age at start of HAART, 
regimen, CD4 at start of HAART and year of starting HAART 
 
The median score was -4.60. Table 8.3.5.3.2 shows the observed and expected 
values stratified by score deciles, in both the training set and the validation set. 
These values are well matched and the Hosmer-Lemeshow p-value is >0.05, 
indicating no evidence of a lack of fit.   
The mean score amongst those who did die was -3.63 and hence patients who had 
a score greater than this were assumed to be at a greater risk of mortality. The 
sensitivity and specificity of this cut-off (using the training set) were 49.0% and 
87.7% respectfully. If the lower 10th percentile of those who died was used to derive 
a cut off (-4.86), the sensitivity was considerably higher at 93.9% but the specificity 
dropped to 37.2%.  
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Table 8.3.5.3.2:  Expected and observed number of deaths stratified by 
regression quintiles 
 Training dataset Validation dataset 
Deciles N Expected Observed N Expected Observed 
1 264 1 0 95 0 1 
2 260 1 1 117 1 2 
3 268 2 1 98 1 1 
4 252 2 3 115 1 0 
5 272 2 2 110 1 1 
6 257 3 3 116 1 1 
7 261 3 6 119 2 0 
8 262 4 5 105 2 3 
9 265 6 7 124 3 2 
10 262 17 21 130 8 9 
All  2623 42 49 887 19 20 
Hosmer-
Lemeshow 
p-value 
0.70 0.99 
 
 
8.3.5.4. Replicating the Swiss score (Approach D) 
In the final approach, the scoring method used in the Swiss study (525) was 
replicated using the UK CHIC dataset. The same criteria and cut-points were used 
(see Appendix B for cut-points), though four measures of toxicity that were used in 
the Swiss study were not routinely collected in UK CHIC and were hence excluded 
from the analyses (lactate, neutrophil count, platelet count and CPK). Only patients 
with at least one other laboratory measure available at baseline were included 
(n=6121). Scores were assigned according to the Table for Grading Severity of 
Adult Adverse Experiences and the overall score was calculated by summing the 
individual scores for each measure. Patients with missing baseline laboratory 
measures and those with measures below the cut-off for mild toxicity were given a 
score of 0.  
The median score per individual was 1 (0, 2). In univariable analyses, a linear 
relationship was seen between the overall score and mortality – as the score 
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increased, so did the risk of mortality. The score was then fitted as a continuous 
variable – for a unit increase in score, the risk of mortality was 31% higher.  
After adjusting for potential confounders, the score remained significantly associated 
with the risk of mortality (1.31 (1.23, 1.39) per 1 unit increase). The c-statistic of the 
model was 0.75 and the Hosmer-Lemeshow p-value 0.60, indicating no evidence of  
a lack of fit.  
 
In sensitivity analyses, only those patients with all laboratory measures used to 
compile this score were included (n=2527). Results of the multivariable analyses 
were similar to those seen above – a one unit increase in score was associated with 
a 28% increase in the risk of mortality (1.28 (1.18, 1.38)).  
    
 
 
    
3
3
2 
Table 8.3.5.4.1: Association between replicated Swiss score (derived from measures of ALT, ALK AMY, BIL, CRE, HAE and URE) and 
mortality 
   Univariable Multivariable 
Score N Dead OR (95% CI) P-value OR (95% CI) P-value 
0 2489 27 (1.1) 1    
1 2056 39 (1.9) 1.76 (1.08, 2.89) 0.02   
2 883 41 (4.6) 4.44 (2.72, 7.27) 0.001   
>2 693 44 (6.4) 6.18 (3.80, 10.06) <0.0001   
Continuous 6362 151 1.31 (1.23, 1.39) <0.0001 1.28 (1.18, 1.38) <0.0001 
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8.3.5.5. Comparison of approaches A-D 
A comparison of the four approaches is shown in Table 8.3.5.5.1. The sensitivity 
and specificity of Approaches A and D could not be calculated as a cut-off was not 
chosen. The c-statistic for Approach A was the smallest of the four approaches, 
though the absolute difference was marginal. No approaches showed evidence of 
lack of fit. The sensitivity of the chosen cut-off was highest using Approach B, but 
this approach also had the lowest specificity.  
  
Table 8.3.5.5.1: Comparison of approaches A-D 
 A B C D 
N 6121 4302 2623 2527 
Score cut-off - -3.90 -3.63  
c-statistic 0.72 0.81 0.77 0.75 
Hosmer-Lemeshow 0.41 0.45 0.70 0.60 
Sensitivity  - 60.5% 49.0%  
Specificity - 80.8% 87.7%  
 
 
8.3.6. Short-term association between laboratory measurements and 
mortality (mortality within 6 months of laboratory measurements) 
To measure the short-term association between laboratory and death, follow-up was 
split into 6-month periods. In total, there were 53829 distinct periods of follow-up, in 
which 218 deaths occurred. The number of follow-up periods with laboratory 
measures available and the median measure at start of follow-up (+/- 3 months) are 
shown in Table 8.3.6.1. With the exception of GLU, HDL and LDL, at least 60% of 
the periods of follow-up had laboratory measures available at the start of follow-up.  
 
The association between each laboratory measure at the start of the period 
(continuous) and death was analysed using logistic regression (Approach B). This 
approach was initially chosen since Approach A did not yield a convincing significant 
association between laboratory scores and mortality within 2 years of starting 
HAART. It was not possible to perform the principal component analysis for time-
updated variables (and nor did the principal component analysis approach work 
effectively since fewer than 3 variables were associated with most components), 
whilst the replication of the Swiss score is discussed towards the end of this Section. 
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Table 8.3.6.1: Median laboratory measures in each period of follow-up 
 Number of periods of follow-up in 
which a measure is available N (%) 
Median (IQR) 
ALT 46662 (86.7) 26 (18, 39) 
ALB 48974 (91.0) 43 (40, 46) 
AMY 35747 (66.4) 64 (48, 87) 
ALK 52348 (97.2) 81 (66, 101) 
BIL 52342 (97.2) 8 (6, 10) 
CHL 45256 (84.1) 5 (4, 6) 
CRE 52034 (96.7) 82 (72, 92) 
GLU 31857 (59.2) 5 (4, 5) 
HAE 53026 (98.5) 14 (13, 15) 
HDL 28505 (53.0) 1 (1, 2) 
LDL 28814 (53.5) 3 (2, 3) 
TRI 43999 (81.7) 2 (1, 2) 
URE 46104 (85.6) 5 (4, 6) 
CD4 52801 (98.1) 390 (260, 546) 
VL 52524 (97.6) 50 (50, 100) 
  
Unadjusted and adjusted odds ratios for each laboratory measure are shown in 
Table 8.3.6.2. All measures apart from AMY and GLU were significantly associated 
with death in univariable analyses. After adjusting for potential confounders, only 
ALB, HAE and URE were significantly associated with death (URE was of borderline 
significance). Patients of older age (1.45 (1.09, 1.90) per 10 years higher) were also 
at an increased risk of mortality. Interestingly, the CD4 count at the start of the 
period was not associated with death (0.95 (0.87, 1.04)), though the viral load at the 
start of the period was of borderline significance (1.21 (0.96, 1.53) per 1 log 
copies/mL higher).  
 
A score was derived using the parameter estimates from the logistic regression 
model, as previously described. Only significant and borderline significant variables 
in the multivariable model were included in the score. Hence, ALB, HAE, URE and 
age at start of period were used to derive the score. The median score overall was -
6.60. Amongst those who died, the mean score was -5.23 and hence patients with a 
score of -5.23 were presumed to be at an increased risk of mortality. The sensitivity 
of this score was 44.3% and the specificity was 93.9%.   
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Table 8.3.6.2: Associations between laboratory measures and death during 6-
month periods 
 Univariable Multivariable1 
 OR (95% CI) P-value OR (95% CI) P-value 
ALT2  1.01 (1.00, 1.02) 0.01 1.00 (1.00, 1.01) 0.36 
ALB3 0.85 (0.84, 0.86) <0.0001 0.91 (0.88, 0.94) <0.0001 
AMY2 0.99 (0.96, 1.03) 0.69 Excluded - 
ALK2 1.04 (1.03, 1.05) <0.0001 1.01 (0.99, 1.03) 0.41 
BIL2 1.23 (1.19, 1.30) <0.0001 1.09 (0.95, 1.26) 0.21 
CHL3 0.62 (0.53, 0.72) <0.0001 0.67 (0.34, 1.31) 0.24 
CRE2 1.02 (1.01, 1.03) 0.003 0.97 (0.91, 1.03) 0.28 
GLU3 1.08 (1.01, 1.16) 0.23 Excluded - 
HAE3 0.59 (0.56, 0.63) <0.0001 0.75 (0.66, 0.86) <0.0001 
HDL3 0.37 (0.22, 0.64) 0.0004 1.04 (0.75, 2.40) 0.93 
LDL3 0.68 (0.53, 0.87) 0.002 1.34 (0.75, 2.40) 0.32 
TRI3 1.07 (0.99, 1.17) 0.09 1.06 (0.84, 1.34) 0.63 
URE3 1.15 (1.12, 1.18) <0.0001 1.11 (0.99, 1.26) 0.08 
CD44 0.79 (0.76, 0.82) <0.0001 0.95 (0.87, 1.04) 0.28 
VL5 1.52 (1.39, 1.67) <0.0001 1.21 (0.96, 1.53) 0.10 
Ethnicity     
White  1 - 1 - 
Black  0.68 (0.49, 0.93) 0.02 0.38 (0.13, 1.15) 0.09 
Other  1.00 (0.66, 1.53) 0.98 0.73 (0.32, 1.64) 0.44 
Risk group     
MSM 1 - 1 - 
Heterosexual 1.14 (0.84, 1.55) 0.39 1.04 (0.40, 2.72) 0.94 
Other  3.53 (2.51, 4.95) <0.0001 1.92 (0.89, 4.16) 0.10 
Regimen at start of 6 month period 
NNRTI 1 - 1 - 
PI 1.48 (1.04, 2.14) 0.03 1.41 (0.70, 2.84) 0.34 
Other reg 2.10 (1.55, 2.83) <0.0001 1.70 (0.88, 3.27) 0.11 
Age 1.05 (1.03,1.06) <0.0001 1.44 (1.09, 1.90) 0.01 
1
Adjusted for ethnicity, exposure and regimen at start of 6 month period; 
2
Per 10 unit 
increase; 
3
Per 1 unit increase; 
4
Per 50 cells increase; 
5
Per 1 log increase 
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In sensitivity analyses, Approach D (replication of the Swiss score) was extended to 
include time-updated variables. As in the above approach, follow-up was split into 6 
month-periods and scores were assigned according to the laboratory measures at 
the start of the 6 month period. The cut-offs used for each laboratory marker were 
identical to those used in Approach D (283). Patients with missing measurements at 
the start of the 6 month period and those with measurements not meeting the 
minimum to be defined as a „mild toxicity‟ were given a score of 0. 
 
The median score across the 6 month periods was 0 (0, 1). The proportion of 
patients experiencing mortality increased as the overall score increased, from 0.2% 
for those with a score of 0 to 1.4% for those with a score of >2.  
The unadjusted and adjusted odds ratios for overall score in relation to mortality are 
shown in Table 8.3.6.3. In univariable analyses, patients with a score of >2 were 
over 5 times more likely to experience mortality than those with a score of 1. These 
results remained significant in multivariable analyses. A one unit increase in score 
was associated with a 41% increase in the risk of mortality.  
 
Table 8.3.6.3: Association between time-updated Swiss score and mortality 
Overall 
score 
6-monthly 
periods 
Dead n 
(%) 
Univariable Multivariable 
0 28521 58 (0.2) 0.71 (0.48, 1.05)  
1 14913 43 (0.3) 1  
2 4638 35 (0.8) 2.63 (1.68, 4.11)  
>2 5757 82 (1.4) 5.00 (3.45, 7.24)  
Continuous 53829 218 (0.4) 1.45 (1.40, 1.51) 1.41 (1.35, 1.47) 
1
Adjusted for ethnicity, exposure, current CD4, current viral load, current regimen, current 
age, sex and year of starting of HAART 
 
8.3.7. Comparing long vs. short term risk of mortality 
I used the continuous laboratory measures at baseline and the Swiss scoring 
system to predict mortality initially within 2 years of starting HAART, and then to 
consider the short term risk to mortality (within 6 months). In the former method, the 
estimates of the regression model were used to derive a score, whereas in the latter 
method, a score was assigned to the laboratory measure before entering it into the 
regression model. The differences in the scores in relation to short-term and long-
term risk of mortality are discussed below.  
    337 
 
 
8.3.7.1. Continuous baseline toxicity measures 
The median score for the 2-year risk of mortality (long-term) was -4.65 and the cut-
off relating to an increased risk in mortality was -3.90, whilst for the 6-month risk of 
mortality, the median score was lower, at -6.60, as was the cut-off relating to an 
increased risk of mortality (-5.23). The variables required for the derivation of the 
score and the weights of each variable are shown below. 
 
Table 8.3.7.1.1: Variables contributing to long-term and short-term risk to 
mortality scores 
Long-term risk Short-term risk 
Variable Weight Variable Weight 
Intercept -4.84  -4.89 
ALB -0.10 ALB -0.10 
TRI 0.19 HAE -0.28 
Heterosexual 0.27 URE 0.11 
Other risk 1.23 Current age 0.37 
Age 0.44   
CD4 -0.002   
VL 0.34   
 
ALB contributed equal weighting to both long-term and short-term risk of mortality. 
However, whilst TRI also contributed to the long-term risk, it did not contribute to the 
short term risk. HAE and URE on the other hand contributed to the short-term risk 
score but did not contribute to the long-term risk score. Age contributed to both risk 
scores, whilst CD4, VL and risk group contributed only to the long-term risk score. 
 
8.3.7.2. Swiss score replication  
The median score using this approach was 1 when analysing the risk to mortality 
within 2 years of starting HAART. However, when taking into account time-updated 
variables, the median score per individual was 0. A one unit increase in score was 
associated with a 28% increased risk of long-term mortality using the Swiss score, 
and a 41% increased risk of short-term mortality.  
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8.4. Discussion 
The median number of laboratory measurements per patient was notably higher 
after HAART initiation than before, for all measurements. This is not surprising given 
the known side-effects of HAART, but another explanation for this finding may be 
that patients who have started HAART are more likely to be under follow-up than 
those who haven‟t. Hence the opportunity to perform these laboratory tests will be 
greater amongst the former group. Furthermore, patients who have started HAART 
are likely to be older than those not receiving HAART - patients of older age may 
also be more likely to have laboratory tests performed as some variables are age-
dependent, even in the HIV-negative population. The duration between 
measurements was also generally shorter amongst the HAART-experienced 
population and this is likely to be attributable to the same reasons. Having started 
HAART was positively associated with having a laboratory measurement in 
multivariable analyses, further supporting the above points. A prior abnormal 
measurement was associated with having further measurements, which is expected. 
Patients with abnormal measurements are likely to be re-tested to confirm the 
measurement and are also likely to be monitored more frequently as clinicians 
attempt to deal with the abnormalities. 
 
Patients who had started HAART but had no laboratory measurements available 
within 2 years after the start of HAART were more likely to be of „other‟ exposure 
group and of white ethnicity. Patients classified into „other‟ exposure groups may be 
those who generally have limited data recorded. Although these differences were 
statistically significant, the absolute values of the differences were small and hence, 
clinically, were unlikely to be of significance. Most of the 7434 patients with 
laboratory measurements available after the start of HAART were typical of the 
CHIC dataset as a whole – male patients of white ethnicity, MSM risk group, who 
started HAART on NNRTI-based regimens. Over 70% of patients had at least one 
measure of most laboratory variables after starting HAART, though this was 
considerably lower for AST (23%). ALT and AST are similar measures of liver 
function and whilst ALT is primarily found in the liver, AST is also found in the brain, 
pancreas, heart and lungs. ALT is therefore a more specific indicator of liver function 
and, for this reason, clinics may prefer to perform just an ALT test, rather than AST 
as well. Furthermore, BHIVA guidelines on monitoring practice state that ALT and/or 
AST tests should be performed when starting therapy and hence both tests may not 
be deemed necessary by the clinician (526) . Interestingly, these guidelines also 
state that all laboratory measurements listed in Section 8.3.1 should be routinely 
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measured. Even amongst those who were included in the main analyses, around 
40% of patients did not have GLU, HDL or LDL measured within 2 years of starting 
HAART.  
 
The association between abnormal values of these laboratory markers and 
morbidity and/or mortality in HIV-positive patients is well recognised. High ALT 
levels suggest liver tissue damage whilst low ALB has been shown to be associated 
with mortality (38;41;527). Abnormal AMY values are indicative of pancreatitis; 
common HIV drugs such as ddI have been reported to cause elevated AMY levels 
(401;404). TDF increases the concentration of ddI in the blood and so patients 
receiving this drug may also be at an increased risk of pancreatitis (402;403). TDF 
has also been associated with elevated ALK (528). Abnormalities in ALK may signify 
obstructed bile flow and liver complications.  Elevated BIL levels have been reported 
in patients receiving IDV (75;396-399) and are also linked to anaemia. Low 
haemoglobin, in turn,  is associated with an increased risk of mortality (38;356). 
Dyslipidemia is an important risk factor for cardiovascular disease and is commonly 
observed in HIV-positive patients (529). Patients receiving ART have been shown to 
be at increased risk of myocardial infarction (530). Both HIV itself, and the 
antiretrovirals used to treat HIV, have been linked to kidney damage. CRE and URE 
are used to measure kidney function. Whilst it is possible that other factors may 
contribute to the abnormal measurements seen amongst patients on HAART, it is 
likely that HAART itself does play a major role. This was demonstrated in earlier 
analyses which showed that most laboratory measurements were higher amongst 
patients receiving HAART than amongst those who had not yet received HAART.  
Given the number of laboratory markers that may be associated with mortality, there 
is a need for distinction between those abnormalities which may contribute more to 
mortality than other abnormalities. 
 
To derive a score relating laboratory measurements to mortality, several approaches 
were used. In some approaches, the score was derived by assigning a weight to the 
raw laboratory measurements. The overall score was then calculated by summing 
up the individual weights and the odds ratio of the overall score was used to assess 
the association between the score and mortality risk. In other approaches, 
laboratory variables in their raw form were included in regression models and the 
estimates from the regression models were used to derive a score. Both methods 
have previously been used to derive scores (525;531-535).  
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For the first method, Approach A, values of laboratory measurements were split into 
quintiles and a score of 1-5 assigned to each quintile. The sum of these individual 
scores were calculated for each individual and fitted into a regression model. Only a 
very weak association was seen between overall score and mortality. This was a 
very crude method of assigning scores and despite a c-statistic of >0.5, this method 
does not take account of any clinical implications of the quintiles. Consequently, no 
association was seen between the overall score and mortality. In Approach D, 
methods used in the Swiss HIV Cohort study were used to assign a score to the raw 
toxicity measures (525). The Table for Grading Severity of Adult Adverse 
Experiences was used to stratify each toxicity measurement into mild, moderate, 
severe and very severe and a score of 1 (mild) to 4 (very severe) was assigned to 
each measurement. Patients who did not meet the minimum criteria to be assigned 
to the „mild‟ category and those with missing laboratory measurements were given a 
score of 0. These cut-offs were based on the „normal‟ value of each toxicity and 
hence were of clinical significance. The overall score was also statistically significant 
in relation to mortality. The main issue with this score was that it was reliant on a 
large number of toxicity measurements, which as the CHIC records have shown, are 
not always available. In the replicated score in this chapter, I did not initially restrict 
analyses to only those patients who had all toxicity measurements available. 
Instead, patients with a missing value of any toxicity were given a score of 0. This 
however, may also be problematic, since those with missing values may not always 
have normal values. Patients who have reported no adverse effects may be less 
likely to have a laboratory test performed, and whilst in most cases it is likely that 
their laboratory values are in the normal range, this may not always be the case.  
 
For approach B, scores were assigned using estimates from regression models.  
I fitted the continuous laboratory variables into regression models, and hence 
excluded all patients with missing baseline values. The score derived included only 
ALB and TRI. A potential bias with this method is that only patients who had all 
laboratory measurements available at baseline were included and were therefore 
either from centres who regularly monitored these toxicities, or were patients who 
had prior abnormal values of these measures and were hence being closely 
monitored. I used the mean score of those who did experience mortality to define 
the cut off associated with an increased risk of mortality; this score had a sensitivity 
of 61% and specificity of 81%. In an alternative method of choosing a cut-off, I used 
the 10th percentile of the score amongst those who died. The sensitivity of this cut-
off was 97.7%, but this was at the cost of the specificity, which was 10.1%.  
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Another method of choosing a cut off is adding 2 standard deviations to the mean 
score of those who did not experience mortality (536;537). Only 2.5% of patients 
would have a score greater than this cut-off and in some cases it may be assumed 
that those who do have a score greater than this cut-off are at an increased risk of 
experiencing the event in question. However, in this situation, though the cut-off 
would have a high specificity, it would be at the cost of the sensitivity, as many 
patients who did experience mortality would not have a score above the cut-off. 
Hence, instead, I used the mean score of those who died as the cut-off. This would 
ensure that around 50% of the population would be correctly identified, though the 
specificity may not be optimal. Approach B had the disadvantage of a smaller 
dataset and the biases associated with including only those patients with laboratory 
measures available. Further, fitting laboratory measurements as continuous 
variables also involves the assumption of a linear association. However, Approach B 
did have the advantage of using the raw values of the laboratory measurements and 
hence not relying on other statistical procedures which may introduce further biases 
into deriving a score.  
 
The final method I used in deriving a score was principal component analyses. The 
main advantage of this method was that it would considerably reduce the number of 
variables fitted into a regression model, whilst still taking into account each 
variable‟s contribution to the outcome. The main issue with this method however, 
was that only patients with a measurements available could be included in the 
analysis. Only 13% of patients had all measurements available, whilst 47% had all 
but AMY and GLU available. I felt that 47% was still too small a subset and hence I 
also excluded HDL and LDL from the analysis, leaving 61% of patients available for 
analysis. The 9 laboratory variables left were reduced to 4 components but only 1 of 
these 4 components remained significantly associated with mortality in multivariable 
analysis. This component was primarily weighted by ALB and HAE. A score was 
derived using this component, together with all other significant estimates of the 
multivariable model; the sensitivity of this score was 49% and specificity 88%. HAE 
was not used to derive the score in any of the earlier methods, though ALB did 
contribute to the score when using the continuous toxicity variables. This method 
had the best balance of sensitivity and specificity, though did have the disadvantage 
of being difficult to implement in a clinical setting. Each component consisted of 
weighted laboratory variables and so not only would patients require values for all 
laboratory measurements, but the score calculation was also more complicated than 
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the other approaches. Hence, to use this method, the score calculation would have 
to be programmed on an existing computer system or smart-phone.  
 
Scores associated with the short-term (6-month) risk to mortality using continuous 
baseline measures included HAE and URE, which did not contribute to the long-
term risk of mortality. This suggests that current HAE and URE levels are strong 
predictors of death, but measures at baseline are not associated with mortality over 
the longer term. Conversely, TRI levels at baseline did predict long-term mortality, 
though current values of either measurement were not associated with death. 
Patients with high baseline measures of TRI may be more prone to certain 
lifestyle/dietary habits, which may explain this finding. These variables may be 
surrogates for other confounding factors which have not been adjusted for. For 
example, it may be possible that a patient with high TRI is also overweight and 
hence has other medical issues contributing to mortality. When the Swiss score was 
replicated to include time-updated variables, similar findings to those in the fixed 
variable analyses were seen. However, the association between the score and 
mortality was more pronounced when analysing short term risk of mortality 
compared to the long term risk of mortality. This can be explained by the fact that 
the laboratory measurements are more likely to be accurate for a short-term follow 
up period, rather than a long-term follow-up period.  
 
Initial checks on the laboratory data in UK CHIC revealed important discrepancies. 
AST, CPK, GGT and LAC were not routinely collected within the CHIC clinics, whilst 
only some centres provided data on GLU, HDL and LDL. Four centres provided very 
limited laboratory data and were hence excluded from the analyses. The proportion 
of patients with laboratory measurements in one centre declined from 2004 
onwards, and hence follow-up from this centre was censored at Dec 2003. These 
checks are extremely important in analyses such as those shown in this Chapter, as 
discrepancies are likely to impact on the any score which may be derived. 
Laboratory tests are used to identify abnormalities with the liver, lipid levels and 
kidney functions. HAART has been associated with such abnormalities and hence 
the monitoring of such values is important amongst those receiving treatment. In 
particular, patients receiving NVP, d4T and ddI may be at an increased risk of liver 
injury (270;272;276) and hence it is important to monitor ALT, ALK, BIL, ALB and 
GGT levels. GGT, in particular, was not included in these analyses as it was not 
routinely monitored in the UK CHIC cohort. IDV and TDF have been associated with 
chronic kidney disease (339) and patients receiving these drugs should be 
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monitored closely for abnormal CRE and URE levels. Patients receiving ART for 
long periods of time have been reported to be at an increased risk of myocardial 
infarction (530) and hence lipid levels should also be monitored routinely, in 
particular, HDL, LDL and TRI levels. 
 
All-cause mortality is one of several outcomes that a score can be used to predict. 
As discussed in the last Chapter, it does has the limitation of having low specificity; 
the associations between all-cause mortality and laboratory markers are likely to be 
weakened as a result of patients dying from causes such as suicide or other non-
HIV-related illnesses. With hindsight, it may have been more appropriate to consider 
an outcome such as treatment interruption, as well as all-cause mortality. Abnormal 
laboratory markers are likely to be strongly associated with interrupting treatment 
(and in particular, interrupting the drug associated with the laboratory abnormality), 
and in most cases, the interruption is likely to be the result of greater than 1 
laboratory abnormality. Hence, this outcome may have resulted in a better 
comparison between the approaches I used.  Other studies have successfully 
calculated scores to predict treatment modification (525). 
 
Deriving a score to accurately predict mortality is difficult, given the many variables 
that could potentially contribute to the score, the diversity of the causes of death and 
the various methods in both assigning a score and a cut-off point to identify patients 
of high-risk. The score must take into account both clinical and statistical issues; in a 
real life setting where it is unlikely that a patient will have all laboratory 
measurements available, it is of little use having a score which relies on a full 
laboratory medical record. Hence, though replication of the Swiss score did result in 
a positive association with mortality, in these analyses, where 0 was assigned to 
those who did not have a measurement available, it may not necessarily be the best 
method to derive a score. Rather, a method in which only 2 or 3 laboratory variables 
are needed is preferred. The score derived using the principal component analyses 
is likely to be difficult to implement in practice. For these reasons, using the score 
derived from the time-updated continuous variables is likely to be the best of the 
approaches discussed above. Only the latest ALB, HAE and URE values are 
needed to predict the risk of mortality and all three variables have been associated 
with drug related toxicities. ALB is a measure of liver function and patients receiving 
drugs such as NVP, d4T and ddI have been shown to be at an increased risk of liver 
injury (270;272;276). The association between ZDV and anaemia has been well 
documented (363-365) and even when used as part of combination therapy, ZDV 
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use has been shown to be a risk factor for anaemia (366). DdI and d4T have also 
been associated with low haemoglobin levels, though not as frequently or as 
strongly as ZDV (367;368). DdI, together with 3TC and PIs has also been 
associated with an increased risk of hyperuricemia (390;391), whilst patients 
receiving TDF may be at an increased risk of hypouricemia (392;393).  
 
Finally, ALB, HAE and URE are routinely measured in clinical practice, and the 
method used to derive the score also has the advantages of being both statistically 
and clinically applicable.  
 
8.5. Summary 
The aim of this Chapter was to derive a score to predict mortality. Several methods 
were used and discussed, each of which had advantages and disadvantages. The 
replication of the Swiss score confirmed findings reported from the Swiss HIV 
Cohort Study and developing this score, in particular, to include time-updated 
variables was one of the better approaches. However, in order to implement this 
approach, all laboratory measurements were required to avoid the biases of 
assigning a score of 0 to missing measurements. For these reasons, together with 
the disadvantages discussed above of other scoring methods, I feel using the short-
term mortality score derived from the continuous baseline measures approach, in 
which only ALB, HAE and URE are required, is the optimum scoring strategy. 
Further, a 2-year risk score may be more relevant to the general population than the 
HIV-positive population. HIV-positive patients are seen frequently at clinical centres 
and hence a 6-month risk score is likely to be more relevant for this population.  
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Chapter 9: Concluding remarks 
9.  
 
9.1. Summary of main findings 
The introduction of HAART around 1996 has transformed HIV from a terminal 
disease, to one which can be well managed with treatment. Therapy has advanced 
significantly since HAART was first introduced, both in terms of pill-burden and 
adverse events associated with it. However, almost 15 years after HAART was first 
introduced, interlinked barriers (resistance, drug toxicity, adherence) to successful 
treatment still exist in the developed world.  
 
In Chapter 2 I extensively reviewed the literature associated with some of these 
barriers to successful treatment. Resistance to therapy, both transmitted and that 
which has developed whilst receiving therapy, is a major concern amongst HIV-
positive individuals. There is evidence to suggest that transmitted resistance is 
actually increasing, whilst a lack of adherence amongst those on therapy has 
resulted in resistance to current drugs being received. One likely reason for lack of 
adherence is the adverse events still associated with particular antiretroviral drugs. 
Hepatotoxicity, especially, is an ongoing concern for patients. The differing 
definitions of hepatotoxicty make it difficult to differentiate between what may be 
normal elevations in liver function markers (such as ALT), elevations due to hepatitis 
co-infection and abnormal rises due to HAART. HAART is also associated with 
abnormal values in a number of other markers, such as haemoglobin, creatinine and 
urea. A consequence of lack of adherence is viral rebound. Patients may switch 
treatments or take a treatment break altogether due to the adverse events 
associated with therapy and this in turn is likely to result in viral rebound. The 
literature on the association between treatment interruptions and viral rebound 
favours continuous therapy, though little information is available on the effect of 
treatment interruptions on viral rebound amongst patients who were able to 
suppress their viral load after interruption.  
 
The methodology of the thesis was described in Chapter 3. This included the 
processes involved in establishing the UK CHIC Study and the linkages to the UK 
HIV Drug Resistance Database. I summarised trends over time in markers of clinical 
success; the proportion of white MSMs under follow-up had decreased over time, 
whist those of black ethnicity and heterosexual risk group had increased. This is 
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likely to be due to an increase in immigration from sub-saharan Africa for a period of 
time. Three-quarters of patients were receiving HAART in 2007, and of these, 84% 
had an undetectable viral load.  
 
The barriers to successful treatment start with transmitted resistance and hence 
Chapter 4, the impact of transmitted drug-resistance on treatment selection and 
outcome of first-line HAART, was the first of the Results chapters. In this Chapter, I 
showed that over 9% of patients starting first-line therapy have evidence of 
resistance mutations and over 5% of patients have resistance to drugs in their initial 
HAART regimen. This resulted in 3% of patients having a GSS <3 to their first 
HAART regimen. These patients were less likely to achieve virological suppression, 
though no association was found between viral rebound and GSS <3, nor CD4 
increase of >50 cells/mm3 and GSS <3. NRTI resistance appeared to be 
compensated for by use of a PI/r-based regimen. The contribution of NRTI 
resistance to virological failure is an important finding and use of PI-based regimens 
alone is often not enough to reduce the risk of virological failure. Hence other 
methods to improve virological outcomes amongst patients with transmitted NRTI 
resistance need to be explored.  
 
Drug-resistance after receiving ART was explored in Chapter 5. The proportion of 
patients who switched regimen within 4 months of a resistance test result was 
considerably lower than anticipated, even if using a relatively relaxed definition of 
switching (56%). However, those with mutations detected were more likely to switch 
therapy, and this number increased as the GSS of the current regimen decreased. 
Of concern, a third of patients with a GSS <1 had only 0-3 drug options available – 
this is likely to explain the relatively low proportion of patients switching regimen 
after having a resistance test performed. In analyses restricted to only those with 
detectable mutations, GSS was still found to be an independent predictor of 
switching regimen. In the second part of this Chapter, the need for two fully active 
NRTIs in a second-line PI/r based regimen was investigated. No association was 
seen between the number of new NRTIs, nor the NRTI GSS and risk of virological 
failure of second-line HAART; the benefit of including active NRTIs in second-line 
regimens appeared to be small in comparison to the efficacy of PI/r alone. 
 
In Chapter 6, a second barrier to successful treatment was explored – ALT flares. 
Flares are associated with particular drugs and are likely to result in either a switch 
in regimen, or a break in treatment altogether. This can cause resistance to ART 
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drugs which was the focus of Chapter 5. The existing definition of an ALT flare was 
questioned and a new definition, based on HAART-naïve, HBV/HCV-negative 
patients was derived; 2 ALTs >200 IU, >2 weeks apart. This new definition is more 
stringent than the present most commonly used definition (1 ALT >200 IU) and 
hence it is less likely that random fluctuations in ALT will be defined as ALT flares. 
Using this definition, 4.6% of patients were identified as having an ALT flare. 
Stronger relationships were seen between CD4 count and the risk of an ALT flare 
when using the standard definition compared to the derived definition, which may 
lead to unnecessary concern by clinicians when analyzing CD4 count. Also, the 
significance of regimen, viral load and hepatitis status appeared to be 
underestimated using the standard definition. This Chapter also highlighted the need 
to consider monitoring bias when analyzing outcomes such as ALT flares, as 
definitions based on single values are particularly prone to be affected by this. 
 
In Chapter 7, the issues surrounding treatment interruption were investigated. This 
relates to both Chapters 5 and 6, since interrupting treatment can be due to 
toxicities associated with particular drugs, such as ALT flares, whilst also being a 
cause of the first barrier to successful treatment – resistance to ART drugs.  
A quarter of patients had interrupted therapy before achieving viral suppression and 
the number of prior interruptions was linearly associated with a raised risk of viral 
rebound. In particular, patients who interrupted therapy with a detectable VL were at 
a higher risk of viral rebound, whilst no association was seen between risk of viral 
rebound and interrupting therapy whilst the VL was undetectable. Another important 
finding from this Chapter is the association between duration of viral suppression, 
number of regimens previously failed and risk of viral rebound. Patients with longer 
durations of viral suppression were less likely to experience viral rebound, whilst 
those with a greater number of previous failed regimens were at an increased risk of 
viral rebound. A significant interaction was seen between duration of suppression 
and number of regimens previously failed, suggesting that though patients with a 
higher number of previous regimens failed were at an increased risk of viral 
rebound, this risk decreased as the duration of suppression increased.  
 
Finally, in Chapter 8, the association between laboratory abnormalities and mortality 
was investigated by deriving a score to characterise these abnormalities. Toxicity to 
drugs is a main barrier of successful treatment in the developed world and is a likely 
cause of both treatment interruptions (discussed in Chapter 7) and resistance 
(discussed in Chapter 5). Several methods of assigning a score were explored, 
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whilst an existing method was reproduced. For a number of methods, all laboratory 
measures were needed for each patient, but for the vast majority of patients these 
were not available. The method which I felt was the most appropriate was based on 
the estimates from a regression model in which the current continuous laboratory 
measurements were fitted. Only three laboratory measures were needed to 
calculate the score (ALB, HAE and URE), all of which are routinely measured and 
have been linked to specific drug toxicity. This method eliminates the need for a full 
laboratory medical record and is both clinically and statistically viable.  
 
9.2. Relevance and limitations of main findings  
In this thesis, I have focused on the main barriers to successful treatment in the 
developed world. Resistance and toxicity to drugs limit the potential success of ART, 
whilst treatment interruptions are both a cause and consequence of these barriers. 
In clinical practice, whilst resistance testing before starting HAART is now 
mandatory, not all patients start HAART with a fully active regimen. This finding 
needs to be investigated further. Also of concern, is that only a small proportion of 
resistance tests after starting treatment are followed by a switch in treatment. The 
reasons as to why the resistance tests were performed, and more importantly, why 
the results of these tests were not acted upon, also need further investigation. Both 
these findings have serious potential consequences for patient well-being and raise 
questions about optimum clinical practice.   
 
After failure of a first-line NNRTI-regimen, it is of popular belief that the second-line 
regimen should consist of 2 fully active NRTIs and a PI/r. However, I have shown 
that the role of the NRTIs is questionable and should be investigated further on a 
larger dataset, or perhaps in collaboration with other cohort studies. Though the 
CHIC dataset used in these analyses consisted of over 32,000 patients, only 403 
patients met the strict inclusion criteria used to investigate the role of NRTIs in 
second-line regimens.  
 
I believe the findings in Chapter 7 are of key clinical importance. Patients continue to 
interrupt treatment, despite clinical advice against treatment interruptions. These 
patients should be warned of the risks of interrupting therapy, and in particular, have 
knowledge of the fact that suppressed viral load after treatment interruption is not 
sufficient on its own to outweigh the risk of interruption. Instead, longer duration of 
suppression is a key protective factor against viral rebound and this is only 
achievable through maintenance of high levels of adherence. The positive finding 
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that this is also true for patients who have failed a high number of previous regimens 
should be stressed as it provides motivation for adherence to the current regimen.  
 
The relevance of a score to predict mortality is important in a clinical setting. There 
are many laboratory markers that are measured after patients start HAART, and 
whilst a high proportion of patients have some of these markers measured, it is of 
concern that markers such as HDL, TRI and GGT are not routinely measured. 
Though most of these markers may be used to predict morbidity, measurement of a 
smaller number of markers, such as ALB, HAE, and URE, are enough to predict 
short-term mortality. This is of importance in settings in which not all makers can be 
measured, perhaps for financial or patient convenience reasons.  
 
These analyses have generally been performed with established statistical methods 
on firm endpoints and hence can easily be reproduced. Though UK CHIC does 
contain information from most of the large HIV clinics in the UK, there is the 
limitation that some large centres, such as those located in Manchester and 
Birmingham, and others in London, are not yet part of UK CHIC. Given the likely 
number of HIV-positive patients seen at these clinics, it is possible that the results 
are biased towards those patients seen at the large London clinics, who may have a 
different demographic profile to those seen elsewhere in the UK. There is a drive 
towards including additional centres in UK CHIC and hence in future research, 
analyses should be less affected by such biases.  
It would be interesting to replicate some analyses, in particular, those performed in 
Chapters 4 and 5 in other datasets which are not UK-based in order to compare 
results.  
 
Another potential limitation with this research is that it was based on a cohort study, 
in which there is inevitably unmeasured confounding which by definition cannot be 
controlled for. In particular, given the focus of this research was barriers to 
successful treatment, the role of adherence would have been very interesting to 
explore. Unfortunately, information on adherence is not collected in UK CHIC and 
hence surrogate markers, such as CD4 count measurements were used instead. 
Though a randomized controlled trial (RCT) would be the desirable gold standard for 
answering most research questions, it is not always the most viable option. For 
example, in the second Section of Chapter 5, I was only able to include 403 
patients. Recruiting patients to a trial to answer the question set out in Chapter 5 
would have been extremely difficult, given the strict inclusion criteria. Further, RCTs 
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are expensive as intensive follow-up is required. Therefore, patients are often 
observed for only short periods of time and so some clinical outcomes, such as 
death, may not be available. A particular limitation of RCTs in relation to analysing 
toxicities associated with HAART is that abnormal laboratory markers are usually 
not the primary endpoint of a RCT. Within the HIV field, the majority of trials are 
designed to evaluate the efficacy of a new drug and hence are unlikely to be 
powered to detect differences in prevalence of abnormal laboratory markers 
(538;539). Hence, the role of cohort studies in HIV research is of extreme 
importance, and though cohort studies do have limitations, there are often statistical 
methods which are able to at least partly correct for any known biases.  
 
In conclusion, based on analyses performed in this thesis, I believe that the full 
potential of ART is yet to be achieved. The results of resistance tests need to be 
acted upon effectively and counselling on treatment interruptions needs to be 
prioritised. Toxicity of ART drugs is improving, but those with abnormal laboratory 
measures should have repeat tests to confirm the measurement is not just a random 
independent fluctuation. It is difficult to choose cut-off points for these laboratory 
measurements to define an abnormal measurement, and the score proposed in 
Chapter 8, though needing validation can be used as an overall predictor of all-
cause mortality. In relation to abnormal laboratory measurements and mortality, 
collection of information on just three markers would ease the workload of the 
clinician and would reduce the inconvenience of the patient and hence the score 
should be verified in order to be put into practice.  
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Appendix A: Proportion of patients with laboratory 
measurements stratified by year under follow-up and 
centre  
 Year under follow-up 
Centre 101 2000 2001 2002 2003 2004 2005 2006 2007 
N under follow-up 653 738 852 963 1068 1186 1296 1385 
Any laboratory 
measurement (%) 
83 81 83 83 78 84 91 93 
ALT (%) 82 79 82 82 77 82 90 91 
ALB (%) 79 78 80 81 77 83 91 92 
AMY (%) 76 71 57 31 11 8 6 7 
AST (%) 5 2 3 3 2 1 2 5 
ALK (%) 82 80 83 82 77 82 91 92 
BIL (%) 82 80 83 82 77 82 91 92 
CHL (%) 74 74 77 76 73 70 77 78 
CPK (%) 5 3 4 3 3 5 5 4 
CRE (%) 78 79 83 83 77 82 91 92 
GGT (%) 5 5 5 6 6 4 5 3 
GLU (%) 67 69 74 74 69 69 76 77 
HAE (%) 83 80 83 83 78 83 91 92 
HDL (%) 70 70 74 75 70 69 77 78 
LAC (%) 10 9 8 6 5 3 1 1 
LDL (%) 66 66 72 75 70 67 75 75 
TRI (%) 6 6 36 76 73 68 75 76 
URE (%) 82 79 82 82 76 82 90 92 
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 Year under follow-up 
Centre 102 2000 2001 2002 2003 2004 2005 2006 2007 
N under follow-up 1917 2048 2201 2349 2511 2641 2703 2756 
Any laboratory 
measurement (%) 
82 84 85 84 82 82 86 85 
ALT (%) 79 82 82 82 81 81 83 83 
ALB (%) 76 79 80 80 80 81 84 84 
AMY (%) 54 59 61 60 60 60 64 62 
AST (%) 6 7 8 12 15 15 15 16 
ALK (%) 80 82 83 82 82 81 84 84 
BIL (%) 80 82 83 82 82 81 84 84 
CHL (%) 69 71 72 71 75 75 80 80 
CPK (%) 7 9 8 10 10 18 19 17 
CRE (%) 79 80 82 81 81 81 84 84 
GGT (%) 19 28 21 24 25 23 17 17 
GLU (%) 62 67 70 71 75 77 78 80 
HAE (%) 80 82 83 81 81 81 84 84 
HDL (%) 3 4 5 6 6 73 80 80 
LAC (%) 5 5 3 1 3 5 2 2 
LDL (%) 2 4 5 6 6 71 69 12 
TRI (%) 68 70 71 71 75 75 80 80 
URE (%) 28 23 37 44 23 43 59 63 
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 Year under follow-up 
Centre 103 2000 2001 2002 2003 2004 2005 2006 2007 
N under follow-up 3702 3993 4224 4477 4794 5097 5327 5427 
Any laboratory 
measurement (%) 
75 76 76 77 54 20 16 8 
ALT (%) 73 74 74 75 51 19 15 7 
ALB (%) 31 31 35 46 33 19 15 8 
AMY (%) 62 61 61 61 40 9 6 2 
AST (%) 7 8 8 10 8 4 4 2 
ALK (%) 74 75 75 76 52 19 16 8 
BIL (%) 74 75 75 76 52 19 16 8 
CHL (%) 66 65 40 11 33 16 13 7 
CPK (%) 0 0 0 1 0 1 1 1 
CRE (%) 73 74 74 76 52 20 16 8 
GGT (%) 17 20 19 19 10 7 6 3 
GLU (%) 4 5 11 7 7 7 7 5 
HAE (%) 74 76 75 76 52 20 16 8 
HDL (%) 2 4 5 6 8 8 8 7 
LAC (%) 43 52 19 3 22 7 0 0 
LDL (%) 2 3 6 6 8 8 8 6 
TRI (%) 66 64 39 11 33 16 13 7 
URE (%) 73 74 73 74 50 18 15 7 
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 Year under follow-up 
Centre 104 2000 2001 2002 2003 2004 2005 2006 2007 
N under follow-up 1911 2129 2341 2568 2763 2951 3101 3236 
Any laboratory 
measurement (%) 
78 89 90 90 89 88 89 90 
ALT (%) 68 81 84 82 80 80 79 88 
ALB (%) 65 79 82 80 80 80 80 89 
AMY (%) 20 19 15 14 15 4 2 3 
AST (%) 3 4 4 4 3 3 3 2 
ALK (%) 69 81 85 82 81 80 80 89 
BIL (%) 69 81 84 82 81 80 80 88 
CHL (%) 34 53 55 60 61 65 68 66 
CPK (%) 4 0 4 3 3 3 3 2 
CRE (%) 52 47 83 82 81 80 80 89 
GGT (%) 13 17 18 17 12 7 7 5 
GLU (%) 27 47 47 43 44 45 41 41 
HAE (%) 77 87 89 90 89 88 88 89 
HDL (%) 26 46 51 58 58 64 68 66 
LAC (%) 4 6 7 5 4 2 2 1 
LDL (%) 24 44 49 56 57 63 66 64 
TRI (%) 33 53 54 60 61 65 68 66 
URE (%) 67 80 84 82 80 80 79 88 
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 Year under follow-up 
Centre 105 2000 2001 2002 2003 2004 2005 2006 2007 
N under follow-up 958 1134 1303 1438 1552 1653 1755 1732 
Any laboratory 
measurement (%) 
80 79 79 80 84 84 87 91 
ALT (%) 14 13 12 12 11 11 12 11 
ALB (%) 76 75 75 78 83 84 86 91 
AMY (%) 55 66 71 71 76 62 59 49 
AST (%) 1 1 1 1 2 1 1 1 
ALK (%) 79 78 78 79 84 84 86 91 
BIL (%) 79 78 78 79 83 83 86 91 
CHL (%) 57 68 72 73 79 78 83 86 
CPK (%) 0 0 0 0 0 1 1 0 
CRE (%) 79 77 78 79 83 83 86 90 
GGT (%) 75 72 72 75 79 80 82 86 
GLU (%) 15 16 15 16 20 10 4 4 
HAE (%) 79 78 79 80 84 84 86 91 
HDL (%) 4 8 9 11 20 31 61 78 
LAC (%) 13 16 9 5 4 5 4 2 
LDL (%) 4 8 9 11 20 30 59 75 
TRI (%) 57 68 72 72 79 78 82 86 
URE (%) 18 18 18 19 20 22 24 87 
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 Year under follow-up 
Centre 106 2000 2001 2002 2003 2004 2005 2006 2007 
N under follow-up 1298 1419 1619 1767 1891 2016 2035 1335 
Any laboratory 
measurement (%) 
87 89 90 90 91 90 92 80 
ALT (%) 85 88 89 89 87 89 91 78 
ALB (%) 84 87 88 89 90 90 91 78 
AMY (%) 4 4 4 3 2 1 1 2 
AST (%) 80 83 84 84 85 85 87 70 
ALK (%) 85 88 89 90 90 90 91 78 
BIL (%) 85 88 89 90 90 90 91 78 
CHL (%) 58 65 79 87 89 89 91 76 
CPK (%) 0 0 0 0 0 1 0 0 
CRE (%) 85 87 89 90 90 90 91 78 
GGT (%) 79 82 82 85 85 86 87 70 
GLU (%) 59 58 74 86 87 88 89 74 
HAE (%) 83 88 89 89 90 89 89 77 
HDL (%) 24 36 67 85 87 88 91 76 
LAC (%) 12 13 12 8 7 5 2 0 
LDL (%) 23 32 64 83 85 87 90 72 
TRI (%) 57 64 79 87 89 89 91 76 
URE (%) 85 88 89 89 89 89 91 78 
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 Year under follow-up 
Centre 108 2000 2001 2002 2003 2004 2005 2006 2007 
N under follow-up 445 461 467 482 508 545 575 577 
Any laboratory 
measurement (%) 
87 88 90 90 92 94 95 99 
ALT (%) 87 88 90 90 91 94 95 99 
ALB (%) 78 80 82 80 72 83 82 91 
AMY (%) 67 75 67 61 64 57 60 68 
AST (%) 1 1 0 0 0 0 3 9 
ALK (%) 87 88 90 90 91 94 95 99 
BIL (%) 87 88 90 90 91 93 95 99 
CHL (%) 20 20 34 22 19 22 23 21 
CPK (%) 42 63 62 56 60 60 74 77 
CRE (%) 86 88 90 90 92 93 95 99 
GGT (%) 0 0 0 0 0 0 0 0 
GLU (%) 0 0 0 0 0 0 1 1 
HAE (%) 87 88 89 90 92 93 95 99 
HDL (%) 0 0 0 0 0 0 1 1 
LAC (%) 1 2 2 3 2 1 1 1 
LDL (%) 0 0 3 9 9 15 17 17 
TRI (%) 21 20 25 3 3 2 2 2 
URE (%) 34 38 56 34 36 40 37 38 
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Appendix B: Table for Grading Severity of Adverse 
Experiences  
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http://www.ucdmc.ucdavis.edu/clinicaltrials/documents/DAIDS_AE_GradingTable_Fin
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Appendix C: Published research 
 
 
Impact of transmitted drug-resistance on treatment selection and outcome of first-
line Highly Active Antiretroviral Therapy (HAART).(Chapter 4) 
Bansi L, Geretti AM, Dunn D, Hill T, Green H, Fearnhill E, Gazzard B, Nelson M, 
Porter K, Phillips A, Sabin C; UK Collaborative Group on HIV Drug Resistance and 
UK Collaborative HIV Cohort (CHIC) Study. J Acquir Immune Defic Syndr. 2010 
Apr;53(5):633-9. 
 
The impact of HIV drug resistance testing on changes to treatment (Chapter 5) 
Loveleen Bansi, Colette Smith, Andrew Phillips, Stuart Kirk, Anna-Maria Geretti, 
Margaret Johnson, Nicola Mackie, Frank Post, Brian Gazzard, David Dunn, and 
Caroline Sabin on behalf of the UK Collaborative HIV Cohort (CHIC) Study and the 
UK Collaborative Group on HIV Drug Resistance (HDRD). AIDS, 2011; In press 
 
Is 1 alanine transaminase >200 IU enough to define an alanine transaminase flare 
in HIV-infected populations? A new definition derived from a large cohort study 
(Chapter 6) 
Bansi L, Turner J, Gilson R, Post F, Gazzard B, Leen C, Anderson J, Porter K, Hill 
T, Fisher M, Ainsworth J, Pillay D, Johnson M, Winston A, Orkin C, Easterbrook P, 
Phillips A, Sabin C; UK Collaborative HIV Cohort Study. J Acquir Immune Defic 
Syndr. 2009 Nov 1;52(3):391-6. 
 
Are previous treatment interruptions associated with higher viral rebound rates in 
patients with viral suppression? (Chapter 7) 
Bansi LK, Benzie AA, Phillips AN, Portsmouth S, Hill T, Leen C, Schwenk A, 
Johnson M, Anderson J, Gilson R, Easterbrook P, Gazzard B, Fisher M, Orkin C, 
Porter K, Pillay D, Taylor GP, Walsh JC, Sabin CA; UK Collaborative HIV Cohort 
(UK CHIC) Study. AIDS. 2008 Jan 30;22(3):349-56. 
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